



#### RESOURCE AND PATIENT MANAGEMENT SYSTEM

## **Clinical Reporting System**

(BGP)

# CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures

Version 15.0 November 2014

Office of Information Technology (OIT)

Division of Information Resource Management

## **Table of Contents**

1.0	Introdu	uction	1
2.0	Perfori	mance Measure Logic	2
	2.1	Performance Measure Logic Basics	2
	2.1.1	CRS Denominator Definitions	2
	2.1.2	Performance Measure Logic Example	
	2.1.3	Age Ranges	. 12
	2.1.4	Standard Health Care Codes	. 13
	2.2	Diabetes Related Measure Topics	
	2.2.1	Diabetes Prevalence	
	2.2.2	Diabetes Comprehensive Care	. 17
	2.2.3	Diabetes: Glycemic Control	
	2.2.4	Diabetes: Blood Pressure Control	
	2.2.5	Diabetes: LDL Assessment	. 32
	2.2.6	Diabetes: Nephropathy Assessment	. 35
	2.2.7	Diabetic Retinopathy	
	2.2.8	RAS Antagonist Use in Diabetic Patients	. 44
	2.2.9	Diabetes: Access to Dental Services	. 50
	2.3	Dental Measure Topics	
	2.3.1	Access to Dental Services	
	2.3.2	Dental Sealants	. 56
	2.3.3	Topical Fluoride	
	2.4	Immunization Measure Topics	. 62
	2.4.1	Influenza	. 62
	2.4.2	Adult Immunizations	. 67
	2.4.3	Childhood Immunizations	. 73
	2.4.4	Adolescent Immunizations	. 85
	2.5	Childhood Diseases Group	. 89
	2.5.1	Appropriate Treatment for Children with Upper Respiratory Infection	. 89
	2.5.2	Appropriate Testing for Children with Pharyngitis	
	2.6	Cancer Related Measure Topics	
	2.6.1	Cancer Screening: Pap Smear Rates	
	2.6.2	Cancer Screening: Mammogram Rates	
	2.6.3	Colorectal Cancer Screening	103
	2.6.4	Comprehensive Cancer Screening	107
	2.6.5	Tobacco Use and Exposure Assessment	
	2.6.6	Tobacco Cessation	120
	2.7	Behavioral Health Related Performance Measure Topics	127
	2.7.1	Alcohol Screening (FAS Prevention)	127
	2.7.2	Alcohol Screening and Brief Intervention (ASBI) in the ER	131
	2.7.3	Intimate Partner (Domestic) Violence Screening	137

2.7.4	Depression Screening	140
2.7.5	Antidepressant Medication Management	145
2.8	Cardiovascular Disease Related Measure Topics	
2.8.1	Obesity Assessment	
2.8.2	Childhood Weight Control	153
2.8.3	Weight Assessment and Counseling for Nutrition and Physical	
	Activity	
2.8.4	Nutrition and Exercise Education for At Risk Patients	
2.8.5	Physical Activity Assessment	
2.8.6	Comprehensive Health Screening	
2.8.7	Cardiovascular Disease and Cholesterol Screening	
2.8.8	Cardiovascular Disease and Blood Pressure Control	
2.8.9	Controlling High Blood Pressure	
2.8.10	Controlling High Blood Pressure (Million Hearts)	
2.8.11	Comprehensive CVD-Related Assessment	
2.8.12	Appropriate Medication Therapy after a Heart Attack	196
2.8.13	11 1	
	Attack	
2.8.14		
2.8.15		
0 0 4 0	Atrial Fibrillation at Discharge	230
2.8.16	Cholesterol Management for Patients with Cardiovascular	000
0.0.47	Conditions	
2.8.17		
2.9	STD-Related Measure Topics	
2.9.1	HIV Screening	
2.9.2	HIV Quality of Care	
2.9.3	Hepatitis C Screening	
2.9.4	Chlamydia Screening	
2.9.5 2.10	Sexually Transmitted Infection Screening  Other Clinical Measures Topics	
2.10.1	Osteoporosis Management	
	Osteoporosis Screening in Women	
	Rheumatoid Arthritis Medication Monitoring	
2.10.3	Osteoarthritis Medication Monitoring	
	Asthma	
	Asthma Assessments	
2.10.7		
2.10.7	·	
	Chronic Kidney Disease Assessment	
	O Proportion of Days Covered by Medication Therapy	
	1 Primary Medication Non-adherence	
	2 Medications Education	

	2.10.13 Medication Therapy Management Services	299
	2.10.14 Self Management (Confidence)	301
	2.10.15 Public Health Nursing	
	2.10.16 Breastfeeding Rates	
	2.10.17 Use of High-Risk Medications in the Elderly	
	2.10.18 Use of Benzodiazepine Sedative Hypnotic Medications in the	
	Elderly	314
	2.10.19 Functional Status Assessment in Elders	
	2.10.20 Fall Risk Assessment in Elders	318
	2.10.21 Palliative Care	321
	2.10.22 Annual Wellness Visit	323
	2.10.23 Goal Setting	324
Cont	act Information	328

## **Preface**

The Government Performance and Results Act (GPRA) requires federal agencies to report annually on how the agency measured up against the performance targets set in its annual Plan. The Indian Health Service (IHS) GPRA report includes measures for clinical prevention and treatment, quality of care, infrastructure, and administrative efficiency functions.

The IHS Clinical Reporting System (CRS) is a Resource and Patient Management System (RPMS) software application designed for national reporting as well as Area Office and local monitoring of clinical GPRA and developmental measures. CRS was first released for Fiscal Year (FY) 2002 performance measures (as GPRA+) and is based on a design by the Aberdeen Area (GPRA2000).

This manual contains the FY 2015 clinical performance measure definitions and logic for the CRS 2015 Version 15.0 software. CRS is the reporting tool used by the IHS Office of Planning and Evaluation to collect and report clinical performance results annually to the Department of Health and Human Services and to Congress.

Each year, an updated version of CRS software is released to reflect changes in the logic descriptions of the different denominators and numerators. Additional performance measures may also be added. Local facilities can run reports as often as they want to and can also use CRS to transmit data to their Area. The Area Office can use CRS to produce an aggregated Area report for either annual GPRA or Area Director Performance reports.

CRS produces reports on demand from local RPMS databases for both GPRA and developmental clinical measures that are based on RPMS data, thus eliminating the need for manual chart audits for evaluating and reporting clinical measures.

To produce reports with comparable data across every facility, the GPRA measures definitions was "translated" into programming code with the assistance of clinical subject matter experts. CRS uses predefined taxonomies to find data items in the RPMS Patient Care Component (PCC) to determine if a patient meets the performance measure criteria. Taxonomies contain groups of codes (e.g., diagnoses or procedures) or site-specific terms. Each performance measure has one or more defined denominators and numerators.

Administrative and clinical users can produce reports for selected measures at any time to:

• Identify potential data issues in their RPMS, i.e., missing or incorrect data.

- Monitor their site's performance against past national performance and upcoming agency goals.
- Identify specific areas where the facility is not meeting the measure in order to initiate business process or other changes.
- Quickly measure impact of process changes on performance measures.
- Identify areas meeting or exceeding measures to provide lessons learned.

#### Users of the RPMS CRS include:

- Area Office and site quality improvement staff
- Compliance Officers
- GPRA coordinators
- Clinical staff, such as physicians, nurses, nurse practitioners, and other providers
- Area Office directors
- Any staff involved with quality assurance initiatives
- Staff who run various CRS reports

## 1.0 Introduction

This manual provides information on the performance measure logic used by the Clinical Reporting System (CRS) Version 15.0 Selected Measures (Local) Report (Fiscal Year [FY] 2015 Clinical Performance Measures). For information on system setup, available reports and steps for running the reports, and performing Area Office functions, refer to the CRS Version 15.0 User Manual.

## 2.0 Performance Measure Logic

This section provides the following information for each performance measure topic:

- For Government Performance and Results Act (GPRA) measures, the measure description is provided as stated in the Indian Health Service (IHS) Annual Performance Report to Congress
- Definitions of all denominators and numerators for each performance measure topic
- Detailed description of the logic for the denominator and numerator, including specific codes, fields, taxonomies, and/or values searched
- Key changes to logic from the previous year, if any
- Description of which patients and information are contained on the patient list
- Performance measure source and past IHS performance, if any, and IHS or Healthy People (HP) 2020 targets for the performance measure
- · Report examples
- Patient list examples

**Note:** All report examples and patient list examples used in this section were produced from "scrubbed" demonstration databases and do not represent individual patient data.

## 2.1 Performance Measure Logic Basics

#### 2.1.1 CRS Denominator Definitions

Each performance measure topic has one or more define denominators and numerators. The denominator is the total population that is being reviewed for a specific measure. For the National GPRA/GPRAMA Report, only one denominator for each topic is reported. These denominators are pre-defined, based on the Active Clinical Population definition. For the Selected Measures reports for local use (CRS Version 15.0 User Manual, Section 5.11), multiple denominators may be reported to provide a complete picture of clinical performance. There are also additional options available to further refine denominator definitions.

#### 2.1.1.1 Denominator Definitions for National GPRA Reporting

The Active Clinical population is the denominator definition used as the basis for *most* GPRA measures. This denominator was developed in FY 2003 specifically for clinical performance measures because it is more representative of the active clinical population.

Prior to FY 2003, the GPRA User Population denominator definition was used for national reporting, similar to the agency's IHS User Population definition.

The *Active Clinical* population for the National GPRA/GPRAMA Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the Resource and Patient Management System (RPMS) Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have two visits to medical clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology

Clinic Code	Clinic Description
07	ENT
08	Family Planning
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology - Hepatology
B9	Oncology - Hematology
C3	Colposcopy

- Patient must be alive on the last day of the report period.
- Patient must be American Indian/Alaska Native (AI/AN) (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA
  community taxonomy, defined as all communities of residence in the CHS
  catchment area specified in the community taxonomy specified by the user.

The *Active Clinical Plus Behavioral Health Population* for National GPRA/GPRAMA Reports is defined as follows:

Patients with the name of "DEMO, PATIENT" or who are included in the RPMS
Demo/Test Patient Search Template (DPST option located in the Patient Care
Component [PCC] Management Reports, Other section) will be automatically
excluded from the denominator.

• Patient must have *two* visits to *medical* clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
14	Mental Health
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology

Clinic Code	Clinic Description
43	Alcohol & Substance Abuse
48	Medical Social Services
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology – Hepatology
В9	Oncology – Hematology
C3	Colposcopy
C4	Behavioral Health
C9	Telebehavioral Health

- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy that is specified by the user.

The *GPRA User Population* for the National GPRA/GPRAMA Report is defined by the following criteria:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS
  Demo/Test Patient Search Template (DPST option located in the PCC
  Management Reports, Other section) will be automatically excluded from the
  denominator.
- Patient must have been seen at least once in the 3 years prior to the end of the time period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- Patient must be AI/AN (defined as Beneficiary 01). This data item is entered and updated during the patient registration process.
- Patient must reside in a community included in the site's "official" GPRA
  community taxonomy, defined as all communities of residence in the CHS
  catchment area specified in the community taxonomy specified by the user.

**Note:** The GPRA User Population definition is similar, but not identical, to the definition used by IHS headquarters (HQ) for annual user population statistics. GPRA "visits" are not required to be workload reportable as defined by IHS HQ.

#### 2.1.1.2 Denominator Definitions for Selected Measures Reports

In addition to the National GPRA/GPRAMA Report, CRS provides Selected Measures reports intended for local facility use for specific public health and/or performance improvement initiatives (CRS Version 15.0 User Manual, Section 5.11). Multiple denominators and numerators will be reported for each measure (e.g., *both* Active Clinical and GPRA User Population). Users have additional options to define the denominators as explained below.

The Active Clinical Population for Selected Measures (Local) Reports is defined as follows:

- Patients with name "DEMO, PATIENT" or who are included in the RPMS
  Demo/Test Patient Search Template (DPST option located in the PCC
  Management Reports, Other section) will be automatically excluded from the
  denominator.
- Patient must have two visits to medical clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be either to one of the core medical clinics in the previous list or to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk
27	General Preventive
31	Hypertension
32	Postpartum
37	Neurology
38	Rheumatology
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology - Hepatology
B9	Oncology - Hematology
C3	Colposcopy

- Patient must be alive on the last day of the Report period.
- User defines population type: AI/AN patients only, non AI/AN, or both. This data item is entered and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

The Active Clinical Plus Behavioral Health Population for Selected Measures (Local) Reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be automatically excluded from the denominator.
- Patient must have *two* visits to *medical* clinics in the past 3 years. At least one visit must be to one of the following core medical clinics:

Clinic Code	Clinic Description
01	General
06	Diabetic
10	GYN
12	Immunization
13	Internal Medicine
20	Pediatrics
24	Well Child
28	Family Practice
57	EPSDT
70	Women's Health
80	Urgent Care
89	Evening

The second visit can be *either* to one of the core medical clinics in the previous list *or* to one of the following additional medical clinics:

Clinic Code	Clinic Description
02	Cardiac
03	Chest And TB
05	Dermatology
07	ENT
08	Family Planning
14	Mental Health
16	Obstetrics
19	Orthopedic
23	Surgical
25	Other
26	High Risk

Clinic Code	Clinic Description
27	General Preventive
31	Hypertension
38	Rheumatology
43	Alcohol & Substance Abuse
48	Medical Social Services
49	Nephrology
50	Chronic Disease
69	Endocrinology
75	Urology
81	Men's Health Screening
85	Teen Clinic
88	Sports Medicine
B8	Gastroenterology – Hepatology
В9	Oncology – Hematology
C3	Colposcopy

- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both. This data item is typed and updated during the patient registration process.
- User defines general population: single community; group of multiple communities (community taxonomy); user-defined list of patients (patient panel); or all patients, regardless of community of residence.

The *User Population* for Selected Measures (Local) reports is defined as follows:

- Patients with the name of "DEMO, PATIENT" or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the PCC Management Reports, Other section) will be excluded from the denominator automatically.
- Patient must have been seen at least once in the 3 years prior to the end of the time period, regardless of the clinic type.
- Patient must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy); user-defined list of patient (patient panel); or all patients regardless of community of residence.

## 2.1.2 Performance Measure Logic Example

**Cancer Screening: Mammogram Rates**: During FY 2015, achieve the target rate of 54.8% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

For CRS, the GPRA measure definition is defined as:

- Denominator (total number of patients evaluated): Active Clinical female patients ages 52 through 64, excluding those with documented history of bilateral mastectomy. (The clinical owner of the measure has determined based on current medical guidelines that "eligible" women are defined as ages 52 through 64.)
- Numerator (those from the denominator who meet the criteria for the measure): patients with documented mammogram in past 2 years.

For the programmer, the Mammogram measure is described in terms of the following logic:

- 1. Begin with the Active Clinical population definition.
  - Exclude any patients with the name of "DEMO, PATIENT."
  - Exclude any patient records that are included in the RPMS Demo/Test Patient Search Template.
  - Exclude any patients with a date of death in the Patient Registration file.
  - Exclude any patients who do *not* have value 01 (AI/AN) in the Beneficiary field in Patient Registration file.
  - Exclude any patients whose Community of Residence is not included in the site's defined GPRA Community Taxonomy for this report.
  - For the remaining patients, search Visit files for the 3 years prior to the selected report end date; exclude any patient records whose visits do not meet the "two medical clinics" definition.
- 2. From these patients, identify the subset that are female and at least age 52 on the first day of the current report period and less than age 65 on the last day of the report period.

- 3. Exclude patients with documented bilateral mastectomy by searching the V Procedure file for Procedure Codes ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HTV0ZZ or V CPT for CPT Codes 19300.50-19307.50 OR 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, 19240, w/modifier of 50 or 09950 any time before the end of the report period; *or* who have two separate occurrences for either CPT Codes 19300-19307, or old codes 19180, 19200, 19220, 19240 or Procedure Codes ICD-9: 85.41, 85.43, 85.45, 85.47; ICD-10: 07T50ZZ, 07T60ZZ, 07T70ZZ, 07T80ZZ, 07T90ZZ, 0HTT0ZZ, 0HTU0ZZ, 0KTH0ZZ, 0KTJ0ZZ on either two different dates of service or on the same date of service if the codes include both a right side modifier (RT) and left side modifier (LT).
- 4. For these patients (the denominator), check for a mammogram in the past 2 years in the following order:
  - a. Check V Radiology or V CPT for the following CPT Codes: 77052 through 77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206; G0204, G0202
  - b. Check the Purpose of Visit file (V POV) for a diagnosis of ICD-9: V76.11 Screening Mammogram for High Risk Patient; V76.12 Other Screening Mammogram; 793.80 Abnormal Mammogram, Unspecified; 793.81 Mammographic Microcalcification; 793.89 Other Abnormal Findings On Radiological Exam of Breast or ICD-10: R92.0, R92.1, R92.8, Z12.31.
  - c. Check V Procedures for a procedure of ICD-9: 87.36 Xerography of Breast, 87.37 Other Mammography or ICD-10: BH00ZZZ, BH01ZZZ, BH02ZZZ.
  - d. Check the Women's Health Tracking package for documentation of a procedure called Mammogram Screening, Mammogram Dx Bilat, or Mammogram Dx Unilat and where the result does *not* have "ERROR/DISREGARD".

If a visit with any of the specified codes is found, the patient is considered to have met the measure, and the program checks the next patient.

## 2.1.3 Age Ranges

Unless otherwise noted, for the purposes of CRS reports, the age of a patient is calculated at the beginning of the report period. For example, for a report period of July 1, 2014 through June 30, 2015, Jane Doe is defined as age 74 if her birth date is June 10, 1940, even though she becomes age 75 during the report period.

#### 2.1.4 Standard Health Care Codes

#### 2.1.4.1 Current Procedural Terminology Codes

One of several code sets used by the healthcare industry to standardize data, and allow for comparison and analysis. Current Procedural Terminology (CPT) was developed and is updated annually by the American Medical Association, and is widely used in producing bills for services rendered to patients. CPTs include codes for diagnostic and therapeutic procedures, and specify information that differentiates the codes based on cost. CPT codes are the most widely accepted nomenclature in the United States for reporting physician procedures and services for federal and private insurance third-party reimbursement. CRS searches for CPT and other codes as specified in the logic definition to determine if a patient meets a denominator or numerator definition.

#### 2.1.4.2 International Classification of Disease Codes

One of several code sets used by the healthcare industry to standardize data. The International Classification of Disease (ICD) is an international diagnostic coding scheme. In addition to diseases, ICD also includes several families of terms for medical-specialty diagnoses, health status, disablements, procedure, and reasons for contact with healthcare providers. IHS currently uses ICD, Ninth Revision (ICD-9) for coding, but will be switching to ICD-10 in 2015. CRS searches for ICD and other codes as specified in the logic definition, to determine if a patient meets a denominator or numerator definition.

#### 2.1.4.3 Logical Observation Identifiers Names and Codes

Logical Observation Identifiers Names and Codes (LOINC®). A standard coding system originally initiated for laboratory values, the system is being extended to include non-laboratory observations (electrocardiograms, vital signs, etc.). Standard code sets are used to define individual tests and mitigate variations in local terminologies for laboratory and other healthcare procedures, for example, Glucose or Glucose Test. IHS began integrating LOINC values into RPMS in several pilot sites in 2002.

Refer to the CRS Version 15.0 Technical Guide for a list of specific LOINC codes included in each LOINC taxonomy.

## 2.2 Diabetes Related Measure Topics

#### 2.2.1 Diabetes Prevalence

#### **Denominators**

All *User Population patients*. Broken down by gender and age groups (less than (<)15, 15 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 64, greater than (>) 64 years).

#### **Numerators**

Anyone diagnosed with Diabetes at any time before the end of the Report Period.

Anyone diagnosed with Diabetes during the Report Period.

#### **Logic Description**

Age is calculated at the beginning of the Report Period.

*Diabetes definition*: At least one POV diagnosis of ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*.

#### Key Logic Changes from CRS Version 14.1

None.

## **Patient List Description**

List of diabetic patients with most recent diagnosis.

#### **Measure Source**

HP 2010 5-2, 5-3

#### **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	14.0%
IHS FY 2013 Performance	13.9%
IHS FY 2012 Performance	13.4%
IHS FY 2011 Performance	12.8%
IHS FY 2010 Performance	12.0%
IHS FY 2009 Performance	12.0%
IHS FY 2008 Performance	12.0%

Performance	Percent
IHS FY 2007 Performance	11.0%
IHS FY 2006 Performance	11.0%
IHS FY 2005 Performance	11.0%
IHS FY 2004 Performance	10.0%

```
DII
                              November 25, 2015
                                                                      Page 1
       *** IHS 2015 Selected Measures with Community Specified Report ***
                             DEMO INDIAN HOSPITAL
                  Report Period: Jan 01, 2015 to Dec 31, 2015
              Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                 Baseline Period: Jan 01, 2010 to Dec 31, 2010
Diabetes Prevalence
Denominator(s):
- All User Population patients. Broken down by gender and by age groups: < 15,
15-19, 20-24, 25-34, 35-44, 45-54, 55-64, > 64.
Numerator(s):
 - Anyone diagnosed with Diabetes at any time before the end of the Report
 - Anyone diagnosed with Diabetes during the Report Period.
Age is calculated at the beginning of the Report Period. Diabetes
diagnosis is defined as at least one POV diagnosis ICD-9: 250.00-250.93
or ICD-10: E10.*-E13.*.
Performance Measure Description:
Continue tracking (i.e., data collection and analyses) Area age-specific
diabetes prevalence rates to identify trends in the age-specific
prevalence of diabetes (as a surrogate marker for diabetes incidence) for
the AI/AN population.
Past Performance and/or Target:
IHS Performance: FY 2014 - 14.0%, FY 2013 - 13.9%, FY 2012 - 13.4%, FY 2011 -
12.8%, FY 2010 - 12%, FY 2009 - 12%, FY 2008 - 12%, FY 2007 - 11%, FY 2006 - 11%,
FY 2005 - 11%, FY 2004 - 10%
Source:
HP 2010 5-2, 5-3
Diabetes Prevalence
                                                                    % CHG from
                     REPORT
                               % PREV YR
                                              % CHG from BASE
                                                PREV YR % PERIOD
                                                                       BASE %
                     PERIOD
                                 PERIOD
# User Pop
                     2,896
                                     2,456
                                                            2,346
# w/ any DM DX
                        265
                              9.2
                                       243
                                           9.9
                                                    -0.7
                                                             197
                                                                   8.4
                                                                            +0.8
# w/ DM DX
                                            5.9
                                                    +0.0
w/in past year
                        173
                              6.0
                                      146
                                                             100
                                                                   4.3
                                                                            +1.7
```

# Male User Pop	1,368		1,152			1,109			
# w/ any DM DX	114	8.3	104	9.0	-0.7	72	6.5	+1.8	
# w/DM DX w/in past year	82	6.0	78	6.8	-0.8	48	4.3	+1.7	
# Female User Pop	1,528		1,304			1,237			
# w/ any DM DX	151	9.9	139	10.7	-0.8	125	10.1	-0.2	
# w/ DM DX w/in past year	91	6.0	68	5.2	+0.7	52	4.2	+1.8	

Figure 2-1: Sample Summary Report, Diabetes Prevalence Topic

DU November 25, 2015 Page 2  *** IHS 2015 Selected Measures with Community Specified Report ***								
DEMO INDIAN HOSPITAL Report Period: Jan 01, 2015 to Dec 31, 2015								
Previous							4	
			an 01,				•	
Diabetes Prevalence (co	on't)							
		TOTAL U	SER POP	-				
		15 10		Distri		45 54		- A
	<15	15-19	20-24	25-34	35-44	45-54	55-64	>64 yrs
CURRENT REPORT PERIOD								
	730					390		
	1				57		50	43
% w/ DM DX ever	0.1	1.3	2.7	9.2	14.7	17.2	19.1	19.4
# w/DM DX in past yr	0	2	3	14	42	49	34	29
% w/DM DX in past yr	0.0					12.6	13.0	13.1
PREVIOUS YEAR PERIOD								
Total # User Pop	711	227	243	352	316	277	181	149
# w/ DM DX ever	3							40
% w/ DM DX ever	0.4							
,								
# w/DM DX in past yr	1			9	33	37	31	29
% w/DM DX in past yr	0.1	1.3	1.2	2.6	10.4	13.4	17.1	19.5
CHANGE FROM PREV YR %								
w/ DM DX ever	-0.3	-0.5	-1.0	+0.4	-2.4	-3.4	-5.8	-7.5
w/DM DX in past yr			-0.1				-4.1	
BASELINE REPORT PERIOD								
Total # User Pop	787 2 0.3	208	217					
# w/ DM DX ever	2	4		20	38	46		
% w/ DM DX ever	0.3	1.9	5.5	6.1	13.0	20.2	22.0	30.8
# w/DM DX in past yr	2	1	3	7	18	21	20	28
# w/DM DX in past yr % w/DM DX in past yr	0.3	0.5	1.4	2.1	6.1	9.2	14.2	19.6
CHANGE FROM BASE YR %								
w/ DM DX ever	-0 1	-0.7	-2.8	+3 1	+1 7	-3 0	-2 9	-11 4
W/ DIT DIT CVCI	0.1	J.,	2.0	, J . 1	/	5.0	۷.۶	TT.1

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

```
w/DM DX in past yr -0.3 +0.4 -0.2 +1.3 +4.7 +3.4 -1.2 -6.5
```

Figure 2-2: Sample Age Breakdown Page, Diabetes Prevalence Topic

```
November 25, 2015
  DH
                                                                   Page 1
         *** IHS 2015 Clinical Performance Measure Patient List ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
                        Entire Patient List
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Diabetes Prevalence: List of diabetic patients with most recent diagnosis
PATIENT NAME
                      HRN
                             COMMUNITY
                                          SEX AGE
DENOMINATOR
                            NUMERATOR
PATIENT1, DEBORAH
                     000001 COMMUNITY #1 F 20
                           02/01/15 POV 250.00
02/01/15 POV 250.00
PATIENT2, TARA 000002 COMMUNITY #1 F 21
                            05/24/14 POV E11.21
05/24/14 POV E11.21
PATIENT3,BOBBIE 000003 COMMUNITY #1 F 28
                            03/30/14 POV 250.00
PATIENT4, WINONA 000004 COMMUNITY #1 F 37
                            04/30/15 POV 250.00
PATIENT5, NADINE 000005 COMMUNITY #1 F 44
                         03/19/14 POV 250.00
PATIENT6, RUTH
                      000006 COMMUNITY #1 F 44
                      03/19/15 POV E10.10
```

Figure 2-3: Sample Patient List, Diabetes Prevalence, Patients with Diabetes Diagnosis

## 2.2.2 Diabetes Comprehensive Care

#### **Denominators**

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two diabetes mellitus- (DM-) related visits ever.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral blindness.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two diabetes mellitus- (DM-) related visits ever, without a documented history of bilateral foot amputation or two separate unilateral foot amputations.

#### **Numerators**

Patients with hemoglobin A1c documented during the Report Period, regardless of result

Patients with blood pressure (BP) documented during the Report Period

Patients with controlled BP, defined as less than (<) 140/90, i.e., the mean systolic value is less than (<) 140 and the mean diastolic value is less than (<) 90

Patients with low-density lipoprotein (LDL) completed during the Report Period, regardless of result

Patients with nephropathy assessment, defined as an estimated GFR with result and a urine albumin-to-creatinine ratio (UACR) during the Report Period *or* with the evidence of diagnosis and/or treatment of end-stage renal disease (ESRD) at any time before the end of the Report Period

Patients receiving a qualified retinal evaluation during the Report Period

**Note**: This numerator does *not* include refusals.

Patients with diabetic foot exam during the Report Period

**Note**: This numerator does *not* include refusals.

Patients with comprehensive diabetes care (Documented A1c and Blood Pressure and LDL and Nephropathy Assessment and Retinal Exam and Diabetic Foot Exam).

#### **Logic Description**

*Diabetes definition*: First Purpose of Visit (POV) ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the POV file prior to the Report Period.

*A1c definition*: Searches for most recent A1c test with a result during the Report Period. If none found, CRS searches for the most recent A1c test without a result. A1c defined as: CPT 83036, 83037, 3044F through 3046F, 3047F (old code); LOINC taxonomy; or site-populated taxonomy DM AUDIT HGB A1C TAX.

*BP documented definition*: Having a minimum of 2 BPs documented during the Report Period.

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) BPs and dividing by 3 (or 2).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

Controlled BP definition: CRS uses a mean, as described above. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from BP measurements, it will search for the most recent of any of the following CPT codes documented during the Report Period: BP Documented: 0001F, 2000F, G9273, G9274 or POV ICD-9: V81.1; *or* Systolic 3074F, 3075F, or 3077F *with* Diastolic: 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combinations represent BP less than (<) 140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F *and* 3078F or 3079F; *or* G9273. All other combinations *will not* be included in the Controlled BP numerator.

LDL definition: Finds last test done during the Report Period; defined as CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F, G9271, G9272; LOINC taxonomy; site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX.

Nephropathy assessment definition: (1) Estimated GFR with result during the report period, defined as any of the following: (A) Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or (B) LOINC taxonomy, and (2) Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, defined as any of the following: (A) CPT 82043 WITH 82570; (B) LOINC taxonomy; or (C) site-populated taxonomy BGP QUANT UACR TESTS.

**Note**: Be sure and check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values.

(3) ESRD diagnosis/treatment defined as any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

Qualified retinal evaluation definition: (1) diabetic retinal exam or (2) other eye exam. The following methods are qualifying for this measure: (1) dilated retinal evaluation by an optometrist or ophthalmologist, or (2) seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist, or (3) any photographic method formally validated to seven standard fields (ETDRS).

- Diabetic Retinal Exam: Any of the following during the Report Period: (1) Exam Code 03 Diabetic Eye Exam (dilated retinal examination or formally validated\* ETDRS photographic equivalent), (2) CPT 2022F Dilated retinal eye exam; 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist; 2026F Eye imaging formally validated\* to match the diagnosis from seven standard field stereoscopic photos; S0620 Routine ophthalmological examination including refraction; new patient; S0621 Routine ophthalmological examination including refraction; established patient; S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.
- Other Eye Exam: (1) Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or formally validated\* teleophthalmology retinal evaluation clinics or (2) non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order: Clinic Codes A2 (Diabetic Retinopathy)\*\*, 17, 18; Provider Code 24, 79, 08; CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014.

Bilateral blindness defined as: 1) Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0 through H54.12.

<sup>\*</sup>Validation study properly powered and controlled against the ETDRS gold standard.

<sup>\*\*</sup>Validated photographic (teleophthalmology) retinal surveillance.

Diabetic foot exam definition: (1) Exam Code 28 Diabetic Foot Exam, Complete; (2) non-DNKA visit with a podiatrist (Provider Codes 33, 84 or 25), (3) non-DNKA visit to Podiatry Clinic (Clinic Code 65), or (4) CPT 2028F, G9226.

Bilateral foot amputation definition: CPT 27290.50 through 27295.50, 27590.50 through 27592.50, 27598.50, 27880.50 through 27882.50 (50 modifier indicates bilateral), G9224; 2) Procedure ICD-10: 0Y640ZZ.

Unilateral foot amputation definition: Must have two separate occurrences for either CPT or Procedure codes on 2 different dates of service: (1) CPT 27290 through 27295, 27590 through 27592, 27598, 27880 through 27882, or (2) Procedure ICD-9: 84.10, 84.13 through 84.19; ICD-10: 0Y620ZZ, 0Y630ZZ, 0Y670ZZ, 0Y680ZZ, 0Y6C0Z\*, 0Y6D0Z\*, 0Y6F0ZZ, 0Y6G0ZZ, 0Y6H0Z\*, 0Y6J0Z\*, 0Y6M0Z0, 0Y6N0Z0.

#### **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS code G9226 to diabetic foot exam definition.
- 2. Added HCPCS code G9224 to bilateral foot amputation definition.
- 3. Added HCPCS code G9231 to ESRD definition.
- 4. Added HCPCS codes G9271, G9272 to LDL definition.
- 5. Added HCPCS codes G9273, G9274 to BP documented definition.
- 6. Added HCPCS code G9273 to BP controlled definition.

#### **Patient List Description**

List of diabetic patients with documented tests, if any.

#### **Measure Source**

Foot Exam: HP 2020 D-9

## **Measure Past Performance and Long-Term Targets**

Target	Percent
HP 2020 goal for foot exam	74.8%

```
DU November 25, 2015 Page 9

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Diabetes Comprehensiv	e Care							
	REPORT	%		%	CHG from		%	
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Active Diabetic Pts	144		97			87		
# w/Comp Diabetes								
Care # w/Alc done	10	6.9	1	1.0	+5.9	0	0.0	+6.9
w/ or w/o result	92	63.9	70	72.2	-8.3	52	59.8	+4.1
# w/ BPs documented	120	83.3	78	80.4	+2.9	74	85.1	-1.7
# w/Controlled BP								
<140/90		19.4		20.6			14.9	
# w/ LDL done # w/ est GFR & UACR	78	54.2	46	47.4	+6.7	23	26.4	+27.7
or w/ESRD	53	36.8	11	11.3	+25.5	6	6.9	+29.9
Active Diabetic Pts w	//0							
Hx of Bilateral								
Blindness	141		97			87		
# w/Retinal Evaluatio	n							
-No Refusals		37.6	38	39.2	-1.6	44	50.6	-13.0
Active Diabetic Pts w	/0							
Hx of Bilateral								
Amputation	137		97			87		
# w/Diabetic Foot Exa	m							
-No Refusals	20	14.6	18	18.6	-4.0	16	18.4	-3.8

Figure 2-4: Sample Summary Report, Diabetes Comprehensive Care Topic

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Diabetes Comprehensive Care: List of diabetic patients with documented tests,
if any.
PATIENT NAME
DENOMINATOR
                    HRN COMMUNITY SEX AGE
                     NUMERATOR
PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45
                          Alc: 02/28/15 6.6; BPs: 143/92 UNC; LDL: 10/28/15 119;
EYE: 01/07/15 Cl 18
PATIENT2, TARA 000002 COMMUNITY #1 F 51
                      BP: <140/90: BPs: 118/61; ESRD: 03/03/15 90951; FOOT
AMPUTATION
PATIENT3, BARBIE 000003 COMMUNITY #1 F 52
                           Alc: 04/09/15 6.5; BPs: 148/86 UNC; GFR: 04/09/15 &
UACR: 03/31/15 QUANT UACR; EYE: 03/30/15 Cl 18; FOOT EXAM: 01/07/15 Cl 65
PATIENT4, DONALD 000004 COMMUNITY #1 M 25
                           BILATERAL BLINDNESS
```

Figure 2-5: Sample Patient List, Diabetes Comprehensive Care

#### 2.2.3 Diabetes: Glycemic Control

#### **GPRAMA Measure Description, Good Glycemic Control**

During FY 2015, achieve the target rate of 47.7% for the proportion of patients with diagnosed diabetes who have good glycemic control (defined as A1c less than (<) 8).

#### **Denominators**

All *User Population patients* diagnosed with diabetes prior to the report period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRAMA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever; (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### **Numerators**

Number of patients with a Hemoglobin A1c documented during the Report Period, regardless of result.

*Poor Control*: Total of Poor and Very Poor Control: Patients with A1c greater than (>) 9.5.

*Very Poor Control*: Patients with A1c equal to or greater than (=>) 12.

*Poor Control*: Patients with A1c greater than (>) 9.5 and less than (<) 12.

Fair Control: Patients with A1c equal to or greater than (=>) 8 and less than or equal to (<=) 9.5.

Patients with A1c equal to or greater than (=>) 7 and less than (<) 8.

Good Control: Patients with A1c less than (<) 8. (GPRAMA Numerator)

Patients with A1c less than (<) 7.

Without Result: Patients with A1c documented but no value.

#### **Logic Description**

*Diabetes definition*: First Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Hemoglobin A1c definition: Searches for most recent A1c test with a result during the Report Period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If both tests have a result, the last test done on the visit will be used. If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result. Without result is defined as A1c documented but with no value.

CRS uses the following definitions:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
Hemoglobin A1c	83036, 83037, 3044F-3046F, 3047F (old code) <b>Note</b> : CPT 3044F represents A1c less than (<) 7 and will be included in the A1c less than (<) 7 and A1c less than (<) 8 numerators.	Yes	DM AUDIT HGB A1C TAX

In the CPT Codes column, specific LOINC codes used CRS are located in the *CRS Technical Manual*.

## **Key Logic Changes from CRS Version 14.1**

None.

#### **Patient List Description**

List of diabetic patients with most recent A1c value, if any.

#### **Measure Source**

HEDIS; HP 2020 D-11, D-5

## **Measure Past Performance and Long-Term Targets Hemoglobin A1c Documented**

Performance	Percent
IHS FY 2014 Performance	85.7%
IHS FY 2013 Performance	85.2%
IHS FY 2012 Performance	84.9%
IHS FY 2011 Performance	83.0%
IHS FY 2010 Performance	82.0%
IHS FY 2009 Performance	80.0%
IHS FY 2008 Performance	79.0%
IHS FY 2007 Performance	79.0%
IHS FY 2006 Performance	79.0%
IHS FY 2005 Performance	78.0%
IHS FY 2004 Performance	77.0%
IHS FY 2003 Performance	75.0%
IHS FY 2002 Performance	73.0%
HP 2020 Goal	71.1%

## Good Glycemic Control (A1c less than (<) 8)

Performance	Percent
IHS FY 2014 Performance	48.6%
IHS FY 2013 Performance	48.3%

## Poor Glycemic Control (A1c greater than (>) 9.5)

Performance	Percent
IHS FY 2014 Performance	20.7%
IHS FY 2013 Performance	20.7%
IHS FY 2012 Performance	19.8%
IHS FY 2011 Performance	19.1%
IHS FY 2010 Performance	18.0%
IHS FY 2009 Performance	18.0%
IHS FY 2008 Performance	17.0%
IHS FY 2007 Performance	16.0%
IHS FY 2006 Performance	16.0%
IHS FY 2005 Performance	15.0%
IHS FY 2004 Performance	17.0%

Performance	Percent
IHS FY 2003 Performance	17.0%
IHS FY 2002 Performance	18.0%

## Ideal Glycemic Control (A1c less than (<) 7)

Performance	Percent
IHS FY 2012 Performance	33.2%
IHS FY 2011 Performance	31.9%
IHS FY 2010 Performance	32.0%
IHS FY 2009 Performance	31.0%
IHS FY 2008 Performance	32.0%
IHS FY 2007 Performance	31.0%
IHS FY 2006 Performance	31.0%
IHS FY 2005 Performance	30.0%
IHS FY 2004 Performance	27.0%
IHS FY 2003 Performance	28.0%
IHS FY 2002 Performance	25.0%
HP 2020 Goal	58.9%

DU November 25, 2015 Page 11  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Diabetes: Glycemic	Control							
	REPORT PERIOD	%	PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %
User Pop w/ DM DX								
prior to report								
end date	233		203			180		
# w/Alc done w/								
or w/o result	97	41.6	72	35.5	+6.2	53	29.4	+12.2
# w/A1c =>12	4	1.7	2	1.0	+0.7	3	1.7	+0.1
# w/A1c >9.5								
and <12	15	6.4	4	2.0	+4.5	8	4.4	+2.0
# w/A1c =>8						_		
and =<9.5	11	4.7	18	8.9	-4.1	10	5.6	-0.8
# w/A1c=>7	1-		1-		1 0	_	2 2	. 0 . 5
and <8		6.4		7.4			3.9	
# w/Alc <8		22.7		23.6			16.7	
# w/Alc <7	38	16.3	33	16.3	+0.1	23	12.8	+3.5
# w/Alc w/o Result	14	6.0	0	0.0	+6.0	2	1.1	+4.9

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

147		99			87		
94	63.9	70	70.7	-6.8	52	59.8	+4.2
19	12.9	6	6.1	+6.9	11	12.6	+0.3
4	2.7	2	2.0	+0.7	3	3.4	-0.7
15	10.2	4	4.0	+6.2	8	9.2	+1.0
11	7.5	18	18.2	-10.7	10	11.5	-4.0
15	10.2	15	15.2	-4.9	7	8.0	+2.2
50	34.0	46	46.5	-12.5	29	33.3	+0.7
35	23.8	31	31.3	-7.5	22	25.3	-1.5
14	9.5	0	0.0	+9.5	2	2.3	+7.2
104		76			63		
73	70.2	61	80.3	-10.1	46	73.0	-2.8
3	2.9	1	1.3	+1.6	3	4.8	-1.9
13	12.5	3	3.9	+8.6	7	11.1	+1.4
10	9.6	17	22.4	-12.8	8	12.7	-3.1
12	11.5						+2.0
41					28	44.4	-5.0
29	27.9	28	36.8	-9.0	22	34.9	-7.0
6	5.8	0	0.0	+5.8	0	0.0	+5.8
	94 19 4 15 11 15 50 35 14 104 73 3 13 10 12 41 29	94 63.9 19 12.9 4 2.7 15 10.2 11 7.5 15 10.2 50 34.0 35 23.8 14 9.5 104 73 70.2 3 2.9 13 12.5 10 9.6 12 11.5 41 39.4 29 27.9	94 63.9 70 19 12.9 6 4 2.7 2 15 10.2 4 11 7.5 18 15 10.2 15 50 34.0 46 35 23.8 31 14 9.5 0  104 76  73 70.2 61 3 2.9 1 13 12.5 3 10 9.6 17 12 11.5 12 41 39.4 40 29 27.9 28	94 63.9 70 70.7 19 12.9 6 6.1 4 2.7 2 2.0 15 10.2 4 4.0 11 7.5 18 18.2 15 10.2 15 15.2 50 34.0 46 46.5 35 23.8 31 31.3 14 9.5 0 0.0  104 76  73 70.2 61 80.3 3 2.9 1 1.3 13 12.5 3 3.9 10 9.6 17 22.4 12 11.5 12 15.8 41 39.4 40 52.6 29 27.9 28 36.8	94       63.9       70       70.7       -6.8         19       12.9       6       6.1       +6.9         4       2.7       2       2.0       +0.7         15       10.2       4       4.0       +6.2         11       7.5       18       18.2       -10.7         15       10.2       15       15.2       -4.9         50       34.0       46       46.5       -12.5         35       23.8       31       31.3       -7.5         14       9.5       0       0.0       +9.5         104       76         73       70.2       61       80.3       -10.1         3       2.9       1       1.3       +1.6         13       12.5       3       3.9       +8.6         10       9.6       17       22.4       -12.8         12       11.5       12       15.8       -4.3         41       39.4       40       52.6       -13.2         29       27.9       28       36.8       -9.0	94       63.9       70       70.7       -6.8       52         19       12.9       6       6.1       +6.9       11         4       2.7       2       2.0       +0.7       3         15       10.2       4       4.0       +6.2       8         11       7.5       18       18.2       -10.7       10         15       10.2       15       15.2       -4.9       7         50       34.0       46       46.5       -12.5       29         35       23.8       31       31.3       -7.5       22         14       9.5       0       0.0       +9.5       2         104       76       63         73       70.2       61       80.3       -10.1       46         3       2.9       1       1.3       +1.6       3         13       12.5       3       3.9       +8.6       7         10       9.6       17       22.4       -12.8       8         12       11.5       12       15.8       -4.3       6         41       39.4       40       52.6       -13.2       28 <td>94       63.9       70       70.7       -6.8       52       59.8         19       12.9       6       6.1       +6.9       11       12.6         4       2.7       2       2.0       +0.7       3       3.4         15       10.2       4       4.0       +6.2       8       9.2         11       7.5       18       18.2       -10.7       10       11.5         15       10.2       15       15.2       -4.9       7       8.0         50       34.0       46       46.5       -12.5       29       33.3         35       23.8       31       31.3       -7.5       22       25.3         104       76       63         73       70.2       61       80.3       -10.1       46       73.0         3       2.9       1       1.3       +1.6       3       4.8         13       12.5       3       3.9       +8.6       7       11.1         10       9.6       17       22.4       -12.8       8       12.7         12       11.5       12       15.8       -4.3       6       9.5     &lt;</td>	94       63.9       70       70.7       -6.8       52       59.8         19       12.9       6       6.1       +6.9       11       12.6         4       2.7       2       2.0       +0.7       3       3.4         15       10.2       4       4.0       +6.2       8       9.2         11       7.5       18       18.2       -10.7       10       11.5         15       10.2       15       15.2       -4.9       7       8.0         50       34.0       46       46.5       -12.5       29       33.3         35       23.8       31       31.3       -7.5       22       25.3         104       76       63         73       70.2       61       80.3       -10.1       46       73.0         3       2.9       1       1.3       +1.6       3       4.8         13       12.5       3       3.9       +8.6       7       11.1         10       9.6       17       22.4       -12.8       8       12.7         12       11.5       12       15.8       -4.3       6       9.5     <

Figure 2-6: Sample Report, Diabetes: Glycemic Control Topic

P	PATIENT5, NADINE	000005 COMMUNITY #1	F	61
U	JP,AD,AAD	02/01/15 A1c:	6.5	
P	PATIENT6, RUTH	000006 COMMUNITY #1	F	64
U	JP			

Figure 2-7: Sample Patient List, Diabetes: Glycemic Control

#### 2.2.4 Diabetes: Blood Pressure Control

#### **GPRA Measure Description**

During FY 2015, achieve the target rate of 63.8% for the proportion of patients with diagnosed diabetes who have achieved blood pressure control (defined as less than (<)140/90).

#### **Denominators**

All *User Population patients* diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM-related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### **Numerators**

Patients with BP documented during the report period.

Patients with controlled BP, defined as less than (<) 140/90, i.e., the mean systolic value is less than 140 and the mean diastolic value is less than 90 (GPRA Numerator).

Patients with BP that is not controlled.

#### **Logic Description**

*Diabetes definition*: First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

BP documented definition: CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of the last 2 BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F-3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

Controlled BP definition: CRS uses a mean, as described above where BP is less than (<)140/90. If the mean systolic and diastolic values do not *both* meet the criteria for controlled, then the value is considered not controlled.

BP documented and Controlled BP: If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented during the Report Period: BP Documented: CPT 0001F, 2000F, G9273, G9274 or ICD-9: POV V81.1; or Systolic: CPT 3074F, 3075F or 3077F with Diastolic: CPT 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used. The following combinations represent BP less than (<)140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F and 3078F or 3079F; or G9273. All other combinations will not be included in the Controlled BP numerator.

CRS uses the following definition:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX

In the LOINC Codes column, specific LOINC codes by CRS are location in the CRS Technical Manual.

#### **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS codes G9273, G9274 to BP documented definition.
- 2. Added HCPCS code G9273 to BP controlled definition.

## **Patient List Description**

List of diabetic patients with BP value, if any.

#### **Measure Source**

HP 2020 D-7

## **Measure Past Performance and Long-Term Targets Controlled BP**

Performance	Percent
IHS FY 2014 Performance	63.8%
IHS FY 2013 Performance	64.6%
Former definition of BP less than (<) 130/80:	
IHS FY 2012 Performance	38.9%
IHS FY 2011 Performance	37.8%
IHS FY 2010 Performance	38.0%
IHS FY 2009 Performance	37.0%
IHS FY 2008 Performance	38.0%
IHS FY 2007 Performance	39.0%
IHS FY 2006 Performance	37.0%
IHS FY 2005 Performance	37.0%
IHS FY 2004 Performance	35.0%
IHS FY 2003 Performance	37.0%
IHS FY 2002 Performance	36.1%
HP 2020 Goal	57.0%

#### **BP Assessed**

Performance	Percent
IHS FY 2012 Performance	88.5%
IHS FY 2011 Performance	87.9%
IHS FY 2010 Performance	89.0%
IHS FY 2009 Performance	88.0%
IHS FY 2008 Performance	89.0%
IHS FY 2005 Performance	89.0%

DU November 25, 2015 Page 13

\*\*\* IHS 2015 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL

Previo	us Year	Period	l: Jan 01	, 201	Dec 31, 20 4 to Dec 31 to Dec 31,	1, 2014		
Diabetes: Blood Pressure Control								
	REPORT PERIOD		PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %
User Pop w/ DM DX pr to report period			202			180		
<pre># w/ BPs Documented # w/controlled BP</pre>	132	57.6	88	43.6	+14.1	84	46.7	+11.0
<pre># w/controlled BP &lt; 140/90 # w/Not controlled</pre>	32	14.0	24	11.9	+2.1	18	10.0	+4.0
# W/NOC CONCLOTTED  BP	100	43.7	64	31.7	+12.0	66	36.7	+7.0
Active Diabetic Pts (GPRA)	144		97			87		
# w/ BPs Documented # w/Controlled BP	120	83.3	78	80.4	+2.9	74	85.1	-1.7
< 140/90 (GPRA)	28	19.4	20	20.6	-1.2	13	14.9	+4.5
# w/Not controlled BP	92	63.9	58	59.8	+4.1	61	70.1	-6.2
Active Adult Diabeti Patients	.c 102		75			63		
<pre># w/ BPs Documented # w/Controlled BP</pre>	82	80.4	61	81.3	-0.9	56	88.9	-8.5
<pre># w/concrotted Br &lt; 140/90 # w/Not controlled</pre>	20	19.6	14	18.7	+0.9	8	12.7	+6.9
BP Controlled	62	60.8	47	62.7	-1.9	48	76.2	-15.4

Figure 2-8: Sample Report, Diabetes: Blood Pressure Control Topic

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Diabetes: Blood Pressure Control: List of diabetic patients with BP value, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45
UP, AD, AAD 133/82 CON
PATIENT2, TARA 000002 COMMUNITY #1 F 51 3074F/3080F UNC UP,AD,AAD PATIENT3, BOBBIE 000003 COMMUNITY #1 F 52 UP,AD,AAD 138/66 CON

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

PATIENT4, WINONA	000004 COMMUNITY #1	F	53		
PATIENT5, NADINE	000005 COMMUNITY #1	F	61		
UP,AD,AAD PATIENT6,RUTH	159/86 UNC 000006 COMMUNITY #1	F	64		
UP	139/74 CON	-	0 -		

Figure 2-9: Sample Patient List, Diabetes: Blood Pressure Control

#### 2.2.5 Diabetes: LDL Assessment

#### **GPRA Measure Description**

During FY 2015, achieve the target rate of 71.8% for the proportion of patients with diagnosed diabetes who are assessed for dyslipidemia (LDL cholesterol).

#### **Denominators**

All *User Population patients* diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are age 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### **Numerators**

Patients with LDL completed during the Report Period, regardless of result. (GPRA Numerator)

Patients with *LDL results* less than (<) 130.

- a. Patients with LDL results less than (<) 100
- b. Patients with LDL results 100–129

#### **Logic Description**

*Diabetes definition*: First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

LDL definition: Searches for most recent LDL test with a result during the Report Period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

CRS uses the following to define the tests:

Subject Defined	CPT Codes	LOINC Codes.	Taxonomy
Creatinine (for Active Adult Diabetic denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
LDL Done	80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F, G9271, G9272	Yes	DM AUDIT LDL CHOLESTEROL TAX
LDL less than (<)130	3048F, 3049F		Tests in above taxonomy with LDL less than (<)130
LDL less than (<)100	3048F, G9271		Tests in above taxonomy with LDL less than (<)100

In the LOINC Codes column, specific LOINC codes used by CRS are located in the CRS Technical Manual.

### **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS codes G9271, G9272 to LDL definition.
- 2. Added HCPCS codes G9271 to LDL < 100 definition.

#### **Patient List Description**

List of diabetic patients with documented LDL cholesterol test, if any.

#### **Measure Source**

HP 2010 12-15

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	73.4%
IHS FY 2013 Performance	72.7%
IHS FY 2012 Performance	71.0%
IHS FY 2011 Performance	68.7%
IHS FY 2010 Performance	67.0%
IHS FY 2009 Performance	65.0%
IHS FY 2008 Performance	63.0%
IHS FY 2007 Performance	61.0%
IHS FY 2006 Performance	60.0%
IHS FY 2005 Performance	53.0%
IHS FY 2004 Performance	53.0%
IHS FY 2003 Performance	47.5%
IHS FY 2002 Performance	43.7%

DU November 25, 2015 Page 15  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010  Diabetes: LDL Assessment									
	REPORT	%	PREV YR	왕	CHG from	BASE			
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %	
# w/ LDL done	84	36.7	48	23.8	+12.9	23	12.8	+23.9	
# w/LDL <130		25.3		19.8	+5.5	15	8.3	+17.0	
A. # w/LDL =<100	37	16.2							
B. # w/LDL 101-129	17	7.4	9	4.5	+3.0	7	3.9	+3.5	
Active Diabetic Pts									
(GPRA)	144		97			87			
# w/ LDL done									
(GPRA)	78	54.2	46	47.4	+6.7	23	26.4	+27.7	
# w/LDL <130	54	37.5	38	39.2	-1.7	15	17.2	+20.3	
A. # w/LDL =<100	35	24.3	30	30.9	-6.6			+15.1	
B. # w/LDL 101-129	15	10.4	8	8.2	+2.2	7	8.0	+2.4	
Active Adult Diabeti	.C								
Patients	102		75			63			
# w/ LDL done	60	58.8	43	57.3	+1.5	21	33.3	+25.5	
# w/LDL <130	41	40.2	35	46.7	-6.5	13	20.6	+19.6	

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

A. # w/LDL =<100	26	25.5	26	34.7	-9.2	8	12.7	+12.8	
B. # w/LDL 101-129	12	11.8	9	12.0	-0.2	5	7.9	+3.8	

Figure 2-10: Sample Report, Diabetes: LDL Assessment

Figure 2-11: Sample Patient List, Diabetes: LDL Assessment

# 2.2.6 Diabetes: Nephropathy Assessment

#### **GPRA Measure Description**

During FY 2015, achieve the target rate of 60.0% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

#### **Denominators**

All *User Population patients* diagnosed with diabetes prior to the Report Period.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever (GPRA Denominator).

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are aged 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5.

#### **Numerator**

Patients with nephropathy assessment, defined as an estimated GFR with result and a urine albumin-to-creatinine ratio (UACR) during the Report Period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the Report Period (GPRA Numerator).k

## **Logic Description**

*Diabetes definition*: First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

Nephropathy assessment definition:

- Estimated GFR with result during the Report Period and Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, *or*
- ESRD diagnosis/treatment defined as any diagnosis ever.

CRS uses the following to define the tests/diagnoses:

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
Creatinine (for Active Adult Diabetic Denominator)	CPT codes are not included since they do not store the result, which is used in this topic	Yes	DM AUDIT CREATININE TAX
Estimated GFR		Yes	BGP GPRA ESTIMATED GFR TAX
Urine Albumin-to- Creatinine Ratio (UACR)	<b>CPT</b> : 82043 WITH 82570	Yes	BGP QUANT UACR TESTS Note: Be sure and check with your laboratory supervisor that the names you add to your taxonomy reflect quantitative test values

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
End Stage Renal Disease	CPT: 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918 through 90925, 90935, 90937, 90994, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old code), G0393 (old code), G0393 (old code), G0393 (old code), G9231, S2065, or S9339 POV: ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56*; ICD-10: N18.6, Z48.22, Z49.*, Z91.15, Z94.0, Z99.2 Procedure: ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6*		

In the LOINC Codes column, specific LOINC codes used by CRS are located in the CRS Technical Manual.

# **Key Logic Changes from CRS Version 14.1**

1. Added HCPCS code G9231 to ESRD defintion.

# **Patient List Description**

List of diabetic patients with nephropathy assessment, if any.

#### **Measure Source**

HP 2010 5-11

### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	60.0%
IHS FY 2013 Performance	68.2%
IHS FY 2012 Performance	66.7%

Performance	Percent
IHS FY 2011 Performance	56.5%
IHS FY 2010 Performance	55.0%
IHS FY 2009 Performance	50.0%
IHS FY 2008 Performance	50.0%
IHS FY 2007 Performance (new baseline established; revised standards of care resulted in revised measure definition)	40.0%
IHS FY 2006 Performance (measure definition was different from current definition)	55.0%
IHS FY 2005 Performance (measure definition was different from current definition)	47.0%
IHS FY 2004 Performance (measure definition was different from current definition)	42.0%
IHS FY 2003 Performance (measure definition was different from current definition)	37.5%
IHS FY 2002 Performance (measure definition was different from current definition)	35.0%

DU November 25, 2015 Page 17  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Diabetes: Nephropath	ny Assess	ment							
					CHG from PREV YR %				
User Pop w/ DM DX pr to Report Period			202			180			
# w/ est GFR & quant UP assmt or w/ESRD	55	24.0	16	7.9	+16.1	8	4.4	+19.6	
Active Diabetic Pts (GPRA)	144		97			87			
# w/ est GFR & quant UP assmt or w/ESRD (GPRA)	53	36.8	11	11.3	+25.5	6	6.9	+29.9	
Active Adult Diabeti Patients	.c 102		75			63			
# w/ est GFR & quant UP assmt or									

w/ESRD	41 40.2	6 8.0	+32.2	4	6.3	+33.8	
--------	---------	-------	-------	---	-----	-------	--

Figure 2-12: Sample Report, Diabetes: Nephropathy Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Diabetes: Nephropathy Assessment: List of diabetic patients with nephropathy assessment, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45 UP,AD,AAD

PATIENT2,TARA

000002 COMMUNITY #1 F 51

UP,AD,AAD

GFR: 08/06/15 & UACR: 08/06/15 CPT 82043/82570

PATIENT3,BOBBIE

UP,AD,AAD

GFR: 09/09/15 & QUANT UP: 03/31/15 QUANT URINE UP,AD,AAD PROTEIN PATIENT4, WINONA 000004 COMMUNITY #1 F 53 PATIENT5, NADINE 000005 COMMUNITY #1 F 61
UP, AD, AAD ESRD: 03/03/15 CPT 9
PATIENT6, RUTH 000006 COMMUNITY #1 F 64 ESRD: 03/03/15 CPT 90967 UP PATIENT7, DANIELLE 000007 COMMUNITY #1 F 79 ESRD: 11/01/15 POV V56.8

Figure 2-13: Sample Patient List, Diabetes: Nephropathy Assessment

# 2.2.7 Diabetic Retinopathy

### **GPRA Measure Description**

During FY 2015, achieve the target rate of 60.1% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

#### **Denominators**

All *User Population patients* diagnosed with diabetes prior to the Report Period, without a documented history of bilateral blindness.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, without a documented history of bilateral blindness. (GPRA Denominator)

Active Adult Diabetic patients, defined by meeting the following criteria: (1) who are 19 or older at the beginning of the Report Period, (2) whose first ever DM diagnosis occurred prior to the Report Period; (3) who had at least two DM related visits ever, (4) at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period; and (5) never have had a creatinine value greater than (>) 5, without a documented history of bilateral blindness.

#### Numerators

Patients receiving a qualified retinal evaluation during the Report Period.

**Note**: This numerator does not include refusals. (GPRA Numerator)

- a. Patients receiving diabetic retinal exam during the Report Period
- b. Patients receiving other eye exams during the Report Period
- c. Patients with a JVN visit during the Report Period.
- d. Patients with an Ophthalmology visit during the Report Period.
- e. Patients with an Optometry visit during the Report Period.

# **Logic Description**

*Diabetes definition*: First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Serum creatinine definition (used with Active Adult Diabetic denominator): Site-populated taxonomy DM AUDIT CREATININE TAX; or LOINC taxonomy (NOTE: CPT codes are not included since they do not store the result, which is used in this topic.).

Qualified retinal evaluation definition: (1) Diabetic retinal exam or (2) other eye exam, as shown below. The following methods are qualifying for this measure:

- Dilated retinal evaluation by an optometrist or ophthalmologist
- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist
- Any photographic method validated to sevenk standard fields (ETDRS).

CRS searches in the following order for:

# Diabetic Retinal Exam (any of the following during the report period)

Exam	CPT Codes	Other Codes
Diabetic Retinal Exam	2022F, 2024F, 2026F, S0620, S0621, S3000	Exam: 03 (dilated retinal examination or formally validated* photographic equivalent)

# Other Eye Exam (any of the following during the report period)

Exam	CPT Codes	Other Codes
Non-Did Not Keep Appointment (DNKA) visit to ophthalmology or optometry or formally validated* tele-ophthalmology retinal evaluation clinics		Clinic codes: A2 (Diabetic Retinopathy)**, 17, 18
Non-DNKA visit to an optometrist or ophthalmologist	67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014	Provider Codes: 24, 79, 08

<sup>\*</sup>Validation study properly powered and controlled against the ETDRS gold standard.

# JVN visit (any of the following during the report period)

Subject Defined	Other Codes
JVN	Clinic code: A2

### Ophthalmology visit (any of the following during the report period)

Subject Defined	Other Codes
1 37	Clinic code: A2 Provider Code: 79

# Optometry visit (any of the following during the report period)

Subject Defined	Other Codes
1 - 1 3	Clinic code: 18 Provider Code: 08, 24

<sup>\*\*</sup>Validated photographic (teleophthalmology) retinal surveillance.

#### Bilateral Blindness Exclusion

Subject Defined	Other Codes
Bilateral blindness	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 369.01, 369.03, 369.04; ICD- 10: H54.0 through H54.12

# **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of diabetic patients with qualified retinal evaluation, if any.

#### **Measure Source**

HP 2020 D-10

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	59.9% (National rate)
IHS FY 2013 Performance	57.6% (National rate)
IHS FY 2012 Performance	55.7% (National rate)
IHS FY 2011 Performance	54.8% (National rate)
IHS FY 2010 Performance	53.0% (National rate)
IHS FY 2009 Performance	51.0% (National rate)
IHS FY 2008 Performance	50.0% (National rate)
IHS FY 2007 Performance	49.0% (National rate)
IHS FY 2006 Performance	49.0% (National Rate) 52.0% (Designated Sites Rate)
IHS FY 2005 Performance	50.0% (National Rate) 50.0% (Designated Sites Rate)
IHS FY 2004 Performance	47.0% (National Rate) 55.0% (Designated Sites Rate)
IHS FY 2003 Performance	49.0%
IHS FY 2002 Performance	49.0%
HP 2020 Goal	58.7%

```
DU November 25, 2015 Page 19

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014
```

Baselin	e Pe	eriod:	Jan 01,	2010	to Dec 31,	2010			
Diabetic Retinopathy									
	ORT IOD		PREV YR PERIOD		CHG from PREV YR %			CHG from BASE %	
User Pop w/ DM DX prior to report perod w/o Hx o Bilateral Blindness	f 227		200			180			
<pre># w/Retinal Evaluation   -No Refusals A. # w/ DM Retinal</pre>	64	28.2	46	23.0	+5.2	54	30.0	-1.8	
exam B. # w/Other	7	3.1	6	3.0	+0.1	6	3.3	-0.2	
Eye Exams	57	25.1	40	20.0	+5.1	48	26.7	-1.6	
Active Diabetic Pts w/o of Bilateral Blindness (GPRA)	Hx 141		97			87			
# w/Retinal Evaluation -No Refusals (GPRA) A. # w/ DM Retinal	53	37.6	38	39.2	-1.6	44	50.6	-13.0	
exam B. # w/Other	7	5.0	6	6.2	-1.2	6	6.9	-1.9	
Eye Exams C. # w/JVN visit		32.6		33.0			43.7	-11.1 +0.7	
D. # w/Ophthalmology visit		15.6						-9.7	
E. # w/ Optometry visit	33	23.4	36	37.1	-13.7	31	35.6	-12.2	
Active Adult Diabetic Pa w/o Hx of Bilateral	tien	ıts							
Blindness	99		75			63			
# w/Retinal Evaluation -No Refusals A. # w/ DM Retinal	38	38.4	31	41.3	-2.9	39	61.9	-23.5	
exam	6	6.1	4	5.3	+0.7	6	9.5	-3.5	
B. # w/Other Eye Exams	32	32.3	27	36.0	-3.7	33	52.4	-20.1	

Figure 2-14: Sample Report, Diabetic Retinopathy

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Diabetic Retinopathy: List of diabetic patients with qualified retinal
evaluation, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

```
UP, AD, AAD
                             Eval: 01/07/15 Cl 18; Optom: 01/07/15 Cl 18
                       000002 COMMUNITY #1 F 51
PATIENT2, TARA
UP,AD,AAD
                       000003 COMMUNITY #1 F 52
PATIENT3, BOBBIE
UP, AD, AAD
                            Eval: 05/29/15 Cl 17; Ophth: 05/29/15 Cl 17
PATIENT4, WINONA
                       000004 COMMUNITY #1 F 53
                       000005 COMMUNITY #1 F 61
PATIENT5, NADINE
UP,AD,AAD
                            Eval: 02/06/15 Cl A2; JVN: 02/06/15 Cl A2
PATIENT6, RUTH
                       000006 COMMUNITY #1 F 64
PATIENT7, JONELLE
                       000007 COMMUNITY #1 F 69
                             03/29/15 Diab Eye Ex
UP, AD, AAD
```

Figure 2-15: Sample Patient List, Diabetic Retinopathy

# 2.2.8 RAS Antagonist Use in Diabetic Patients

#### **Denominator**

Active Diabetic patients with HTN, defined as all Active Clinical patients diagnosed with diabetes and hypertension prior to the Report Period, AND at least two visits during the Report Period, AND two DM-related visits ever, and no documented history of ESRD.

#### **Numerators**

Patients receiving a RAS Antagonist medication during the Report Period.

Patients with contraindication/previous adverse reaction to RAS Antagonist therapy.

#### **Logic Description**

*Diabetes definition*: First Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report Period.

Hypertension definition: Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 401.\*; ICD-10: I10 prior to the Report Period, and at least one hypertension POV during the Report Period.

ESRD diagnosis/treatment definition: Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

#### **RAS Antagonist Numerator Logic**

Renin Angiotensin System (RAS) Antagonist medication codes defined with medication taxonomy BGP PQA RASA MEDS.

ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Lisinopril-hydrochlorothiazide, Moexipril-hydrochlorothiazide, Quinapril-hydrochlorothiazide, Trandolapril-verapamil).

ARB medications are: Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan).

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Irbesartan-hydrochlorothiazide, Losartan-hydrochlorothiazide, Olmesartan-amlodipine-hydrochlorothiazide, Olmesartan-hydrochlorothiazide, Telmisartan-hydrochlorothiazide, Valsartan-hydrochlorothiazide).

Direct Renin Inhibitor medications are: Direct Renin Inhibitors (Aliskiren).

Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-hydrochlorothiazide, Aliskiren-hydrochlorothiazide, Aliskiren-valsartan).

CRS uses the following codes to define contraindications to ACE inhibitors/ARBs.

Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		POV or Problem List: At least two visits during the Report Period with ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 666.*3, 667.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 674.*3, 675.*3, 676.*3, 678.*3, 679.*3, V22.0 through V23.9, V28.81, V28.82, V28.89, V72.42, V89.01 through V89.09; ICD-10: O00.*, O01.*, O03.1, O03.31 through O03.83, O04.6, O04.81 through O04.83, Z33.2 to abortion definition. (3) Added ICD-10 POV code O03.9 to miscarriage definition. (4) Added ICD-10 POV codes O09.00 through O10.02, O10.111 through O10.12, O10.211 through O10.32, O10.411 through O10.42, O10.911 through O10.92, O11.1 through O15.1, O15.9 through O24.02, O24.111 through O24.12, O24.311 through O24.32, O24.41*, O24.811 through O24.82, O24.911 through O24.92, O25.10 through O25.2, O26.00 through O26.62, O26.711 through O26.72, O26.811 through O26.93, O29.011 through O30.93, O31.* through O48.*, O60.0*, O61.* through O66.*, O68, O69.*, O71.00 through O75.81, O75.89, O75.9, O76 through O75.81, O75.89, O75.9, O76 through O77.*, O88.011 through O88.02, O88.111 through O88.12, O88.211 through O88.22, O88.311 through O88.32, O88.811 through O88.82, O90.3, O91.011 through O91.019, O91.111 through O91.119, O91.211 through O91.219,

Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		O92.011 through O92.019, O92.20, O92.29, O98.011 through O98.02, O98.111 through O98.12, O98.211 through O98.22, O98.311 through O98.32, O98.411 through O98.42, O98.511 through O98.52, O98.611 through O98.62, O98.711 through O98.72, O98.811 through O98.82, O98.911 through O99.02, O99.011 through O99.02, O99.111 through O99.12, O99.210 through O99.214, O99.280 through O99.284, O99.310 through O99.314, O99.320 through O99.324, O99.330 through O99.34, O99.340 through O99.344, O99.350 through O99.354, O99.411 through O99.52, O99.611 through O99.62, O99.711 through O99.72, O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840 through O99.844, O99.89, O9A.111 through O9A.12, O9A.211 through O9A.22, O9A.311 through O9A.22, O9A.311 through O9A.32, O9A.411 through O9A.42, O9A.511 through O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion (defined below) occurring after the second pregnancy POV.

Contraindication to RAS Antagonist (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy	<b>Abortion:</b> Any of the following: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59856, 59857, S2260-S2267	Abortion: Any of the following POVs: ICD-9: 635*, 636*, or 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedures: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z
Pregnancy	<b>Miscarriage:</b> Any of the following: 59812, 59820, 59821, 59830	<b>Miscarriage:</b> Any of the following POVs: ICD-9: 630, 631, 632, 633*, or 634*; ICD-10: O03.9
Breastfeeding		POV: ICD-9: V24.1; ICD-10: Z39.1 during the Report Period  Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		Refusal: NMI (not medically indicated) refusal for any RAS Antagonist at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to RAS Antagonists.

# **Adverse Drug Reaction/Allergy to RAS Antagonists**

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
Entry in ART (Patient Allergies File): "ace inhibitor", "ACEI", "Angiotensin Receptor Blocker" or "ARB"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3 or V14.8; ICD-10: Z88.8: "ace i*", "ACEI", "Angiotensin Receptor Blocker" or "ARB"

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS code G9231 to ESRD definition.
- 2. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.
- 3. Updated BGP PQA RASA MEDS taxonomy.

#### **Patient List Description**

List of diabetic patients with hypertension, with RAS Antagonist medication, contraindication, or ADR, if any.

#### **Measure Source**

PQA (Pharmacy Quality Alliance)

### Measure Past Performance and Long-Term Targets

None

DU November 25, 2015 Page 24  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010					
RAS Antagonist Use :			% CHG from PREV YR %	BASE S	& CHG from BASE %
Active Diabetic Pts w/ HTN	79	57		54	
<pre># w/RAS Antagonist   Rx # w/contra/ADR</pre>	55 69 14 17		84.2 -14.6 3.5 +14.2		

Figure 2-16: Sample Report, ACEI/ARB Use in Diabetic Patients

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

ACEI/ARB Use in Diabetic Patients: List of diabetic patients with
hypertension, with RAS Antagonist medication, contraindication, or ADR, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR
```

```
000001 COMMUNITY #1 F 20
PATIENT1, DEBORAH
                             ACEI/ARB Contra pregnant
                       000002 COMMUNITY #1 F 44
PATIENT2, TARA
                             06/05/15
AD
PATIENT3, BOBBIE
                       000003 COMMUNITY #1 F 45
                             01/29/15
PATIENT4, WINONA
                       000004 COMMUNITY #1 F 57
                             ACEI/ARB Allergy: 05/05/13 ADR POV 995.2 + E942.6
                       000005 COMMUNITY #1 F 57
PATIENT5, NADINE
PATIENT6, RUTH
                       000006 COMMUNITY #1 F 61
                             09/22/15
PATIENT7, JONELLE
                       000007 COMMUNITY #1 M 25
                             06/01/15 ACEI/ARB Contra POV 425.1
```

Figure 2-17: Sample Patient List: ACEI/ARB Use in Diabetic Patients

#### 2.2.9 Diabetes: Access to Dental Services

#### **Denominator**

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

#### **Numerators**

Patients with documented dental visit during the Report Period.

**Note**: This numerator does *not* include refusals.

#### **Logic Description**

*Diabetes definition:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Dental visit definition:* For non-CHS dental visits, searches for Dental ADA codes 0000, 0190, or 0191; CPT codes D0190 or D0191; Exam 30; or POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21. For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

### **Key Logic Changes from CRS Version 14.1**

None.

#### **Patient List Description**

List of diabetic patients with documented dental visit, if any.

#### **Measure Source**

HP 2020 D-8

#### **Measure Past Performance and Long-Term Targets:**

Past Performance	Percent
IHS FY 2005 Performance	39.0%
IHS FY 2004 Performance	37.0%
IHS FY 2003 Performance	36.0%
IHS FY 2002 Performance	36.0%
HP 2020 Goal	61.2%

#### **Performance Improvement Tip**

If your facility's dental services are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```
DU
                           November 25, 2015
                                                                 Page 26
      *** IHS 2015 Selected Measures with Community Specified Report ***
                           DEMO INDIAN HOSPITAL
                Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Diabetes: Access to Dental Services
                   REPORT
                             % PREV YR
                                          % CHG from BASE
                                                                % CHG from
                   PERIOD PERIOD
                                            PREV YR % PERIOD
                                                                   BASE %
Active Diabetic Pts
                     144
                                     97
                                                           87
# w/dental visit in
                                     20 20.6
 past yr-No Refusals 17 11.8
                                                 -8.8
                                                          18 20.7
                                                                       -8.9
```

Figure 2-18: Sample Report, Diabetes and Dental Access

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Diabetes: Access to Dental Services: List of diabetic patients and documented dental visit, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR

PATIENT1, DEBORAH 000001 COMMUNITY #1 F 45
AD 03/03/15 ADA 0000
PATIENT2, TARA 000002 COMMUNITY #1 F 51
AD
```

000003 COMMUNITY #1 F	52
01/06/15 ADA 0190	
000004 COMMUNITY #1 F	61
000005 COMMUNITY #1 F	68
000006 COMMUNITY #1 F	69
03/29/15 ADA 0000	
	01/06/15 ADA 0190 000004 COMMUNITY #1 F 000005 COMMUNITY #1 F 000006 COMMUNITY #1 F

Figure 2-19: Sample Patient List, Diabetes and Dental Access

# 2.3 Dental Measure Topics

#### 2.3.1 Access to Dental Services

# **GPRA Measure Description**

During FY 2015, achieve the target rate of 27.9% for the proportion of patients who receive dental services.

#### **Denominators**

All patients in the *User Population*. Broken down by age groups (0 through 5, 6 through 21, 22 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)74). (GPRA Denominator)

#### **Numerators**

Patients with documented dental visit during the Report Period.

Note:	This numerator does <i>not</i> include refusals. (GPRA
	Numerator)

#### **Logic Description**

*Dental visit definition:* For non-CHS dental visits, searches for Dental ADA codes 0000, 0190, or 0191; CPT codes D0190 or D0191; Exam 30; or POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21. For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

#### **Key Logic Changes from CRS Version 14.1**

None.

#### **Patient List Description**

List of patients with documented dental visit and date.

#### **Measure Source**

HP 2020 OH-7

#### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	28.8%
IHS FY 2013 Performance	28.3%
IHS FY 2012 Performance	28.8%
IHS FY 2011 Performance	26.9%

Performance	Percent
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	25.0%
IHS FY 2008 Performance	25.0%
IHS FY 2007 Performance	25.0%
IHS FY 2006 Performance	23.0%
IHS FY 2005 Performance	24.0%
IHS FY 2004 Performance	24.0%
IHS FY 2003 Performance	25.0%
IHS FY 2002 Performance	24.9%
HP 2020 Goal	49.0%

### **Performance Improvement Tip**

If your facility's dental services are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```
DII
                                                                     Page 28
                             November 25, 2015
       *** IHS 2015 Selected Measures with Community Specified Report ***
                             DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Access to Dental Services
                              % PREV YR
                                             % CHG from BASE
                                                                    % CHG from
                    REPORT
                    PERIOD
                                 PERIOD
                                                PREV YR % PERIOD
                                                                      BASE %
# User Pop
(GPRA)
                     2,896
                                    2,456
                                                           2,346
# w/dental visit in
past yr-No Refusals
 (GPRA)
                       252
                             8.7
                                      201
                                            8.2
                                                    +0.5
                                                             207
                                                                  8.8
                                                                           -0.1
```

Figure 2-20: Sample Report, Access to Dental Services

```
DU November 25, 2015 Page 29

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Access to Dental Services (con't)

TOTAL USER POPULATION

Age Distribution
```

	0-5	6-21	22-34	35-44	45-54	55-74	>74 yrs	
	0 5	0 21	22 31	33 11	15 51	33 / 1	7,1,115	
CURRENT REPORT PERIOD								
Total # User Pop	355	759	577	407	397	411	81	
# w/dental visit in past								
Refusals (GPRA)	25	71	63	35	32	25	1	
% w/dental visit in past	yr-N	o						
Refusals (GPRA)	7.0	9.4	10.9	8.6	8.1	6.1	1.2	
PREVIOUS YEAR PERIOD								
Total # User Pop	361	704	517	332	284	292	56	
# w/dental visit in past	yr-N	o						
Refusals (GPRA)	19	59	46	24	24	25	4	
% w/dental visit in past								
Refusals (GPRA)	5.3	8.4	8.9	7.2	8.5	8.6	7.1	
CHANGE FROM PREV YR %								
w/dental visit in past y	r-No							
Refusals (GPRA)	+1.8	+1.0	+2.0	+1.4	-0.4	-2.5	-5.9	
BASELINE REPORT PERIOD								
Total # User Pop	363	728	455	293	228	236	52	
# w/dental visit in past	yr-N	o						
Refusals (GPRA)			39	31	27	20	3	
% w/dental visit in past	yr-N	o						
Refusals (GPRA)	4.7	9.6	8.6	10.6	11.8	8.5	5.8	
CHANGE FROM BASE YR %								
w/dental visit in past y	r-No							
Refusals (GPRA)		-0.3	+2.3	-2.0	-3.8	-2.4	-4.5	

Figure 2-21: Sample Age Breakdown Report, Access to Dental Services

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Access to Dental Service: List of patients with documented dental visit and date. (con't) HRN COMMUNITY SEX AGE PATIENT NAME DENOMINATOR NUMERATOR PATIENT10, JOHN 000010 COMMUNITY #1 M 17 UP 01/03/15 ADA 0190 PATIENT11, HOWARD 000011 COMMUNITY #1 M 25
UP 01/24/15 ADA 0000
PATIENT12, JAMES 000012 COMMUNITY #1 M 31 UP 02/19/15 ADA 0000 PATIENT13,STEVEN 000013 COMMUNITY #1 M 32 02/19/15 ADA 0000 01/24/15 ADA 0000 UP 01/24/15 ADA 0000 PATIENT14,EDWARD 000014 COMMUNITY #1 M 32 06/10/15 ADA 0000 PATIENT15, DAVID 000015 COMMUNITY #1 M 33 04/10/15 ADA 0190

Figure 2-22: Sample Patient List, Access to Dental Services

#### 2.3.2 Dental Sealants

### **GPRA Measure Description**

During FY 2015, achieve the target rate of 14.1% for the proportion of patients with at least one or more intact dental sealants.

#### **Denominator**

User Population patients ages 2 through 15. Broken down by age groups: 3 through 5, 6 through 9, 10 through 12, 13 through 15, and 5 through 19 (GPRA Denominator)

No denominator. This measure is a total count only, not a percentage.

#### **Numerators**

Patients with at least one or more intact dental sealants (GPRA Numerator) For patients meeting the *User Population* definition, the total number of dental sealants during the report period.

**Note**: This numerator does not include refusals.

- a. Dental sealants in patients 2 through 15 years.
- b. Dental sealants in patients greater than (>) 15 yrs.

Age breakouts are based on Healthy People 2020 age groups for dental sealants.

# **Logic Description**

Age of the patient is calculated at the beginning of the report period.

Sealants definition: Dental ADA Code 1351 or 1352 or CPT Code D1351 or D1352 documented during the Report Period or Dental ADA code 0007 documented during the past 3 years from the end of the Report Period, as long as the 007 code is not documented on the same visits as 1351, 1352, D1351, or D1352. If both ADA and CPT codes are found on the same visit, only the ADA will be counted.

For the count measure, only two sealants per tooth will be counted during the Report Period. Each tooth is identified by the data element Operative Site in RPMS.

# **Key Logic Changes from CRS Version 14.1**

1. Added new age group 5 through 19.

#### **Patient List Description**

List of patients with intact dental sealants.

#### **Measure Source**

HP 2020 OH-2

### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	14.6%
IHS FY 2013 Performance	13.9%

Performance	# of Sealants
IHS FY 2012 Performance	295,734
IHS FY 2011 Performance	276,893
IHS FY 2010 Performance	275,459
IHS FY 2009 Performance	257,067
IHS FY 2008 Performance	241,207
IHS FY 2007 Performance	245,449
IHS FY 2006 Performance	246,645
IHS FY 2005 Performance	249,882
IHS FY 2004 Performance	230,295
	287,158
IHS FY 2003 Performance	232,182
IHS FY 2002 Performance	227,945
IHS FY 2001 Performance	212,612

For the IHS FY 2004 Performance, # of Sealants, please note this was reported by the National Patient Information Reporting System (NPIRS).

# **Performance Improvement Tip**

If your facility's dental visits are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

```
DU November 25, 2015 Page 30

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014

Baseline Period: Jan 01, 2010 to Dec 31, 2010

Dental Sealants

REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %

User Pop Pts 2-15
```

(GPRA)	621		629			670		
<pre># w/intact dental sealants (GPRA)</pre>	19	3.1	11	1.7	+1.3	14	2.1	+1.0
Total User Population, Ages 3-5yrs	152		143			141		
<pre># w/intact dental   sealants (GPRA)</pre>	2	1.3	1	0.7	+0.6	0	0.0	+1.3
Total User Population, Ages 6-9yrs	181		173			194		
<pre># w/intact dental sealants (GPRA)</pre>	8	4.4	5	2.9	+1.5	7	3.6	+0.8
Total User Population, Ages 10-12yrs	120		121			125		
<pre># w/intact dental   sealants (GPRA)</pre>	2	1.7	2	1.7	+0.0	3	2.4	-0.7
Total User Population, Ages 13-15yrs	126		131			149		
<pre># w/intact dental sealants (GPRA)</pre>	5	4.0	3	2.3	+1.7	4	2.7	+1.3
Total User Population, Ages 5-19yrs	719		727			753		
<pre># w/intact dental   sealants (GPRA)</pre>	34	4.7	41	5.6	-0.9	43	5.7	-1.0
Total # of Sealants Documented	56		61		-5	81		-25
A. # Dental Sealants documented pts 2-15 yrs	52		40		+12	80		-28
B. # Dental Sealants documented pts >15 yrs	4		21		-17	1		+3

Figure 2-23: Sample Report, Dental Sealants

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Dental Sealants: List of patients with intact dental sealants.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

Figure 2-24: Sample Patient List, Dental Sealants

# 2.3.3 Topical Fluoride

#### **GPRA Measure Description**

During FY 2015, achieve the target rate of 26.4% for the proportion of patients who received one or more topical fluoride applications.

#### **Denominator**

User Population patients ages 1-15 (GPRA Denominator).

No denominator. This measure is a total count only, not a percentage.

#### **Numerators**

Patients who received one or more topical fluoride applications during the report period (GPRA Numerator).

For patients meeting the *User Population* definition, the total number of patients with at least one topical fluoride treatment during the Report Period.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

a. Topical fluoride treatment in patients 1 through 15 yrs.

For patients meeting the *User Population* definition, the total number of appropriate topical fluoride applications based on a maximum of four per patient per year.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

*Topical fluoride application definition:* (1) Dental ADA Codes 1201 (old code), 1203 (old code), 1204 (old code), 1205 (old code), 1206, 1208 or 5986; (2) CPT Codes D1201 (old code), D1203 (old code), D1204 (old code), D1205 (old code), D1206, D1208 or D5986; 3) POV ICD-9: V07.31.

For the count measure, a maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

# **Key Logic Changes from CRS Version 14.1**

None.

### **Patient List Description**

List of patients who received at least one topical fluoride application during Report Period.

#### **Measure Source**

Not Available

### **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	27.9%
IHS FY 2013 Performance	26.7%

Performance	Number of Patients
IHS FY 2012 Performance	169,083
IHS FY 2011 Performance	161,461
IHS FY 2010 Performance	145,181
IHS FY 2009 Performance	136,794
IHS FY 2008 Performance	120,754
IHS FY 2007 Performance	107,934
IHS FY 2006 Performance	95,439
IHS FY 2005 Performance	85,318
IHS FY 2005 Performance	113,324

For the IHS FY 2005 Performance, Number of Patients (113,324) is the number of applications.

### **Performance Improvement Tip**

If your facility's dental visits are paid for with CHS funds, ensure the final payment for each purchase order is posted and the CHS to PCC link is set to the "on" position. Having the CHS to PCC link on will enable the CHS data to be passed from CHS/MIS to PCC, where CRS can find it and include it in your CRS reporting.

November 25, 2015  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010					
Topical Fluoride					
			% CHG from PREV YR %		
User Pop Pts 1-15 (GPRA)	684	679		734	
<pre># w/topical fluoride application (GPRA)</pre>	24 3	.5 5	0.7 +2.8	2 0.	.3 +3.2
Total # of patients w/A Least 1 Topical Fluorid -No Refusals		26	+21	15	+32
A: # Topical Fluoride Appts 1-15 yrs	op, 25	5	+20	2	+23
Total # of Topical Fluo: Applications	ride 52	26	+26	15	+37

Figure 2-25: Sample Report, Topical Fluoride

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Topical Fluoride: List of patients who received or refused at least one topical fluoride application during Report period. DENOMINATOR PATIENT NAME HRN COMMUNITY SEX AGE NUMERATOR \_\_\_\_\_\_ PATIENT20,GEORGE 000020 COMMUNITY #1 M 5
UP 1 topical fluoride: 06/18/15 CPT D5986 PATIENT21,RYAN

000021 COMMUNITY #1 M 8

UP

1 topical fluoride: 06/18/15 CPT D5986

1 topical fluoride: 03/03/15 ADA 1201

PATIENT22,MICHAEL

000022 COMMUNITY #1 M 9

1 topical fluoride: 03/03/15 CPT D1203 1 topical fluoride: 03/03/15 CPT D1203 PATIENT23, MARTY 000023 COMMUNITY #1 M 15

UP 2 topical fluoride: 01/07/15 ADA 1204; 08/27/15 ADA 1204

Figure 2-26: Sample Patient List, Topical Fluoride

# 2.4 Immunization Measure Topics

#### 2.4.1 Influenza

### **GPRA Measure Description**

During FY 2015, achieve the target rate of 67.2% for the proportion of non-institutionalized adults aged 65 years and older who receive an influenza immunization.

#### **Denominators**

All Active Clinical patients. Broken down by age groups.

- a. Active Clinical patients younger than age 18.
- b. Active Clinical patients ages 18 through 49.
- c. Active Clinical patients ages 18 through 49 and considered high risk for influenza.
- d. Active Clinical patients ages 50 through 64.
- e. Active Clinical patients ages 65 and older. (GPRA Denominator)

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

All *User Population patients*. Broken down by age groups.

- a. User Population patients younger than age 18.
- b. User Population patients ages 18 through 49.
- c. User Population patients ages 18 through 49 and considered high risk for influenza.
- d. User Population patients ages 50 through 64.
- e. User Population patients ages 65 and older.

#### **Numerators**

Patients with influenza vaccine documented during the report period or with a contraindication documented at any time before the end of the report period.

**Note**: The only refusals included in this numerator are not medically indicated (NMI) refusals. (GPRA Numerator)

a. Patients with a contraindication or a documented NMI refusal.

#### **Logic Description**

Age of the patient is calculated at the beginning of the report period.

*Diabetes:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Influenza definition:* Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Influenza vaccine	90654-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)	Immunization (CVX) Codes: 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158  POV: ICD-9: V04.8 (old code), V04.81  NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142

- 2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.
- 3. **High Risk for Influenza:** Persons considered high risk for influenza are defined as those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

High Risk Category	ICD-9 Codes	ICD-10 Codes
HIV Infection	042, 042.0 through 044.9 (old codes), 079.53, V08	B20, B52.0, B97.35, Z21
Diabetes	250.00 through 250.93	E08.2*, E09.2*, E10.* through E13.*
Rheumatic Heart Disease	393. through 398.99	105.* through 109.*
Hypertensive Heart Disease	402.00 through 402.91	I11.*

High Risk Category	ICD-9 Codes	ICD-10 Codes
Hypertensive Heart/Renal Disease	404.00 through 404.93	I13.*
Ischemic Heart Disease	410.00 through 414.9	I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9
Pulmonary Heart Disease	415.0 through 416.9	I26.* through I27.*
Other Endocardial Heart Disease	424.0 through 424.9	I34.* through I39
Cardiomyopathy	425.0 through 425.9	142.*, 143
Congestive Heart Failure	428.0 through 428.9, 429.2	I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
Chronic Bronchitis	491.0 through 491.9	J41.*, J42
Emphysema	492.0 through 492.8	J43.*
Asthma	493.00 through 493.91	J45.21 through J45.902
Bronchiectasis, CLD, COPD	494.0 through 496.	J44.*, J47.*
Pneumoconioses	500 through 505	J60 through J64, J66.8 through J67.6, J67.8 through J67.9
Chronic Liver Disease	571.0 through 571.9	K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
Nephrotic Syndrome	581.0 through 581.9	N02.*, N04.*, N08
Renal Failure	585.6, 585.9	N18.6 through N19
Transplant	996.80 through 996.89	T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
Kidney Transplant	V42.0 through V42.89	
Chemotherapy	V58.1	Z51.11, Z51.12
Chemotherapy follow-up	V67.2	Z08

# **Key Logic Changes from CRS Version 14.1**

1. Added CPT code 90687 to influenza definition.

### **Patient List Description**

List of patients with Influenza code, if any.

#### **Measure Source**

HP 2020 IID-12.7

# Measure Past Performance and Long-Term Targets for Patients => 65 Vaccine Rate:

Performance	Percent
IHS FY 2014 Performance	68.1%
IHS FY 2013 Performance	68.0%
IHS FY 2012 Performance	65.0%
IHS FY 2011 Performance	62.0%
IHS FY 2010 Performance	62.0%
IHS FY 2009 Performance	59.0%
IHS FY 2008 Performance	62.0%
IHS FY 2007 Performance	59.0%
IHS FY 2006 Performance	58.0%
IHS FY 2005 Performance	59.0%
IHS FY 2004 Performance	54.0%
IHS FY 2003 Performance	51.0%
IHS FY 2002 Performance	51.4%
HP 2020 Goal	90.0%

#### **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in Influenza Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

```
DU
                             November 25, 2015
                                                                    Page 35
       *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Influenza
                              % PREV YR
                                            % CHG from BASE
                                                                   % CHG from
                    REPORT
                                 PERIOD
                                               PREV YR % PERIOD
                                                                      BASE %
                    PERTOD
                                   1,209
Active Clinical Pts 1,554
                                                          1,101
Total # w/Flu vaccine/
```

contra/NMI Refusal 194 A. # w/ Contraind/ NMI Ref		115	9.5	+3.0	49	4.5	+8.0	
w/ % of Total IZ 12	6.2	2	1.7	+4.4	0	0.0	+6.2	
Active Clinical Pts		416			435			
<10 442		410			433			
Total # w/Flu vaccine/	10.0	0.1	- 0				10.0	
contra/NMI Refusal 54 A. # w/ Contraind/ NMI Ref		21	5.0	+7.2	6	1.4	+10.8	
w/% of Total IZ 3		0	0.0	+5.6	0	0.0	+5.6	
Active Clinical Pts								
18-49 752		572			486			
Total # w/Flu vaccine/								
contra/NMI Refusal 48 A. # w/ Contraind/ NMI Ref		33	5.8	+0.6	14	2.9	+3.5	
w/ % of Total IZ 3		2	6.1	+0.2	0	0.0	+6.3	
Active Clinical Pts								
18-49 high risk 166		109			69			
Total # w/Flu vaccine/								
contra/NMI Refusal 25 A. # w/ Contraind/ NMI Ref		25	22.9	-7.9	7	10.1	+4.9	
w/ % of Total IZ 3		1	4.0	+8.0	0	0.0	+12.0	
Active Clinical Patients								
ages 50-64 244		157			115			
Total # w/Flu								
vaccine/contra/ NMI Refusal 59	24 2	37	23 6	+0.6	14	12 2	+12 0	
A. # w/ Contraind/ NMI	21.2	37	23.0	10.0	11	12.2	112.0	
Ref w/ % of Total IZ 5	8.5	0	0 0	+8.5	0	0.0	+8.5	
10001 12	0.5	U	0.0	10.5	U	0.0	10.5	

Figure 2-27: Sample Report, Adult Immunizations: Influenza

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Influenza: List of patients with Influenza code, if any. HRN PATIENT NAME COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, DEBORAH 000001 COMMUNITY #1 F 15
AD 01/28/15 Imm 88
PATIENT2, CRYSTAL 000002 COMMUNITY #1 F 24 UP,AC PATIENT3, DEMETRIA 000003 COMMUNITY #1 F 35 UP,AC, HR 02/25/15 Imm 140 000004 COMMUNITY #1 F 50 PATIENT4, JADE PATIENT5, MARIE 000005 COMMUNITY #1 F 65

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

UP, AC, AD, HR

01/21/15 NMI Refusal

Figure 2-28: Sample Patient List, Adult Immunization: Influenza

## 2.4.2 Adult Immunizations

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 85.7% for the proportion of adult patients age 65 years and older who receive a pneumococcal immunization.

#### **Denominators**

Active Clinical patients ages 19 through 59.

Active Clinical patients ages 60 through 64.

Active Clinical patients ages 65 or older. (GPRA Denominator)

Active Clinical patients ages 18 through 64 and considered high risk for pneumococcal.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

Active Clinical patients ages 18 and older.

All *User Population patients* 19 through 59.

All *User Population patients* 60 through 64.

All User Population patients ages 65 or older.

*User Population patients* ages 18 through 64 and considered high risk for pneumococcal.

User Population patients ages 18 and older.

#### **Numerators**

Patients who have received 1 dose of Tdap/Td in the past 10 years, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received 1 dose of Tdap ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients with influenza vaccine documented during the Report Period or with a contraindication documented at any time before the end of the Report Period.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received 1 dose of Zoster ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients with Pneumococcal vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumovax after the age of 65 or a dose of pneumovax in the past 2 years. (GPRA Numerator)

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period), including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever), including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients who have received the 1:1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever, 1 up-to-date Pneumovax), including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

a. Patients with a contraindication or a documented NMI refusal.

Patients with Pneumococcal vaccine or contraindication documented at any time before the end of the Report Period.

**Note**: The only refusals included in this numerator are NMI refusals.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report period.

*Diabetes definition:* First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Pneumococcal Immunization definition:* Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Pneumoccocal immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Pneumoccocal	90669, 90670, 90732,	Immunization (CVX) Codes:
Vaccine	G0009, G8115 (old	33, 100, 109, 133, 152
	code), G9279	<b>POV:</b> ICD-9: V06.6; V03.82

- 2. **Pneumoccocal Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.
- 3. **High Risk for Pneumococcal:** Persons considered high risk for pneumococcal are defined as those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following:

High Risk Category	ICD-9 Codes	ICD-10 Codes
HIV Infection	042, 042.0 through 044.9 (old codes), 079.53, V08	B20, B52.0, B97.35, Z21
Diabetes	250.00 through 250.93	E08.2*, E09.2*, E10.* through E13.*
Chronic alcoholism	303.90, 303.91	F10.20, F10.220 through F10.29

High Risk Category	ICD-9 Codes	ICD-10 Codes
Congestive Heart Failure	428.0 through 428.9, 429.2	I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
Emphysema	492.0 through 492.8	J43.*
Asthma	493.00 through 493.91	J45.21 through J45.902
Bronchiectasis, CLD, COPD	494.0 through 496.	J44.*, J47.*
Pneumoconioses	500 through 505	J60 through J64, J66.8 through J67.6, J67.8 through J67.9
Chronic Liver Disease	571.0 through 571.9	K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
Nephrotic Syndrome	581.0 through 581.9	N02.*, N04.*, N08
Renal Failure	585.6, 585.9	N18.6 through N19
Injury to spleen	865.00 through 865.19	
Transplant	996.80 through 996.89	T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
Kidney Transplant	V42.0 through V42.89	
Chemotherapy	V58.1	Z51.11, Z51.12
Chemotherapy follow-up	V67.2	Z08

Tdap/Td Immunization definition: Any of the following documented during the applicable time frame.

1. **Tdap/Td immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Tdap Vaccine	90715	Immunization (CVX) Codes: 115
Td Vaccine	90714, 90718	Immunization (CVX) Codes: 9, 113, 138, 139
		<b>POV:</b> ICD-9: V06.5

2. **Tdap/Td Contraindication:** (A) Contraindication in the Immunization Package of "Anaphylaxis" or (B) PCC NMI Refusal.

*Influenza definition:* Any of the following documented during the Report Period unless otherwise noted.

1. **Influenza immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Influenza vaccine	90654-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)	Immunization (CVX) Codes: 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158  POV: ICD-9: V04.8 (old code), V04.81  NOT documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, V06.6 NOT documented with 90663, 90664, 90666, 90666, 90470, G9141 or G9142

2. **Contraindication:** Any of the following documented at any time before the end of the Report Period, defined as: (A) Contraindication in the Immunization Package of "Egg Allergy" or "Anaphylaxis" or (B) PCC NMI Refusal.

Zoster definition: Any of the following documented any time before the end of the Report Period unless otherwise noted.

1. **Zoster immunization:** Any of the codes in the table below.

Immunization	CPT Codes	ICD and Other Codes
Zoster Vaccine	90736	Immunization (CVX) Codes: 121

2. **Zoster Contraindication:** (A) Contraindication in the Immunization Package of "Immune Deficiency" or "Anaphylaxis" or (B) PCC NMI Refusal.

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS code G9279 to Pneumovax definition.
- 2. Added CPT code 90687 to influenza definition.

## **Patient List Description**

List of patients equal to or greater than (=>)18 yrs or DM DX with IZ, evidence of disease, contraindication, if any.

#### **Measure Source**

HP 2020 IID-13.1

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	85.7%
IHS FY 2013 Performance	89.2%
IHS FY 2012 Performance	88.5%
IHS FY 2011 Performance	85.5%
IHS FY 2010 Performance	84.0%
IHS FY 2009 Performance	82.0%
IHS FY 2008 Performance	82.0%
IHS FY 2007 Performance	79.0%
IHS FY 2006 Performance	74.0%
IHS FY 2005 Performance	69.0%
IHS FY 2004 Performance	69.0%
IHS FY 2003 Performance	65.0%
IHS FY 2002 Performance	64.0%
HP 2020 Goal for % of patients equal to or greater than (=>) 65	90.0%

# **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in Pneumo Vax Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU November 25, 2015 Page 41  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Adult Immunizations									
					CHG from PREV YR %				
Active Clinical Pts 65 & older (GPRA)	128		74			65			
Total # w/up to date	/ Pneumo	vax/							
contra/NMI Refusal (GPRA) A. # w/ Contraind/ NI Ref w/ % of		38.3	39	52.7	-14.4	29	44.6	-6.3	
Total IZ	_	9.6	3	6.7	+2.9	0	0.0	+9.6	
Total # w/Pneumovax/ contra/NMI Refusal		40.6	45	60.8	-20.2	37	56.9	-16.3	
Active Clinical Pts									

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

18-64 high risk	233		169			105			
Total # w/up to date/ P contra/NMI Refusal A. # w/ Contra/ NMI Ref	55		47	27.8	-4.2	39	37.1	-13.5	
w/ % of Total IZ		0.0	0	0.0	+0.0	0	0.0	+0.0	
Active Diabetic Pts	148		99			87			
Total # w/up to date Pneumovax/contra/NMI Refusal	56	37.8	49	49.5	-11.7	46	52.9	-15.0	
A. # w/ Contraind/ NMI Ref w/ % of Total IZ	0	0.0	0	0.0	+0.0	0	0.0	+0.0	

Figure 2-29: Sample Report, Adult Immunization: Pneumovax

```
UP-User Pop; AC-Active Clinical; AD-Active Diabetic; AAD-Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Adult Immunizations: List of patients =>18 yrs or DM DX with IZ, evidence
of disease or contraindication, if any.
PATIENT NAME
                    HRN COMMUNITY SEX AGE
 DENOMINATOR
                         NUMERATOR
______
PATIENT1, DEBORAH 000001 COMMUNITY #1 F 18
UP, AC, HR TDAP/TD: 12/22/13 Imm 9 (past 10 yrs)
PATIENT2, TARA 000002 COMMUNITY #1 F 27
UP, AC TDAP: 03/03/14 Imm 115 (ever); TDAP/TD: 03/03/15
PATIENT3, BOBBIE 000003 COMMUNITY #1 F 41
UP,AC
PATIENT4, NADINE 000004 COMMUNITY #1 F 55 UP, AC, HR, AD Pneumo: 03/27/12 Imm
                                Pneumo: 03/27/12 Imm 33 (ever) (up-to-date);
TDAP/TD: 03/27/12 Imm 9 (past 10 yrs)
PATIENT5, SHERRY 000005 COMMUNITY #1 F 68
                                 Pneumo: 02/03/15 CPT 90669
UP, AC, HR
```

Figure 2-30: Sample Patient List, Adult Immunization: Pneumovax

## 2.4.3 Childhood Immunizations

## **GPRAMA Measure Description**

During FY 2015, achieve the target rate of 73.9% for the proportion of American Indian/Alaska Native children ages 19 through 35 months who have received the recommended immunizations.

#### **Denominators**

Active Clinical patients ages 19 through 35 months at end of Report Period.

User Population patients ages 19 through 35 months at end of Report Period.

*User Population patients active in the Immunization Package* who are 19 through 35 months at end of Report Period. (GPRAMA Denominator)

**Note:** Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

#### **Numerators**

Patients who have received the 4:3:1:3\*:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 or 4 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals. (GPRAMA Numerator)

Patients who have received 4 doses of DTaP ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of Polio ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of MMR ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 or 4 doses of HiB ever, including contraindications.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of Hepatitis B vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Varicella ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 4 doses of Pneumococcal conjugate vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Hepatitis A vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 2 or 3 doses of Rotavirus vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 2 doses of Influenza vaccine ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

For each of the above numerators, the following sub-numerators are included:

a. Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal

## **Logic Description**

Age definition: Age of the patient is calculated at the beginning of the Report Period. Therefore the age range will be adjusted to 7 through 23 months, which makes the patient between the ages of 19 through 35 months at the end of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

Active Immunization Package Patients denominator definition: Same as User Pop definition except includes only patients flagged as active in the Immunization Package.

**Note**: Only values for the Current Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the Previous Year or Baseline Periods.

Dosage and types of immunization definitions:

- 4 doses of DTaP: (1) 4 DTaP/DTP/Tdap; (2) 1 DTaP/DTP/Tdap and 3 DT/td; (3) 1 DTaP/DTP/Tdap and 3 each of Diphtheria and Tetanus; (4) 4 DT and 4 Acellular Pertussis; (5) 4 Td and 4 Acellular Pertussis; or (6) 4 each of Diphtheria, Tetanus, and Acellular Pertussis.
- 3 doses of Polio: (1) v OPV; (2) 3 IPV; or (3) combination of OPV and IPV totaling 3 doses.
- One dose of MMR: (1) MMR; (2) 1 M/R and 1 Mumps; (3) 1 R/M and 1 Measles; or (4) 1 each of Measles, Mumps, and Rubella.
- 3 doses of Hep B
- 3 or 4 doses of HIB, depending on the vaccine administered
- 1 dose of Varicella
- 4 doses of Pneumococcal
- 1 dose of Hepatitis A
- 2 or 3 doses of Rotavirus, depending on the vaccine administered
- 2 doses of Influenza

NMI refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note**: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g. 2 or 3 Rotavirus): To count toward the numerator with the smaller number of doses, all of the patient's vaccinations must be part of the smaller dose series. For example, for a patient to count toward the Rotavirus numerator with only 2 doses, all 2 doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need 3 doses to count toward the numerator. An exception to this is for the HIB vaccine: if the first 2 doses are CVX code 49, then the patient only needs 3 doses (even if the third dose is included in the 4-dose series).
- Each immunization must be refused and documented separately. For example, if a
  patient has an NMI refusal for Rubella only, then there must be an immunization,
  contraindication, or separate NMI refusal for the Measles and Mumps
  immunizations.
- For immunizations where required number of doses is greater than (>) 1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period.)
- To be counted in sub-numerator A, a patient must meet the numerator definition and have a REF refusal in PCC or a Parent or Patient Refusal in the IZ program for any of the immunizations in the numerator. For example, if a patient refused Rubella only but had immunizations for Measles and Mumps, the patient would be included in sub-numerator A.

NMI refusals are defined as PCC Refusal type NMI for any of the following IZ codes:

Immunization	Immunization Codes for Refusals	CPT Codes for Refusals
DTaP	20, 50, 102, 106, 107, 110, 120, 130, 132, 146	90696, 90698, 90700, 90721, 90723
DTP	1, 22, 102	90701, 90711 (old code), 90720
Tdap	115	90715
DT (Diphtheria & Tetanus)	28	90702
Td (Tetanus & Diphtheria)	9, 113, 138, 139	90714, 90718
Tetanus	35, 112	90703
Acellular Pertussis	11	
OPV	2, 89	90712

Immunization	Immunization Codes for Refusals	CPT Codes for Refusals
IPV	10, 89, 110, 120, 130, 132, 146	90696, 90698, 90711 (old code), 90713, 90723
MMR	3, 94	90707, 90710; M/R: 90708
M/R (Measles/ Rubella)	4	
R/M (Rubella/ Mumps)	38	90709 (old code)
Measles	5	90705
Mumps	7	90704
Rubella	6	90706
HiB	17, 22, 46-49, 50, 51, 102, 120, 132, 146	90645-90648, 90698, 90720- 90721, 90737 (old code), 90748
Hepatitis B	8, 42-45, 51, 102, 104, 110, 132, 146	90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)
Varicella	21, 94	90710, 90716
Pneumococcal	33, 100, 109, 133, 152	90669, 90670, 90732, G0009, G8115 (old code), G9279
Hepatitis A	1, 52, 83, 84, 85, 104	90632-90634, 90636, 90730 (old code)
Rotavirus	74, 116, 119, 122	90680
Influenza	15, 16, 88, 111, 135, 140, 141, 149, 150, 151, 153, 155, 158	90654-90658, 90659 (old code), 90660-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)

Childhood immunizations are defined in the following ways:

Immunization	CPT Codes	ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes
DTaP	90696, 90698, 90700, 90721,	Immunization (CVX) Codes: 20, 50, 102, 106, 107, 110, 120, 130, 132, 146
	90723	<b>POV:</b> ICD-9: V06.1
		Contraindications: Immunization Package contraindication of "Anaphylaxis."
DTP	90701, 90711 (old	Immunization (CVX) Codes: 1, 22, 102
	code), 90720	<b>POV:</b> ICD-9: V06.1, V06.2, V06.3
		Contraindications: Immunization Package contraindication of "Anaphylaxis."
Tdap	90715	Immunization (CVX) Codes: 115
		Contraindications: Immunization Package contraindication of "Anaphylaxis."

Immunization	CPT Codes	ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes					
DT (Diphtheria	90702	Immunization (CVX) Codes: 28					
& Tetanus)		<b>POV:</b> ICD-9: V06.5					
		Contraindications: Immunization Package contraindication of "Anaphylaxis."					
Td (Tetanus &	90714, 90718	Immunization (CVX) Codes: 9, 113, 138, 139					
Diphtheria)		<b>POV:</b> ICD-9: V06.5					
		Contraindications: Immunization Package contraindication of "Anaphylaxis."					
Diphtheria	90719	<b>POV:</b> ICD-9: V03.5					
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."					
Tetanus	90703	Immunization (CVX) Codes: 35, 112					
		<b>POV:</b> ICD-9: V03.7					
		Contraindications: Immunization Package contraindication of "Anaphylaxis."					
Acellular		Immunization (CVX) Codes: 11					
Pertussis		<b>POV:</b> ICD-9: V03.6					
		Contraindications: Immunization Package contraindication of "Anaphylaxis."					
OPV	90712	Immunization (CVX) Codes: 2, 89					
		<b>Contraindications</b> : Immunization Package contraindication of "Immune Deficiency."					
IPV	90696, 90698,	Immunization (CVX) Codes: 10, 89, 110, 120, 130, 132, 146					
	90711 (old code),	<b>POV:</b> ICD-9: V04.0, V06.3					
	90713, 90723	<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 730.70-730.79; ICD-10: M89.6*					
		Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Neomycin Allergy."					
MMR	90707, 90710	Immunization (CVX) Codes: 3, 94					
		<b>POV:</b> ICD-9: V06.4					
		Contraindications: Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," or "Neomycin Allergy."					
M/R (Measles/	90708	Immunization (CVX) Codes: 4					
Rubella)		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis"					
R/M (Rubella/	90709 (old code)	Immunization (CVX) Codes: 38					
Mumps)		Contraindications: Immunization Package contraindication of "Anaphylaxis"					

Immunization		ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes
Measles	90705	Immunization (CVX) Codes: 5
		<b>POV:</b> ICD-9: V04.2
		Evidence of Disease: POV or PCC Problem List (active or inactive) ICD-9: 055*; ICD-10: B05.*
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
Mumps	90704	Immunization (CVX) Codes: 7
		<b>POV:</b> ICD-9: V04.6
		<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 072*; ICD-10: B26.*
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
Rubella	90706	Immunization (CVX) Codes: 6
		<b>POV:</b> ICD-9: V04.3
		<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: 056*, 771.0; ICD-10: B06.*
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
HiB – 3-dose	90647, 90748	Immunization (CVX) Codes: 49, 51
series		<b>POV:</b> ICD-9: V03.81
		Contraindications: Immunization Package contraindication of "Anaphylaxis"
HiB – 4-dose	90645, 90646,	Immunization (CVX) Codes: 17, 22, 46-48, 50, 102, 120, 132, 146
series	90648, 90698,	<b>POV:</b> ICD-9: V03.81
	90720-90721, 90737 (old code)	Contraindications: Immunization Package contraindication of "Anaphylaxis"
Hepatitis B	90636, 90723,	Immunization (CVX) Codes: 8, 42-45, 51, 102, 104, 110, 132, 146
	90731 (old code), 90740, 90743-	<b>Evidence of Disease:</b> POV or PCC Problem List (active or inactive) ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B19.1*, Z22.51
	90748, G0010, Q3021, (old code) Q3023 (old code)	Contraindications: Immunization Package contraindication of "Anaphylaxis"
Varicella	90710, 90716	Immunization (CVX) Codes: 21, 94
	,	<b>POV:</b> ICD-9: V05.4
		Evidence of Disease: 1) POV or PCC Problem List (active or inactive) ICD-9: 052*, 053*; ICD-10: B01.* through B02.* or 2) Immunization Package contraindication of "Hx of Chicken Pox" or "Immune."
		Contraindications: Immunization Package contraindication of "Anaphylaxis," "Immune Deficiency," or "Neomycin Allergy."
Pneumococcal	90669, 90670,	Immunization (CVX) Codes: 33, 100, 109, 133, 152
	90732, G0009,	<b>POV:</b> ICD-9: V06.6; V03.82
	G8115 (old code), G9279	Contraindications: Immunization Package contraindication of "Anaphylaxis"

Immunization		ICD and Other Codes NOTE: IZ Program Numerators Do Not Use POV, Procedure, Evidence of Disease, Contraindication or Refusal Codes
Hepatitis A	90632-90634, 90636, 90730 (old code)	Immunization (CVX) Codes: 31, 52, 83, 84, 85, 104  Evidence of Disease: POV or PCC Problem List (active or inactive) ICD-9: 070.0, 070.1; ICD-10: B15.*  Contraindications: Immunization Package contraindication of "Anaphylaxis"
Rotavirus – 2- dose series	90681	Immunization (CVX) Codes: 119 Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"
Rotavirus – 3- dose series	90680	Immunization (CVX) Codes: 74, 116, 122 POV: ICD-9: V05.8 Contraindications: Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"
Influenza	90654-90658, 90659 (old code), 90660-90662, 90672, 90673, 90685-90688, 90724 (old code), G0008, G8108 (old code)	Immunization (CVX) Codes: 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158  POV: ICD-9: V04.8 (old code), V04.81, V06.6  Contraindications: Immunization Package contraindication of "Egg Allergy" or "Anaphylaxis"

## **Key Logic Changes from CRS Version 14.1**

- 1. Added CVX code 102 to Dtap definition.
- 2. Added CPT code 90687 to influenza definition.
- 3. Added HCPCS code G9279 to Pneumovax definition.

## **Patient List Description**

List of patients 19 through 35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.

**Notes:** Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7 through 23 months.

The order of the display for the immunizations is: 4 Dtap/Dtp;3 IPV/OPV;MMR;3 or 4 HIB;3 HEP;Vari;4 PNEUMO. A blank value in the Numerator column means the patient didn't meet the requirements for any of the immunizations. Another example is "MMR; vari;4 PNEUMO," which means the patient did not have 4 Dtap/Dtp, 3 IPV/OPV, 3 or 4 HIB and 3 Hep B immunizations.

#### **Measure Source**

CDC; HP 2020 IID-7, IID-8; HEDIS

## **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 GPRA Performance Active Immunization Package 4:3:1:3*:3:1:4	75.4%
(rate for children age 19 through 35 months)	
IHS FY 2013 GPRA Performance Active Immunization Package 4:3:1:3*:3:1:4	74.8%
(rate for children age 19 through 35 months)	
IHS FY 2012 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4 (rate for children age 19 through 35 months)	76.8%
IHS FY 2011 GPRA Performance Active Immunization Package 4:3:1:3:3:1:4 (rate for children age 19 through 35 months)	75.9%
IHS FY 2010 GPRA Performance Active Immunization Package 4:3:1:3:3:1 (rate for children age 19 through 35 months)	79.0%
IHS FY 2009 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months)	79.0%
IHS FY 2008 GPRA Performance Active Immunization Package 4:3:1:3:3 (rate for children age 19 through 35 months)	78.0%
IHS FY 2008 Non-GPRA Performance Active Clinical 4:3:1:3:3 (rate for children age 19 through 35 months)	68.0%
IHS FY 2007 GPRA Performance Active Immunization Package 4:3:1:3:3(rate for children age 19 through 35 months)	78.0%

Performance	Percent
IHS FY 2006 Performance (rate for children age 19 through 35 months)	80.0%
IHS FY 2005 Performance (rate for children age 19 through 35 months)	75.0%
IHS FY 2004 Performance(baseline rate for children age 19 through 35 months)	72.0%
IHS FY 2004 Performance(rate for children age 3 through 27 months)	81.0%
IHS FY 2003 Performance(rate for children age 3 through 27 months)	80.0%
IHS FY 2002 Performance(rate for children age 3 through 27 months)	80.0%
HP 2020 goal for % of children age 19 through 35 months with 4:3:1:3:3:4 vaccines	80.0%
HP 2020 goal for % of children age 19 through 35 months with each individual vaccine	90.0%

For the IHS FY 2006 Performance (rate for children 19 through 35 months), the Percent (80.0) please consider: All 2002 through 2006 rates reported on this table were reported by the Immunization Program from the quarterly immunization reports. Effective in 2007, CRS reports the rate and not the Immunization Program. The CRS rate is reported using the CRS Active Immunization Package denominator.

## **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in appropriate vaccine order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU November 25, 2015 Page 51  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Childhood Immunizations  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %								
Active Clinical Pts 19-35 months	63	41		55				
<pre># w/ 4313*314 combo or w/Dx/Contraind/ NMI Refusal A. # w/ Dx/Contraind</pre>		.9 0	0.0 +7.9	0 0.0 +7.9				

Ref w/ % of Total 4313*314	1	20.0	0	0.0	+20.0	0	0.0	+20.0
A. # w/ Contraind/NMI	25	39.7	3	7.3	+32.4	9	16.4	+23.3
Ref w/ % of Total DTaP	7	28.0	0	0.0	+28.0	0	0.0	+28.0
<pre># w/ 3 doses Polio   or w/ Dx/ Contraind/   NMI Refusal A. # w/ Dx/Contraind/NMI</pre>	32	50.8	12	29.3	+21.5	12	21.8	+29.0
Ref w/ % of Total Polio	7	21.9	0	0.0	+21.9	0	0.0	+21.9
<pre># w/ 1 dose MMR or w/ Dx/Contraind/ NMI Refusal A. # w/Dx/Contraind/NMI Ref w/ % of Total MMR</pre>					+16.8			
<pre># w/ 3-4 doses HIB   or w/Contraind   NMI Refusal A. # w/ Contraind/NMI   Ref w/ % of   Total HIB</pre>					+16.9			
<pre># w/ 3 doses Hep B or w/ Dx/Contraind/ NMI Refusal A. # w/ Dx/Contraind/NMI</pre>					+22.4			
Ref w/ % of Total HEP B	5	16.1	0	0.0	+16.1	0	0.0	+16.1

Figure 2-31: Sample Report, Childhood Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Childhood Immunizations: List of patients 19-35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP. NOTE: Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7-23 months. HRN PATIENT NAME COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, ANDREA 000001 COMMUNITY #1 F 0 4 DTaP/DTP; 3 Polio; MMR; 3 3-Dose Hib; 3 Hep B; UP,AC,IMM Vari; 2 Influenza
PATIENT2, HEATHER

000002 COMMUNITY #1 F 1 UP,AC,IMM NMI DTaP/DTP; NMI Polio; 2 Hep A; 2 Influenza

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

PATIENT3, TONYA	000003 COMMUNITY #1	F 1
UP PATIENT4, JAMES	000004 COMMUNITY #1	м 0
UP,AC,IMM		3 Hep B; Vari; NMI Rota
PATIENT5, SCOTT UP, AC, IMM	000005 COMMUNITY #1	M 0 2 Hep A; 3 Rota; 2 Influenza
OF, AC, INN	4 4-Dose mid/	z nep Ar 3 kotar z inituenza

Figure 2-32: Sample Patient List, Childhood Immunizations

## 2.4.4 Adolescent Immunizations

#### **Denominators**

Active Clinical patients age 13. Broken down by gender where noted.

Active Clinical patients ages 13 through 17. Broken down by gender where noted.

#### **Numerators**

Patients who have received the 1:1:3 combination (i.e., 1 Td/Tdap, 1 meningococcal, 3 HPV), including contraindications and evidence of disease.

Notes: The only refusals included in this numerator are NMI refusals.

This numerator is broken down by gender.

Patient who have received the 1:1 combination (i.e., 1 Td/Tdap, 1 meningococcal), including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of Tdap/Td ever, including contraindications and evidence of disease.

- a. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
- b. Patients who have received 1 dose of Tdap ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 1 dose of meningococcal ever, including contraindications and evidence of disease.

**Note**: The only refusals included in this numerator are NMI refusals.

Patients who have received 3 doses of HPV ever, including contraindications and evidence of disease.

**Notes**: The only refusals included in this numerator are NMI refusals.

This numerator is broken down by gender.

For each of the above numerators, the following sub-numerators are included:

a. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

## **Logic Description**

Age definition: Age of the patient is calculated at the beginning of the Report Period. Because IZ data comes from multiple sources, any IZ codes documented on dates within ten days of each other will be considered as the same immunization.

Dosage and types of immunization definitions:

- 1 dose of Td or Tdap
- 1 dose of Meningococcal
- 3 doses of HPV

Not Medically Indicated (NMI) refusals, evidence of disease and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

**Note**: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations where required number of doses is greater than (>)1, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for HPV, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than (>)1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HPV, the patient will be included in the numerator.
- Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period).

Adolescent immunizations are defined in the following ways:

Immunization	CPT Codes	ICD and Other Codes
Tdap	90715	Immunization code: 115
		NMI Refusals: Immunization code 115
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."
Td	90714, 90718	Immunization codes: 9, 113, 138, 139
		<b>POV:</b> ICD-9: V06.5
		NMI Refusals: Immunization codes 9, 113, 138, 139
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."
Meningococcal	90733, 90734	Immunization codes: 32, 108, 114, 136, 147
		NMI Refusals: Immunization codes 32, 108, 114, 136, 147 Contraindications: Immunization Package contraindication of "Anaphylaxis."
HPV	90649, 90650	Immunization codes: 62, 118, 137
		NMI Refusals: Immunization codes 62, 118, 137
		<b>Contraindications</b> : Immunization Package contraindication of "Anaphylaxis."

## **Key Logic Changes from CRS Version 14.1**

1. Removed all measures that include MMR, Varicella, or Hepatitis B.

# **Patient List Description**

List of patients 13 through 17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 HPV, no IZ will be listed for HPV.

**Note:** An absent value in the Numerator column means the patient did not meet the requirements for any of the immunizations. An example for a female patient age 13 with a value of ";3 HPV" which means the patient did not have 1 Td/Tdap and 1 Meningococcal immunizations.

## **Measure Source**

HEDIS, HP 2020 IID-11

## **Measure Past Performance and Long-Term Targets:**

Target	Percent
HP 2020 goal for each individual IZ: Tdap, Meningococcal, HPV	80.0%
HP 2020 goal for each individual IZ: varicella	90.0%

## **Performance Improvement Tips**

- Providers should ask about and record off-site historical immunizations (IZ type, date received and location) on PCC forms. Data entry mnemonic: HIM
- Providers should document refusals; write "Refused" in appropriate vaccine Order box on PCC form. Data entry mnemonic: REF (Immunization, Value, Date Refused).

DU November 25, 2015 Page 66  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Adolescent Immunizations									
	EPORT ERIOD				CHG from PREV YR %				
Active Clinical patien age 13	ts 20		17			28			
<pre># w/1:1:3 Combo or w/   Dx/Contraind/   NMI Refusal A. # w/ Dx/ Contraind/   NMI Ref w/ % of Total   1:1:3</pre>					+10.0				
Male Active Clinical Pts age 13	8		12			15			
<pre># w/1:1:3 Combo or w/   Dx/Contraind/   NMI Refusal A. # w/ Dx/ Contraind/   NMI Ref w/ % of Total   1:1:3</pre>		12.5			+12.5				
Female Active Clinical Pts age 13	12		6			13			
<pre># w/1:1:3 Combo or w/ Dx/Contraind/ NMI Refusal A. # w/ Dx/ Contraind/ NMI Ref w/ % of Total</pre>		8.3	0	0.0	+8.3	0	0.0	+8.3	
1:1:3	0	0.0	0	0.0	+0.0	0	0.0	+0.0	

Figure 2-33: Sample Report, Adolescent Immunizations

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic

Figure 2-34: Sample Patient List, Adolescent Immunizations

# 2.5 Childhood Diseases Group

# 2.5.1 Appropriate Treatment for Children with Upper Respiratory Infection

## **Denominators**

Active Clinical patients who were ages 3 months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the report period through the first 6 months of the report period.

*User Population patients* who were ages 3 months through 18 years of age who were diagnosed with an *upper respiratory infection* during the period 6 months (182 days) prior to the report period through the first 6 months of the report period.

## **Numerator**

Patients who were *not* prescribed an antibiotic on or within 3 days after diagnosis. In this measure, appropriate treatment is *not* to receive an antibiotic.

## **Logic Description**

Age is calculated as follows: Children 3 months as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

- 1. Patient's diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit. Upper Respiratory Infection defined as POV ICD-9: 460 or 465.\*; ICD-10: J00. Outpatient visit defined as Service Category A, S, or O.
- 2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.
- 3. Patient's visit must only have a diagnosis of URI. If any other diagnosis exists, the visit will be excluded.
- 4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the URI visit date.
- 5. The patient did not have an active prescription for antibiotics as of the URI visit date. "Active" prescription defined as:

Rx Days Supply greater than or equal to (>=) (URI Visit Date–Prescription Date)

If multiple visits exist that meet the above criteria, the first visit will be used.

Antibiotic medications defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329. (Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Ceftibuten, Cefpodoxime proxetil, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxacin, Loracarbef, Minocycline, Ofloxacin, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol.) Medications must not have a comment of RETURNED TO STOCK.

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients 3 months to 18 years of age with upper respiratory infection, with antibiotic prescription, if any.

#### **Measure Source**

**HEDIS** 

## **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 72  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Appropriate Treatment f	Appropriate Treatment for Children with Upper Respiratory Infection (con't)								
	REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %								
Active Clinical 3 month w/Upper Respiratory Infection	38	yrs	36			30			
# w/o Antibiotic Rx	37	97.4	35	97.2	+0.1	27	90.0	+7.4	
User Pop 3 months-18 yrs w/Upper Respiratory Infection 43 38 35									
# w/o Antibiotic Rx	42	97.7	37	97.4	+0.3	32	91.4	+6.2	

Figure 2-35: Sample Report, Appropriate Treatment for Children with Upper Respiratory Infection

UP,AC	MEETS MEASURE
PATIENT3, JAMES	000003 COMMUNITY #3 M 0
UP,AC	MEETS MEASURE
PATIENT4, HENRY	000004 COMMUNITY #3 M 12
UP,AC	MEETS MEASURE
PATIENT25, HEATHER	000025 COMMUNITY #4 F 7
UP,AC	MEETS MEASURE
PATIENT26, DYLAN	000026 COMMUNITY #4 M 3
UP,AC	MEETS MEASURE
PATIENT27, CODY	000027 COMMUNITY #4 M 4
UP,AC	MEETS MEASURE
PATIENT28, KAREN	000028 COMMUNITY #5 F 0
UP,AC	antibiotic injection: 01/06/15 DOES NOT MEET MEASURE
UP,AC	antibiotic injection: 01/06/15 DOES NOT MEET MEASURE

Figure 2-36: Sample Patient List, Appropriate Treatment for Children with Upper Respiratory Infection

# 2.5.2 Appropriate Testing for Children with Pharyngitis

#### **Denominators**

Active Clinical patients who were ages 2 through 18 years who were diagnosed with pharyngitis and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

*User Population patients* who were ages 2 through 18 years who were diagnosed with *pharyngitis* and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

#### **Numerator**

Patients who received a Group A strep test.

## **Logic Description**

Age is calculated as follows: Children two years as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

In order to be included in the denominator, *all* of the following conditions must be met:

- 1. Patient's diagnosis of pharyngitis must have occurred at an outpatient visit. Pharyngitis defined as POV ICD-9: 462, 463, 034.0; ICD-10: J02.0, J03.\*. Outpatient visit defined as Service Category A, S, or O.
- 2. If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with pharyngitis diagnosis.
- 3. Patient's visit must only have a diagnosis of pharyngitis. If any other diagnosis exists, the visit will be excluded.

- 4. The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.
- 5. The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. "Active" prescription defined as:
- 6. Rx Days Supply greater than or equal to (>= )(URI Visit Date Prescription Date)
- 7. The patient filled a prescription for antibiotics on or within 3 days after the pharyngitis visit.

If multiple visits exist that meet the above criteria, the first visit will be used.

Antibiotic medications defined with medication taxonomy BGP HEDIS ANTIBIOTIC MEDS or Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329. (Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Ceftibuten, Cefpodoxime proxetil, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxacin, Loracarbef, Minocycline, Ofloxacin, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol.) Medications must not have a comment of RETURNED TO STOCK.

To be included in the numerator, a patient must have received a Group A Streptococcus test within the 7-day period beginning 3 days prior through 3 days after the Pharyngitis visit date.

*Group A Streptococcus* test defined as: CPT 87430 (by enzyme immunoassay), 87650-87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture), 3210F (Group A Strep Test); site-populated taxonomy BGP GROUP A STREP TESTS; and LOINC taxonomy.

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients 2 through 18 years of age with pharyngitis and a Group A Strep test, if any.

#### **Measure Source**

**HEDIS** 

## Measure Past Performance and Long-Term Targets

None

DU November 25, 2015 Page 75  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Appropriate Testing for Children with Pharyngitis (con't)  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %								
Active Clinical 2-18 pharyngitis and Antibiotic Rx	yrs w/		5			8		
# w/Group A Strep Test	9	90.0	3	60.0	+30.0	2	25.0	+65.0
User Pop 2-18 yrs w/ Pharyngitis and Antibiotic Rx	11		7			10		
# w/Group A Strep Test	9	81.8	4	57.1	+24.7	2	20.0	+61.8

Figure 2-37: Sample Report, Appropriate Testing for Children with Pharyngitis

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Appropriate Testing for Children with Pharyngitis: List of patients 2-18 years
with pharyngitis and a Group A Strep test, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1,MICHAEL 000001 COMMUNITY #1 M 9
UP,AC 03/19/15 RAPID ANTIGEN (STREP A)
PATIENT2,JOSEPH 000002 COMMUNITY #1 M 12
UP,AC 05/01/15 RAPID ANTIGEN (STREP A)

```
PATIENT3, LESTER 000003 COMMUNITY #1 M 13
UP
PATIENT24, MONICA 000024 COMMUNITY #2 F 5
UP, AC 01/23/15 RAPID ANTIGEN (STREP A)
PATIENT25, MICHAEL JAMES 000025 COMMUNITY #2 M 7
UP, AC 03/12/15 RAPID ANTIGEN (STREP A)
```

Figure 2-38: Sample Patient List, Appropriate Testing for Children with Pharyngitis

# 2.6 Cancer Related Measure Topics

## 2.6.1 Cancer Screening: Pap Smear Rates

## **GPRA Measure Description**

During FY 2015achieve the target rate of 54.6% for the proportion of female patients ages 24 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous 3 years, or if the patient is over 30, had a Pap screen in the past 3 years or a Pap screen and HPV DNA within the previous 5 years.

#### **Denominators**

*Female Active Clinical patients* ages 24 through 64 without documented history of Hysterectomy. (GPRA Denominator)

*Female Active Clinical patients* ages 24 through 29 without documented history of Hysterectomy.

Female Active Clinical patients ages 30 through 64 without documented history of Hysterectomy.

*Female User Population patients* ages 24 through 64 without documented history of Hysterectomy.

Female User Population patients ages 24 through 29 without documented history of Hysterectomy.

Female User Population patients ages 30 through 64 without documented history of Hysterectomy.

#### **Numerators**

Patients with a Pap smear documented in the past 3 years, or if patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years. (GPRA Numerator)

**Note**: This numerator does *not* include refusals.

Patients with a Pap Smear documented in the past 3 years.

Patients with a Pap Smear documented 3-5 years ago and an HPV DNA documented in the past 5 years

# **Logic Description**

Age of the patient is calculated at the beginning of the report period. Patients must be at least 24 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

Subject Defined	CPT Codes	II('I) and ()that ('Adae	LOINC Codes	Taxonomy
Hysterectomy	51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200- 58294, 58548, 58550-58554, 58570-58573, 58951, 58953- 58954, 58956, 59135	Procedure: ICD-9: 68.4-68.9; ICD-10: 0UT9*ZZ Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 618.5, 752.43, V67.01, V76.47, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710- Z90.712, Q51.5 Women's Health: Procedure called Hysterectomy.		
Pap Smear	88141-88154, 88160-88167, 88174-88175, G0123, G0124, G0141, G0143- G0145, G0147, G0148, P3000, P3001, Q0091	Lab: PAP SMEAR POV: ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 Women's Health: Procedure called Pap Smear and where the result does NOT have "ERROR/DISREGARD"	Yes	BGP PAP SMEAR TAX

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
HPV DNA	87620-87622	Lab: HPV POV: ICD-9: V73.81, 079.4, 796.75, 795.05, 795.15, 796.79, 795.09, 795.19; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.811, R87.820, R87.821, Z11.51	Yes	BGP HPV TAX

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of women 24 through 64 with documented Pap Smear and HPV, if any.

#### **Measure Source**

HP 2020 C-15

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	54.6%
IHS FY 2013 Performance	61.7%
IHS FY 2012 Performance	57.1%
IHS FY 2011 Performance	58.1%
IHS FY 2010 Performance	59.0%
IHS FY 2009 Performance	59.0%
IHS FY 2008 Performance	59.0%
IHS FY 2007 Performance	59.0%
IHS FY 2006 Performance	59.0%
IHS FY 2005 Performance	60.0%
IHS FY 2004 Performance	58.0%
IHS FY 2003 Performance	61.0%
IHS FY 2002 Performance	62.0%
HP 2020 Goal	93.0%

## **Performance Improvement Tips**

• Providers should ask about and record off-site tests (date received and location) on PCC forms. Data entry mnemonic: HPAP

• Providers should document refusals; write "Refused" in Pap Order box on PCC form. Data entry mnemonic: REF (Lab Test Value, Date Refused).

Previous Yea	ed Meas DEM Period: ar Perio	O INDIAN H Jan 01, 20 d: Jan 01	Commun HOSPITA 115 to	L Dec 31, 20	)15 L, 2014		ge 77 *
Cancer Screening: Pap Smea REPOR	RT %	PREV YR		CHG from PREV YR %			
Female Active Clinical 24-64 years (GPRA) 46	55	328			271		
<pre># w/Pap Smear recorded w/in 3 years - No Refusal (GPRA) 15 A. # aged 24-29 w/Pap</pre>		140	42.7	-8.5	113	41.7	-7.5
Smear recorded w/in 3 years-No Refusals B. # aged 30-64 w/Pap Smear recorded w/in	19 10.5	48	14.6	-4.1	40	14.8	-4.2
3 years-No Refusals 10	9 23.4	92	28.0	-4.6	73	26.9	-3.5
C. # aged 30-64 w/Pap Smear and HPV	1 0.2	0	0.0	+0.2	0	0.0	+0.2
Female User Pop 24-64 yrs 75	51	656			547		
# w/Pap Smear recorded w/s 3 years - No Refusals A. # aged 24-29 w/Pap Smea	171 22	.8 15	59 24.	2 -1.5	5 12	8 23.	4 -0.6
B. # aged 30-64 w/Pap Smea	55 7.3	60	9.1	-1.8	45	8.2	-0.9
		99	15.1	+0.2	83	15.2	+0.1
C. # aged 30-64 w/Pap Smea and HPV		0	0.0	+0.1	0	0.0	+0.1

Figure 2-39: Sample Report, Cancer Screening: Pap Smear Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Cancer Screening: Pap Smear Rates: List of women 25-64 with documented Pap smear, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR

```
PATIENT1, EVELYN
                      000001 COMMUNITY #1 F 21
                           05/05/13 POV 795.06
                      000002 COMMUNITY #1 F 22
PATIENT2, MICHELLE
UP,AC
                           05/31/15 Lab
PATIENT3, KAITLYN
                      000003 COMMUNITY #1 F 22
UP,AC
                          05/08/13 CPT 88150
PATIENT4, BRITNEY
                      000004 COMMUNITY #1 F 22
                          01/10/15 POV V72.32
UP,AC
PATIENT5, KATY
                      000005 COMMUNITY #1 F 31
                     PAP: 07/01/11 PROC 91.46; HPV: 01/10/12 POV 079.4
UP,AC
```

Figure 2-40: Sample Patient List, Cancer Screening: Pap Smear rates

# 2.6.2 Cancer Screening: Mammogram Rates

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 54.8% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

#### **Denominators**

*Female Active Clinical patients* ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies. (GPRA Denominator)

*Female Active Clinical patients* ages 52 through 74 without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

Female User Population patients ages 52 through 64 without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

*Female User Population patients* ages 52 through 74 without a documented history of bilateral mastectomy or two separate unilateral mastectomies. (GPRA Developmental Denominator)

#### **Numerators**

All patients who had a Mammogram documented in the past 2 years.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented mammogram refusal in the past year

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period. For all denominators, patients must be at least the minimum age as of the beginning of the Report Period. For the 52 through 64 denominators, the patients must be less than 65 years of age as of the end of the Report Period.

Subject Defined	CPT Codes	ICD and Other Codes
Bilateral Mastectomy	19300.50-19307.50 or old code 19180, 19200, 19220 <b>OR</b> 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral) <b>OR</b> 19240, with modifier of 50 or 09950	<b>Procedure:</b> ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HTV0ZZ
Unilateral Mastectomy	Must have 2 separate occurrences on either 2 different dates of service or on the same date of service if the codes include both a right side modifier (RT) and left side modifier (LT). 19300-19307, or old codes 19180, 19200, 19220, 19240	Procedure: Must have 2 separate occurrences on 2 different dates of service. ICD-9: 85.41, 85.43, 85.45, 85.47; ICD-10: 07T50ZZ, 07T60ZZ, 07T70ZZ, 07T80ZZ, 07T90ZZ, 0HTT0ZZ, 0HTU0ZZ, 0KTH0ZZ, 0KTJ0ZZ
Mammogram	Rad or CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	POV: ICD-9: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 Procedure: ICD-9: 87.36-87.37; ICD-10: BH00ZZZ, BH01ZZZ Women's Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD"
Refusal (in past year)	Rad Mammogram for CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of women 52 through 74 with mammogram/refusal, if any.

#### **Measure Source**

HP 2020 C-17

# **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	54.2%
IHS FY 2013 Performance	53.8%
IHS FY 2012 Performance	51.9%
IHS FY 2011 Performance	49.8%
IHS FY 2010 Performance	48.0%
IHS FY 2009 Performance	45.0%
IHS FY 2008 Performance	45.0%
IHS FY 2007 Performance	43.0%
IHS FY 2006 Performance	41.0%
IHS FY 2005 Performance	41.0%
IHS FY 2004 Performance	40.0%
IHS FY 2003 Performance	40.0%
IHS FY 2002 Performance	42.0%
HP 2020 Goal	81.1%

# **Performance Improvement Tips**

- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should document refusals; write "Refused" in Mammogram Order box on PCC form. Data entry mnemonic: REF (Mammogram, Procedure (CPT) Code, Date Refused).

DU November 25, 2015 Page 79  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Cancer Screening: Mamm	Cancer Screening: Mammogram Rates (con't)								
	EPORT ERIOD		PREV YR PERIOD		CHG from F			CHG from BASE %	
Female Active Clinical 52-64 (GPRA)	97		60			47			
# w/Mammogram recorded	w/in								
2 years-No Refusals (GPRA)	31	32.0	22	36.7	-4.7	22	46.8	-14.8	
# w/ Mammogram Refusal	7	7.2	0	0.0	+7.2	0	0.0	+7.2	
# Female Active Clinic 42+ (GPRA Dev.)	al 293		188			163			

									_
# w/Mammogram recorded									
w/in 2 years-No Refusa	la								
(GPRA Dev.)		21.5	60	22 0	-11.5	ΕΛ	33.1	-11.6	
	0.3	21.5	02	33.0	-11.5	34	33.1	-11.0	
# w/ Mammogram			_						
Refusal	9	3.1	0	0.0	+3.1	0	0.0	+3.1	
# Female User Pop									
52-64	175		122			102			
# w/Mammogram recorded									
w/in 2 years-No									
Refusals	3./	19.4	26	21.3	-1.9	23	22.5	-3.1	
	24	19.1	20	21.3	-1.9	23	44.5	-3.1	
# w/ Mammogram	_	4 0	0	0 0	. 4 0	0	0 0	. 4 0	
Refusal	7	4.0	0	0.0	+4.0	0	0.0	+4.0	
_									
# Female User Pop									
42+	513		380			333			
# w/Mammogram recorded									
w/in 2 years-No									
Refusals	67	13.1	69	18.2	-5.1	5.8	17.4	-4.4	
# w/ Mammogram	3 /		0,5		3.1	30	_,,,	•••	
Refusal	9	1.8	0	0.0	+1.8	0	0.0	+1.8	
KELUSAL	9	1.0	U	0.0	+1.0	U	0.0	71.0	

Figure 2-41: Sample Report, Cancer Screening: Mammogram rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Cancer Screening: Mammogram Rates: List of women 42+ with mammogram/refusal, if PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, CARLA 000001 COMMUNITY #1 F 43 10/01/13 CPT 77052 000002 COMMUNITY #1 F 42 PATIENT2, CRYSTAL PATIENT3, ALEXA 000003 COMMUNITY #1 F 45
UP, AC 04/24/13 CPT 76090
PATIENT4, HANNAH 000004 COMMUNITY #1 F 42 PATIENT5, MARTHA 000005 COMMUNITY #1 F 43 DP PATIENT6, TARA OF,AC 01/15/15 Refused CPT (
PATIENT7,CAROL LYNN 000007 COMMUNITY #1 F 44
UP,AC 03/05/15 RAD 76092
PATIENT8,MARY ANN 000008 COMMUNITY
UP,AC 01/15/15 Refused CPT G0206 UP,AC PATIENT9, BARBARA 000009 COMMUNITY #1 F 52 04/22/15 CPT 77057 UP,AC

Figure 2-42: Sample Patient List, Cancer Screening: Mammogram rates

# 2.6.3 Colorectal Cancer Screening

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 35.2% for the proportion of clinically appropriate patients ages 50-75 who have received colorectal screening.

### **Denominators**

All *Active Clinical patients* ages 50 through 75 without a documented diagnosis of colorectal cancer or total colectomy. Broken down by gender. (GPRA Denominator)

All *User Population patients* ages 50 through 75 without any documented diagnosis of colorectal cancer or total colectomy.

### **Numerators**

Patients who have had any CRC screening, defined as any of the following: (1) Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the Report period; (2) flexible sigmoidoscopy in the past 5 years; or (3) colonoscopy in the past 10 years.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

Patients with documented CRC screening refusal in the past year.

Patients with FOBT or FIT during the Report Period.

Patients with a flexible sigmoidoscopy in the past 5 years or a colonoscopy in the past 10 years.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

**Denominator Exclusions** 

Any diagnosis ever of one of the following:

- 1. **Colorectal Cancer:** POV ICD-9: 153.\*, 154.0, 154.1, 197.5, V10.05; ICD-10: C18.\*, C19, C20, C78.5, Z85.030, Z85.038; CPT G0213–G0215 (old codes), G0231 (old code).
- 2. **Total Colectomy:** CPT 44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210 through 44212; Procedure ICD-9: 45.8\*; ICD-10: 0DTE\*ZZ.

Colorectal cancer screening definition: The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

# Colorectal Cancer Screening (CRS looks for the most recent of any of the following during timeframes specified in numerator section above)

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Fecal Occult Blood lab test (FOBT) or Fecal Immuno- chemical Test (FIT)	82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)		Yes	BGP GPRA FOB TESTS
Flexible Sigmoidoscopy	45330-45345, G0104	<b>Procedure:</b> ICD-9: 45.24; ICD-10: 0DJD8ZZ		
Colonoscopy	44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121, G9252, G9253	Procedure: ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K4ZZ, 0D5K8ZZ, 0D5L4ZZ, 0D5L4ZZ, 0D5N4ZZ, 0D5N4ZZ, 0D5N4ZZ, 0D5N4ZZ, 0D5N4ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E3ZX, 0D9F3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G4ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H3ZX, 0D9H4ZX, 0D9H3ZX, 0D9H3ZX, 0D9L3ZX, 0D9L3ZX, 0D9L3ZX, 0D9L3ZX, 0D9L3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0D9N3ZX, 0DBF3ZX, 0DBF3ZX, 0DBE3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBG3ZX, 0DBG3ZX, 0DBG3ZX, 0DBG3ZX, 0DBG3ZX, 0DBG3ZX, 0DBH3ZX, 0DBM3ZX, 0DBN3ZX, 0DBN3ZZ, 0DBN3ZX, 0DBN3ZX, 0DBN3ZZ, 0DBN3ZX, 0DBN3ZZ, 0DBN3ZX, 0DBN3ZZ, 0DBN3		

# Refusal definition: Any of the following in the past year:

Subject CPT Codes ICD and Other Codes Defined	s Taxonomy
Refusals   FOBT or FIT: 82270, 82274, 89205 (old code), G0107 (old code), G0328, or G0394 (old code)   Flexible Sigmoidoscopy: 45330-45345, G0104   Colonoscopy: 44388 through 44394, 44397, 45355, 45378 through 45387, 45391, 45392, G0105, G0121, G9252, G9253   G09252, G9253   G0984ZX, 0D9967ZX, 0D9963ZX, 0D9963ZX, 0D9963ZX, 0D9963ZX, 0D9963ZX, 0D9963ZX, 0D9968ZX, 0D9968ZX, 0D9967ZX, 0D966ZX, 0D966ZX, 0D966ZX, 0D966ZX, 0D966ZX, 0D966ZX, 0D967ZX, 0D966ZX, 0D967ZX, 0D96ZX, 0D96ZX, 0D96ZX, 0D96ZX, 0D96ZX, 0D96ZX, 0D96ZZX, 0D96ZZX, 0D96ZZX, 0D96ZZX, 0D96ZZX, 0D96ZZX, 0D6GZZ, 0D86ZZ, 0D86ZZ	D-10:  Blood Test  D-10:  Blood Test  D-10:  Blood Test  D-10:  Blood Test  D-10:  D-1

# **Key Logic Changes from CRS Version 14.1**

1. Added HCPCS codes G9252, G9253 to colonoscopy and colonoscopy refusal definitions.

# **Patient List Description**

List of patients 50 through 75 with CRC screening or refusal, if any.

### **Measure Source**

HEDIS, HP 2020 C-16

## **Measure Past Performance and Long-Term Targets:**

Performance	Percent
IHS FY 2014 Performance	37.5%
IHS FY 2013 Performance	35.0%
Former definition of CRC:	
IHS FY 2012 Performance	46.1%
IHS FY 2011 Performance	41.7%
IHS FY 2010 Performance	37.0%
IHS FY 2009 Performance	33.0%
IHS FY 2008 Performance	29.0%
IHS FY 2007 Performance	26.0%
IHS FY 2006 Performance	22.0%
HP 2020 Goal	70.5%

# **Performance Improvement Tip**

Providers should ask about and record off-site historical tests (test type, date received and location) on PCC forms. Data entry mnemonics: HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG (sigmoidoscopy). Providers should also enter as a refusal if the patient refuses the colorectal cancer screening. Refusals may be entered with the data entry mnemonic of REF (refusal).

DU November 25, 2015 Page 82  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
R	Colorectal Cancer Screening (con't)  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %							
AC Pts 50-75 w/o color cancer or total colect (GPRA)			201			157		
<pre># w/CRC Screening -No Refusals (GPRA) # w/ CRC Screening Refusal # w/FOBT/FIT during</pre>					-4.4 +2.5			+3.4
Report period	12	3.8	11	5.5	-1.7	0	0.0	+3.8

# w/Flex Sig or Colonoscopy	40	12.6	31	15.4	-2.8	19	12.1	+0.5
Male Active Clinical 50-75	157		97			72		
<pre># w/CRC Screening -No Refusals # w/ CRC Screening</pre>	23	14.6	18	18.6	-3.9	9	12.5	+2.1
Refusal	4	2.5	0	0.0	+2.5	0	0.0	+2.5
<pre># w/FOBT/FIT during   Report period # w/Flex Sig or</pre>	7	4.5	3	3.1	+1.4	0	0.0	+4.5
Colonoscopy	18	11.5	15	15.5	-4.0	9	12.5	-1.0

Figure 2-43: Sample Report, Colorectal Cancer Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Colorectal Cancer Screening: List of patients 51-80 with CRC screening or refusal, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, DANIELLE 000001 COMMUNITY #1 F 51
UP FOB: 08/19/13 CPT G0107
PATIENT2, MARIE 000002 COMMUNITY #1 F 51
UP, AC COLO: 02/12/13 Refused 0
PATIENT3, MARY ANN 000003 COMMUNITY #1 F 52 COLO: 02/12/13 Refused CPT UP,AC PATIENT4, BOBBIE 000004 COMMUNITY #1 F 52 UP,AC PATIENT5, WINONA 000005 COMMUNITY #1 F 53 UP,AC PATIENT6, DARLENE 000006 COMMUNITY #1 F 54 UP,AC SIG: 04/07/10 45.24 PATIENT7, JOYCE 000007 COMMUNITY #1 F 57 COLO: 07/07/13 POV V76.51 UP,AC

Figure 2-44: Sample Patient List, Colorectal Cancer Screening

# 2.6.4 Comprehensive Cancer Screening

## **GPRA Measure Description**

Increase the proportion of patients ages 24 through 75 who received a comprehensive cancer screening.

### **Denominators**

Active Clinical patients ages 24 through 75 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening. (GPRA Developmental Denominator)

- a. Active Clinical female patients ages 24 through 75.
- b. Active Clinical male patients ages 50 through 75.

### **Numerators**

Patients who have had all screenings for which they are eligible.

**Note**: This numerator does *not* include refusals. (GPRA Developmental Numerator)

- a. Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
- b. Male patients with colorectal cancer screening.

# **Logic Description**

Age is calculated at the beginning of the Report Period.

Cervical Cancer Screening definition: To be eligible for this screening, patients must be female Active Clinical ages 24 through 64 and not have a documented history of hysterectomy. Patients must be at least 24 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Pap Smear documented in the past 3 years, or if the patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hysterectomy	51925, 56308 (old code), 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200-58294, 58548, 58550-58573, 58951, 58953-58954, 59135	Procedure: ICD-9: 68.4-68.9; ICD-10: 0UT9*ZZ  Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted): ICD-9: 618.5, 752.43, V67.01, V76.47, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710-Z90.712, Q51.5  Women's Health: Procedure called Hysterectomy.		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Pap Smear	88141-88154, 88160-88167, 88174-88175, G0123, G0124, G0141, G0143- G0145, G0147, G0148, P3000, P3001, Q0091	Lab: PAP SMEAR POV: ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 Women's Health: Procedure called Pap Smear	Yes	BGP PAP SMEAR TAX
HPV DNA	87620-87622	Lab: HPV POV: ICD-9: V73.81, 079.4, 796.75, 795.05, 795.15, 796.79, 795.09, 795.19; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.811, R87.820, R87.821, Z11.51	Yes	BGP HPV TAX

Breast Cancer Screening definition: To be eligible for this screening, patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies. Patients must be at least age 52 as of the beginning of the Report Period and must be less than 65 years of age as of the end of the Report Period. To be counted as having the screening, the patient must have had a Mammogram documented in the past 2 years.

CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes
Bilateral Mastectomy	19300.50-19307.50 or old code 19180, 19200, 19220 <b>OR</b> 19300-19307 w/modifier 09950 (50 and 09950 modifiers indicate bilateral) <b>OR</b> 19240, with modifier of 50 or 09950	<b>Procedure: ICD-9:</b> 85.42, 85.44, 85.46, 85.48; ICD-10: 0HTV0ZZ
Unilateral Mastectomy	Must have 2 separate occurrences on either 2 different dates of service or on the same date of service if the codes include both a right side modifier (RT) and left side modifier (LT).  19300-19307, or old codes 19180, 19200, 19220, 19240	Procedure: Must have 2 separate occurrences on 2 different dates of service. ICD-9: 85.41, 85.43, 85.45, 85.47; ICD-10: 07T50ZZ, 07T60ZZ, 07T70ZZ, 07T80ZZ, 07T90ZZ, 0HTT0ZZ, 0HTU0ZZ, 0KTH0ZZ, 0KTJ0ZZ

Subject Defined	CPT Codes	ICD and Other Codes
Mammogram	Rad or CPT: 77052-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202	POV: ICD-9: V76.11, V76.12, 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 Procedure: ICD-9: 87.36-87.37; ICD-10: BH00ZZZ, BH01ZZZ
		Women's Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does NOT have "ERROR/DISREGARD".

Colorectal cancer screening definition: To be eligible for this screening, patients must be Active Clinical ages 50 through 75 and not have a documented history ever of colorectal cancer or total colectomy. To be counted as having the screening, patients must have had any of the following: (1) FOBT or FIT during the Report Period; (2) flexible sigmoidoscopy or double contrast barium enema in the past 5 years; or (3) colonoscopy in the past 10 years.

The most recent of any of the following tests and procedures during applicable timeframes. CRS identifies the tests and procedures described in the numerators above with the following codes:

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Colorectal Cancer	G0213 through G0215, G0231	<b>POV:</b> ICD-9: 153.*, 154.0, 154.1, 197.5, V10.05; ICD-10: C18.*, C19, C20, C78.5, Z85.030, Z85.038		
Total Colectomy	44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210-44212	Procedure: ICD-9: 45.8*; ICD-10: 0DTE*ZZ		
Fecal Occult Blood lab test (FOBT) or Fecal Immuno- chemical Test (FIT)	82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)		Yes	BGP GPRA FOB TESTS
Flexible Sigmoidoscopy	45330 through 45345, G0104	Procedure: ICD-9: 45.24; ICD-10: 0DJD8ZZ		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Colonoscopy	44397, 45355, 45378-	Procedure: ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5F8ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5H4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E3ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F3ZX, 0D9G3ZX, 0D9G4ZX, 0D9G3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9H3ZX, 0D9H7ZX, 0D9H8ZX, 0D9H3ZX, 0D9H3ZX, 0D9H3ZX, 0D9H3ZX, 0D9H3ZX, 0D9M3ZX, 0D9M3ZX, 0D9M3ZX, 0D9M3ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0D9M5ZX, 0DBE3ZX, 0DBE3ZX, 0DBE3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBF3ZX, 0DBH3ZX, 0DBM3ZX, 0DBM3ZZ, 0DBM3ZZ		

# **Key Logic Changes from CRS Version 14.1**

1. Added HCPCS codes G9252, G9253 to colonoscopy definition.

# **Patient List Description**

List of patients 25 through 75 with comprehensive cancer screening, if any.

### **Measure Source**

Not Available

# **Measure Past Performance and Long-Term Targets**

None

## **Performance Improvement Tip**

- Providers should ask about and record off-site Pap tests (date received and location) on PCC forms. Data entry mnemonic: HPAP
- Providers should ask about and record off-site mammogram procedures (date received and location) on PCC forms. Data entry mnemonic: HRAD.
- Providers should ask about and record off-site historical colorectal cancer tests
  (test type, date received and location) on PCC forms. Data entry mnemonics:
  HBE (barium enema); HCOL (colonoscopy); HFOB (Fecal Occult Blood); HSIG
  (sigmoidoscopy).

DU November 25, 2015 Page 87  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Comprehensive Cancer Sc	reeni	.ng						
					CHG from PREV YR %			
Active Clinical 24-75 (GPRA Dev.)	721		509			424		
<pre># w/ Comprehensive Cand Screening-No Refusals (GPRA Dev.)</pre>		31.3	195	38.3	-7.0	153	36.1	-4.7
A. Female 24-75	570		416			359		
A. # Female w/all Screens	199	34.9	177	42.5	-7.6	144	40.1	-5.2
B. Male 50-75	151		93			65		
B. # Male w/CRC Screen	27	17.9	18	19.4	-1.5	9	13.8	+4.0

Figure 2-45: Sample Report, Comprehensive Cancer Screening

```
AC, PAP
                             PAP: 05/05/14 POV 795.0
PATIENT2, MARIE
                       000002 COMMUNITY #1 F 51
AC, PAP
PATIENT3, MARY ANN
                       000003 COMMUNITY #1 F 52
AC, MAM
                             MAM: 07/06/14 CPT 77055
PATIENT4, BOBBIE
                       000004 COMMUNITY #1 F 53
AC, PAP, MAM, CRCS
                            CRCS: 07/20/15 POV V76.51
PATIENT5, WINONA
                       000005 COMMUNITY #1 F 57
AC, PAP, MAM, CRCS
                            MAM: 10/01/14 CPT 77052
PATIENT6, HARRY
                       000006 COMMUNITY #1 M 56
                            CRCS: 04/07/11 Proc 45.24
AC, CRCS
PATIENT7, LARRY
                       000007 COMMUNITY #1 M 57
AC, CRCS
                       000008 COMMUNITY #1 M 63
PATIENT8.BARRY
AC, CRCS
                             CRCS: 02/18/15 CPT 45330
```

Figure 2-46: Sample Patient List, Comprehensive Cancer Screening

# 2.6.5 Tobacco Use and Exposure Assessment

### **Denominators**

Active Clinical patients ages 5 and older. Broken down by gender and age groups (5 through 13, 14 through 17, 18 through 24, 25 through 44, 45 through 64, and 65 and older), based on HP 2010 age groups.

All *pregnant female User Population patients* with no documented miscarriage or abortion.

All *User Population patients* ages 5 and older. Broken down by gender.

### **Numerators**

Patients who have been screened for tobacco use during the Report Period.

Patients identified as current tobacco users during the Report Period, both smokers and smokeless users.

- a. Patients identified as current smokers during the Report Period.
- b. Patients identified as current smokeless tobacco users during the Report Period.

Patients identified as exposed to environmental tobacco smoke (ETS) (second-hand smoke) during the Report Period.

### **Logic Description**

Ages are calculated at beginning of Report Period.

For screening, an additional eight months is included for patients who were pregnant during the Report Period but who had their tobacco assessment prior to that.

CRS uses the following codes to define the denominators and numerators:

Subject Defined	CPT Codes	ICD and Other Codes
Pregnancy (At least two visits during the past 20 months, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.) An additional 8 months is included for patients who were pregnant during the Report period but who had their tobacco assessment prior to that.		POV: ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 674.*3, 675.*3, 676.*3, 678.*3, 679.*3, V22.0-V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O99.711-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.384, O99.310-O99.314, O99.320-O99.384, O99.310-O99.314, O99.320-O99.344, O99.30-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.844, O99.830, O99.844, O99.830, O99.844, O99.80, O99.8441-
Missarriage (ofter second programs)	50912 50920 50921 F0920	O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36 <b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*;
Miscarriage (after second pregnancy POV in past 20 months)	59812, 59820, 59821, 59830	ICD-10: O03.9

Subject Defined	CPT Codes	ICD and Other Codes
Abortion (after second pregnancy POV in past 20 months)	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267	POV: ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z
Screened for Tobacco Use (time frame for pregnant patients is past 20 months)	D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8453 (old code), G8455- G8457 (old codes), G8402 (old code), G9275, G9276,	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z87.891
	1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non- User), 1000F (Tobacco Use Assessed)	Patient Education codes: "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276
		Dental code: 1320
Tobacco Users (time frame for pregnant patients is past 20 months)	99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), G8455 (old code), G8456 (old code), G8453 (old code), G9276	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2*0, F17.2*3, F17.2*8, F17.2*9, O99.33*  Dental code: 1320
Current Smokers (time frame for pregnant patients is past 20 months)	99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), G8455 (old code), G8402 (old code), G8453 (old code)	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.200, F17.203-F17.210, F17.213-F17.290, F17.293-F17.299, O99.33*  Dental code: 1320
Current Smokeless (time frame for pregnant patients is past 20 months)	1035F (Current Smokeless Tobacco User), G8456 (old code)	POV or Problem List entry where the status is not Inactive or Deleted: ICD-10: F17.220, F17.223-F17.229

For numerator definitions, all existing national Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS-CHEWING/DIP), and TOBACCO (EXPOSURE) Health Factors are listed below with the numerator to which they apply.

Health Factor	Numerator
Ceremonial	Screened (does NOT count as Smoker)
Cessation-Smokeless	Screened; Tobacco Users; Smokeless User
Cessation-Smoker	Screened; Tobacco Users; Smoker
Current Smokeless	Screened; Tobacco Users; Smokeless User

Health Factor	Numerator
Current Smoker	Screened; Tobacco Users; Smoker
Current Smoker, status unknown	Screened; Tobacco Users; Smoker
Current smoker, every day	Screened; Tobacco Users; Smoker
Current smoker, some day	Screened; Tobacco Users; Smoker
Heavy Tobacco Smoker	Screened; Tobacco Users; Smoker
Light Tobacco Smoker	Screened; Tobacco Users; Smoker
Non-Tobacco User	Screened
Previous Smokeless	Screened
Previous (Former) Smokeless	Screened
Previous Smoker	Screened
Previous (Former) Smoker	Screened
Smoke Free Home	Screened
Smoker In Home	Screened; ETS
Current Smoker & Smokeless	Screened; Tobacco Users; Smoker; Smokeless User
Exposure To Environmental Tobacco Smoke	Screened; ETS

## **Key Logic Changes from CRS Version 14.1**

- 1. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.
- 2. Added HCPCS codes G9275, G9276 to tobacco screening definition.
- 3. Added HCPCS code G9276 to tobacco user definition.

## **Patient List Description**

List of patients 5 and older with documented tobacco screening, if any.

### **Measure Source**

HP 2020 TU-1.1 Cigarette smoking 18 and older; TU-1.2 Smokeless tobacco use 18 and older; TU-11 Exposure to ETS-nonsmokers 3 and older

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance (Screening)	67.3%
IHS FY 2013 Performance (Screening)	66.6%
IHS FY 2012 Performance (Screening)	64.3%
IHS FY 2011 Performance (Screening)	62.0%
IHS FY 2010 Performance (Screening)	60.0%
IHS FY 2009 Performance (Screening)	57.0%

Performance	Percent
IHS FY 2008 Performance (Screening)	54.0%
IHS FY 2005 Performance (Screening)	34.0%
IHS FY 2004 Performance (Screening)	27.0%

Performance	Percent
IHS FY 2014 Performance (Tobacco Users)	28.1%
IHS FY 2013 Performance (Tobacco Users)	28.6%
IHS FY 2012 Performance (Tobacco Users)	30.7%
IHS FY 2011 Performance (Tobacco Users)	31.6%
IHS FY 2010 Performance (Tobacco Users)	27.0%
IHS FY 2009 Performance (Tobacco Users)	26.0%
IHS FY 2008 Performance (Tobacco Users)	29.0%
HP 2020 Goals: TU-1.1 (Cigarette smoking 18 and older): 12%; TU-1.2 (Smokeless tobacco use 18 and older): 0.3%; TU-11 (Exposure to ETS-non smokers 18 and older): 68%	

DU November 25, 2015 Page 90  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Tobacco Use and Exposure	Asses	ssment	(con't)						
					CHG from B. PREV YR % P.				
% PREV YR % CHG fr PER					n PREV YR % P	ERIOD		BASE %	
# Active Clinical Pts => 5 1,	357		1,031			911			
<pre># w/Tobacco Screening # Tobacco Users w/ % of</pre>	624 4	16.0	426	41.3	+4.7	328	36.0	+10.0	
Total Screened	294 4	17.1	165	38.7	+8.4	130	39.6	+7.5	
A. # Smokers w/ % of Total Tobacco Users B. # Smokeless Tobacco	277 9	94.2	164	99.4	-5.2	130	100.0	-5.8	
Users w/ % of Total Tobacco Users # exposed to ETS/	29	9.9	5	3.0	+6.8	3	2.3	+7.6	
smoker in home w/ % of Total Screened	4	0.6	2	0.5	+0.2	1	0.3	+0.3	

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

# Male Active Clinical									
ages => 5	570		430			374			
# w/Tobacco									
Screening	230	40.4	152	35.3	+5.0	128	34.2	+6.1	
# Tobacco Users w/ % of									
Total Screened  A. # Smokers w/ % of	136	59.1	69	45.4	+13.7	59	46.1	+13.0	
Total Tobacco Users	124	91.2	69	100.0	-8.8	59	100.0	-8.8	
B. # Smokeless Tobacco									
Users w/ % of Total			_						
Tobacco Users # exposed to ETS/	22	16.2	2	2.9	+13.3	3	5.1	+11.1	
smoker in home w/ % of									
Total Screened	1	0.4	0	0.0	+0.4	1	0.8	-0.3	
# Female Active Clinical	1								
ages => 5	787		601			537			
# w/Tobacco									
Screening	394	50.1	274	45.6	+4.5	200	37.2	+12.8	
# Tobacco Users w/ % of									
Total Screened A. # Smokers w/ % of	158	40.1	96	35.0	+5.1	71	35.5	+4.6	
Total Tobacco Users	153	96.8	95	99.0	-2.1	71	100.0	-3.2	
B. # Smokeless Tobacco									
Users w/ % of Total									
Tobacco Users # exposed to ETS/	7	4.4	3	3.1	+1.3	0	0.0	+4.4	
smoker in home w/% of									
Total Screened	3	0.8	2	0.7	+0.0	0	0.0	+0.8	

Figure 2-47: Sample Report, Tobacco Use Assessment Tobacco Use and Exposure Assessment

DU November 25, 2015 Page 95  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Tobacco Use and Exposure	e Asse	ssment	(con't)				
			Age	AL POPU Distri 25-44	bution	65 and olde	er
CURRENT REPORT PERIOD							
# Active Clinical	171	74	177	448	371	116	
# w/Tobacco Screening	10	19	102	243	199	51	
% w/Tobacco Screening	5.8	25.7	57.6	54.2	53.6	44.0	
<pre># Tobacco Users % Tobacco Users w/ % of</pre>	3	8	46	118	104	15	
Total Screened	30.0	42.1	45.1	48.6	52.3	29.4	

# Smokers 2 8 43 108 102 14 % Smokers w/ % of
% Smokers w/ % of
Total Tobacco Users 66.7 100.0 93.5 91.5 98.1 93.3
# Smokeless 1 0 3 15 8 2
% Smokeless w/% of
Total Tobacco Users 33.3 0.0 6.5 12.7 7.7 13.3
10tal 10bacco 0sels 33.3 0.0 0.3 12.7 7.7 13.3
# ETS/Smk Home 0 0 0 3 1 0
% ETS/Smk Home w/ % of
Total Screened 0.0 0.0 0.0 1.2 0.5 0.0
PREVIOUS YEAR PERIOD
# Active Clinical 176 62 168 323 238 64
# w/Tobacco Screening 11 14 87 147 128 39
% w/Tobacco Screening 6.3 22.6 51.8 45.5 53.8 60.9
# Tobacco Users 0 5 41 60 50 9
% Tobacco Users w/ % of
Total Screened 0.0 35.7 47.1 40.8 39.1 23.1
# Smokers 0 5 40 60 50 9 % Smokers w/% of
Total Tobacco Users 0.0 100.0 97.6 100.0 100.0 100.0
10tal 10bacco 0sels 0.0 100.0 97.0 100.0 100.0 100.0
# Smokeless 0 0 1 3 1 0
% Smokeless w/% of
Total Tobacco Users 0.0 0.0 2.4 5.0 2.0 0.0
# ETS/Smk Home 0 0 0 2 0 0
% ETS/Smk Home w/ % of
Total Screened 0.0 0.0 0.0 1.4 0.0 0.0
CHANGE FROM PREV YR %
# w/Tobacco Screening -0.4 +3.1 +5.8 +8.7 -0.1 -17.0
Tobacco Users +30.0 +6.4 -2.0 +7.7 +13.2 +6.3
Smokers $+66.7 +0.0 -4.1 -8.5 -1.9 -6.7$
Smokeless +33.3 +0.0 +4.1 +7.7 +5.7 +13.3
ETS +0.0 +0.0 +0.0 -0.1 +0.5 +0.0

Figure 2-48: Sample Age Breakdown Report, Tobacco Use Assessment

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

```
PATIENT4, MARY
                       000004 COMMUNITY #1 F 35
                             04/10/15 SCREEN, 04/10/15 USER, 04/10/15 SMOKELESS
UP, AC, PREG
PATIENT5, HARRY B
                       000005 COMMUNITY #1 M 13
                             03/15/15 SCREEN
PATIENT6, EMERSON
                       000006 COMMUNITY #1 M 15
                             05/21/15 SCREEN, 05/21/15 USER, 05/21/15 SMOKER,
UP,AC
05/21/12 ETS
PATIENT7, EUGENE JAY
                       000007 COMMUNITY #1 M 29
                       000008 COMMUNITY #1 M 31
PATIENT8, ROGER
                            01/21/15 SCREEN, 01/21/15 USER, 01/21/15 SMOKER
UP,AC
PATIENT9, ANDREW
                       000009 COMMUNITY #1 M 42
UP
```

Figure 2-49: Sample Patient List, Tobacco Use Assessment

### 2.6.6 Tobacco Cessation

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 46.3% for the proportion of tobacco-using patients who receive tobacco cessation intervention or quit tobacco use.

### **Denominators**

Active Clinical patients identified as current tobacco users or tobacco users in cessation. Broken down by gender and age groups. (GPRA Denominator)

### **Numerators**

Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid anytime during the Report Period.

**Note**: This numerator does *not* include refusals.

Patients identified as having quit their tobacco use anytime during the Report Period.

Patients who received tobacco cessation counseling, received a prescription for a tobacco cessation aid, or quit their tobacco use anytime during the Report Period. (GPRA Numerator)

**Note**: This numerator does *not* include refusals.

### **Logic Description**

Age is calculated at the beginning of the Report Period.

### **Denominator Logic**

Current Tobacco Users or Tobacco Users in Cessation:

CRS will search first for all health factors in the Tobacco, TOBACCO (SMOKING) and TOBACCO (SMOKELESS – CHEWING/DIP) categories documented during the Report Period.

If health factor(s) are found and at least one of them is one of the health factors listed below, the patient is counted as a current tobacco user or tobacco user in cessation. The patient is not counted as receiving cessation counseling.

Tobacco User Health Factors (TUHFs):

- Cessation-Smoker
- Cessation-Smokeless
- Current Smoker
- Current Smokeless
- Current Smoker and Smokeless
- Current Smoker, status unknown
- Current Smoker, every day
- Current Smoker, some day
- Heavy Tobacco Smoker
- Light Tobacco Smoker

If a health factor is found and it is NOT a TUHF, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a tobacco user.

If no TUHF was found, CRS will then search for any of the following codes documented during the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2\*0, F17.2\*3, F17.2\*8, F17.2\*9, O99.33\*.
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276.

If any of these codes are found, the patient will be considered a tobacco user.

If no TUHF or other tobacco user-defining code listed above was found during the specified timeframe, CRS will then search for the most recent health factor documented during an EXPANDED timeframe of any time prior to the report period. For example, a patient with the most recent health factor being documented 5 years prior to the report period.

**Note:** If multiple health factors were documented on the same date and if any of them are TUHFs, all of the health factors will be considered as TUHFs.

If a health factor is found during the expanded timeframe, and is a TUHF, the patient will be considered a potential tobacco user.

If a health factor is found during the expanded timeframe and it is not one of the TUHFs, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a potential tobacco user.

If no health factor was found, CRS will then search for any of the following codes documented through the beginning of the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.1, 305.10-305.12 (old codes), or 649.00-649.04; ICD-10: F17.2\*0, F17.2\*3, F17.2\*8, F17.2\*9, O99.33\*.
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F,
   G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code),
   G9276.

If any of these codes are found, the patient will be considered a potential tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

If the patient is considered a potential tobacco user, CRS will then search for diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2\*1, Z87.891 with a date occurring after the health factor date and through the beginning of the report period. If one of these diagnoses is found, the patient will be considered as having quit their tobacco use and will not be included in the denominator. If a diagnosis is not found, the patient is included as a current tobacco user and will be included in the denominator.

## **Numerator Logic**

## **Tobacco Cessation Counseling**

Any of the following documented anytime during the Report Period:

- Patient education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1\* (old codes), 649.00-649.04, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 or G8453
- Clinic code 94 (tobacco cessation clinic)
- Dental code 1320
- CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 or G8453

## **Prescription for Tobacco Cessation Aid**

Any of the following documented anytime during the Report Period:

- Prescription for medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy that does not have a comment of RETURNED TO STOCK.
- Prescription for any medication with name containing "NICOTINE PATCH", "NICOTINE POLACRILEX", "NICOTINE INHALER", or "NICOTINE NASAL SPRAY" that does not have a comment of RETURNED TO STOCK.
- CPT 4001F

### **Quit Tobacco Use**

Any of the following documented anytime during the Report Period through the end of the Report Period AND after the date of the code found indicating the patient was a current tobacco user.

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2\*1, Z87.891
- Health Factor (looks at the last documented health factor): Previous Smoker, Previous Smokeless, Previous (former) smoker, Previous (former) smokeless

## **Key Logic Changes from CRS Version 14.1**

1. Added HCPCS code G9276 to tobacco user definition.

### **Patient List Description**

List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.

## **Measure Source**

Smoking Cessation Attempts: HP 2020 TU-4

Smoking Cessation Counseling: HP 2020 TU-10

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	48.2%
IHS FY 2013 Performance	45.7%
IHS FY 2012 Performance	36.4%
Former definition:	
IHS FY 2012 Performance	35.2%
IHS FY 2011 Performance	29.4%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	24.0%
IHS FY 2008 Performance	21.0%
IHS FY 2007 Performance	16.0%
IHS FY 2006 Performance	12.0%
HP 2020 goal for increasing smoking cessation attempts for adult smokers	80.0%

DU		ovember 25,				_	ge 101	
*** IHS 2015					ied Rep	ort ***	•	
D ev		EMO INDIAN I			1.5			
	-	: Jan 01, 2		•				
		iod: Jan 0: d: Jan 01,	•		-			
Das	eline Pelio	u. Jan 01,	2010 C	o bec 31,				
Tobacco Cessation (c	on't)							
	REPORT	% PREV YR	9	CHG from	BASE	ي ج	THG from	
		PERIOD						
Active Clinical Toba	cco							
Users/In Cessation								
(GPRA)	499	308			230			
# w/tobacco cessation		g or						
RX for cessation aid	<del></del>	0 50	00 4	. 0 . 17	60	20.0	<i>c</i> 0	
-No Refusals								
# who quit			0.6	+1.8	Т	0.4	+2.0	
# w/tobacco cessation Rx for cessation aid		J ,						
Refusals (GPRA)			22 7	±2 6	7.0	30 4	-4.2	
Verneare (GLVH)	131 20	. 5 / 5	43.7	+∠.0	70	30.4	-4.2	
Male Active Clinical	Tobacco							
Users/In Cessation		147			115			
,								

# w/tobacco cessation of or RX for cessation as		eling,							
No Refusals	64	28.2	35	23.8	+4.4	40	34.8	-6.6	
# who quit	5	2.2	2	1.4	+0.8	1	0.9	+1.3	
# w/tobacco cessation of	counse	eling,							
Rx or cessation aid, o									
No Refusals	69	30.4	36	24.5	+5.9	41	35.7	-5.3	
Female Active Clinical	Tobac	'CO							
Users/In Cessation	272	.00	161			115			
# w/tobacco cessation of	counse	eling,							
or RX for cessation as	ld-								
No Refusals	56	20.6	37	23.0	-2.4	29	25.2	-4.6	
# who quit	7	2.6	0	0.0	+2.6	0	0.0	+2.6	
# w/tobacco cessation of	counse	eling,							
Rx for cessation aid,	or qu	iit-							
No Refusals	62	22.8	37	23.0	-0.2	29	25.2	-2.4	

Figure 2-50: Sample Report, Tobacco Cessation

Tobacco Cessation (con't)					
ACTIVE CLINICAL TOBACCO USERS					
ACTIVE CI		Age Distribution			
	<12	12-17	=>18		
CURRENT REPORT PERIOD					
AC Tob Users/in Cess	3	19	477		
#/babaaaa aaaaabiaa aa					
# w/tobacco cessation counseling or RX for cessation aid-					
No Refusals	1	3	116		
% w/ tobacco cessation counseling	_	ŭ			
or Rx for cessation aid-					
No Refusals	33.3	15.8	24.3		
# who muit	0	1	11		
<pre># who quit % who guit</pre>	0.0	5.3	2.3		
· wilo quit	0.0	3.3	2.5		
<pre># w/tobacco cessation counseling,</pre>					
Rx for cessation aid or quit-					
No Refusals	1	4	126		
% w/ tobacco cessation counseling,					
Rx for cessation aid or quit-					
No Refusals	33.3	21.1	26.4		
PREVIOUS YEAR PERIOD					
AC Tob Users/in Cess	1	10	297		
<pre># w/tobacco cessation counseling</pre>					
or RX for cessation aid-					
No Refusals	0	2	70		
<pre>% w/ tobacco cessation counseling or Rx for cessation aid-</pre>					
No Refusals	0.0	20.0	23.6		
110 ICTUBALD	0.0	20.0	23.0		
# who quit	0	0	2		

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

% who quit	0.0	0.0	0.7	
# w/tobacco cessation counseling	ng,			
Rx for cessation aid or quit-				
No Refusals	0	2	71	
% w/ tobacco cessation counsel:	•			
Rx for cessation aid or quit-	-			
No Refusals	0.0	20.0	23.9	
CHANGE FROM PREV YR %				
w/tobacco cessation counseling				
or RX for cessation aid-				
No Refusals	+33.3	-4.2	+0.7	
# who quit	+0.0	+5.3	+1.6	
# w/tobacco cessation				
counseling, Rx for cessation	aid or quit	_		
No Refusals	+33.3	+1.1	+2.5	

Figure 2-51: Sample Age Breakdown Report, Tobacco Cessation

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Tobacco Cessation: List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use. HRN COMMUNITY SEX AGE PATIENT NAME DENOMINATOR NUMERATOR PATIENT1, BRITNEY 000001 COMMUNITY #1 F 22 UP,AC COUNSEL/RX: 06/10/15 CPT G0375 PATIENT2, LORETTA 000002 COMMUNITY #1 F 22 UP,AC COUNSEL/RX: 01/13/15 305.1-DP PATIENT3, HALEY 000003 COMMUNITY #1 F 25 UP,AC COUNSEL/RX: 02/19/15 TO-LA PATIENT4, ANGEL 000004 COMMUNITY #1 F 30 COUNSEL/RX: 03/05/15 CPT 4000F UP,AC PATIENT5, JOYCE 000005 COMMUNITY #1 F 31 UP,AC QUIT: PREVIOUS (FORMER) SMOKER 05/31/15 PATIENT6, ESTHER UP.AC 000006 COMMUNITY #1 F 32 COUNSEL/RX: 03/05/15 CESSATION MED - NICOTINE 14MG UP,AC TRANSDERMAL PATCH
PATIENT7, SARAH 000007 COMMUNITY #1 F 33 UP,AC PATIENT8, PAULA 000008 COMMUNITY #1 F 34 COUNSEL/RX: 03/17/15 TO-QT UP,AC

Figure 2-52: Sample Patient List Tobacco Cessation

# 2.7 Behavioral Health Related Performance Measure Topics

# 2.7.1 Alcohol Screening (FAS Prevention)

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 66.7% for the proportion of female patients ages 15 to 44 who receive screening for alcohol use.

### **Denominators**

Female Active Clinical patients ages 15 to 44. (GPRA Denominator)

Female User Population patients ages 15 to 44.

### **Numerators**

Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, or received alcohol-related patient education during the report period.

Note:	This numerator does <i>not</i> include refusals. (GPRA
	Numerator)

- a. Patients with alcohol screening during the report period.
- b. Patients with alcohol-related diagnosis or procedure during the report period
- c. Patients with alcohol-related patient education during the report period.

## **Logic Description**

Ages are calculated at beginning of Report Period.

Alcohol screening definition: Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

Subject Defined	ICD and Other Codes
Alcohol Screening	Exam Code: 35
	<b>CPT code:</b> 99408, 99409, G0396, G0397, H0049, H0050, 3016F
	Any CAGE Health Factor
	POV: ICD-9: V11.3 (history of alcoholism), V79.1 (screening for
	alcoholism)
	BHS Problem Code: 29.1 (Screening for Alcoholism)
	Measurement in PCC or BHS: AUDT, AUDC, or CRFT

Subject Defined	ICD and Other Codes
Alcohol-related Diagnosis	POV, Current PCC or BHS Problem List: ICD-9: 303.*, 305.0*, 291.*, 357.5*; ICD-10: F10.1*, F10.20, F10.220-F10.29, F10.982, F10.99, G62.1 BHS POV: 10, 27, 29
Alcohol-related Procedure	<b>Procedure:</b> ICD-9: 94.46, 94.53, 94.61-94.63, 94.67-94.69
Alcohol-related Education	<b>Patient Education codes:</b> "AOD-" or "-AOD", "CD-" or "-CD" (old codes), or containing V11.3, V79.1, 303.*, 305.0*, 291.* 357.5*, 99408, 99409, G0396, G0397, H0049, or H0050, or 3016F

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

## **Recommended Brief Screening Tool**

Single Alcohol Screening Question (SASQ) (below).

### For Women:

When was the last time you had more than four drinks in one day?

### For Men:

When was the last time you had more than five drinks in one day?

Any time in the past 3 months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

### **Alcohol Health Factors**

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

- 1. Have you ever felt the need to Cut down on your drinking?
- 2. Have people Annoyed you by criticizing your drinking?
- 3. Have you ever felt bad or Guilty about your drinking?
- 4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?
- 5. Based on how many YES answers are received, document Health Factor:
  - HF-CAGE 0/4 (all "No" answers)
  - HF-CAGE 1/4

- HF–CAGE 2/4
- HF-CAGE 3/4
- HF-CAGE 4/4

### Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: # of drinks daily

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of female patients with documented alcohol screening, if any.

### **Measure Source**

HP 2010 16-17a

## **Measure Past Performance and Long-term Targets**

Performance	Percent
IHS FY 2014 Performance	66.0%
IHS FY 2013 Performance	65.7%
IHS FY 2012 Performance	63.8%
IHS FY 2011 Performance	57.8%
IHS FY 2010 Performance	55.0%
IHS FY 2009 Performance	52.0%
IHS FY 2008 Performance	47.0%
IHS FY 2007 Performance	41.0%
IHS FY 2006 Performance	28.0%
IHS FY 2005 Performance	11.0%
IHS FY 2004 Performance	7.0%

```
DU
                            November 25, 2015
                                                                   Page 114
       *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Alcohol Screening (FAS Prevention)
                    REPORT
                              % PREV YR
                                            % CHG from BASE
                                                                  % CHG from
                                 PERIOD
                                               PREV YR % PERIOD
                                                                     BASE %
                    PERIOD
```

Female Active Clinical									
	434		348			304			
ages 15-44 (GPRA)	434		340			304			
<pre># w/ alcohol screening/</pre>									
Dx/Proc/Pt Ed									
-No Refusals (GPRA)	50	11.5	2	0.6	+10.9	1	0.3	+11.2	
A. w/alcohol									
screening	43	9.9	1	0.3	+9.6	0	0.0	+9.9	
B. # w/alcohol related									
Dx or procedure	3	0.7	1	0.3	+0.4	1	0.3	+0.4	
C. # w/alcohol related									
patient education	10	2.3	0	0.0	+2.3	0	0.0	+2.3	
Female User Population									
ages 15-44	725		636			588			
# w/ alcohol screening/	Dx/								
Proc/Pt Ed									
-No Refusals	54	7.4	2	0.3	+7.1	2	0.3	+7.1	
A. # w/alcohol						_			
screening	46	6.3	1	0.2	+6.2	0	0.0	+6.3	
B. # w/alcohol related	,	0 6		0.0	0.4			0.0	
Dx or procedure	4	0.6	1	0.2	+0.4	2	0.3	+0.2	
C. # w/alcohol related	1.1	1 -	_	0 0	.1 5	0	0 0	1 5	
patient education	11	1.5	0	0.0	+1.5	0	0.0	+1.5	

Figure 2-53: Sample Report, Alcohol Screening (FAS Prevention)

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Alcohol Screening (FAS Prevention): List of female patients with documented alcohol screening, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR -----\_\_\_\_\_\_ PATIENT1, CHRISTINE S 000001 COMMUNITY #1 F 15 PATIENT2, RITA A 000002 COMMUNITY #1 F 15 UP, AC SCREEN: 03/06/15 POV V11.3 POV V11.3 PATIENT3, DIANE L 000003 COMMUNITY #1 F 15 PATIENT4, ALICIA 000004 COMMUNITY #1 F 15 UP,AC PATIENT5, MELISSA 000005 COMMUNITY #1 F 16
UP, AC PT ED: 02/13/15 99408PATIENT6, LISA MARIE 000006 COMMUNITY #1 F 16
UP, AC SCREEN: 10/13/15 HF CA PT ED: 02/13/15 99408-P SCREEN: 10/13/15 HF CAGE 1/4 PATIENT7, RUTH NELLIE 000007 COMMUNITY #1 F 16 PATIENT8, ALISHA DAWN 000008 COMMUNITY #1 F 16 SCREEN: 03/03/15 CPT 3016F UP,AC

Figure 2-54: Sample Patient List, Alcohol Screening (FAS Prevention)

# 2.7.2 Alcohol Screening and Brief Intervention (ASBI) in the ER

### **Denominators**

Number of visits for *Active Clinical Plus BH patients* age 15 through 34 seen in the ER for injury during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Number of visits for *Active Clinical Plus BH patients* age 15 through 34 seen in the ER for injury and screened positive for hazardous alcohol use during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Number of visits for *User Population patients* age 15 through 34 seen in the ER for injury during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

Number of visits for *User Population patients* age 15 through 34 seen in the ER for injury and screened positive for hazardous alcohol use during the report period. Broken down by gender and age groups (15 through 24 and 25 through 34).

### **Numerators**

Number of visits where patients were screened in the ER for hazardous alcohol use.

a. Number of visits where patients were screened positive.

Number of visits where patients were provided a brief negotiated interview (BNI) at or within 7 days of the ER visit.

- a. Number of visits where patients were provided a BNI at the ER visit.
- b. Number of visits where patients were provided a BNI not at the ER visit but within 7 days of the ER visit.

## **Logic Description**

Age of the patient is calculated as of the beginning of the Report Period.

Emergency room visit definition: Clinic Code 30.

Multiple visits definition: If a patient has multiple ER visits for injury during the Report Period, each visit will be counted in the denominator. For the screening numerator, each ER visit with injury at which the patient was screened for hazardous alcohol use will be counted. For the positive alcohol use screen numerator, each ER visit with injury at which the patient screened positive for hazardous alcohol use will be counted. For the BNI numerators, each visit where the patient was either provided a BNI at the ER or within 7 days of the ER visit will be counted. An example of this logic is shown below.

ER Visit w/Injury	Denom Count	Scrn Num	Pos Scrn Num Count	BNI Num Count	
John Doe, 07/17/15, John Doe, 09/01/15, John Doe, 11/15/15,	Screened Posi	itive at	ER, BNI at E		
********		*****	*****	******	
COUNTS:	3	2	2	1	

CRS uses the following codes:

Subject Defined	ICD and Other Codes
Injury	<b>POV (primary or secondary):</b> ICD-9: 800.0–999.9 or E800.0–E989; ICD-10: (All codes for this taxonomy ending in A, B, or C only)
	S00.00XA, S00.01XA, S00.03XA-S00.05XA, S00.07XA-S00.219A,
	S00.241A-S00.259A, S00.271A-S00.31XA, S00.33XA-S00.35XA,
	S00.37XA-S00.419A, S00.431A-S00.459A, S00.471A-S00.512A,
	S00.531A-S00.552A, S00.571A-S00.81XA, S00.83XA-S00.85XA,
	S00.87XA-S00.91XA, S00.93XA-S00.95XA, S00.97XA, S01.*-S05.*,
	S06.**0A, S06.**1A, S06.**2A, S06.**9A, S07.*-S09.*, S10.0XXA-
	S10.11XA, S10.14XA, S10.15XA, S10.17XA-S10.81XA, S10.83XA-
	S10.85XA, S10.87XA-S10.91XA, S10.93XA-S10.95XA, S10.97XA,
	S11.*-S19.*, S20.00XA-S20.119A, S20.141A-S20.159A, S20.171A-
	S20.319A, S20.341A-S20.359A, S20.371A-S20.419A, S20.441A-
	S20.459A, S20.471A-S20.91XA, S20.94XA, S20.95XA, S20.97XA,
	S21.*-S29.*, S30.0XXA-S30.817A, S30.840A-S30.857A, S30.870A-
	S30.98XA, S31.*-S39.*, S40.011A-S40.219A, S40.241A-S40.259A,
	S40.271A-S40.819A, S40.841A-S40.859A, S40.871A-S40.929A,
	S41.*-S49.*, S50.00XA-S50.319A, S50.341A-S50.359A, S50.371A-
	S50.819A, S50.841A-S50.859A, S50.871A-S50.919A, S51.*-S59.*, S60.00XA-S60.319A, S60.341A-S60.359A, S60.371A-S60.419A,
	S60.440A-S60.459A, S60.470A-S60.519A, S60.541A-S60.559A,
	S60.571A-S60.819A, S60.841A-S60.859A, S60.871A-S60.949A,
	S61.*-S69.*, S70.00XA-S70.219A, S70.241A-S70.259A, S70.271A-
	\$70.319A, \$70.341A-\$70.359A, \$70.371A-\$70.929A, \$71.*-\$79.*,
	S80.00XA-S80.219A, S80.241A-S80.259A, S80.271A-S80.819A,
	S80.841A-S80.859A, S80.871A-S80.929A, S81.*-S89.*, S90.00XA-
	S90.416A, S90.441A-S90.456A, S90.471A-S90.519A, S90.541A-
	S90.559A, S90.571A-S90.819A, S90.841A-S90.859A, S90.871A-
	S90.936A, S91.*-S99.*, T07-T34.*, T36.*X1A, T36.*X2A, T36.*X3A,
	T36.*X4A, T36.91XA-T36.94XA, T37.*X1A, T37.*X2A, T37.*X3A,
	T37.*X4A, T37.91XA-T37.94XA, T38.**1A, T38.**2A, T38.**3A,
	T38.**4A, T39.**1A, T39.**2A, T39.**3A, T39.**4A, T39.91XA-
	T39.94XA, T40.**1A, T40.**2A, T40.**3A, T40.**4A, T41.**1A,
	T41.**2A, T41.**3A, T41.**4A, T41.41XA-T41.44XA, T42.**1A,
	T42.**2A, T42.**3A, T42.**4A, T42.71XA-T42.74XA, T43.**1A,
	T43.**2A, T43.**3A, T43.**4A, T43.91XA-T43.94XA, T44.**1A,
	T44.**2A, T44.**3A, T44.**4A, T45.**1A, T45.**2A, T45.**3A, T45.**4A, T45.91XA-T45.94XA, T46.**1A, T46.**2A, T46.**3A,
	T46. *4A, T45.91XA-145.94XA, T46. TA, T46. ZA, T46. SA, T46.**4A, T47.**1A, T47.**2A, T47.**3A, T47.**4A, T47.91XA-
	T47. 94XA, T48.**1A, T48.**2A, T48.**3A, T48.**4A, T49.**1A,
	T49.**2A, T49.**3A, T49.**4A, T49.91XA-T49.94XA, T50.**1A,
	T50.**2A, T50.**3A, T50.**4A, T51.*-T76.*, T79.*, V00.*-Y35.*
ER Screening for	Any conducted during an ER visit.
Hazardous Alcohol	Exam Code: 35
Use	Any Alcohol Health Factor (i.e., CAGE)
	POV: V79.1 Screening for Alcoholism
	<b>CPT</b> : G0396, G0397, H0049, 99408, 99409, 3016F
	Measurement in PCC: AUDT, AUDC, or CRFT
	INICASUICINCIN FOC. AUDI, AUDO, UI CAFI

Subject Defined	ICD and Other Codes
Positive Screen for	Any of the following for the screening conducted during an ER visit:
Hazardous Alcohol	Exam Code: 35 Alcohol Screening result of "Positive"
Use	Health Factor: CAGE result of 1/4, 2/4, 3/4 or 4/4
	<b>CPT:</b> G0396, G0397, 99408, 99409
	<b>Measurement Result in PCC:</b> AUDT result of equal to or greater than (=>) 8, AUDC result of equal to or greater than (=>) 4 for men and equal to or greater than (=>)3 for women, CRFT result of 2-6
BNI	Any of the following documented at the ER visit or within 7 days of the ER visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:
	<b>CPT:</b> G0396, G0397, H0050, 99408, 99409
	Patient Education Code: AOD-BNI or containing G0396, G0397, H0050, 99408, or 99409

# **Recommended Brief Screening Tool**

SASQ (below).

For Women:

When was the last time you had more than four drinks in one day?

For Men:

When was the last time you had more than five drinks in one day?

Any time in the past 3 months is a positive screen; further evaluation indicated. Provider should note the screening tool used was the SASQ in the COMMENT section of the Exam Code.

### **Alcohol Health Factors**

The existing Health Factors for alcohol screening are based on the CAGE questionnaire, which asks the following four questions:

- 1. Have you ever felt the need to Cut down on your drinking?
- 2. Have people Annoyed you by criticizing your drinking?
- 3. Have you ever felt bad or **G**uilty about your drinking?
- 4. Have you ever needed an **E**ye opener the first thing in the morning to steady your nerves or get rid of a hangover?

Based on how many YES answers are received, document Health Factor:

• HF-CAGE 0/4 (all No answers)

- HF-CAGE 1/4
- HF-CAGE 2/4
- HF-CAGE 3/4
- HF–CAGE 4/4

## Optional values:

- Level/Severity: Mild, Moderate, or Severe
- Quantity: number of drinks daily

## **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of visits for patients seen in the ER for an injury, with screening for hazardous alcohol use, results of screen and BNI, if any.

# **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 117  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Alcohol Screening and Brief Intervention (ASBI) in the ER  REPORT % PREV YR % CHG from BASE % CHG from								
					PREV YR % PEF			
# ER Injury Visits for AC+BH Pts 15-34	34		34			32		
<pre># Visits w/ ER Hazardous Alcohol Screening A. # Visits w/Positive Screen</pre>					+58.8			+58.8
# ER Injury Visits for Male AC+BH Pts 15-34	13	44.1	19	0.0	744.1	20	0.0	T11.1

# Visits w/ ER Hazardous Alcohol Screening A. # Visits w/Positive Screen		61.5	0	0.0	+61.5		0.0	+61.5 +38.5
# ER Injury Visits for Female AC+BH Pts 15-34	21		15			12		
# Visits w/ ER Hazardous Alcohol Screening A. # Visits w/Positive Screen		57.1 47.6	0	0.0	+57.1	0	0.0	+57.1 +47.6
# of ER Injury Visits for AC+BH Pts 15-24	18		16			21		
# Visits w/ ER Hazardous Alcohol Screening A. # Visits w/Positive Screen		61.1	0	0.0	+61.1	0	0.0	+61.1 +50.0
# ER Injury Visit for AC+BH Pts 25-34	16		18			11		
# Visits w/ ER Hazardous Alcohol Screening A. # Visits w/Positive Screen		56.3 37.5	0	0.0	+56.3	0	0.0	+56.3 +37.5

Figure 2-55: Sample Report, Alcohol Screening and Brief Intervention (ASBI) in the ER

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Alcohol Screening and Brief Intervention (ASBI) in the ER: List of visits for patients seen in the ER for an injury, with screening for hazardous alcohol use, results of screen and BNI, if any. HRN COMMUNITY PATTENT NAME SEX AGE DENOMINATOR NUMERATOR PATIENT1, DARLENE S 000001 COMMUNITY #1 F 33
UP, AC+BH ER 1) 02/02/15 POV 816.0
PATIENT2, RITA A 000002 COMMUNITY #1 F 33
UP, AC+BH ER 1) 07/12/15 POV 875.0
PATIENT3, DIANE L 000003 COMMUNITY #1 F 15
UP, AC+BH ER 1) 09/08/15 POV 815.0
PATIENT4, ALICIA 000004 COMMUNITY #1 F 18 ER 1) 02/02/15 POV 816.02, SCREEN: Neg/No Res CPT 3016F ER 1) 07/12/15 POV 875.0, SCREEN: Pos Ex 35, BNI: No ER 1) 09/08/15 POV 815.00, SCREEN: None ER 1) 04/20/15 POV 959.7, SCREEN: Neg/No Res CPT H0049 PATIENT5, MELISSA 000005 COMMUNITY #1 F 16 UP,AC+BH PATIENT6, LISA MARIE 000006 COMMUNITY #1 F 20

UP ER 1) 11/16/15 POV 873.42, SCREEN: None; ER 2) 11/18/15 POV 800.10, SCREEN: Pos Ex 35, BNI: 11/18/15 Yes ER AOD-BNI

Figure 2-56: Sample Patient List, Alcohol Screening and Brief Intervention (ASBI) in the ER

# 2.7.3 Intimate Partner (Domestic) Violence Screening

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 61.6% for the proportion of female patients ages 15 to 40 who receive screening for domestic violence.

## **Denominators**

Female Active Clinical patients ages 13 and older.

Female Active Clinical patients ages 15 through 40. (GPRA Denominator)

Female User Population patients ages 13 and older.

### **Numerators**

Patients screened for intimate partner (domestic) violence at any time during the Report Period.

**Note**: This numerator does *not* include refusals. (GPRA Numerator)

- a. Patients with documented IPV/DV exam
- b. Patients with IPV/DV related diagnosis
- c. Patients provided with education or counseling about IPV/DV

### **Logic Description**

Age of the patient is calculated at the beginning of the report period. CRS uses the following codes to define numerators.

Subject Defined	CPT Codes	ICD and Other Codes
IPV/DV Screening		Exam: Code 34
		BHS Exam: IPV/DV
IPV/DV Diagnosis		POV or current PCC or BHS Problem List: ICD-9: 995.80-995.83, 995.85, V15.41, V15.42, V15.49; ICD-10: T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410 BHS POV: 43.*, 44.*
IPV/DV Education		<b>Patient education codes:</b> "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, or V15.49

Subject Defined	CPT Codes	ICD and Other Codes
IPV/DV Counseling		<b>POV: ICD-9:</b> V61.11; ICD-10: Z69.11

# **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of female patients 13 and older with documented IPV/DV screening, if any.

## **Measure Source**

HP 2010 15-34

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	63.5%
IHS FY 2013 Performance	62.4%
IHS FY 2012 Performance	61.5%
IHS FY 2011 Performance	55.3%
IHS FY 2010 Performance	53.0%
IHS FY 2009 Performance	48.0%
IHS FY 2008 Performance	42.0%
IHS FY 2007 Performance	36.0%
IHS FY 2006 Performance	28.0%
IHS FY 2005 Performance	13.0%
IHS FY 2004 Performance	4.0%

DU November 25, 2015 Page 128  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010						
Intimate Partner (Domestic) Violence Screening (con't)  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %						
# Female Active Clinical ages 13 and older # w/IPV/DV Screening	712	519	460			

-No Refusals A. # w/documented	13	1.8	1	0.2	+1.6	0	0.0	+1.8
IPV/DV exam B. # w/ IPV/DV related	8	1.1	0	0.0	+1.1	0	0.0	+1.1
diagnosis C. # provided DV	4	0.6	0	0.0	+0.6	0	0.0	+0.6
education	4	0.6	1	0.2	+0.4	0	0.0	+0.6
# Female Active Clinical ages 15-40 (GPRA)	380		311			267		
(GIIII)	300		311			207		
# w/IPV/DV screening -No Refusals								
(GPRA) A. # w/ documented	11	2.9	1	0.3	+2.6	0	0.0	+2.9
IPV/DV exam	6	1.6	0	0.0	+1.6	0	0.0	+1.6
B. # w/ IPV/DV related diagnosis	3	0.8	0	0.0	+0.8	0	0.0	+0.8
C. # provided DV education	4	1.1	1	0.3	+0.7	0	0.0	+1.1
# Female User Pop								
_	,218		1,005			917		
# w/IPV/DV Screening								
-No Refusals	13	1.1	1	0.1	+1.0	1	0.1	+1.0
A. # w/ documented IPV/DV exam	8	0.7	0	0.0	+0.7	0	0.0	+0.7
B. # w/ IPV/DV related diagnosis	4	0.3	0	0.0	+0.3	1	0.1	+0.2
C. # provided DV education	4	0.3	1	0.1	+0.2	0	0.0	+0.3
education	4	0.3	1	0.1	<b>⊤∪.</b> ∠	U	0.0	TU.3

Figure 2-57: Sample Report, Intimate Partner (Domestic) Violence Screening

UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Intimate Partner (Domestic) Violence Screening: List of female patients 13 and older with documented IPV/DV screening, if any. HRN COMMUNITY SEX AGE PATTENT NAME PATIENT NAME DENOMINATOR NUMERATOR PATIENT1, ELVIRA 000001 COMMUNITY #1 F 13
UP EXAM: 03/18/15 Ex 34
PATIENT2, SHARON KAY 000002 COMMUNITY #1 F 14 PATIENT3, KRISTINA 000003 COMMUNITY #1 F 15 000004 COMMUNITY #1 F 15 PATIENT4, RITA UP,AC EXAM: 05/06/15 Ex 34 PATIENT5, DIANE LOUISE 000005 COMMUNITY #1 F 15 EXAM: 02/24/15 Ex 34 PATIENT6, ALICE LILA 000006 COMMUNITY #1 F 15

UP,AC

Figure 2-58: Sample Patient List, Intimate Partner (Domestic) Violence Screening

# 2.7.4 Depression Screening

## **GPRAMA Measure Description**

During FY 2015, achieve the target rate of 64.3% for the proportion of adults ages 18 and older who receive annual screening for depression.

#### **Denominators**

Active Clinical patients ages 18 and older. Broken down by gender. (GPRAMA Denominator)

a. Active Clinical patients ages 65 and older. Broken down by gender.

User Population patients ages 18 and older. Broken down by gender.

b. User Population patients ages 65 and older. Broken down by gender.

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. Broken down by gender.

Active CHD patients, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever. Broken down by gender.

#### **Numerators**

Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note**: This numerator does not include refusals. (GPRAMA Numerator)

- a. Patients screened for depression during the Report Period.
- b. Patients with a diagnosis of a mood disorder during the Report Period.

Patients with depression-related education in past year.

**Note:** Depression-related patient education does not count toward the GPRAMA numerator and is included as a separate numerator only.

## **Logic Description**

Age is calculated at beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	ICD and Other Codes
Diabetes	POV: ICD-9: 250.00–250.93; ICD-10: E10.*-E13.*
Coronary Heart Disease	Any of the following:  1) POV: ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9  2) One or more CABG or PCI procedures
CABG	POV: ICD-9: V45.81; ICD-10: Z95.1 CPT: 33510-33514, 33516-33519, 33521-33523, 33533-33536, S2205-S2209 Procedure: ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	POV: ICD-9: V45.82; ICD-10: Z95.5, Z98.61 CPT: 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982, 92995, G0290 Procedure: ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**
Depression Screening	Exam: Exam Code 36 POV: ICD-9: V79.0 CPT: 1220F BHS Problem Code: 14.1 (Screening for Depression) Measurement in PCC or BHS: PHQ2 or PHQ9
Mood Disorders	At least 2 visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.  POV: ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39  BHS POV: 14, 15
Depression-related Patient Education (does not count toward GPRA numerator)	Documented education of any of the following during the Report Period:  Patient education codes: containing "DEP-" (depression), 296.2* or 296.3*, "BH-" (behavioral and social health), 290319, 995.5*, or 995.80–995.85, "SB-" (suicidal behavior) or 300.9, or "PDEP-" (postpartum depression) or 648.44.

# **Recommended Brief Screening Tool**

A sample of a Patient Health Questionnaire (PHQ-2 Scaled Version) appears below.

Over the past 2 weeks, how often have you been bothered by any of the following problems?

- 1. Little interest or pleasure in doing things
  - Not at all Value: 0
  - Several days Value: 1
  - More than half the days Value: 2
  - Nearly every day Value: 3
- 2. Feeling down, depressed, or hopeless
  - Not at all Value: 0
  - Several days Value: 1
  - More than half the days Value: 2
  - Nearly every day Value: 3

Total Possible PHQ-2 Score: Range: 0-6

- 0–2: Negative
- 3–6: Positive; further evaluation indicated

Provider should note the screening tool used was the PHQ-2 Scaled in the COMMENT section of the Exam Code.

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients with documented depression screening/diagnosed with mood disorder, if any.

#### **Measure Source**

USPSTF (US Preventive Services Task Force), HP 2010 developmental indicator 18 through 6.

## Measure Past Performance and Long-Term Targets

Performance	Percent
IHS FY 2014 Performance	66.0%
IHS FY 2013 Performance	65.1%

Performance	Percent
IHS FY 2012 Performance	61.9%
IHS FY 2011 Performance	56.5%
IHS FY 2010 Performance	52.0%
IHS FY 2009 Performance	44.0%
IHS FY 2008 Performance	35.0%
IHS FY 2007 Performance	24.0%
IHS FY 2006 Performance	15.0%

DU November 25, 2015 Page 130  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010										
Depression Screening	(con't)									
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %			CHG from BASE %		
Active Clinical Pts => 18 (GPRAMA)	1,191		815			668				
# w/Depression screening or Mood Disorder DX-No										
Refusals (GPRAMA)  A. # screened for	82	6.9	42	5.2	+1.7	17	2.5	+4.3		
depression	40	3.4	0	0.0	+3.4	0	0.0	+3.4		
B. # w/mood disorder DX	43	3.6	42	5.2	-1.5	17	2.5	+1.1		
<pre># w/depression education</pre>	13	1.1	3	0.4	+0.7	0	0.0	+1.1		
Male Active Clinical										
Pts >=18	480		316			250				
# w/ Depression scre	_									
Refusals	26	5.4	7	2.2	+3.2	1	0.4	+5.0		
A. # screened for depression	15	3.1	0	0.0	+3.1	0	0.0	+3.1		
B. # w/Mood Disorder DX	11	2.3	7	2.2	+0.1	1	0.4	+1.9		
<pre># w/depression education</pre>	3	0.6	1	0.3	+0.3	0	0.0	+0.6		
Female Active Clinic Pts >=18	al 711		499			418				
# w/ Depression scre or Mood Disorder DX Refusals A. # screened for		7.9	35	7.0	+0.9	16	3.8	+4.0		

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

depression B. # w/Mood Disorder	25	3.5	0	0.0	+3.5	0	0.0	+3.5			
DX # w/depression	32	4.5	35	7.0	-2.5	16	3.8	+0.7			
education	10	1.4	2	0.4	+1.0	0	0.0	+1.4			
A. Active Clinical Pts											
=> 65	122		71			65					
# w/ Depression screening or Mood Disorder DX-No											
Refusals	9	7.4	6	8.5	-1.1	2	3.1	+4.3			
A. # screened for depression	3	2.5	0	0.0	+2.5	0	0.0	+2.5			
B. # w/mood disorder  DX	6	4.9	6	8.5	-3.5	2	3.1	+1.8			
<pre># w/depression   education</pre>	2	1.6	2	2.8	-1.2	0	0.0	+1.6			

Figure 2-59: Sample Report, Depression Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Depression Screening: List of patients with documented depression screening/diagnosed with mood disorder, if any. HRN PATIENT NAME COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT55, LORETTA LYNN 000055 COMMUNITY #1 F 78 PATIENT56,TINA MARIE 000056 COMMUNITY #1 F 78
UP,AC,AD,CHD SCREEN: 05/22/15 Meas
PATIENT57,DANIELLE 000057 COMMUNITY #1 F 79
UP.AC PT ED: 02/06/15 296.20 SCREEN: 05/22/15 Meas PHQ9 UP,AC PT ED: 02/06/15 296.20-DP PATIENT58, LESLIE ANN 000058 COMMUNITY #1 F 80 SCREEN: 04/15/15 POV V79.0 UP,AC PATIENT59, DONNA SUE 000059 COMMUNITY #1 F 86 SCREEN: 01/15/15 POV V79.0 PATIENT60, TAYLOR OLIVIA 000060 COMMUNITY #1 PATIENT61, DENNIS GERALD 000061 COMMUNITY #1 M 18 PT ED: 02/01/15 296.20-DP PATIENT62, JOSHUA DALE 000062 COMMUNITY #1 M 18 UP,AC

Figure 2-60: Sample Patient List, Depression Screening

# 2.7.5 Antidepressant Medication Management

#### **Denominators**

As of the 120th day of the Report Period, *Active Clinical Plus BH patients* 18 years of age and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

As of the 120th day of the Report Period, *User Population patients* 18 years of age and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

#### **Numerators**

Effective Acute Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks).

Effective Continuation Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months).

## **Logic Description**

Age is calculated at the beginning of the report period. To be included in the denominator, patient must have filled a prescription for an antidepressant medication (see list of medications below) within the 121st day of the year prior to the Report period to the 120th day of the Report period. For example, if Report period is July 1, 2014 - June 30, 2015, patient must have filled a prescription during 11/1/2013 - 10/29/2014. In V Medication, Date Discontinued must not be equal to the prescription (i.e. visit) date. The Index Prescription Start Date (IPSD) is the date of the earliest prescription for antidepressant medication filled during that time period.

#### **Denominator Exclusions**

Patients who did not have a diagnosis of major depression in an inpatient, outpatient, ED, intensive outpatient or partial hospitalization setting during the 60 days prior to the IPSD (inclusive) through 60 days after the IPSD (inclusive).

Major depression defined as POV ICD-9: 296.20-296.25, 296.30-296.35, 298.0, 311; ICD-10: F32.0-F32.4, F32.8-F33.3, F33.41, F33.9.

Patients who had a new or refill prescription for antidepressant medication (see list of medications below) within 105 days prior to the Index Prescription Start Date are excluded as they do not represent new treatment episodes.

## Effective Acute Phase Treatment Numerator

For all antidepressant medication prescriptions filled (see list of medications below) within 114 days of the Index Prescription Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Prescription Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 30 days or if the patient does not have 84 treatment days within the 114-day time frame, the patient is not included in the numerator.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

## **Example of Patient Included in Numerator:**

- First RX is Index Rx Date: 11/1/2014, # Days Prescribed=30
- Rx covers patient through 12/1/2014
- Second RX: 12/15/2014, # Days Prescribed=30
- Gap #1 = (12/15/2014-12/1/2014) = 14 days
- Rx covers patient through 1/14/2015
- Third RX: 1/10/2015, # Days Prescribed=30
- No gap days
- Rx covers patient through 2/13/2015
- Index Rx Date 11/1/2014 + 114 days = 2/23/2015
- Patient's 84th treatment day occurs on 2/7/2015, which is less than or equal to ( $\leq$ ) 2/23/2015 and # gap days of 14 is less than 30

#### **Example of Patient Not Included in Numerator:**

- First Rx is Index Rx Date: 11/1/2014, # Days Prescribed=30
- Rx covers patient through 12/1/2014
- Second Rx: 12/15/2014, # Days Prescribed=30
- Gap #1 = (12/15/2014-12/1/2014) = 14 days
- Rx covers patient through 1/14/2015
- Third Rx: 2/01/2015, # Days Prescribed=30

• Gap #2 = (2/01/2015 through 1/14/2015) = 18, total # gap days = 32, so patient is not included in the numerator

Effective Continuation Phase Treatment Numerator

For all antidepressant medication prescriptions (see list of medications below) filled within 231 days of the Index Prescription Date, CRS counts the days prescribed (i.e., treatment days) (from V Medication) from the Index Prescription Date until a total of 180 treatment days has been established. If the patient had a total gap exceeding 51 days or if the patient does not have 180 treatment days within the 231 day time frame, the patient is not included in the numerator.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Antidepressant medications defined with medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS. (Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinepherine reuptake inhibitors (SNRI), and other antidepressants.) Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients with new depression DX and acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

#### Measure Source

HEDIS, HP 2010 18-9b

#### Measure Past Performance and Long-Term Targets

None

```
DU November 25, 2015 Page 141

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014
```

Baseli	to Dec 31, 2	2010							
Antidepressant Medication Management (con't)									
	PORT RIOD	•			CHG from E			HG from BASE %	
AC+BH Pts =>18 w/new depression DX and antidepressant meds	17		6			2			
<pre># w/12 week treatment   meds # w/180 day treatment</pre>					-13.7			+52.9	
meds	4	23.5	3	50.0	-26.5	0	0.0	+23.5	
User Pop Pts =>18 w/new depression DX and antidepressant meds			7			3			
<pre># w/12 week treatment   meds # w/180 day treatment</pre>	9	50.0	4	57.1	-7.1	0	0.0	+50.0	
meds	4	22.2	3	42.9	-20.6	0	0.0	+22.2	

Figure 2-61: Sample Report, Antidepressant Medication Management

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Antidepressant Medication Management: List of patients with new depression DX and acute phase treatment (APT) and continuation phase treatment (CONPT), if any. HRN COMMUNITY PATIENT NAME SEX AGE DENOMINATOR NUMERATOR PATIENT1, MICHELLE D 000001 COMMUNITY #1 F 22 UP, AC+BH IESD: 06/06/14; NOT APT: DAYS=60, GAP=1; NOT CONPT: UP,AC+BH
DAYS=60, GAP=1
PATIENT2,PAULA KAY
UP,AC+BH
PATIENT3,RHONDA SUE

000002 COMMUNITY #1 F 34
IESD: 10/29/14; NOT A
000003 COMMUNITY #1 F 35
IESD: 04/21/15; NOT A IESD: 10/29/14; NOT APT: DAYS=68, GAP=28; CONPT IESD: 04/21/15; NOT APT: DAYS=74, GAP=0; NOT CONPT: DAYS=74, GAP=0 PATIENT4, KATHLEEN 000004 COMMUNITY #1 F 38 UP,AC+BH IESD: 11/15/14; APT; CONPT

Figure 2-62: Sample Patient List, Antidepressant Medication Management

# 2.8 Cardiovascular Disease Related Measure Topics

# 2.8.1 Obesity Assessment

#### **Denominators**

Active Clinical patients ages 2 through 74. Broken down by gender and age groups (2 through 5, 6 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74).

All *User Population patients* ages 2 through 74. Broken down by gender.

#### **Numerators**

Patients for whom a Body Mass Index (BMI) could be calculated.

**Note**: This numerator does *not* include refusals.

- 1. For those with a BMI calculated, those considered overweight but not obese using BMI and standard tables
- 2. For those with a BMI calculated, those considered obese using BMI and standard tables
- 3. Total of overweight and obese

Patients with documented refusal in past year.

## **Logic Description**

Age is calculated at beginning of the Report Period.

BMI calculation definition: CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2-18, definitions are based on standard tables. Refusals include REF, NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and weight must be refused during the past year and are not required to be on the same visit.

Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients with current BMI, if any.

#### **Measure Source**

HP 2020: NWS-9 Obesity in Adults 20+, NWS-10.1 (Obesity in Children 2-5), NWS-10.2 Overweight or Obesity in Children 6-11, NWS-10.3 Overweight or Obesity in Adolescents 12-19, NWS-10.4 Overweight or Obesity in Children 2-19

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
Assessed as Obese–IHS FY 2012 Performance	47.1%
Assessed as Obese–IHS FY 2011 Performance	46.9%
Assessed as Obese–IHS FY 2010 Performance	47.0%
Assessed as Obese–IHS FY 2009 Performance	47.0%
Assessed as Obese–IHS FY 2008 Performance	46.0%
BMI Measured–IHS FY 2012 Performance	81.6%
BMI Measured–IHS FY 2011 Performance	78.0%
BMI Measured–IHS FY 2010 Performance	76.0%
BMI Measured–IHS FY 2009 Performance	75.0%
BMI Measured-IHS FY 2008 Performance	74.0%
BMI Measured- FY 2005 Performance	64.0%
BMI Measured-IHS FY 2004 Performance	60.0%
HP 2020 Goal: Obesity in Adults 20+ (NWS-9)	30.6%
HP 2020 Goal: Overweight or Obesity in Children 2–5 (NWS-10.1)	9.6%
HP 2020 Goal: Overweight or Obesity in Children 6–11 (NWS-10.2)	15.7%
HP 2020 Goal: Overweight or Obesity in Adolescents 12–19 (NWS-10.3)	16.1%
HP 2020 Goal: Overweight or Obesity in Children 2–19 (NWS-10.4)	14.6%

## **Performance Improvement Tips**

- 1. A Body Mass Index report can be run from your PCC Management Reports menu. This report can be run for all patients or for a specific template of patients that has been pre-defined with a QMan search. The BMI report will provide you with patient height, weight, date weight taken, BMI and NHANES percentile.
- 2. Recent guidelines indicate that height for adults must be taken at least once every 5 years, rather than once after age 18. Your BMI rates may be lower than anticipated because of height data that is over 5 years old.

- 3. If height and weight measurements are being recorded as cm/kg vs. in/lbs ensure providers are *noting* they are cm/kg *and* that data entry is entering the measurements correctly in PCC, as shown below.
  - Use mnemonics of CHT and KWT (vs. HT and WT), or
  - Add "c" after height value and "k" after weight value (e.g. 100c, 50k)

DU *** THE 2015	DU November 25, 2015 Page 143  *** IHS 2015 Selected Measures with Community Specified Report ***										
^^* IHS 2015	serected		ıres with ) INDIAN H			ттеа кер	ort *				
Report Period: Jan 01, 2015 to Dec 31, 2015											
Previous Year Period: Jan 01, 2014 to Dec 31, 2014											
Baseline Period: Jan 01, 2010 to Dec 31, 2010											
Obesity Assessment (con't)											
REPORT % PREV YR % CHG from BASE % CHG from											
	REPORT	%						CHG from BASE %			
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %			
Active Clinical Pts											
ages 2-74	1,400		1,096			982					
# w/BMI_calculated											
-No Refusals	880	62.9	824	75.2	-12.3	712	72.5	-9.6			
A. # Overweight w/ % of Total BMI	242	27.5	237	28.8	-1.3	101	26.8	+0.7			
B. # Obese w/	242	27.5	237	20.0	-1.3	191	20.0	+0.7			
% of Total BMI	372	42.3	339	41.1	+1.1	267	37.5	+4.8			
C. # Overweight/Obese		12.5	555			20.	57.5				
% of Total BMI		69.8	576	69.9	-0.1	458	64.3	+5.4			
# w/BMI refusal											
(No BMI)	4	0.3	0	0.0	+0.3	0	0.0	+0.3			
Mala Agtiva Clinical											
			465			410					
165 2 71	373		103			110					
# w/BMI calculated											
-No Refusals	341	57.3	331	71.2	-13.9	283	69.0	-11.7			
A. # Overweight w/											
	103	30.2	98	29.6	+0.6	73	25.8	+4.4			
· ·	155	15 E	1 / 1	12 6	+2 0	117	/1 2	+1 1			
		45.5	141	42.0	+4.9	11/	41.3	+4.1			
% of Total BMI		75.7	239	72.2	+3.5	190	67.1	+8.5			
# w/BMI refusal				_							
(no BMI)	2	0.3	0	0.0	+0.3	0	0.0	+0.3			
	_										
			C 2.7			F.F.C					
PTS 2-/4	805		631			572					
# w/BMT calculated											
	539	67.0	493	78.1	-11.2	429	75.0	-8.0			
A. # Overweight w/											
% of Total BMI	139	25.8	139	28.2	-2.4	118	27.5	-1.7			
B. # Obese w/											
# w/BMI refusal (No BMI)  Male Active Clinical Pts 2-74  # w/BMI calculated -No Refusals A. # Overweight w/ % of Total BMI B. # Obese w/ % of Total BMI C. #Overweight/Obese % of Total BMI # w/BMI refusal (no BMI)  Female Active Clinical Pts 2-74  # w/BMI calculated -No Refusals A. # Overweight w/ % of Total BMI	4 595 341 103 155 w/ 258 2 al 805 539	0.3 57.3 30.2 45.5 75.7 0.3	0 465 331 98 141 239 0 631	71.2 29.6 42.6 72.2 0.0	+0.3 -13.9 +0.6 +2.9 +3.5 +0.3	0 410 283 73 117 190 0 572 429	0.0 69.0 25.8 41.3 67.1 0.0	+0.3 -11.7 +4.4 +4.1 +8.5 +0.3			

% of Total BMI C. #Overweight/Obese w/	217	40.3	198	40.2	+0.1	150	35.0	+5.3
% of Total BMI # w/BMI refusal	356	66.0	337	68.4	-2.3	268	62.5	+3.6
(No BMI)	2	0.2	0	0.0	+0.2	0	0.0	+0.2

Figure 2-63: Sample Report, Obesity Assessment

Obesity Assessment (con	't)								
	TOTAL	ACTIVE			_				
	2-5	6-11		Distri 20-24	25-34	35-44	45-54	55-74	
CURRENT REPORT PERIOD Total # Active Clin # w/BMI calculated	109	112	157	133	233	215	216	225	
-No Refusals % w/BMI calculated	52	44	89	117	183	146	128	121	
-No Refusals	47.7	39.3	56.7	88.0	78.5	67.9	59.3	53.8	
# A. Overweight % A. Overweight w/	9	10	21	33	44	39	38	48	
% Total BMI	17.3	22.7	23.6	28.2	24.0	26.7	29.7	39.7	
# B. Obese % B. Obese w/	7	13	28	39	86	86	61	52	
% of Total BMI	13.5	29.5	31.5	33.3	47.0	58.9	47.7	43.0	
# C. Overweight or Obese % C. Overweight or Obes % Total BMI	16 e w/ 30.8	23 52.3	49 55.1		130 71.0	125 85.6	99 77.3	100 82.6	
<pre># w/BMI refusal   (No BMI) % w/BMI refusal   (No BMI)</pre>	1 1.9	0	0	0.0	0.0	1	1	1	
PREVIOUS YEAR PERIOD	_,,	0.0	0.0	0.0	0.0	0.7	0.0	0.0	
Total # Active Clin # w/BMI calculated	111	120	137	128	172	151	140	137	
-No Refusals % w/BMI calculated	49	56	88	114	155	129	113	120	
-No Refusals	44.1	46.7	64.2	89.1	90.1	85.4	80.7	87.6	
# A. Overweight % A. Overweight w/	7	11	20	38	47	33	36	45	
% Total BMI	14.3	19.6	22.7	33.3	30.3	25.6	31.9	37.5	
# B. Obese % B. Obese w/	14	14	26	35	65	77	56	52	
% B. Obese W/ % of Total BMI	28.6	25.0	29.5	30.7	41.9	59.7	49.6	43.3	
# C. Overweight or Obese % C. Overweight or Obes	21 e w/	25	46	73	112	110	92	97	
% Total BMI	42.9	44.6	52.3	64.0	72.3	85.3	81.4	80.8	

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

# w/BMI refusal									
(No BMI)	0	0	0	0	0	0	0	0	
% w/BMI refusal									
(No BMI)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
CHANGE FROM PREV YR %									
w/BMI calculated									
-No Refusals	+3.6	-7.4	-7.5	-1.1	-11.6	-17.5	-21.5	-33.8	
A. Overweight	+3.0	+3.1	+0.9	-5.1	-6.3	+1.1	-2.2	+2.2	
B. Obese	-15.1	+4.5	+1.9	+2.6	+5.1	-0.8	-1.9	-0.4	
C. Overweight									
or Obese	-12.1	+7.6	+2.8	-2.5	-1.2	+0.3	-4.1	+1.8	
w/BMI refusal									
(No BMI)	+1.9	+0.0	+0.0	+0.0	+0.0	+0.7	+0.8	+0.8	
, ,									

Figure 2-64: Sample Report, Age Breakout, Obesity Assessment

UP-User Pop; AC-Active Clinical; AD-Active Diabetic; AAD-Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Obesity Assessment: List of patients with current BMI, if any. HRN COMMUNITY PATIENT NAME SEX AGE DENOMINATOR NUMERATOR PATIENT1, PAMELA 000001 COMMUNITY #1 F 3 UP,AC 16.03
PATIENT2,GLENDA 000002 COMMUNITY #1 F 3 UP,AC 17.49 PATIENT3, SHIRLEY 000003 COMMUNITY #1 F 5 PATIENT4, MARY ANNE 000004 COMMUNITY #1 F 5 UP,AC Refused PATIENT5, JACKIE 000005 COMMUNITY #1 F 9 PATIENT6, ZINNIA 000006 COMMUNITY #1 F 15 29.41 [OVERWEIGHT] PATIENT7, MARY RYAN 000007 COMMUNITY #1 F 15 33.69 [OBESE]

Figure 2-65: Sample Patient List, Obesity Assessment

# 2.8.2 Childhood Weight Control

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 22.8% for the proportion of children with a BMI of 95% or higher.

#### **Denominators**

Active Clinical patients aged 2 through 5 for whom a BMI could be calculated. Broken down by gender and age groups (2, 3, 4, 5). (GPRA Denominator)

#### **Numerators**

Patients with BMI in the 85th to 94th percentile.

Patients with a BMI at or above the 95th percentile. (GPRA Numerator)

Patients with a BMI at or above the 85th percentile.

## **Logic Description**

BMI calculation definition: All patients for whom a BMI could be calculated and who are between the ages of 2 and 5 at the beginning of the Report Period and who do not turn age 6 during the Report Period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be 2 years of age at the beginning of the time period, but is 3 years old at the time of the most current BMI found. That patient will fall into the age 3 group. CRS looks for the most recent BMI in the Report Period. CRS calculates BMI at the time the report is run using NHANES II. A height and weight must be taken on the same day any time during the Report Period. The BMI values for this measure are reported differently than in Obesity Assessment since this age group is children ages 2 through 5, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.

Patients whose BMI either is greater or less than the Data Check Limit range shown below will not be included in the report counts for Overweight or Obese.

#### **BMI Standard Reference Data**

Low-High Ages	Sex	BMI >= (OVERWT)	BMI >= (OBESE)	Data Check Limits BMI>	Data Check Limits BMI <
2-2	MALE	17.7	18.7	36.8	7.2
2-2	FEMALE	17.5	18.6	37.0	7.1
3-3	MALE	17.1	18.0	35.6	7.1
3-3	FEMALE	17.0	18.1	35.4	6.8
4-4	MALE	16.8	17.8	36.2	7.0
4-4	FEMALE	16.7	18.1	36.0	6.9
5-5	MALE	16.9	18.1	36.0	6.9
5-5	FEMALE	16.9	18.5	39.2	6.8

## **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of patients ages 2 through 5, with current BMI.

## **Measure Source**

CDC, National Center for Health Statistics, HP 2020 NWS-10.1

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	22.8%
IHS FY 2013 Performance	22.8%
IHS FY 2012 Performance	24.0%
IHS FY 2011 Performance	24.1%
IHS FY 2010 Performance	25.0%
IHS FY 2009 Performance	25.0%
IHS FY 2008 Performance	24.0%
IHS FY 2007 Performance	24.0%
IHS FY 2006 Performance	24.0%
HP 2020 Goal	9.6%

DU November 25, 2015 Page 156  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010  Childhood Weight Control (con't)									
Chilianood weight	COLLEGE (CO	11 ()							
	REPORT PERIOD				CHG from PREV YR %			CHG from BASE %	
Active Clinical E 2-5 w/BMI	Pts 44		39			40			
# w/BMI 85-94% # w/BMI =>95% # w/BMI =>85%	5	11.4	9	23.1	+3.1 -11.7 -8.6	5	12.5	-1.1	
Active Clinical F Age 2	Pts 2		8			5			
# w/BMI 85-94% # w/BMI =>95% # w/BMI =>85%	0	50.0 0.0 50.0	2	25.0	+50.0 -25.0 +25.0	0	0.0	+30.0 +0.0 +30.0	
Active Clinical E Age 3	Pts 23		15			8			

# w/BMI 85-94%	2	8.7	2	13.3	-4.6	3	37.5	-28.8	
# w/BMI =>95%	3	13.0	3	20.0	-7.0	2	25.0	-12.0	
# w/BMI =>85%	5	21.7	5	33.3	-11.6	5	62.5	-40.8	
Active Clinical Pts									
Age 4	12		10			17			
# w/BMI 85-94%	1	8.3	2	20.0	-11.7	3	17.6	-9.3	
# w/BMI =>95%	1	8.3	2	20.0	-11.7	2	11.8	-3.4	
# w/BMI =>85%	2	16.7	4	40.0	-23.3	5	29.4	-12.7	
Active Clinical Pts									
Age 5	7		6			10			
# w/BMI 85-94%	3	42.9	1	16.7	+26.2	3	30.0	+12.9	
# w/BMI =>95%	1	14.3	2	33.3	-19.0	1	10.0	+4.3	
# w/BMI =>85%	4	57.1	3	50.0	+7.1	4	40.0	+17.1	
# W/ DIAT -\020	4	37.1	3	50.0	T / . 1	4	40.0	T1/.1	

Figure 2-66: Sample Report, Childhood Weight Control

Figure 2-67: Sample Patient List, Childhood Weight Control

# 2.8.3 Weight Assessment and Counseling for Nutrition and Physical Activity

#### **Denominators**

Active Clinical patients ages 3 and older. Broken down by gender and age groups (3 through 11, 12 through 17, 18 and older).

#### **Numerators**

Patients with comprehensive assessment, defined as having BMI documented, counseling for nutrition, and counseling for physical activity during the Report Period.

Patients with BMI documented during the Report Period.

Patients with counseling for nutrition during the Report Period.

Patients with counseling for physical activity during the Report Period.

## **Logic Description**

Age is calculated at the end of the Report Period.

CRS uses any of the following codes to define the numerators.

Subject Defined	CPT Codes	ICD and Other Codes
BMI Documented		BMI: CRS calculates BMI at the time the report is run, using NHANES II. For age 18 and under, a height and weight must be taken on the same day any time during the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.  POV: ICD-9: V85*; ICD-10: Z68.20-Z68.54
Counseling for Nutrition	97802-97804, G0270, G0271, G0447, S9449, S9452, S9470	POV: ICD-9: V65.3; ICD-10: Z71.3  Patient education codes: ending "-N" (nutrition), "-MNT" (medical nutrition therapy), (or old code "-DT" (diet)) or containing V65.3, 97802-97804, G0270, G0271, G0447, S9449, S9452, or S9470.
Counseling for Physical Activity	G0447, S9451	POV: ICD-9: V65.41  Patient education codes: ending "-EX" (exercise) or containing V65.41, G0447, or S9451.

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients ages 3 plus (+) with assessments, if any.

# **Measure Source**

**HEDIS** 

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
N/A	

DU	0-11		ember 25,		- i	64 - 1 D		age 143	
*** IHS 2015	serectea		ires with ) INDIAN H			riea kep	ort *	^ ^	
Re	port Per	iod: J	Tan 01, 20	15 to	Dec 31, 20	015			
					4 to Dec 3				
Bas	eline Pe	riod:	Jan 01,	2010	to Dec 31,	2010			
Weight Assessment and (Con't)	d Counse	ling f	or Nutrit	ion a	nd Physica	l Activi	ty		
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %			CHG from BASE %	
Active Clinical Pts									
Age 3+	1,583		1,151			1,009			
# w/ comprehensive	E 7	3.6	27	2 0	+0.4	52	5.2	-1.6	
assessment # w/BMI	5 /	3.0	3 /	3.2	+0.4	52	5.2	-1.6	
documented	930	58.7	848	73.7	-14.9	733	72.6	-13.9	
# w/ nutrition									
counseling	128	8.1	99	8.6	-0.5	108	10.7	-2.6	
# w/ physical activication counseling	_	5.5	16	4.0	+1.5	61	6 0	-0.5	
Counseling	0 /	3.5	40	4.0	71.5	01	0.0	-0.5	
Male Active Clinical									
Pts Age 3+	664		486			423			
#/ mammala ana mi									
<pre># w/ comprehensive assessment</pre>	23	3.5	14	2.9	+0.6	22	5.2	-1.7	
# w/BMI	23	3.3		2.,		22	3.2	Ξ.,	
documented	360	54.2	342	70.4	-16.2	294	69.5	-15.3	
# w/ nutrition	4.5	6.0	2.5		0.0	2.2	0 0	0.4	
counseling # w/ physical activi	45	6.8	37	7.6	-0.8	39	9.2	-2.4	
counseling	33	5.0	20	4.1	+0.9	25	5.9	-0.9	
Female Active Clinica									
Pts Age 3+	919		665			586			
# w/ comprehensive									
assessment	34	3.7	23	3.5	+0.2	30	5.1	-1.4	
# w/BMI									
documented	570	62.0	506	76.1	-14.1	439	74.9	-12.9	
<pre># w/ nutrition counseling</pre>	83	9.0	62	0 2	-0.3	60	11.8	-2.7	
# w/ physical activi		9.0	UΖ	9.3	-0.3	09	11.0	-2.7	
	•								

counseling	54	5.9	26	3.9	+2.0	36	6.1	-0.3

Figure 2-68: Sample Report, Weight Assessment and Counseling for Nutrition and Physical Activity

Weight Assessment and Counse	ling for Nut	crition and	Physical A	Activity (con't)	
i	Active Clini				
	3 - 1	12 -	17 18+		
CURRENT REPORT PERIOD					
Active Clinical Pts =>3	216	121	1,246		
# w/comprehensive assessment	6	4	47		
% w/comprehensive assessment	2.8	3.3	3.8		
v wy compronent vo appearment		3.3	3.0		
# w/BMI documented	94	58	778		
% w/BMI documented	43.5	47.9	62.4		
% W/ BMI documented	43.5	47.5	02.4		
9/	0	1.1	109		
% w/nutrition counseling	8	11			
% w/nutrition counseling	3.7	9.1	0.0		
<pre># w/physical activity</pre>					
counseling	9	7	71		
% w/physical activity					
counseling	4.2	5.8	5.7		
S .					
PREVIOUS REPORT PERIOD					
Active Clinical Pts =>3	214	107	830		
neerve errinear reb =>3	211	107	030		
# w/comprehensive assessment	0	0	37		
- · · · · · · · ·					
% w/comprehensive assessment	0.0	0.0	4.5		
# w/BMI documented	98	53	697		
% w/BMI documented	45.8	49.5	84.0		
% w/nutrition counseling	2	3	94		
% w/nutrition counseling	0.9	2.8	0.0		
# w/physical activity					
counseling	0	0	46		
% w/physical activity	_	_			
counseling	0.0	0.0	5.5		
Counsering	0.0	0.0	5.5		
CHANGE FROM PREVIOUS YR %					
	. 2 0	. 2 2	0 7		
# w/comprehensive assessment		+3.3	-0.7		
# w/BMI documented	+43.5	+47.9	+58.0		
# w/nutrition counseling	+3.7	+9.1	-4.5		
<pre># w/physical activity</pre>					
counseling	+4.2	+5.8	+1.2		

Figure 2-69: Sample Report, Age Breakout, Weight Assessment and Counseling for Nutrition and Physical Activity

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

```
HR=High Risk Patient
Weight Assessment and Counseling for Nutrition and Physical Activity: List of
patients ages 3+ with assessments, if any.
PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR
PATIENT1, PAMELA 000001 COMMUNITY #1 F 4
PATIENT2,GLENDA 000002 COMMUNITY #1 F 4
                         BMI: 16.03
PATIENT3, SHIRLEY 000003 COMMUNITY #1 F 5
PATIENT4, MARY ANNE 000004 COMMUNITY #1 F 5
                          COMP ASSESS; BMI: V85.53; NUTR: 03/03/15 CPT 97804;
PHY: 03/03/15 DX V65.41
PATIENT5, JACKIE 000005 COMMUNITY #1 F 9
                         PHY: 08/08/15 OBS-EX
PATIENT6, ZINNIA 000006 COMMUNITY #1 F 15
PATIENT7, MARY RYAN 000007 COMMUNITY #1 F 15
                BMI: 35.04; PHY: 03/03/15 DX V65.41
```

Figure 2-70: Sample Patient List, Weight Assessment and Counseling for Nutrition and Physical Activity

## 2.8.4 Nutrition and Exercise Education for At Risk Patients

#### **Denominators**

Active Clinical patients ages 6 and older considered overweight (including obese). Broken down by gender.

a. Active Clinical patients ages 6 and older *considered obese*. Broken down by gender and age groups (6 through 11, 12 through 19, 20 through 39, 40 through 59, 60 years plus).

Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes at least 1 year prior to the end of the Report Period, and at least two visits in the past year, and two diabetes-related visits ever.

#### **Numerators**

Patients provided with medical nutrition therapy during the Report Period.

Patients provided specific nutrition education during the Report Period.

Patients provided specific exercise education during the Report Period.

Patients provided with other related exercise and nutrition (lifestyle) education.

## **Logic Description**

Age of the patient is calculated at beginning of Report Period.

*Diabetes:* First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\* recorded in the V POV file prior to the Report period.

*Overweight*: Ages 19 and older, BMI equal to or greater than (=>) 25. Overweight is defined as including both obese and overweight categories calculated by BMI.

Obese: Ages 19 and older, BMI equal to or greater than (=>) 30. For ages 18 and under, the definition is based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time in the year prior to the end of the Report Period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years; not required to be recorded on same day.

CRS uses any of the following codes to define the numerators.

Subject Defined	CPT Codes	ICD and Other Codes
Medical nutrition therapy	97802-97804, G0270, G0271	Primary or secondary provider codes: 07, 29 Clinic codes: 67 (dietary) or 36 (WIC)
Nutrition education		POV: ICD-9: V65.3 dietary surveillance and counseling; ICD-10: Z71.3  Patient education codes: ending "-N" (nutrition), "-MNT" (medical nutrition therapy), (or old code "-DT" (diet)) or containing V65.3, 97802-97804, G0270, or G0271.
Exercise education		POV: ICD-9: V65.41 exercise counseling Patient education codes: ending "-EX" (exercise) or containing V65.41.
Related exercise and nutrition education	S9449, S9451, S9452, S9470	Patient education codes: ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00 or 278.01, S9449, S9451, S9452, or S9470.

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

A list of at risk patients with education, if any.

# **Measure Source**

HP 2010 19-17

# **Measure Past Performance and Long-Term Targets for Diabetic Education**

Performance	Percent
HP 1997 data	42.0%

DU *** IHS 2015 Se	elected	Measu	mber 25, res with	Commu		fied Rep		age 160 **		
Previous	s Year	Period	: Jan 01	, 201	Dec 31, 20 4 to Dec 33	1, 2014				
Baseline Period: Jan 01, 2010 to Dec 31, 2010										
Nutrition and Exercise Education for At Risk Patient										
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %			CHG from BASE %		
# Overweight Active Cl patients =>6	linical 598		555			442				
<pre># w/medical nutrition therapy # specific nutrition</pre>	44	7.4	23	4.1	+3.2	27	6.1	+1.2		
education provided	83	13.9	79	14.2	-0.4	78	17.6	-3.8		
# w/exercise educ		5.7	28				7.9			
# w/ other exec										
or nutrition educ	75	12.5	59	10.6	+1.9	24	5.4	+7.1		
# Male Overweight Act	ive									
Clinical pts =>6	251		230			182				
# w/medical nutrition										
therapy	18	7.2	8	3.5	+3.7	10	5.5	+1.7		
# specific nutrition										
education provided		14.3		13.9						
<pre># w/exercise educ # w/ other exec</pre>	16	6.4	12	5.2	+1.2	16	8.8	-2.4		
or nutrition educ	41	16.3	22	9.6	+6.8	11	6.0	+10.3		
# Female Overweight Ad	rtive									
Clinical pts =>6	347		325			260				
# w/medical nutrition										
therapy	26	7.5	15	4.6	+2.9	17	6.5	+1.0		
# specific nutrition										
education provided	47	13.5	47	14.5	-0.9	50	19.2	-5.7		
<pre># w/exercise educ # w/ other exec</pre>	18	5.2	16	4.9	+0.3	19	7.3	-2.1		
or nutrition educ	34	9.8	37	11.4	-1.6	13	5.0	+4.8		

Figure 2-71: Sample Report, Nutrition and Exercise Education for At Risk Patients

Nutrition and Exercise Education for At Risk Patient (con't)						
TOTAL OBESE ACTIVE CLINICAL POPULATION  Age Distribution						
# Obese Active Clinical	6-11	_	20-39	40-59	=>60	
CURRENT REPORT REPLAN						
CURRENT REPORT PERIOD # Obese Active Clinical	13	28	167	125	32	
# w/medical nutrition	13	20	107	123	32	
therapy	0	2	15	10	3	
% w/medical nutrition						
therapy	0.0	7.1	9.0	8.0	9.4	
# # w/specific nutrition e	ducation					
provided	0	3	22	28	7	
% # w/specific nutrition e						
provided	0.0	10.7	13.2	22.4	21.9	
# w/exercise educ	0	1	8	14	5	
% w/exercise educ	0.0	3.6	4.8	11.2	15.6	
# w/other exec or					_	
nutrition educ % w/other exec or	0	3	18	16	7	
nutrition educ	0.0	10.7	10.8	12.8	21.9	
nacricion caac	0.0	10.7	10.0	12.0	21.7	
PREVIOUS YEAR PERIOD						
# Obese Active Clinical	14	26	137	116	32	
<pre># w/medical nutrition therapy</pre>	0	3	8	3	2	
% w/medical nutrition	Ŭ	3	Ü	3	2	
therapy	0.0	11.5	5.8	2.6	6.3	
<pre># # w/specific nutrition e provided</pre>	ducation 0	2	19	22	7	
% # w/specific nutrition e	ŭ	۷	10	22	,	
provided	0.0	7.7	13.9	19.0	21.9	
11 /	^	0	4	1.4	4	
<pre># w/exercise educ % w/exercise educ</pre>	0.0	0.0	4 2.9	$\frac{14}{12.1}$	4 12.5	
w/ CACLCIBE Educ	0.0	0.0	۵.۶	12.1	12.5	
# w/other exec or						
nutrition educ	0	2	13	23	3	
<pre>% w/other exec or nutrition educ</pre>	0.0	7.7	9.5	19.8	9.4	
nucricion educ	0.0	7.7	9.5	19.8	9.4	
CHANGE FROM PREV YR %						
medical nutrition						
therapy	+0.0	-4.4	+3.1	+5.4	+3.1	
Spec nutr ed w/exercise educ	+0.0 +0.0	+3.0 +3.6	-0.7 +1.9	+3.4 -0.9	+0.0 +3.1	
w/other exec or	10.0	+3.0	TI.5	-0.9	+3.1	
nutrition educ	+0.0	+3.0	+1.3	-7.0	+12.5	

Figure 2-72: Sample Age Breakout Report, Nutrition and Exercise Education for At Risk Patients

Figure 2-73: Sample Patient List, Nutrition, and Exercise Education for At Risk Patients

## 2.8.5 Physical Activity Assessment

#### **Denominators**

Active Clinical patients ages 5 and older. Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)75).

Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age groups (5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, greater than (>)75).

*User Population patients* ages 5 and older. Broken down by gender.

Numerator 1 (User Population Patients assessed for physical activity during the Report Period). Broken down by gender.

#### **Numerators**

Patients assessed for physical activity during the Report Period.

Patients from Numerator 1 who have received exercise education following their physical activity assessment.

# **Logic Description**

Age of the patient is calculated at beginning of Report Period.

CRS uses any of the following codes to define the numerators.

Subject Defined	ICD and Other Codes
Physical Activity Assessment	<b>Health Factors</b> : Any health factor for category Activity Level documented during the Report Period.
Exercise education	POV: V65.41 exercise counseling
	Patient education codes: ending "-EX" (exercise) or containing V65.41.

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients with physical activity assessment and any exercise education.

DU November 25, 2015 Page 171  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Physical Activity Assessm	ent								
					CHG from PREV YR %				
Active Clinical Pts 5 and older 1,3	57		1,031			911			
# w/ exercise educ		1.4	0	0.0	+1.4	0	0.0	+1.4	
<pre>w/ % of physical activit assessment</pre>	-	21.1	0	0.0	+21.1	0	0.0	+21.1	
Male Active Clinical =>5 5	70		430			374			
<pre># w/ physical activity   assessment # w/ exercise educ</pre>	7	1.2	0	0.0	+1.2	0	0.0	+1.2	
<pre>w/ % of physical activit assessment</pre>		14.3	0	0.0	+14.3	0	0.0	+14.3	
Female Active Clinical =>5 7	87		601			537			
# w/ physical activity									

assessment # w/ exercise educ	12	1.5	0	0.0	+1.5	0	0.0	+1.5	
<pre>w/ % of physical act assessment</pre>	-	25.0	0	0.0	+25.0	0	0.0	+25.0	
User Pop ages									
5 and older	2,592		2,142			2,025			
<pre># w/ physical activit   assessment # w/ exercise educ</pre>	19	0.7	0	0.0	+0.7	0	0.0	+0.7	
w/ % of physical act assessment	-	21.1	0	0.0	+21.1	0	0.0	+21.1	
Male User Pop Pts =>5	1,211		988			945			
<pre># w/ physical activit assessment # w/ exercise educ</pre>	7	0.6	0	0.0	+0.6	0	0.0	+0.6	
<pre>w/ % of physical act assessment</pre>		14.3	0	0.0	+14.3	0	0.0	+14.3	
Female User Pop Pts =>5	1,381		1,154			1,080			
<pre># w/ physical activit assessment # w/ exercise educ</pre>	12	0.9	0	0.0	+0.9	0	0.0	+0.9	
w/ % of physical act assessment		25.0	0	0.0	+25.0	0	0.0	+25.0	

Figure 2-74: Sample Report, Physical Activity Assessment

Physical Activity Assessment (con't)									
	TOTAL	ACTIVE	-	AL5 AND Distri	_				
	5-11	12-19	20-24	25-34	35-44	45-54	55-74	>74 yrs	
CURRENT REPORT PERIOD									
	132	157	133	233	215	216	225	46	
<pre># w/ physical activity   assessment % w/ physical activity</pre>	2	6	3	1	2	0	3	2	
assessment	1.5	3.8	2.3	0.4	0.9	0.0	1.3	4.3	
<pre># w/ exercise educ w/ % of physical activit</pre>	У								
assessment % w/ exercise educ w/		2	1	0	0	0	0	0	
% of physical activit assessment	-	33.3	33 3	0.0	0.0	0.0	0.0	0.0	
	30.0	33.3	33.3	0.0	0.0	0.0	0.0	0.0	
PREVIOUS YEAR PERIOD Total # AC Pts =>5 # w/ physical activity	141	137	128	172	151	140	137	25	
assessment	0	0	0	0	0	0	0	0	

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

% w/ physical activity assessment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
<pre># w/ exercise educ w/     % of physical activity     assessment % w/ exercise educ w/</pre>	0	0	0	0	0	0	0	0	
% of physical activity assessment		0.0	0.0	0.0	0.0	0.0	0.0	0.0	
CHANGE FROM PREV YR % # w/ physical activity assessment w/ exercise educ w/ % of physical activity		+3.8	+2.3	+0.4	+0.9	+0.0	+1.3	+4.3	
		+33.3	+33.3	+0.0	+0.0	+0.0	+0.0	+0.0	

Figure 2-75: Sample Age Breakout Report, Physical Activity Assessment

```
UP-User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Physical Activity Assessment: List of patients with physical activity
assessment and any exercise education.
               HRN COMMUNITY SEX AGE
PATIENT NAME
DENOMINATOR
                     NUMERATOR
_____
PATIENT1, MISTY DAWN 000001 COMMUNITY #1 F 5
UP,AC
                      PHYS ACT: 08/08/15 VERY ACTIVE; EXER ED: 08/08/15 OBS-
EX
PATIENT2, RITA ANN 000002 COMMUNITY #1 F 15
UP,AC
                           PHYS ACT: 03/06/15 SOME ACTIVITY; EXER ED: 03/06/15
TO-EX
PATIENT3, RHONDA SUE 000003 COMMUNITY #1 F 22
                           PHYS ACT: 04/02/15 ACTIVE; EXER ED: 04/02/15 V65.41
UP,AC
PATIENT4, MARY 000004 COMMUNITY #1 F 28
UP, AC PHYS ACT: 11/12/15 SON
                          PHYS ACT: 11/12/15 SOME ACTIVITY;
PATIENT5, JOSEPH HENRY 000005 COMMUNITY #1 M 12
                           PHYS ACT: 08/02/15 SOME ACTIVITY;
PATIENT6, BOB
                      000006 COMMUNITY #1 M 17
                           PHYS ACT: 05/05/12 INACTIVE; EXER ED: 05/05/12 OBS-EX
UP,AC
```

Figure 2-76: Sample Patient List, Physical Activity Assessment

# 2.8.6 Comprehensive Health Screening

#### **Denominators**

Active Clinical patients ages 2 and older.

Active Clinical patients ages 12 to 75.

Active Clinical patients ages 18 and older.

Female Active Clinical patients ages 15 through 40.

Active Clinical patients ages 5 and older.

Active Clinical patients ages 2 through 74.

Active Clinical patients ages 20 and over.

Active Clinical patients ages 5 and older.

#### **Numerators**

ALL Comprehensive Health Screening: Patients with Comprehensive Health Screening for which they are eligible, defined as having alcohol, depression, and Intimate Partner Violence/Domestic Violence (IPV/DV) screening, BMI calculated, and tobacco use, BP, and physical activity assessed.

**Note**: This does *not* include refusals.

Comprehensive Health Screening: Patients with Comprehensive Health Screening minus physical activity assessment for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use and BP assessed.

**Note**: This does *not* include physical activity assessment and does *not* include refusals.

Alcohol Screening: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.

**Note**: This numerator does *not* include refusals or alcohol-related patient education.

Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note**: This numerator does *not* include refusals.

IPV/DV Screening: Patients screened for IPV/DV at any time during the Report Period.

**Note**: This numerator does *not* include refusals.

Tobacco Use Assessed: Patients who have been screened for tobacco use during the Report period.

BMI Available: Patients for whom a BMI could be calculated.

**Note**: This numerator does *not* include refusals.

BP Assessed: Patients with BP value documented at least twice in prior 2 years.

Physical Activity Assessed: Patients assessed for physical activity during the Report Period.

## **Logic Description**

Age of the patient is calculated at beginning of Report Period.

Alcohol screening definition: Any of the following during the Report Period: (a) Alcohol Screening Exam, any CAGE Health Factor, or Screening Diagnosis; (b) Alcohol-related diagnosis in POV, Current PCC or BHS Problem List; (c) Alcohol-related procedure; or (d) Patient education.

Subject Defined	ICD and Other Codes
Alcohol Screening	Exam Code: 35
	<b>CPT code:</b> 99408, 99409, G0396, G0397, H0049, H0050, 3016F
	Any CAGE Health Factor
	<b>POV:</b> ICD-9: V11.3 (history of alcoholism), V79.1 (screening for alcoholism)
	BHS Problem Code: 29.1 (Screening for Alcoholism)
	Measurement in PCC or BHS: AUDT, AUDC, or CRFT
Alcohol-related Diagnosis	POV, Current PCC or BHS Problem List: ICD-9: 303.*, 305.0*, 291.*, 357.5*; ICD-10: F10.1*, F10.20, F10.220-F10.29, F10.920-F10.982, F10.99, G62.1 BHS POV: 10, 27, 29
Alcohol-related Procedure	<b>Procedure:</b> ICD-9: 94.46, 94.53, 94.61-94.63, 94.67-94.69

Alcohol screening may be documented with either an exam code or the CAGE health factor in PCC or BHS. BHS problem codes can also currently be used.

Depression screening definition: CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
Depression Screening	Exam: Exam Code 36
	<b>POV:</b> ICD-9: V79.0
	<b>CPT:</b> 1220F
	BHS Problem Code: 14.1 (Screening for Depression)
	Measurement in PCC or BHS: PHQ2 or PHQ9

Subject Defined	ICD and Other Codes
Mood Disorders	At least two visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.  POV: ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39  BHS POV: 14, 15

IPV/DV screening definition: CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
IPV/DV Screening	Exam: Code 34
	BHS Exam: IPV/DV
IPV/DV Diagnosis	POV or current PCC or BHS Problem List: ICD-9: 995.80-995.83, 995.85, V15.41, V15.42, V15.49; ICD-10: T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410 BHS POV: 43.*, 44.*
IPV/DV Education	<b>Patient education codes:</b> "DV-" or "-DV", 995.80-83, 995.85, V15.41, V15.42, V15.49
IPV/DV Counseling	<b>POV:</b> ICD-9: V61.11; ICD-10: Z69.11

Tobacco screening definition: CRS uses the following codes to define the numerator.

Subject Defined	CPT Codes	ICD and Other Codes
Screened for Tobacco Use	D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed)	POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z87.891  Patient Education codes: "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455-G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276
		Dental code: 1320
		Health Factor categories: Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE)

BMI calculation definition: CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.

Blood pressure definition: Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

CRS uses mean of last 3 Blood Pressures documented in the past 2 years. If 3 BPs are not available, use the mean of last 2 BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not *both* meet the current category, then the value that is least controlled determines the category.

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

*Physical Activity Assessment definition:* CRS uses the following codes to define the numerator.

Subject Defined	ICD and Other Codes
	<b>Health Factors</b> : Any health factor for category Activity Level documented during the Report Period.

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS codes G9275, G9276 to tobacco screening definition.
- 2. Added HCPCS codes G9273, G9274 to BP documented definition.

## **Patient List Description**

List of patients with assessments received, if any.

DU November 25, 2015 Page 181  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Comprehensive Health Screening								
					CHG from PREV YR %			CHG from BASE %
Active Clinical ages 2 and older			1,121			1,007		
<pre># w/ Comprehensive E Screening-No Refusals # w/ Comprehensive E</pre>	56 Mealth	3.9	39	3.5	+0.4	40	4.0	-0.1
Screening-No Refusa or Phys Activity		4.6	46	4.1	+0.5	53	5.3	-0.6
Active Clinical ages 12-75	1,180		867			753		
# w/ alcohol screeni Dx/Proc/-No Refusal or Pt Ed	.s	8.1	12	1.4	+6.7	3	0.4	+7.7
Active Clinical => 18	1,112		793			666		
# w/ Depression screening								

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

or Mood Disorder Dx- No Refusals		7.3	42	5.3	+2.0	17	2.6	+4.7	
# Female Active Clinical ages 15-40	380		311			267			
# w/IPV/DV screening- No Refusals		2.9	1	0.3	+2.6	0	0.0	+2.9	
# Active Clinical Pts =>5	1,357		1,031			911			
# w/Tobacco Screening	624	46.0	426	41.3	+4.7	328	36.0	+10.0	
Active Clinical Pts 2-74	1,400		1,096			982			
# w/BMI calculated- No Refusals	880	62.9	824	75.2	-12.3	712	72.5	-9.6	
Active Clinical Patie	nta								
ages 20 and older	1,068		753			640			
# w/ BPs documented w/in 2 yrs	643	60.2	557	74.0	-13.8	478	74.7	-14.5	
Active Clinical Pts 5 and older	1,357		1,031			911			
# w/ physical activit assessment	:у 19	1.4	0	0.0	+1.4	0	0.0	+1.4	

Figure 2-77: Sample Report, Comprehensive Health Screening

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Comprehensive Health Screening: List of patients with assessments
received, if any.
                     HRN COMMUNITY SEX AGE
PATTENT NAME
PATIENT NAME
DENOMINATOR
                          NUMERATOR
PATIENT1, SANDRA KAY 000001 COMMUNITY #1 F 15
                            ALL COMP HEALTH: ALC: 03/06/15 POV V11.3; IPV:
03/06/15 Ex 34; TOB: 09/05/15 NEVER SMOKED; BMI: 17.49; PHYS ACT: 03/06/15 SOME
ACTIVITY
PATIENT2, CAITLYN
                     000002 COMMUNITY #1 F 16
AC
PATIENT3, BRITNEY
                    000003 COMMUNITY #1 F 16
                            TOB: 10/26/15 CESSATION-SMOKER
PATIENT4, LORETTA 000004 COMMUNITY #1 F 17
                            ALC: 10/14/15 HF CAGE 1/4
PATIENTS, HALEY 000005 COMMUNITY #1 F 18
                           BMI: 19.79; BP: 125/67
```

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

```
PATIENT6, BRITTANY 000006 COMMUNITY #1 F 19
AC ALC: 10/30/15 CPT G0397; TOB: 08/11/15 CURRENT SMOKER,
STATUS UNKNOWN; BMI: 21.01
```

Figure 2-78: Sample Patient List, Comprehensive Health Screening

# 2.8.7 Cardiovascular Disease and Cholesterol Screening

#### **Denominators**

Active Clinical patients ages 23 and older. Broken down by gender.

User Population patients ages 23 and older. Broken down by gender.

Active CHD patients, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever. Broken down by gender.

#### **Numerators**

Patients with documented blood total cholesterol screening any time in the past 5 years.

a. Patients with high total cholesterol levels, defined as equal to or greater than (=>) 240

Patients with LDL completed in the past 5 years, regardless of result.

- a. Patients with LDL less than (<)100
- b. Patients with LDL 100 through 130
- c. Patients with LDL 131 through 160
- d. Patients with LDL greater than (>)160

## **Logic Description**

Age is calculated at the beginning of the Report Period.

CRS uses the following codes to define the CHD denominator.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	Any of the following:
	1) POV: ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-
	10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9
	2) One or more CABG or PCI procedures
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1
	<b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33533-
	33536, S2205-S2209
	<b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*,

Subject Defined	ICD and Other Codes						
	02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*						
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61						
	<b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982, 92995, G0290						
	<b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**						

Total Cholesterol definition: Searches for most recent cholesterol test with a result during the Report Period. If more than one cholesterol test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If a cholesterol test with a result is not found, CRS searches for the most recent cholesterol test without a result.

LDL Cholesterol definition: Searches for most recent LDL test with a result during the Report Period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

CRS uses the following codes to define LDL and total cholesterol.

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
LDL	80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F, G9271, G9272 For numerator LDL less than (<)100, CPT 3048F or G9271 will count as meeting the measure.	Yes	DM AUDIT LDL CHOLESTEROL TAX
Total Cholesterol	82465	Yes	DM AUDIT CHOLESTEROL TAX

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS codes G9271, G9272 to LDL definition.
- 2. Added HCPCS codes G9271 to LDL < 100 definition.

# **Patient List Description**

List of patients with cholesterol or LDL value, if any.

# **Measure Source**

HP 2020 HDS-6, HDS-7

# **Measure Past Performance and Long-Term Targets**

Performance								
IHS FY 2006 Performance (blood total cholesterol screening)	48.0%							
IHS FY 2005 Performance (blood total cholesterol screening)	43.0%							
HP 1998 baseline	67.0%							
HP 2020 goal for adults who have had blood cholesterol checked (HDS-6)	82.1%							
HP 2020 goal for adults with high cholesterol (HDS-7)	13.5%							

DU		Nove	mber 25,	2015			Pag	ge 185				
*** IHS 2015 Selected Measures with Community Specified Report ***												
		DEMO	INDIAN H	OSPIT	AL							
Re	port Per	iod: J	an 01, 20	15 to	Dec 31, 20	15						
Previous Year Period: Jan 01, 2014 to Dec 31, 2014												
Baseline Period: Jan 01, 2010 to Dec 31, 2010												
Cardiovascular Disea	ise and C	holest	erol Scre	enina								
Cararovascarar sisco	ibe dila e	1101656	CIOI DOIC	ciiiii								
	REPORT	%	PREV YR	%	CHG from	BASE	용 (	CHG from				
	PERIOD		PERIOD		PREV YR %	PERIOD	1	BASE %				
Active Clinical Pts												
=> 23	986		676			569						
-> 23	300		070			309						
# w/ Total Cholester	col											
screen w/in 5 yrs	248	25.2	217	32.1	-6.9	201	35.3	-10.2				
A. # w/ High Chol =>	240											
w/ % of Total Chol												
Screen	21	8.5	23	10.6	-2.1	28	13.9	-5.5				
# w/LDL done												
in past 5 yrs	251	25.5	185	27.4	-1.9	114	20.0	+5.4				
A. # w/LDL =<100												
w/ % of Total LDL	100	42.0	٥٦	F1 4	0 2	4.6	40.4	. 0 . 17				
Screen B. # w/LDL 101-130	108	43.0	95	51.4	-8.3	46	40.4	+2.7				
w/% of Total LDL												
Screen	72	20 1	11	23 B	+5.3	25	30 7	_1 6				
C. # w/LDL 131-160	7.5	29.1	77	23.0	+3.3	33	30.7	-1.0				
w/% of Total LDL												
Screen	25	10.0	25	13.5	-3.6	13	11.4	-1.4				
D. # w/LDL >160												
w/ % of Total LDL												
Screen	15	6.0	9	4.9	+1.1	10	8.8	-2.8				

Male Active Clinical									
Pts =>23	408		272			220			
<pre># w/ Total Cholesterol   screen w/in 5 yrs A. # w/ High Chol =&gt;240   w/ % of Total Chol</pre>		26.0	97	35.7	-9.7	85	38.6	-12.7	
Screen # w/LDL done	11	10.4	14	14.4	-4.1	8	9.4	+1.0	
in past 5 yrs A. # w/LDL =<100	115	28.2	91	33.5	-5.3	59	26.8	+1.4	
<pre>w/ % of Total LDL Screen B. # w/LDL 101-130</pre>	53	46.1	45	49.5	-3.4	23	39.0	+7.1	
<pre>w/ % of Total LDL Screen C. # w/LDL 131-160</pre>	25	21.7	18	19.8	+2.0	18	30.5	-8.8	
<pre>w/ % of Total LDL Screen D. # w/LDL &gt;160</pre>	8	7.0	12	13.2	-6.2	5	8.5	-1.5	
w/ % of Total LDL Screen	10	8.7	8	8.8	-0.1	4	6.8	+1.9	

Figure 2-79: Sample Report, CVD and Cholesterol Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Cardiovascular Disease and Cholesterol Screening: List of patients with cholesterol or LDL value if any. PATIENT NAME
DENOMINATOR HRN COMMUNITY SEX AGE NUMERATOR PATIENT100, JASON AARON 000100 COMMUNITY #1 M 46 UP.AC PATIENT101, JOHN THOMAS 000101 COMMUNITY #1 M 47 PATIENT102, DAKOTA CHEY 000102 COMMUNITY #1 M 47 PATIENT103, TRAVIS CLINT 000103 COMMUNITY #1 M 47 CHOL 04/13/15 210 PATIENT104, TRACY MITCHE 000104 COMMUNITY #1 M 47 UP,AC,IHD CHOL 03/15/15 167; LDL 08/15/14 105 PATIENT105, RUSSELL DALE 000105 COMMUNITY #1 M 48 LDL 04/01/15 CPT 3048F PATIENT106, CURTIS DWAYN 000106 COMMUNITY #1 M 49 CHOL 03/04/12 139; LDL 06/04/13 68 UP,AC CHOL 03/04/12 139; LDI PATIENT107,RONALD 000107 COMMUNITY #1 M 49 CHOL 01/07/11 213; LDL 08/01/14 122 UP,AC

Figure 2-80: Sample Patient List, CVD and Cholesterol Screening

# 2.8.8 Cardiovascular Disease and Blood Pressure Control

#### **Denominators**

All Active Clinical patients ages 18 and over. Broken down by gender.

All *User Population patients* ages 18 and older. Broken down by gender.

Active CHD patients, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever. Broken down by gender.

#### **Numerators**

Patients with Blood Pressure value documented during the Report Period.

# **Logic Description**

Age of the patient is calculated at beginning of the Report Period.

CRS uses the following codes to define the CHD denominator.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	Any of the following:  1) POV: ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-
	10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9  2) One or more CABG or PCI procedures
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1
	<b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33533-33536, S2205-S2209
	Procedure: ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61
	<b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982, 92995, G0290
	<b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

Blood pressure definition: CRS uses mean of last 3 Blood Pressures documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

# **Key Logic Changes from CRS Version 14.1**

- 1. Removed sub-category measures.
- 2. Added HCPCS codes G9273, G9274 to BP documented definition.

## **Patient List Description**

List of Patients equal to or greater than (=>) 18 or who have CHD with BP value, if any.

#### **Measure Source**

HP 2020 HDS-5

## Measure Past Performance and Long-Term Targets

Measure	Percent
HP 2020 goal for adults with high blood pressure (140/90)	26.9%

```
DU
                            November 25, 2015
                                                                   Page 196
       *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Cardiovascular Disease and Blood Pressure Control
                                           % CHG from BASE
                   REPORT
                             % PREV YR
                                                                  % CHG from
                   PERIOD
                               PERIOD
                                              PREV YR % PERIOD
                                                                     BASE %
Active Clinical Patients
ages 20 and older 1,068
                                     753
                                                           640
# w/ BPs documented
w/in 2 yrs
                       643 60.2
                                     557 74.0
                                                 -13.8
                                                           478 74.7
                                                                        -14.5
```

A. # w/Normal BP w/ %								
of Total Screened 128	19.9	134	24.1	-4.2	121	25.3	-5.4	
B. # w/Pre HTN I BP w/ %								
of Total Screened 107	16.6	115	20.6	-4.0	83	17.4	-0.7	
C. # w/Pre HTN II BP w/ % of Total Screened 148	23.0	111	20.5	+2.6	105	22.0	+1.1	
D. # w/Stage 1 HTN BP w/	23.0	114	20.5	+2.0	103	22.0	71.1	
% of Total Screened 173	26.9	150	26.9	+0.0	130	27.2	-0.3	
E. # w/Stage 2 HTN BP w/ %	20.5		20.7		200	_,,_	3.3	
of Total Screened 37	5.8	39	7.0	-1.2	39	8.2	-2.4	
Male Active Clinical Patient	s							
ages 20 and older 432		293			241			
<pre># w/ BPs documented w/in 2 yrs 231</pre>	53.5	203	69.3	-15.8	177	73.4	-20.0	
A. # w/Normal BP w/ %	33.3	203	09.3	-15.6	1//	/3.4	-20.0	
of Total Screened 8	3.5	23	11.3	-7.9	22	12.4	-9.0	
B. # w/Pre HTN I BP w/ %	3.3						,,,	
of Total Screened 27	11.7	37	18.2	-6.5	22	12.4	-0.7	
C. # w/Pre HTN II BP w/ %								
of Total Screened 64	27.7	46	22.7	+5.0	45	25.4	+2.3	
D. # w/Stage 1 HTN BP w/								
% of Total Screened 89	38.5	79	38.9	-0.4	63	35.6	+2.9	
E. # w/Stage 2 HTN BP w/ %	6 0	1 77	0 4	-1.4	٥٦	14.1	7 0	
of Total Screened 16	6.9	1/	8.4	-1.4	25	14.1	-7.2	
Female Active Clinical Patie	ents							
ages 20 and older 636		460			399			
# w/ BPs documented								
w/in 2 yrs 412	64.8	354	77.0	-12.2	301	75.4	-10.7	
A. # w/Normal BP w/ %								
of Total Screened 120	29.1	111	31.4	-2.2	99	32.9	-3.8	
B. # w/Pre HTN I BP w/ %	10.4		00.0	0.6	6.1	00 0	0.0	
of Total Screened 80	19.4	78	22.0	-2.6	61	20.3	-0.8	
C. # w/Pre HTN II BP w/ % of Total Screened 84	20.4	60	19.2	+1.2	60	19.9	+0.5	
D. # w/Stage 1 HTN BP w/	20.4	00	19.2	71.2	00	12.2	TU.5	
% of Total Screened 84	20.4	71	20.1	+0.3	67	22.3	-1.9	
E. # w/Stage 2 HTN BP w/ %		, 1		. 0 . 3	· · · · · · · · · · · · · · · · · · ·	,	1.0	
of Total Screened 21	5.1	22	6.2	-1.1	14	4.7	+0.4	

Figure 2-81: Sample Report, CVD and Blood Pressure Control

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

UP	/3080F			
PATIENT3, MICHELLE	000003 COMMUNITY	#1	F	22
UP,AC	125/67			
PATIENT4, CAITLYN	000004 COMMUNITY	#1	F	22
UP,AC,IHD	131/67			
PATIENT5, BRITNEY JANE	000005 COMMUNITY	#1	F	22
UP,AC	102/56			
PATIENT6, KATHRYN ANNE	000006 COMMUNITY	#1	F	22
UP,AC	161/90			
PATIENT7, RHONDA	000007 COMMUNITY	#1	F	22
UP,AC	153/85			

Figure 2-82: Sample Patient List, CVD and Blood Pressure Control

# 2.8.9 Controlling High Blood Pressure

#### **Denominator**

Active Clinical patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD. Broken down by gender and age groups (18 through 45 and 46 through 85).

#### **Numerators**

Number of patients with Blood Pressure value documented during the Report Period.

## **Logic Description**

Age of the patient is calculated at beginning of the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

Blood pressure definition: CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, use the mean of last 2 BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the Report Period.

CRS uses the following codes to define ESRD and hypertension.

Subject Defined	CPT Codes	ICD and Other Codes
ESRD	36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339	POV: ICD-9: 585.6, V42.0, V45.1, (old code), V45.11, V45.12, V56.*; ICD-10: N18.6, Z48.22, Z49.*, Z91.15, Z94.0, Z99.2  Procedure: ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*
Hypertension		POV or Problem List entry where the status is not Inactive or Deleted Prior to the Report Period and at Least One Hypertension POV during Report Period: ICD-9: 401.*; ICD-10: I10

# **Key Logic Changes from CRS Version 14.1**

- 1. Removed sub-category measures.
- 2. Added HCPCS codes G9273, G9274 to BP documented definition.
- 3. Added HCPCS code G9231 to ESRD defintion.

# **Patient List Description**

List of patients with hypertension and BP value, if any.

## **Measure Source**

HP 2020 HDS-5, HDS-12

# **Measure Past Performance and Long-Term Targets**

Measure	Percent
HP 2020 goal for adults with high blood pressure (140/90)	26.9%
HP 2020 goal for adults with high blood pressure and whose blood pressure is controlled	61.2%

DU					November	r 25,	2015			Page	200	
	***	IHS	2015	Selected	Measures	with	Community	Specified	Report	***		

DEMO INDIAN HOSPITAL Report Period: Jan 01, 2015 to Dec 31, 2015 Previous Year Period: Jan 01, 2014 to Dec 31, 2014 Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Controlling High Blood Pressure								
REP PER.					CHG from PREV YR %			
Active Clinical Pts 18-85 w/HTN dx	108		101			91		
# w/ BPs documented A. # w/Normal BP w/ %	96	88.9	92	91.1	-2.2	85	93.4	-4.5
		5.2	6	6.5	-1.3	3	3.5	+1.7
of Total Screened C. # w/Pre HTN II BP w/		8.3		14.1		8		
% of Total Screened D. # w/Stage 1 HTN BP w/		24.0		18.5				+1.6
% of Total Screened E. # w/Stage 2 HTN BP w/			41				49.4	
% of Total Screened  A. Active Clinical Pts	10	10.4	15	16.3	-5.9	13	15.3	-4.9
18-45 w/HTN dx	23		19			13		
# w/ BPs documented A. # w/Normal BP w/ %	17	73.9	16	84.2	-10.3	11	84.6	-10.7
of Total Screened B. # w/Pre HTN I BP w/ %		11.8	2	12.5	-0.7	0	0.0	+11.8
of Total Screened C. # w/Pre HTN II BP w/	1	5.9		6.3		1	9.1	-3.2
% of Total Screened D. # w/Stage 1 HTN BP w/		17.6		12.5				-0.5
% of Total Screened E. # w/Stage 2 HTN BP w/		41.2			+3.7			
% of Total Screened	2	11.8	5	31.3	-19.5	1	9.1	+2.7
B. Active Clinical Pts 46-85 w/HTN dx	85		82			78		
# w/ BPs documented A. # w/Normal BP w/ %	79	92.9	76	92.7	+0.3	74	94.9	-1.9
of Total Screened  B. # w/Pre HTN I BP w/ %	3	3.8	4	5.3	-1.5	3	4.1	-0.3
of Total Screened C. # w/Pre HTN II BP w/	7	8.9	12	15.8	-6.9	7	9.5	-0.6
% of Total Screened D. # w/Stage 1 HTN BP w/	20	25.3	15	19.7	+5.6	17	23.0	+2.3
% of Total Screened E. # w/Stage 2 HTN BP w/	29	36.7	35	46.1	-9.3	35	47.3	-10.6
% of Total Screened	8	10.1	10	13.2	-3.0	12	16.2	-6.1

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

Figure 2-83: Sample Report, Controlling High Blood Pressure

Figure 2-84: Sample Patient List, Controlling High Blood Pressure

# 2.8.10 Controlling High Blood Pressure (Million Hearts)

# **GPRA Measure Description**

During FY 2015, achieve the target rate of 59.5% for the proportion of patients with BP less than (<) 140/90.

#### **Denominator**

User Population patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD or current diagnosis of pregnancy (Million Hearts (NQF 0018)).

#### **Numerators**

Patients with BP less than (<) 140/90, i.e., the systolic value is less than (<) 140 AND the diastolic value is less than (<) 90 (Million Hearts (NQF 0018)).

#### **Logic Description**

Age of the patient is calculated at the end of the Report Period.

*Exclusions:* When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology)...

CRS uses the last Blood Pressure documented during the Report Period.

Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.

CRS uses the following codes to define ESRD and hypertension.

Subject Defined	CPT Codes	ICD and Other Codes
ESRD	36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308-G0327 (old code), G0393 (old code), G9231, S2065, or S9339	POV: ICD-9: 585.6, V42.0, V45.1, (old code), V45.11, V45.12, V56.*; ICD-10: N18.6, Z48.22, Z49.*, Z91.15, Z94.0, Z99.2  Procedure: ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6*
Hypertension		POV or Problem List entry where the status is not Inactive or Deleted ever through the first 6 months of the Report Period, and at least one hypertension POV during Report Period: ICD-9: 401.*; ICD-10: I10

Subject Defined	CPT Codes	ICD and Other Codes
Pregnancy		At least two visits during the Report Period with POV or Problem diagnosis:. ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3, 669.*3, 671.*3, 673.*3, 674.*3, 675.*3, 676.*3, 678.*3, 679.*3, V22.0-V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32, O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02, O24.111-O24.12, O24.311-O24.32, O24.41*, O24.811-O24.82, O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3, O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O99.511-O98.22, O98.311-O98.82, O99.344, O99.310-O99.314, O99.320-O99.324, O99.310-O99.314, O99.320-O99.324, O99.310-O99.314, O99.320-O99.324, O99.310-O99.314, O99.340-O99.344, O99.350-O99.354, O99.411-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.844, O99.89, O99.811-O99.62, O99.711-O99.72, O99.810, O99.834, O99.840-O99.844, O99.89, O9A.111-O9A.12, O9A.211-O9A.22, O9A.311-O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36, where the primary provider is not a CHR (Provider code 53).
Miscarriage	59812, 59820, 59821, 59830	<b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9
Abortion	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260- S2267	<b>POV:</b> ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 <b>Procedure:</b> ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z

# **Key Logic Changes from CRS Version 14.1**

- 1. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.
- 2. Added HCPCS code G9231 to ESRD definition.

## **Patient List Description**

List of patients with hypertension and BP value, if any.

#### **Measure Source**

Not Available

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	59.5%

DU November 25, 2015 Page 200  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Controlling High Blo				%	CHG from PREV YR %			CHG from BASE %	
User Pop Pts 18-85 w/HRN dx (Million Hearts)	144		123			100			
# w/ BP <140/90 (Million Hearts)	45	31.3	54	43.9	-12.7	42	42.0	-10.8	

Figure 2-85: Sample Report, Controlling High Blood Pressure (Million Hearts)

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Controlling High Blood Pressure - Million Hearts: List of patients with
hypertension and BP value, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1, STELLA LYNN 000001 COMMUNITY #1 F 46
```

HTN PT	156/82				
PATIENT2, TARA	000002 COMMUNITY	#1	F	51	
HTN PT	201/87				
PATIENT3, BOBBIE	000003 COMMUNITY	#1	F	52	
HTN PT	3074F/				
PATIENT4, DARLENE	000004 COMMUNITY	#1	F	54	
HTN PT	139/73				
PATIENT5, NADINE	000005 COMMUNITY	#1	F	61	
HTN PT	159/86				

Figure 2-86: Sample Patient List, Controlling High Blood Pressure (Million Hearts)

# 2.8.11 Comprehensive CVD-Related Assessment

## **GPRAMA Measure Description**

During FY 2015, achieve the target rate of 47.3% for the proportion of at-risk patients who have a comprehensive assessment.

#### **Denominators**

Active CHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever. (GPRAMA Denominator)

- a. Active CHD patients ages 22 and older who are not Active Diabetic
- b. Active CHD patients ages 22 and older who are Active Diabetic

#### **Numerators**

*BP Assessed:* Patients with Blood Pressure value documented at least twice in prior 2 years.

LDL Assessed: Patients with LDL completed during the Report Period, regardless of result.

*Tobacco Use Assessed:* Patients who have been screened for tobacco use during the Current Report period.

BMI Available: Patients for whom a BMI could be calculated.

**Note**: This numerator does *not* include refusals.

*Lifestyle Counseling:* Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education or patient goals during the Report Period.

Patients with *comprehensive CVD assessment*, defined as having BP, LDL, and tobacco use assessed, BMI calculated, and lifestyle counseling. (GPRAMA Numerator)

**Note**: This does *not* include depression screening and *does not* include refusals of BMI.

*Depression Screening:* Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note**: This numerator does *not* include refusals.

# **Logic Description**

Age of the patient is calculated at beginning of the Report Period.

Diabetes defined as: Diagnosed with diabetes (first POV in V POV with ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*) prior to the Current Report Period, and at least two visits during the Current Report Period, and two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

CRS uses the following codes and taxonomies to define the denominators.

Subject Defined	ICD and Other Codes
Coronary Heart Disease	Any of the following:
	<b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9
	2) One or more CABG or PCI procedures
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1
	<b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33533-33536, S2205-S2209
	Procedure: ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	<b>POV:</b> ICD-9: V45.82; ICD-10: Z95.5, Z98.61
	<b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982, 92995, G0290
	<b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**

Blood pressure definition: Having a minimum of 2 BPs documented in past 2 years. If CRS does not find 2 BPs, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 or POV ICD-9: V81.1 documented during the past 2 years. The following visits will be excluded: 1) Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation); 2) Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), C1 (Neurosurgery), or D4 (Anesthesiology).

LDL definition: Finds the most recent test done during the Report Period, regardless of the results of the measurement.

*BMI definition*: CRS calculates when the report is run, using NHANES II. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years; not required to be recorded on same day.

CRS uses the following codes and taxonomies to define the numerators.

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
	80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F, G9271, G9272	Yes	DM AUDIT LDL CHOLESTEROL TAX

Subject Defined	CPT Codes		LOINC Codes	Taxonomy
Tobacco Screening	D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code) or G8453 (old code), G9275, G9276	Any health factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE) (see table on next page) POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 305.1, 305.1* (old codes), 649.00-649.04, V15.82; ICD-10: F17.2*, O99.33*, Z87.891		
		Patient education codes: containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455- G8457 (old codes), G8402 (old code) or G8453 (old code), G9275, G9276		
Medical Nutrition	97802-97804,	Dental code: 1320 Primary or secondary provider		
Therapy	G0270, G0271	codes: 07, 29 Clinic codes: 67 (dietary) or 36 (WIC)		
Nutrition Education		POV: ICD-9: V65.3 dietary surveillance and counseling; ICD-10: Z71.3  Patient education codes: ending "-N" (nutrition) or "-MNT" (medical nutrition therapy) (or old code "-DT" (diet)) or containing V65.3; or Patient Goal with Goal Type of "Nutrition" and Goal Status of "Goal Set", "Goal Met", "Maintaining Goal", or "No Change" during the Report Period		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Exercise Education		POV: ICD-9: V65.41 exercise counseling Patient education codes: ending "-EX" (exercise) or containing V65.41; or Patient Goal with Goal Type of "Physical Activity" and Goal Status of "Goal Set", "Goal Met", "Maintaining Goal", or "No Change" during the Report Period		
Related Exercise and Nutrition Education		Patient education codes: ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00 or 278.01.		
Depression Screening		Exam: Exam Code 36 POV: ICD-9: V79.0 CPT: 1220F BHS Problem Code: 14.1 (Screening for Depression) Measurement in PCC or BH: PHQ2 or PHQ9		
Mood Disorders		At least 2 visits in PCC or BHS for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS (see codes below).  POV: ICD-9: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, 311; ICD-10: F06.31-F06.34, F1*.*4, F10.159, F10.180, F10.181, F10.188, F10.259, F10.280, F10.281, F10.288, F10.959, F10.980, F10.981, F10.988, F30.*, F31.0-F31.71, F31.73, F31.75, F31.77, F31.81-F31.9, F32.*-F39 BHS POV: 14, 15		
Suicide Ideation		POV: ICD-9: V62.84; ICD-10: R45.851 BHS POV: 39		

All existing national Tobacco Health Factors listed below are counted as tobacco screening.

Health Factor
Ceremonial
Cessation-Smokeless
Cessation-Smoker
Current Smokeless
Current Smoker
Current Smoker, status unknown
Current smoker, every day
Current smoker, some day
Non-Tobacco User
Previous Smokeless
Previous (Former) Smokeless
Previous Smoker
Previous (Former) Smoker
Smoke Free Home
Smoker In Home
Current Smoker & Smokeless
Exposure To Environmental Tobacco Smoke

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS codes G9275, G9276 to tobacco screening definition.
- 2. Added HCPCS codes G9271, G9272 to LDL definition.
- 3. Added HCPCS codes G9273, G9274 to BP documented definition.

# **Patient List Description**

List of patients with assessments received, if any.

#### **Measure Source**

Not Available

# **Measure Past Performance Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance (Comprehensive CVD Assessment)	52.3%

Performance	Percent
IHS FY 2013 Performance (Comprehensive CVD Assessment)	46.7%
IHS FY 2012 Performance (Comprehensive CVD Assessment)	37.5%
IHS FY 2011 Performance (Comprehensive CVD Assessment)	32.2%
Former definitions:	
IHS FY 2012 Performance (Comprehensive CVD Assessment)	45.4%
IHS FY 2011 Performance (Comprehensive CVD Assessment)	39.8%
IHS FY 2010 Performance (Comprehensive CVD Assessment)	35.0%
IHS FY 2009 Performance (Comprehensive CVD Assessment)	32.0%
IHS FY 2008 Performance (Comprehensive CVD Assessment)	30.0%
IHS FY 2007 Performance (Comprehensive CVD Assessment)	30.0%
IHS FY 2011 Performance (BP Assessed)	97.2%
IHS FY 2010 Performance (BP Assessed)	98.0%
IHS FY 2009 Performance (BP Assessed)	97.0%
IHS FY 2008 Performance (BP Assessed)	98.0%
IHS FY 2011 Performance (LDL Assessed)	92.9%
IHS FY 2010 Performance (LDL Assessed)	92.0%
IHS FY 2009 Performance (LDL Assessed)	91.0%
IHS FY 2008 Performance (LDL Assessed)	90.0%
IHS FY 2011 Performance (Tobacco Assessed)	84.2%
IHS FY 2010 Performance (Tobacco Assessed)	84.0%
IHS FY 2009 Performance (Tobacco Assessed)	83.0%
IHS FY 2008 Performance (Tobacco Assessed)	79.0%
IHS FY 2011 Performance (BMI Assessed)	97.2%
IHS FY 2010 Performance (BMI Assessed)	98.0%
IHS FY 2008 Performance (BMI Assessed or Refused)	85.0%
IHS FY 2011 Performance (Lifestyle Counseling)	45.3%
IHS FY 2010 Performance (Lifestyle Counseling)	41.0%
IHS FY 2009 Performance (Lifestyle Counseling)	39.0%
IHS FY 2008 Performance (Lifestyle Counseling)	38.0%
IHS FY 2011 Performance (Depression Screen)	75.7%
IHS FY 2010 Performance (Depression Screen)	72.0%
IHS FY 2009 Performance (Depression Screen)	62.0%
IHS FY 2008 Performance (Depression Screen)	53.0%

```
DU November 25, 2015 Page 207

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014

Baseline Period: Jan 01, 2010 to Dec 31, 2010
```

Comprehensive CVD-Re	lated As	sessme	nt						
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %		%	CHG from BASE %	
Active CHD Pts 22+									
(GPRAMA)	73		40			31			
# w/ BPs documented									
w/in 2 yrs	54	74.0	38	95.0	-21.0	31	100.0	-26.0	
# w/ LDL done	49	67.1	25	62.5	+4.6	14	45.2	+22.0	
# w/Tobacco Screenin	q								
w/in 1 yr	57	78.1	32	80.0	-1.9	23	74.2	+3.9	
# w/BMI calculated									
-No Refusals	58	79.5	38	95.0	-15.5	31	100.0	-20.5	
# w/ lifestyle									
educ w/in 1 yr	40	54.8	21	52.5	+2.3	20	64.5	-9.7	
# w/ BP, LDL, tobacc	o, BMI an	nd							
life counseling-No	Refusals	or De	р						
(GRPAMA)		26.0	_	37.5	-11.5	6	19.4	+6.7	
# w/ Depression scre	ening, o	r mood							
disorder or suicide									
DX-No Refusals	22	30.1	3	7.5	+22.6	1	3.2	+26.9	
A. Active CHD Pts 22	+								
and are NOT Active									
Diabetic	40		19			13			
Diabetic	10		19			13			
# w/ BPs documented									
w/in 2 yrs	25	62.5	18	94.7	-32.2	13	100.0	-37.5	
# w/LDL done	22	55.0	13	68.4	-13.4	8	61.5	-6.5	
# w/Tobacco Screenin	g								
w/in 1 yr	27	67.5	13	68.4	-0.9	10	76.9	-9.4	
# w/BMI calculated									
-No Refusals	29	72.5	18	94.7	-22.2	13	100.0	-27.5	
# w/ lifestyle									
educ w/in 1 yr	21	52.5	7	36.8	+15.7	5	38.5	+14.0	
# w/ BP, LDL, tobacc									
life counseling-No	Refusals	or De	р						
Screen (GPRA Dev.)		22.5		31.6	-9.1	2	15.4	+7.1	
# w/ Depression scre	ening, o	r mood							
disorder or suicide	ideation	n							
DX-No Refusals	14	35.0	1	5.3	+29.7	1	7.7	+27.3	

Figure 2-87: Sample Report, Comprehensive CVD-Related Assessment

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Comprehensive CVD-Related Assessment: List of patients with assessments
received, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1, CAITLYN 000001 COMMUNITY #1 F 22

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

```
ALL: BP: 131/67; LDL: 06/08/15; TOB: 07/25/15 NEVER
SMOKED; BMI: 25.4; LIFE: 08/15/15 UTI-N SN; DEP: 05/03/15 Meas PHQ9
PATIENT2, CARLA 000002 COMMUNITY #1 F 40
                            BP: 112/66; TOB: 08/26/15 NEVER SMOKED; BMI: 33.7
IHD
PATIENT3, JENNY 000003 COMMUNITY #1 F 47
                            BP: 3074F/; TOB: 11/01/15 D1320; BMI: 39.5; LIFE:
IHD
03/03/15 Prv 97; DEP: 11/01/15 CPT 1220F
PATIENT4,SHERRY 000004 COMMUNITY #1 F 68
                            ALL: BP: 150/82; LDL: 09/13/15; TOB: 10/30/15 NEVER
SMOKED; BMI: 26.8; LIFE: 10/19/15 PM-LA
PATIENTS, PAULINE 000005 COMMUNITY #1 F 70
                       BP: 149/72; LDL: 10/24/15; TOB: 10/24/15 CURRENT
IHD, AD
SMOKER, STATUS UNKNOWN; BMI: 37.5
PATIENT6, TINA MARIE 000006 COMMUNITY #1 F 78
                            BP: 3077F/; TOB: 01/27/15 G8402; BMI: 43.4; DEP:
09/11/15 Meas PHQ2
```

Figure 2-88: Sample Patient List: Comprehensive CVD-Related Assessment

# 2.8.12 Appropriate Medication Therapy after a Heart Attack

#### **Denominator**

Active Clinical patients aged 35 and older discharged for an AMI during the first 51 weeks of the Report Period and were not readmitted for any diagnosis within 7 days of discharge. Broken down by gender.

#### **Numerators**

Patients with active prescription for or who have a contraindication/previous adverse reaction to *beta-blockers*.

**Note**: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

**Note**: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *ACEIs/ARBs*.

**Note**: This numerator does *not* include refusals.

Patients with active prescription for or who have a contraindication/ previous adverse reaction to *statins*.

**Note**: This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with active prescriptions for *all post-AMI medications* (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, and statin), and/or who have a contraindication/previous adverse reaction.

**Note**: This numerator does *not* include refusals.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

Acute Myocardial Infarction (AMI) definition: POV ICD-9: 410.\*1; ICD-10: I21.\*, I22.\* (i.e., first eligible episode of an AMI) with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the Report Period, CRS will include only the first discharge.

#### **Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

- 1. Patients with Discharge Type of Irregular (AMA), Transferred, or contains "Death."
- 2. Patients readmitted for any diagnosis within 7 days of discharge.
- 3. Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
- 4. Patients with a Provider Narrative beginning with "Consider"; "Doubtful"; "Maybe"; "Possible"; "Perhaps"; "Rule Out"; "R/O"; "Probable"; "Resolved"; "Suspect"; "Suspicious"; or "Status Post."

#### Numerator Logic

In the logic below, "ever" is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below:

- 1. An active prescription (not discontinued as of [discharge date plus (+) 7 days] and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within 7 days after discharge. "Active" prescription defined as: Days Prescribed greater than (>) ((Discharge Date plus (+) 7 days) Order Date); *or*
- 2. Have a contraindication/previous adverse reaction to the indicated medication.

Contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy will be counted in subnumerator B.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

# **Beta-Blocker Numerator Logic**

Beta-blocker medication codes defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.)

CRS uses the following codes to define contraindications to beta-blockers.

Contraindication to Beta- Blockers (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		<b>POV:</b> 1 diagnosis of ICD-9: 458*; ICD-10: 195.*

Heart Block greater than (>)1 Degree		<b>POV:</b> 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: 144.1, 144.2, 145.2, 145.3, 145.6
Sinus Bradycardia		<b>POV:</b> 1 diagnosis of ICD-9: 427.81; ICD-10: 149.5, R00.1
COPD		POV: 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta- blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during hospital stay through 7 days after discharge date	Refusal: NMI (not medically indicated) refusal for any beta-blocker at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to beta-blockers.

# Adverse Drug Reaction/Allergy to Beta-Blockers

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.0
Entry in ART (Patient Allergies File): "beta block*"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "beta block*", "bblock*" or "b block*"

# ASA (aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated DM AUDIT ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Active prescription for Warfarin/Coumadin at time of arrival or prescribed at discharge		Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS
Hemorrhage		<b>POV</b> : ICD-9: 459.0; ICD-10: R58
NMI Refusal	G8008 (old code) at least once during hospital stay through 7 days after discharge date	Refusal: NMI (not medically indicated) refusal for any aspirin at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to ASA/other anti-platelets.

## Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

ICD and Other Codes
<b>POV</b> : ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*
Entry in ART (Patient Allergies File): "aspirin"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ASA" or "aspirin"

# **ACEI/ARB Numerator Logic**

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

CRS uses the following codes to define contraindications to ACE inhibitors.

Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition

Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
		Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		Refusal: NMI (not medically indicated) refusal for any ACE inhibitor at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to ACE inhibitors.

# Adverse Drug Reaction/ Allergy to ACE Inhibitors

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
Entry in ART (Patient Allergies File): "ace inhibitor" or "ACEI"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ace i*" or "ACEI"

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
		Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		<b>Refusal:</b> NMI refusal for any ARB at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to ARBs.

# **Adverse Drug Reaction/Allergy to ARBs**

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6
Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Angiotensin Receptor Blocker" or "ARB"

# **Statins Numerator Logic**

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.

Contraindication to Statins (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition

Contraindication to Statins (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
		Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Acute Alcoholic Hepatitis		<b>POV:</b> ICD-9: 571.1; ICD-10: K70.10, K70.11 during the Report Period
NMI Refusal		<b>Refusal:</b> NMI refusal for any statin at least once during hospital stay through 7 days after discharge date

CRS uses the following codes to define adverse drug reactions/documented allergies to statins.

# **Adverse Drug Reaction/Allergy to Statins**

ICD and Other Codes
Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period
Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period
<b>POV:</b> Myopathy/Myalgia, defined as any of the following during the Report Period: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1
POV: ICD-9: 995.0-995.3 AND E942.9
Entry in ART (Patient Allergies File): "statin" or "statins"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Statin" or "Statins"

Subject Defined	ICD and CPT Codes
Pregnancy	POV or Problem List: At least two visits during the Report Period with ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 669.*3, 671.*3, 673.*3, 674.*3, 675.*3, 676.*3, 678.*3, 679.*3, V22.0-V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: 009.00-010.02, 010.111-010.12, 010.211-010.22, 010.311-010.32, 010.411-010.42, 010.911-010.92, 011.1-015.1, 015.9-024.02, 024.111-024.12, O24.311-024.32, O24.41*, O24.811-024.82, O24.911-024.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-026.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-071.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O98.22, O92.29, O99.011-O90.2, O99.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.82, O99.82, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.844, O99.830, O99.834, O99.840-O99.844, O99.89, O99.811-O98.42, O99.811-O98.22, O98.311-O98.22, O98.311-O98.22, O98.311-O98.32, O99.330, O99.834, O99.840-O99.844, O99.89, O94.111-O94.12, O94.211-O94.22, O94.311-O94.32, O94.411-O94.42, O94.511-O94.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36, where the primary provider is not a CHR (Provider code 53), and with no documented miscarriage or abortion (defined below) occurring after the second pregnancy POV. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period,
Abortion	CRS will use the first two visits in the Report Period.  CPT: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267  POV: ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z,
Miscarriage	0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z  CPT: 59812, 59820, 59821, 59830  POV: ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9

# **All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

# **Key Logic Changes from CRS Version 14.1**

- 1. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.
- 2. Added ICD-10 codes J45.901-J45.998 to Asthma definition.
- 3. Added HCPCS code G9190 to beta-blocker contraindication definition.
- 4. Updated BGP PQA STATIN MEDS taxonomy.

## **Patient List Description**

List of patients with AMI, with appropriate medication therapy, if any.

#### **Measure Source**

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

# **Measure Past Performance and Long-Term Targets**

None

Previous	t Per Year	Measu DEMC iod: J Period	D INDIAN HO Jan 01, 201 A: Jan 01,	ommu SPIT 5 to 201		2014	_	ge 216
Appropriate Medication	Thera	py aft	er a Heart	Att	ack			
	ORT RIOD	-		-	CHG from BASI PREV YR % PEI	_		
Active Clinical Pts 35+ hospitalized for AMI	71		0			0		
<pre># w/beta-blocker Rx/contra/ADR -No Refusals</pre>	27	38.0	0	0 0	+38.0	0	0.0	+38.0
A. # w/beta-blocker								
Rx w/ % of Total B. # w/contra/ADR	5	18.5	0	0.0	+18.5	0	0.0	+18.5
w/ % of Total	22	81.5	0	0.0	+81.5	0	0.0	+81.5
# w/ASA Rx/contra/ADR -No Refusals	9	12.7	0	0.0	+12.7	0	0.0	+12.7
A. # w/ASA Rx w/% of Total	3	33.3	0	0.0	+33.3	0	0.0	+33.3
B. # w/contra/ADR w/ % of Total	6	66.7	0	0.0	+66.7	0	0.0	+66.7

# w/ACEI/ARB								
Rx/contra/ADR								
-No Refusals	19	26.8	0	0.0	+26.8	0	0.0	+26.8
A. # w/ACEI/ARB  Rx w/% of Total	1	21.1	0	0.0	+21.1	0	0.0	+21.1
B. # w/contra/ADR	4	21.1	U	0.0	TZ1.1	U	0.0	721.1
w/ % of Total	15	78.9	0	0.0	+78.9	0	0.0	+78.9
# w/statin								
Rx/contra/ADR								
-No Refusals	17	23.9	0	0.0	+23.9	0	0.0	+23.9
A. # w/statin								
Rx w/% of Total	5	29.4	0	0.0	+29.4	0	0.0	+29.4
B. # w/contra/ADR								
w/ % of Total	12	70.6	0	0.0	+70.6	0	0.0	+70.6
# m/Dm/gontmo/ADD of ALL								
<pre># w/Rx/contra/ADR of ALL meds-No Refusals</pre>	4	5.6	0	0.0	+5.6	0	0.0	+5.6
meds-No Kelusais	4	5.0	U	0.0	+5.0	U	0.0	+3.0

Figure 2-89: Sample Report, Appropriate Medication Therapy after a Heart Attack

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Appropriate Medication Therapy after a Heart Attack: List of patients with AMI, with appropriate medication therapy, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, CECELIA 000001 COMMUNITY #1 F 37 BETA: 06/30/15 Contra 2/3 heart block POV 426.3 PATIENT2, KATHLEEN 000002 COMMUNITY #1 F 38 ACEI/ARB: Contra pregnant; STATIN: Contra pregnant AC PATIENT3, KIMBERLY A 000003 COMMUNITY #1 F 49 ASA: 11/16/15 CLOPIDOGREL BISULFATE 75MG TAB; ACEI/ARB: 01/14/15 Contra BF-HC; STATIN: 01/14/15 Contra BF-HC PATIENT4, TIMOTHY JOHN 000004 COMMUNITY #1 M 57 ACEI/ARB: 06/01/15 Contra NMI CAPTOPRIL 25MG TABS PATIENT5, FELIPE 000005 COMMUNITY #1 M 57 PATIENT6, JAMES DALTON 000006 COMMUNITY #1 M 77 ALL MEDS: BETA: 07/23/15 Contra CPT G8011; ASA: 07/23/15 Contra CPT G8008; ACEI/ARB: 07/27/12 Contra POV 396.0; STATIN: 06/05/15 SIMVASTATIN 40MG TAB

Figure 2-90: Sample Patient List: Appropriate Medication Therapy after a Heart Attack

# 2.8.13 Persistence of Appropriate Medication Therapy after a Heart Attack

#### **Denominator**

Active Clinical patients 35 and older diagnosed with an AMI 6 months prior to the Report Period through the first 6 months of the Report Period. Broken down by gender.

#### **Numerators**

Patients with a 135-day course of treatment with beta-blockers, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

**Note**: This numerator does *not* include refusals.

Patients with a 135-day course of treatment with ASA (aspirin) or other anti-platelet agent or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

**Note**: This numerator does *not* include refusals.

Patients with a 135-day course of treatment with ACEIs/ARBs or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

**Note**: This numerator does *not* include refusals.

Patients with a 135-day course of treatment with statins or who have a contraindication/previous adverse reaction to statin therapy.

**Note**: This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- Patients with contraindication/previous adverse reaction to the specified medication

Patients with a 135-day course of treatment for all post-AMI medications (i.e., beta-blocker, ASA/anti-platelet, ACEI/ARB, and statin) following first discharge date or visit date, including previous active prescriptions; and/or who have a contraindication/previous adverse reaction.

**Note**: This numerator does *not* include refusals.

# **Logic Description**

Age is calculated at the beginning of the Report Period.

Acute Myocardial Infarction (AMI) definition: POV ICD-9: 410.0\* through 410.9\*, 412; ICD-10: I21.\*, I22.\*. AMI diagnosis may be made at an inpatient or outpatient visit but must occur between 6 months prior to beginning of Report Period through first 6 months of the Report Period. Inpatient visit defined as Service Category of H (Hospitalization). If patient has more than one episode of AMI during the timeframe, CRS will include only the first hospital discharge or ambulatory visit.

#### **Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

- If inpatient visit, patients with Discharge Type of Irregular (AMA), Transferred, or contains "Death."
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).
- Patients with a Provider Narrative beginning with "Consider," "Doubtful,"
   "Maybe," "Possible," "Perhaps," "Rule Out," "R/O," "Probable," "Resolved,"
   "Suspect," "Suspicious," or "Status Post."

# **Numerator Logic**

In the logic below, "ever" is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below.

- 1. A total days' supply greater than or equal to (>=) 135 days in the 180 days following discharge date for inpatient visits or visit date for ambulatory visits. Medications must not have a comment of RETURNED TO STOCK. Prior active prescriptions can be included if the treatment days fall within the 180 days following discharge/visit date. Prior active prescription defined as most recent prescription (see codes below) prior to admission/visit date with the number of days supply equal to or greater than the discharge/visit date minus the prescription date; or
- 2. Have a contraindication/previous adverse reaction to the indicated medication.
- 3. Contraindications/previous ADR/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/allergy will be counted in sub-numerator B.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator who has prior active prescription:

- Admission Date: 2/1/2015, Discharge Date: 2/15/2015
- Must have 135 days prescribed by 8/13/2015 (Discharge Date+180)
- Prior Beta-Blocker Rx Date: 1/15/2015
- # Days Prescribed: 60 (treats patient through 3/15/2015)
- Discharge Date minus Rx Date: 2/15/2015 through 1/15/2015 = 31, 60 is greater than or equal to (>=) 31, prescription is considered Prior Active Rx
- 3/15/2015 is between 2/15 and 8/13/2015, thus remainder of Prior Active Rx can be counted toward 180-day treatment period
- # Remaining Days Prescribed from Prior Active Rx:
- (60-(Discharge Date-Prior Rx Date) = 60-(2/15/2015-1/15/2015) = 60-31 = 29
- Rx #2: 4/1/2015, # Days Prescribed: 90
- Rx #3: 7/10/2015, #Days Prescribed: 90
- Total Days Supply Prescribed between 2/15 and 8/13/2015: 29+90+90=209

## **Beta-Blocker Numerator Logic**

Beta-blocker medication codes defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol and Hydrochlorothiazide-propranolol.)

CRS uses the following codes to define contraindications to beta-blockers.

Contraindication to Beta- Blockers (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		<b>POV:</b> 1 diagnosis of ICD-9: 458*; ICD-10: 195.*
Heart Block greater than (>)1 Degree		<b>POV:</b> 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6
Sinus Bradycardia		<b>POV:</b> 1 diagnosis of ICD-9: 427.81; ICD-10: 149.5, R00.1
COPD		POV: 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta- blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during the period admission/visit date through the 180 days after discharge/visit date	Refusal: NMI refusal for any beta-blocker at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documented allergies to beta-blockers.

# Adverse Drug Reaction/Allergy to Beta-Blockers

ICD and Other Codes
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.0
Entry in ART (Patient Allergies File): "beta block*"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "beta block*", "bblock*" or "b block*"

# ASA (Aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever, unless otherwise noted)		ICD and Other Codes
Active prescription for Warfarin/Coumadin during the period admission/visit date through the 180 days after discharge/visit date		Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS
Hemorrhage		<b>POV</b> : ICD-9: 459.0; ICD-10: R58
NMI Refusal	G8008 (old code) at least once during the period admission/visit date through the 180 days after discharge/visit date	Refusal: NMI (not medically indicated) refusal for any aspirin/other anti-platelet at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documented allergies to ASA/other anti-platelets.

# Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

ICD and Other Codes			
<b>POV:</b> ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*			
Entry in ART (Patient Allergies File): "aspirin"			
Entry in Problem List or in Provider Narrative for			

# **ACEI/ARB Numerator Logic**

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil).

CRS uses the following codes to define contraindications to ACE inhibitors.

Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the period admission/visit date through the 180 days after discharge/visit date
		Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
NMI Refusal		Refusal: NMI refusal for any ACE inhibitor at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documented allergies to ACE inhibitors.

## **Adverse Drug Reaction/Allergy to ACE Inhibitors**

ICD and Other Codes				
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*				
Entry in ART (Patient Allergies File): "ace inhibitor" or "ACEI"				
Contained within or Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ace i*" or "ACEI"				

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications are: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.).

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		POV: ICD-9: V24.1; ICD-10: Z39.1 during the period admission/visit date through the 180 days after discharge/visit date  Patient Education: BF-BC, BF-BP, BF-CS,
		BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
NMI Refusal		Refusal: NMI refusal for any ARB at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documented allergies to ARBs.

## Adverse Drug Reaction/Allergy to ARBs

ICD and Other Codes			
<b>POV:</b> ICD-9: 995.0-995.3 AND E942.6			
Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB"			
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Angiotensin Receptor Blocker" or "ARB"			

## **Statins Numerator Logic**

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.

Contraindication to Statins (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the period admission/visit date through the 180 days after discharge/visit date
		Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date
Acute Alcoholic Hepatitis		POV: ICD-9: 571.1; ICD-10: K70.10, K70.11 during the period admission/visit date through the 180 days after discharge/visit date
NMI Refusal		Refusal: NMI refusal for any statin at least once during the period admission/visit date through the 180 days after discharge/visit date

CRS uses the following codes to define adverse drug reactions/documented allergies to statins.

# **Adverse Drug Reaction/Allergy to Statins**

ICD and Other Codes				
Site-Populated Lab Taxonomy or LOINC Taxonomy: DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the period admission/visit date through the 180 days after discharge/visit date				
Site-Populated Lab Taxonomy or LOINC Taxonomy: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the period admission/visit date through the 180 days after discharge/visit date				

**POV:** Myopathy/Myalgia, defined as any of the following during the period admission/visit date through the 180 days after discharge/visit date: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1

POV: ICD-9: 995.0-995.3 AND E942.9

Entry in ART (Patient Allergies File): "statin" or "statins"

Entry in Problem List or in Provider Narrative for any ICD-9: POV 995.0-995.3, V14.8; ICD-10: Z88.8: "Statin" or "Statins"

Subject Defined	ICD and CPT Codes
Pregnancy	POV or Problem List: At least two visits during the period
	admission/visit date through the 180 days after discharge/visit date
	with ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3,
	647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3,
	657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 668.*3,
	669.*3, 671.*3, 673.*3, 674.*3, 675.*3, 676.*3, 678.*3, 679.*3, V22.0-
	V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10:
	O09.00-O10.02, O10.111-O10.12, O10.211-O10.22, O10.311-O10.32,
	O10.411-O10.42, O10.911-O10.92, O11.1-O15.1, O15.9-O24.02,
	024.111-024.12, 024.311-024.32, 024.41*, 024.811-024.82,
	O24.911-O24.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72,
	O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-
	O66.*, O68, O69.*, O71.00-O71.1, O71.89, O71.9, O74.0-O75.81,
	O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12,
	O88.211-O88.22, O88.311-O88.32, O88.811-O88.82, O90.3,
	O91.011-O91.019, O91.111-O91.119, O91.211-O91.219, O92.011-
	O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12,
	098.211-098.22, 098.311-098.32, 098.411-098.42, 098.511-
	O98.52, O98.611-O98.62, O98.711-O98.72, O98.811-O98.82,
	098.911-098.92, 099.011-099.02, 099.111-099.12, 099.210-
	099.214, 099.280-099.284, 099.310-099.314, 099.320-099.324,
	099.330-099.334, 099.340-099.344, 099.350-099.354, 099.411-
	099.42, 099.511-099.52, 099.611-099.62, 099.711-099.72,
	O99.810, O99.814, O99.820, O99.824, O99.830, O99.834, O99.840-
	099.844, 099.89, 09A.111-09A.12, 09A.211-09A.22, 09A.311-
	O9A.32, O9A.411-O9A.42, O9A.511-O9A.52, Z03.7*, Z32.01, Z33.1,
	Z34.*, Z36, where the primary provider is not a CHR (Provider code
	53), and with no documented miscarriage or abortion (defined below)
	occurring after the second pregnancy POV. Pharmacy-only visits
	(clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the time period, CRS
	, , , , , , , , , , , , , , , , , , , ,
	will use the first two visits in the time period.

Abortion	<b>CPT:</b> 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267 <b>POV:</b> ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2
	<b>Procedure</b> : ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z
Miscarriage	<b>CPT:</b> 59812, 59820, 59821, 59830 <b>POV:</b> ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9

## **All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

## **Key Logic Changes from CRS Version 14.1**

- 1. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.
- 2. Added ICD-10 codes J45.901-J45.998 to Asthma definition.
- 3. Added HCPCS code G9190 to beta-blocker contraindication definition.
- 4. Updated BGP PQA STATIN MEDS taxonomy.

# **Patient List Description**

List of patients with AMI, with persistent medication therapy, if any.

## **Measure Source**

American Heart Association/American College of Cardiology Guidelines for the Treatment of AMI.

## **Measure Past Performance and Long-Term Targets**

None

```
DH
                             November 25, 2015
                                                                    Page 228
       *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Persistence of Appropriate Medication Therapy after a Heart Attack
                   REPORT
                           % PREV YR
                                            % CHG from BASE
                                                                  % CHG from
                    PERIOD
                                 PERIOD
                                                PREV YR % PERIOD
                                                                      BASE %
```

Active Clinical Pts 35+								
w/ AMI DX	61		4			4		
# w/135-day beta-blocker	:							
Rx/contra/ADR								
-No Refusals	23	37.7	2	50.0	-12.3	3	75.0	-37.3
A. $\#$ w/135-day beta bloc	ker							
Rx w/ % of Total	3	13.0	2	100.0	-87.0	2	66.7	-53.6
B. # w/contra/ADR								
w/ % of Total	20	87.0	0	0.0	+87.0	1	33.3	+53.6
.,								
# w/135-day ASA								
Rx/contra/ADR								
-No Refusals	5	8.2	0	0.0	+8.2	2	50.0	-41.8
A. # w/135-day ASA								
Rx w/% of Total	1	20.0	0	0.0	+20.0	2	100.0	-80.0
B. # w/contra/ADR								
w/% of Total	4	80.0	0	0.0	+80.0	0	0.0	+80.0
, v 01 100a1	-		Ŭ	0.0		ŭ	•••	
# w/135-day ACEI/ARB								
Rx/contra/ADR								
-No Refusals	13	21.3	1	25.0	-3.7	1	25.0	-3.7
A. # w/135-day ACEI/ARB		21.3	_	23.0	3.,	_	23.0	<i>3.</i> /
Rx w/% of Total	1	7.7	1	100.0	-92.3	1	100.0	-92.3
B. # w/contra/ADR	_	. • .	_		, 2	_		,2.5
w/% of Total	12	92.3	0	0.0	+92.3	0	0.0	+92.3
, v 01 100a1		,2.0	Ŭ	0.0	,,,,,	ŭ	•••	.,2.,3
# w/135-day statin								
Rx/contra/ADR								
-No Refusals	6	9.8	2	50.0	-40.2	2	50.0	-40.2
A. # w/135-day statin	J		ے	50.0	10.2		30.0	10.2
Rx w/% of Total	2	33.3	2	100.0	-66.7	2	100.0	-66.7
B. # w/contra/ADR	-	55.5	ے	_00.0	00.,		_00.0	00.7
w/ % of Total	4	66.7	0	0.0	+66.7	0	0.0	+66.7
", J OI IOCAI		00.7	J	0.0	100.7	0	0.0	. 00.7
# w/Rx/contra/ADR of ALI								
meds-No Refusals	2	3.3	٥	0.0	+3.3	1	25.0	-21.7
meds no retubats		5.5	J	0.0	10.0		25.0	21.1

Figure 2-91: Sample Report, Persistence of Appropriate Medication Therapy after a Heart Attack

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Persistence of Appropriate Medication Therapy after a Heart Attack: List of
patients with AMI, with persistent medication therapy, if any
PATIENT NAME
                     HRN
                             COMMUNITY
                                          SEX AGE
DENOMINATOR
                           NUMERATOR
PATIENT1,RHONDA 000001 COMMUNITY #1 F 35
                           ALL MEDS: BETA: 03/07/13 03/13/13 Contra 2 POV asthma;
ASA: 05/23/15 Contra NMI ASPIRIN 325MG CAP; ACEI/ARB: 07/01/15 ADR Problem List
995.0 ACEI; STATIN: 07/01/15 ADR creat kinase of 5000
PATIENT2, KATHLEEN 000002 COMMUNITY #1 F 38
                            BETA: 06/02/15 ADR POV V14.8
PATIENT3, KIMBERLY A 000003 COMMUNITY #1 F 49
```

```
AC BETA: 03/01/15 Contra 2/3 heart block POV 426.12;

ACEI/ARB: 05/02/15 Contra pregnant; STATIN: 05/02/15 Contra pregnant

PATIENT4, TIMOTHY 000004 COMMUNITY #1 M 57

AC ACEI/ARB: 06/15/15 Contra POV V24.1; STATIN: 06/15/15

Contra POV V24.1

PATIENT5, JOSHUA 000005 COMMUNITY #1 M 63

AC ACEI/ARB: 02/03/15 Contra Aortic POV 395.0
```

Figure 2-92: Sample Patient List: Persistence of Appropriate Medication Therapy after a Heart Attack

# 2.8.14 Appropriate Medication Therapy in High Risk Patients

#### **Denominators**

Active CHD patients ages 22 and older; defined as all Active Clinical patients diagnosed with coronary heart disease (CHD) prior to the Report Period, and at least two visits during the Report Period, and two CHD-related visits ever.

- Active CHD patients ages 22 and older who are not Active Diabetic.
- Active CHD patients ages 22 and older who are Active Diabetic

#### **Numerators**

Patients with a 180-day course of treatment with *beta-blockers* during the Report Period, or who have a contraindication/previous adverse reaction to beta-blocker therapy.

**Note**: This numerator does *not* include refusals.

Patients with a 180-day course of treatment with ASA (aspirin) or other anti-platelet agent during the Report Period, or who have a contraindication/previous adverse reaction to ASA/anti-platelet therapy.

**Note**: This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *ACEIs/ARBs* during the Report Period, or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.

**Note**: This numerator does *not* include refusals.

Patients with a 180-day course of treatment with *statins* during the Report Period, or who have a contraindication/previous adverse reaction to statin therapy.

**Note**: This numerator does *not* include refusals.

Also included for the numerators above are sub-numerators:

- a. Patients with active prescription for the specified medication
- b. Patients with contraindication/previous adverse reaction to the specified medication

Patients with a 180-day course of treatment for *all medications* (i.e., beta-blocker, aspirin/anti-platelet, ACEI/ARB, *and* statin) during the Report Period, and/or who have a contraindication/previous adverse reaction.

**Note**: This numerator does *not* include refusals.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominators.

Subject Defined	ICD and Other Codes
Coronary Heart	Any of the following:
Disease	<b>1) POV:</b> ICD-9: 410.0–413.*, 414.0–414.9, 429.2; ICD-10: I20.0-I22.8, I24.0-I25.83, I25.89, I25.9
	2) One or more CABG or PCI procedures
CABG	<b>POV:</b> ICD-9: V45.81; ICD-10: Z95.1
	<b>CPT:</b> 33510-33514, 33516-33519, 33521-33523, 33533-33536, S2205-S2209
	<b>Procedure:</b> ICD-9: 36.1*, 36.2*; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*
PCI	POV: ICD-9: V45.82; ICD-10: Z95.5, Z98.61
	<b>CPT:</b> 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982, 92995, G0290
	<b>Procedure:</b> ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**

*Diabetes* defined as: Diagnosed with diabetes (first POV in V POV with ICD-9: 250.00 through 250.93 or ICD-10: E10.\* through E13.\*) prior to the Current Report Period, *and* at least two visits during the Current Report period, *and* two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

Numerator Logic

In the logic below, "ever" is defined as anytime through the end of the Report Period.

To be included in the numerators, a patient must meet one of the two conditions below:

- 1. Prescription(s) for the indicated medication with a total days supply of 180 days or more during the Report Period. Medications must not have a comment of RETURNED TO STOCK; *or*
- 2. Have a contraindication/previous adverse reaction to the indicated medication

Contraindications/previous ADR/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication/ADR/ allergy will be counted in sub-numerator B.

For prescriptions, the days supply requirement may be met with a single prescription or from a combination of prescriptions for the indicated medication that were filled during the Report Period and prescriptions filled prior to the Report Period but which are still active (i.e., prior active prescription). Prior active prescriptions can be included if the treatment days fall within the Report Period. Prior active prescription defined as most recent prescription for the indicated medication (see codes below) prior to Report Period Start Date with the number of days supply equal to or greater than the Report Period Start Date minus the prescription date.

Note: If a prescription for a medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator with prior active prescription:

- Report Period: 07/01/2014 through 06/30/2015
- Must have 180 days supply of indicated medication 6/30/2015 (end of Report Period)
- Prior Beta-Blocker Rx Date: 06/01/2014
- # Days Prescribed: 60 (treats patient through 07/31/2014)
- Report Period Start Date minus Rx Date: 07/01/2014-06/01/2014 = 30; 60 (#Days Prescribed) is greater than or equal to (>=) 30, prescription is considered Prior Active Rx
- 07/31/2014 is between the Report Period of 07/01/2014 and 06/30/2015, thus remainder of Prior Active Rx can be counted toward 180-days supply
- # Remaining Days Prescribed from Prior Active Rx:

- (# Days Prescribed-(Report Period Start Date-Prior Rx Date) = 60-(07/01/2014-06/01/2014) = 60-30 = 30
- Rx #2: 08/05/2014, # Days Prescribed: 90
- Rx #3: 11/10/2014, #Days Prescribed: 90
- Total Days Supply Prescribed between 07/01/2014 and 06/30/2015, including prior active prescription: 30+90+90=210

## **Beta-Blocker Numerator Logic**

Beta-blocker medication codes defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. Medications are: Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol.

CRS uses the following codes to define contraindications to beta-blockers.

Contraindication to Beta- Blockers (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
Asthma		<b>POV:</b> 2 diagnoses of ICD-9: 493*; ICD-10: J45.* on different visit dates
Hypotension		<b>POV:</b> 1 diagnosis of ICD-9: 458*; ICD-10: 195.*
Heart Block greater than (>)1 Degree		POV: 1 diagnosis of ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: 144.1, I44.2, I45.2, I45.3, I45.6
Sinus Bradycardia		<b>POV:</b> 1 diagnosis of ICD-9: 427.81; ICD-10: I49.5, R00.1
COPD		POV: 2 diagnoses on different visit dates of ICD-9: 491.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496

Contraindication to Beta- Blockers (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
NMI Refusal	G8011 (old code), G9190 (Documentation of medical reason(s) for not prescribing beta- blocker therapy (e.g., allergy, intolerance, other medical reasons)) at least once during the Report Period	Refusal: NMI refusal for any beta-blocker at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to beta-blockers.

# Adverse Drug Reaction/Allergy to Beta-Blockers

ICD and Other Codes		
<b>POV</b> : ICD-9: 995.0-995.3 AND E942.0		
Entry in ART (Patient Allergies File): "beta block*"		
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "beta block*", "bblock*" or "b block*"		

# ASA (aspirin)/Other Anti-Platelet Numerator Logic

ASA medication codes defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

Other anti-platelet medication codes defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

CRS uses the following codes to define contraindications to ASA/other anti-platelets.

Contraindication to ASA/Other Anti-Platelets (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
180-day course of treatment for Warfarin/Coumadin during the Report Period		Site-Populated Drug Taxonomy: BGP CMS WARFARIN MEDS
Hemorrhage		<b>POV</b> : ICD-9: 459.0; ICD-10: R58

NMI Refusal	G8008 (old code) at	Refusal: NMI (not medically indicated)
	least once during the	refusal for any aspirin at least once during
	Report Period	the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to ASA/other anti-platelets.

# Adverse Drug Reaction/Allergy to ASA/Other Anti-Platelets

ICD and Other Codes		
<b>POV</b> : ICD-9: 995.0-995.3 AND E935.3; ICD-10: T39.015* or T39.095*		
Entry in ART (Patient Allergies File): "aspirin"		
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ASA" or "aspirin"		

# **ACEI/ARB Numerator Logic**

Ace Inhibitor (ACEI) medication codes defined with medication taxonomy BGP HEDIS ACEI MEDS. ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril.)

Antihypertensive Combinations: (Amlodipine-benazepril, Benazepril-hydrochlorothiazide, Captopril-hydrochlorothiazide, Enalapril-hydrochlorothiazide, Fosinopril-hydrochlorothiazide, Hydrochlorothiazide-lisinopril, Hydrochlorothiazide-moexipril, Hydrochlorothiazide-quinapril, Trandolapril-verapamil.)

CRS uses the following codes to define contraindications to ACE inhibitors.

Contraindication to ACE Inhibitors (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		POV: ICD-9: V24.1; ICD-10: Z39.1 during the Report Period  Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		Refusal: NMI refusal for any ACE inhibitor at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to ACE inhibitors.

## Adverse Drug Reaction/Allergy to ACE Inhibitors

ICD and Other Codes
<b>POV</b> : ICD-9: 995.0-995.3 AND E942.6; ICD-10: T46.4X5*
Entry in ART (Patient Allergies File): "ace inhibitor" or "ACEI"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "ace i*" or "ACEI"

ARB (Angiotensin Receptor Blocker) medication codes defined with medication taxonomy BGP HEDIS ARB MEDS. ARB medications are: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-hydrochlorothiazide-olmesartan, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan, Amlodipine-Telmisartan, Amlodipine-valsartan, Azilsartan-chlorthalidone, Candesartan-hydrochlorothiazide, Eprosartan-hydrochlorothiazide, Hydrochlorothiazide-Irbesartan, Hydrochlorothiazide-Losartan, Hydrochlorothiazide-olmesartan, Hydrochlorothiazide-Telmisartan, Hydrochlorothiazide-Valsartan).

CRS uses the following codes to define contraindications to ARBs.

Contraindication to ARBs (any of the codes occurring ever unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		<b>POV:</b> ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
		Patient Education: BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Moderate or Severe Aortic Stenosis		<b>POV:</b> ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, or 747.22
NMI Refusal		Refusal: NMI (not medically indicated) refusal for any ARB at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to ARBs.

# Adverse Drug Reaction/Allergy to ARBs

ICD and Other Codes
<b>POV</b> : ICD-9: 995.0-995.3 AND E942.6
Entry in ART (Patient Allergies File): "Angiotensin Receptor Blocker" or "ARB"
Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Angiotensin Receptor Blocker" or "ARB"

# **Statins Numerator Logic**

Statin medication codes defined with medication taxonomy BGP PQA STATIN MEDS. Statin medications are: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

Statin Combination Products: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

CRS uses the following codes to define contraindications to statins.

Contraindication to ACE Inhibitors (any of the codes occurring ever, unless otherwise noted)	CPT Codes	ICD and Other Codes
Pregnancy		See below for definition
Breastfeeding		POV: ICD-9: V24.1; ICD-10: Z39.1 during the Report Period
		<b>Patient Education</b> : BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the Report Period
Acute Alcoholic Hepatitis		<b>POV</b> : ICD-9: 571.1; ICD-10: K70.10, K70.11 during the Report Period
NMI Refusal		Refusal: NMI refusal for any statin at least once during the Report Period

CRS uses the following codes to define adverse drug reactions/documented allergies to statins.

# Adverse Drug Reaction/Allergy to Statins

#### ICD and Other Codes

Site-Populated Lab Taxonomy or LOINC

**Taxonomy**: DM AUDIT ALT TAX, with ALT and/or AST greater than (>) 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the Report Period

Site-Populated Lab Taxonomy or LOINC

**Taxonomy**: BGP CREATINE KINASE TAX, with Creatine Kinase (CK) levels greater than (>) 10x ULN or CK greater than (>) 10,000 IU/L during the Report Period

**POV**: Myopathy/Myalgia, defined as any of the following during the Report Period: ICD-9: 359.0-359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80-M60.9, M79.1

POV: ICD-9: 995.0-995.3 AND E942.9

Entry in ART (Patient Allergies File): "statin" or "statins"

Entry in Problem List or in Provider Narrative for any POV ICD-9: 995.0-995.3, V14.8; ICD-10: Z88.8: "Statin" or "Statins"

Subject Defined	ICD and CPT Codes
Pregnancy	POV or Problem List: At least two visits during the Report Period with ICD-9: 640.*3, 641.*3, 642.*3, 643.*3, 644.*3, 645.*3, 646.*3, 647.*3, 648.*3, 649.*3, 651.*3, 652.*3, 653.*3, 654.*3, 655.*3, 656.*3, 657.*3, 658.*3, 659.*3, 660.*3, 661.*3, 662.*3, 663.*3, 665.*3, 665.*3, 671.*3, 673.*3, 674.*3, 675.*3, 676.*3, 678.*3, 679.*3, V22.0-V23.9, V28.81, V28.82, V28.89, V72.42, V89.01-V89.09; ICD-10: 009.00-010.02, 010.111-010.12, 010.211-010.22, 010.311-010.32, 010.411-010.42, 010.911-010.92, 011.1-015.1, 015.9-024.02, 024.111-024.12, O24.311-024.32, O24.41*, O24.811-024.82, O24.911-024.92, O25.10-O25.2, O26.00-O26.62, O26.711-O26.72, O26.811-026.93, O29.011-O30.93, O31.*-O48.*, O60.0*, O61.*-O66.*, O68, O69.*, O71.00-071.1, O71.89, O71.9, O74.0-O75.81, O75.89, O75.9, O76-O77.*, O88.011-O88.02, O88.111-O88.12, O88.211-O98.22, O92.29, O99.011-O90.2, O99.211-O91.219, O92.011-O92.019, O92.20, O92.29, O98.011-O98.02, O98.111-O98.12, O98.211-O98.22, O98.311-O98.32, O98.411-O98.42, O98.511-O98.52, O98.611-O98.62, O98.711-O98.72, O98.82, O99.82, O99.011-O99.02, O99.111-O99.12, O99.210-O99.214, O99.280-O99.284, O99.310-O99.314, O99.320-O99.324, O99.330-O99.334, O99.340-O99.344, O99.350-O99.354, O99.411-O99.42, O99.511-O99.52, O99.611-O99.62, O99.711-O99.72, O99.810, O99.814, O99.820, O99.844, O99.830, O99.834, O99.840-O99.844, O99.89, O99.811-O98.42, O99.811-O98.22, O98.311-O98.22, O98.311-O98.22, O98.311-O98.32, O99.330, O99.834, O99.840-O99.844, O99.89, O94.111-O94.12, O94.211-O94.22, O94.311-O94.32, O94.411-O94.42, O94.511-O94.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36, where the primary provider is not a CHR (Provider code 53), and with no documented miscarriage or abortion (defined below) occurring after the second pregnancy POV. Pharmacy-only visits (clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS
Abortion	will use the first two visits in the Report Period.  CPT: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267  POV: ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z,
Miscarriage	OWHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z  CPT: 59812, 59820, 59821, 59830  POV: ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9

# **All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, *and* statin).

# **Key Logic Changes from CRS Version 14.1**

- 1. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.
- 2. Added ICD-10 codes J45.901-J45.998 to Asthma definition.
- 3. Added HCPCS code G9190 to beta-blocker contraindication definition.
- 4. Updated BGP PQA STATIN MEDS taxonomy.

## **Patient List Description**

List of CHD patients 22 plus (+) with 180-day medication therapy during the Report Period, if any.

#### **Measure Source**

American Heart Association/American College of Cardiology Guidelines

# **Measure Past Performance and Long-Term Targets**

None

DU								age 241	
*** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL									
Re	nort Der				аь Dec 31, 2	115			
•	-		•		4 to Dec 31				
				•	to Dec 31,	•			
Appropriate Medicati	on Thera	ny in	Uich Dick	Dati	ents				
Appropriate Medicati	on mera	by III	HIGH KISK	Pati	encs				
	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from	
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %	
Action CID who 22:	Ε0		38			30			
Active CHD pts 22+	59		38			30			
# w/180 day beta-blo	cker								
Rx/contra/ADR									
-No Refusals		54.2	22	57.9	-3.7	14	46.7	+7.6	
A. # w/180 day beta-		E 6 2	1.4	62 6	-7.4	11	70 6	-22.3	
B: # w/contra/ADR	10	50.5	14	03.0	-7.4	11	70.0	-22.3	
w/% of Total	14	43.8	8	36.4	+7.4	3	21.4	+22.3	
# w/180 day ASA									
Rx/contra/ADR	2.2	27 2	0.1	FF 2	-18.0	2.2	76 7	20. 4	
-No Refusals A. # w/180 day ASA	22	3/.3	21	33.3	-18.0	23	/6./	-39.4	
Rx w/% of Total	17	77.3	18	85.7	-8.4	18	78.3	-1.0	
B. # w/contra/ADR									
w/ % of Total	5	22.7	3	14.3	+8.4	5	21.7	+1.0	

# w/180 day ACEI/ARB									
Rx/contra/ADR									
-No Refusals	29	49.2	15	39.5	+9.7	18	60.0	-10.8	
A. # w/180 day ACEI/ARB									
Rx w/% of Total	26	89.7	14	93.3	-3.7	17	94.4	-4.8	
B. # w/contra/ADR			_			_			
w/ % of Total	3	10.3	1	6.7	+3.7	1	5.6	+4.8	
# w/180 day statin									
Rx/contra/ADR									
-No Refusals	3.0	50.8	22	57 9	-7.0	14	46 7	+4.2	
A. # w/180 day statin	30	30.0	22	37.5	, . 0		10.7	. 1.2	
_	26	86.7	20	90.9	-4.2	14	100.0	-13.3	
B. # w/contra/ADR									
w/ % of Total	4	13.3	2	9.1	+4.2	0	0.0	+13.3	
# w/180 day Rx/contra/AD	R/								
of ALL meds									
-No Refusals	16	27.1	8	21.1	+6.1	6	20.0	+7.1	

Figure 2-93: Sample Report, Appropriate Medication Therapy in High Risk Patients

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Appropriate Medication Therapy in High Risk Patients: List of CHD patients 22+ with 180-day medication therapy during the Report Period, if any. COMMUNITY SEX AGE PATIENT NAME HRN DENOMINATOR NUMERATOR PATIENT1, CAITLYN 000001 COMMUNITY #1 F 22 PATIENT2, CARLA 000002 COMMUNITY #1 F 40 PATIENT3, GENEVA 000003 COMMUNITY #1 F 47 JACKSON, SHERRY LADAWN 100939 BRAGGS F 68 ACEI/ARB: (268 TOTAL DAYS); STATIN: (319 TOTAL DAYS) PATIENT4, SHERRY LISA 000004 COMMUNITY #1 F 68 BETA: 09/12/15 Contra hypotension POV 458.9; ASA: aspirin Contra total days WARFARIN: 372; STATIN: (328 TOTAL DAYS) PATIENT5, PAULINE 000005 COMMUNITY #1 F 70 CHD, AD ALL MEDS; BETA: (305 TOTAL DAYS); ASA: (291 TOTAL DAYS); ACEI/ARB: (405 TOTAL DAYS); STATIN: (305 TOTAL DAYS)

Figure 2-94: Sample Patient List: Appropriate Medication Therapy in High Risk Patients

# 2.8.15 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

#### **Denominator**

Number of visits for *User Population patients* ages 18 and older who were hospitalized during the Report Period with ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation.

#### Numerators

Number of visits where patients received a prescription for anticoagulant at discharge

Number of visits where patients did not receive anticoagulation therapy

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes to define ischemic stroke or transient ischemic attack with atrial fibrillation.

Subject Defined	ICD and Other Codes
Ischemic Stroke or TIA with Atrial Fibrillation (Non-CHS inpatient visit - Type not equal to C and Service Category=H)	POV: ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9; ICD-10: G45.0-G45.2, G45.8, G45.9, G46.0-G46.2, I63.* AND ICD-9: 427.31; ICD-
The patient must be admitted to the hospital during the report period with a condition described here but the discharge may occur after the report period.	10: I48.0-I48.2, I48.91 (atrial fibrillation)

Anticoagulant Therapy: Patient must meet one of the conditions below to be counted as receiving anticoagulant therapy. For all prescriptions, medications must not have a comment of RETURNED TO STOCK.

1. Active prescription for Warfarin, aspirin, or other anti-platelet as of discharge date. "Active" prescription defined as:

Rx Days Supply greater than or equal to (>=) (Discharge Date - Prescription Date), where the prescription has not been discontinued as of the discharge date.

2. Prescription for Warfarin, aspirin, or other anti-platelet on discharge date.

*Warfarin Medication:* Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.

Aspirin Medication: Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

Other Anti-Platelet/Anticoagulant Medication: Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

*No Anticoagulant Therapy:* Patients who did not have an active prescription for anticoagulant therapy at time of discharge.

# **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

# **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 248  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge								
	REPORT PERIOD		PREV YR PERIOD		CHG from BASE PREV YR % PERI			CHG from BASE %	
# Stroke/TIA w/ Atria Fib Visits for User									
Pop Pts 18+	17		0			0			
<pre># Visits w/ Anticoagulant Rx # Visits w/ No Anticoagulant</pre>	5	29.4	0	0.0	+29.4	0	0.0	+29.4	
Therapy	12	70.6	0	0.0	+70.6	0	0.0	+70.6	

Figure 2-95: Sample Report, Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial
Fibrillation at Discharge: List of patients with stroke/TIA and atrial
fibrillation with anticoagulant therapy, if any.
PATIENT NAME
                       HRN
                            COMMUNITY
DENOMINATOR
                        NUMERATOR
_____
PATIENT1, SHERRY 000001 COMMUNITY #1 F 38
                        Visit: 1) 04/01/15 POV 433.81 + POV 427.31 THERAPY:
UP
NOT MET: NO THERAPY
PATIENT2, CODY JACK

000002 COMMUNITY #1 M 31
Visit: 1) 05/01/15 POT 40
                            Visit: 1) 05/01/15 POV 433.81 + POV 427.31 THERAPY:
05/01/15 MET: WARF; 2) 09/01/15 POV 433.21 + POV 427.31 THERAPY: NOT MET: NO
THERAPY; 3) 10/15/15 POV 434.01 + POV 427.31 THERAPY: 10/15/15 MET: ASA
PATIENT3, TIMOTHY ALLEN 000003 COMMUNITY #1 M 33
                             Visit: 1) 04/01/15 POV 433.21 + POV 427.31 THERAPY:
NOT MET: NO THERAPY
PATIENT4,TRACE 000004 COMMUNITY #1 M 37
                            Visit: 1) 06/01/15 POV 434.01 + POV 427.31 THERAPY:
NOT MET: NO THERAPY
```

Figure 2-96: Sample Patient List: Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

# 2.8.16 Cholesterol Management for Patients with Cardiovascular Conditions

#### **Denominators**

Active Clinical patients ages 18 to 75 who, during the year prior to the beginning of the Report Period, were diagnosed with AMI, coronary artery bypass graft (CABG), or percutaneous coronary interventions (PCI) or who were diagnosed with IVD during the Report Period and the year prior to the Report Period. Broken down by gender.

*User Population patients* ages 18 to 75 who, during the year prior to the beginning of the Report period, were diagnosed with AMI, coronary artery bypass graft (CABG), or percutaneous coronary interventions (PCI) *or* who were diagnosed with IVD during the Report Period and the year prior to the Report Period. Broken down by gender.

#### **Numerators**

Patients with LDL completed during the Report Period, regardless of result.

- a. Patients with LDL less than (<)100, completed during the Report Period.
- b. Patients with LDL 100 through 130, completed during the Report Period.

c. Patients with LDL greater than (>)130, completed during the Report Period.

# **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Searches for most recent LDL test with a result during the Report Period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result. For numerator LDL less than (<)100, CPT 3048F or G9271 will count as meeting the measure.

CRS uses the following codes to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
AMI		POV: ICD-9: 410.*0, 410.*1; ICD-10: I21.*		
PCI	92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980, 92982, 92995, G0290	Procedure: ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734**  POV: ICD-9: V45.82; ICD-10: Z95.5, Z98.61		
CABG	33510-33514, 33516-33519, 33521-33523, 33533-33536, S2205-S2209	POV: ICD-9: V45.81; ICD-10: Z95.1  Procedure: ICD-9: 36.1*, 36.2; ICD-10: 02100**, 021049*, 02104A*, 02104J*, 02104K*, 02104Z*, 02110**, 021149*, 02114A*, 02114J*, 02114K*, 02114Z*, 02120**, 021249*, 02124A*, 02124J*, 02124K*, 02124Z*, 02130**, 021349*, 02134A*, 02134J*, 02134K*, 02134Z*		
IVD		POV: ICD-9: 411.*, 413.*, 414.0*, 414.2, 414.8, 414.9, 429.2, 433.*-434.*, 440.1, 440.2*, 440.4, 444.*, 445.*; ICD-10: I20.*, I24.*, I25.1*, I25.5-I25.812, I70.201- I70.299, I70.92, I75.*		

Subject Defined	CPT Codes	LOINC Codes	Taxonomy
LDL	80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F, G9271, G9272	Yes	DM AUDIT LDL CHOLESTEROL TAX

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS codes G9271, G9272 to LDL definition.
- 2. Added HCPCS codes G9271 to LDL < 100 definition.

# **Patient List Description**

List of patients with AMI, CABG, PCI, or IVD w/LDL value, if any.

## **Measure Source**

**HEDIS** 

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 250  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Cholesterol Managemer	nt for P	atient	s with Ca	rdiova	ascular Con	nditions			
					CHG from PREV YR %				
Active Clinical pts 1 with DX of AMI, CABG									
PCI, or IVD	42		28			18			
<pre># w/LDL done A. # w/LDL &lt;=100 w/% of Total</pre>	38	90.5	21	75.0	+15.5	9	50.0	+40.5	
Screened B. # w/LDL 101-130	14	36.8	12	57.1	-20.3	3	33.3	+3.5	
<pre>w/% of Total Screened C. # w/LDL &gt;130 w/% of Total</pre>	5	13.2	3	14.3	-1.1	2	22.2	-9.1	

Screened	5	13.2	4	19.0	-5.9	4	44.4	-31.3	
Male Active Clinical pt									
18-75 with DX of AMI, (PCI, or IVD	22		16			10			
# w/LDL done A. # w/LDL <=100 w/% of Total	20	90.9	11	68.8	+22.2	4	40.0	+50.9	
Screened B. # w/LDL 101-130	5	25.0	4	36.4	-11.4	1	25.0	+0.0	
w/% of Total Screened C. # w/LDL >130	2	10.0	3	27.3	-17.3	1	25.0	-15.0	
w/% of Total Screened	4	20.0	2	18.2	+1.8	2	50.0	-30.0	
Female Active Clinical 18-75 with DX of AMI, (	-								
PCI, or IVD	20		12			8			
<pre># w/LDL done A. # w/LDL &lt;=100 w/% of Total</pre>	18	90.0	10	83.3	+6.7	5	62.5	+27.5	
Screened B. # w/LDL 101-130 w/% of Total	9	50.0	8	80.0	-30.0	2	40.0	+10.0	
Screened C. # w/LDL >130	3	16.7	0	0.0	+16.7	1	20.0	-3.3	
w/% of Total Screened	1	5.6	2	20.0	-14.4	2	40.0	-34.4	

Figure 2-97: Sample Report, Cholesterol Management for Patients with Cardiovascular Conditions

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Cholesterol Management for Patients with Cardiovascular Conditions: List of patients with AMI, CABG, PCI, or IVD w/LDL value, if any.

PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR

PATIENT1, SHERRY 000001 COMMUNITY #1 F 68
UP, AC 07/15/15 LDL: CPT 3048F
PATIENT2, CODY JACK 000002 COMMUNITY #1 M 41
UP, AC 10/17/15 LDL: 136
PATIENT3, TIMOTHY ALLEN 000003 COMMUNITY #1 M 43
UP, AC 10/17/15 LDL: 136
PATIENT4, TRACE 000004 COMMUNITY #1 M 47
UP
PATIENT5, KENNETH 000005 COMMUNITY #1 M 60
UP, AC 08/06/15 LDL: 108

Figure 2-98: Sample Patient List: Cholesterol Management for Patients with Cardiovascular Conditions

# 2.8.17 Heart Failure and Evaluation of LVS Function

#### Denominator

Active Clinical patients ages 18 or older discharged with heart failure during the Report Period.

#### **Numerators**

Patients whose LVS function was evaluated before arrival, during hospitalization, or is planned for after discharge.

# **Logic Description**

Age of the patient is calculated as of the hospital admission date.

Denominator exclusions are defined as any of the following:

- 1. Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).
- 2. Patients with a Discharge Type of Transferred or Irregular or containing "Death."
- 3. Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

CRS uses the following codes to define the denominator and numerators.

## **Denominator Exclusions**

Subject Defined	CPT Codes	ICD and Other Codes
Comfort Measures		POV: ICD-9: V66.7 (Encounter for palliative care); ICD-10: Z51.5 documented during hospital stay
LVAD/Heart Transplant		Procedure: ICD-9: 33.6, 37.41, 37.51–37.54, 37.61–37.66, 37.68; ICD-10: 02HA**Z, 02PA*RZ, 02RK0JZ, 02RL0JZ, 02UA4JZ, 02WA0JZ, 02WA0QZ, 02WA0RZ, 02WA3QZ, 02WA3RZ, 02WA4QZ, 02WA4RZ, 02YA0Z*, 5A02*10, 5A02*16, 5A02*1D documented during hospital stay

## **Denominator Definition**

Subject Defined	CPT Codes	ICD and Other Codes
Heart Failure		POV (Primary Diagnosis only): ICD-9: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 429.1, 997.1;
		ICD-10: I11.0, I13.0, I13.2, I50.* and with Service Category H (hospitalization).  NOTE: If a patient has multiple admissions matching these criteria during the Report Period, the earliest admission will be used.

# Numerator Definition (Evaluation of LVS Function): Any of the codes listed below

Subject Defined	CPT Codes	ICD and Other Codes
Ejection Fraction (ordered or documented anytime one year prior to discharge date)	78414, 78468, 78472, 78473, 78480, 78481, 78483, 78494, 93303, 93304, 93307, 93308, 93312, 93314–93318, 93350, 93543, 93555	Measurement: "CEF" Procedure: ICD-9: 88.53, 88.54; ICD-10: B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ
RCIS Order for Cardiovascular Disorders Referral (ordered during the hospital stay but no later than the hospital discharge date)		ICD Diagnostic Category: "Cardiovascular Disorders" AND one of the following: CPT Categories: "Evaluation and/or Management," "Non-surgical Procedures" or "Diagnostic Imaging"
Other Procedures (documented anytime one year prior to discharge date)		Echocardiogram: Procedure ICD-9: 88.72, 37.28, 00.24; ICD-10: B245YZZ, B245ZZ4, B245ZZZ, B246YZZ, B246ZZZ, B24BYZZ, B24BZZZ  Nuclear Medicine Test: Procedure ICD-9: 92.2*;  Cardiac Catheterization with a Left Ventriculogram: Procedure ICD-9: 37.22, 37.23, 88.53, 88.54; ICD-10: 4A02*N7, 4A02*N8, B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ

# **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of Active Clinical heart failure patients 18 plus (+) who received evaluation of LVS function, if any.

#### **Measure Source**

CMS HF-2

## **Measure Past Performance and Long-Term Targets**

None

```
DIJ
                           November 25, 2015
                                                                  Page 255
      *** IHS 2015 Selected Measures with Community Specified Report ***
                           DEMO INDIAN HOSPITAL
                Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Heart Failure and Evaluation of LVS Function
                  REPORT % PREV YR % CHG from BASE PERIOD PERIOD PREV YR % PERIOD
                                                               % CHG from
                                           PREV YR % PERIOD
                                                                    BASE %
AC 18+ w/Heart
                       44
Failure Dx
Patients w/Eval
of LVS Function 14 31.8
                                       0 0.0 +31.8 0 0.0 +31.8
```

Figure 2-99: Sample Report, Heart Failure and Evaluation of LVS Function

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Heart Failure and Evaluation of LVS Function: List of Active Clinical heart failure patients 18+ who received evaluation of LVS function, if any. PATIENT NAME HRN COMMUNITY DENOMINATOR NUMERATOR PATIENT1, JOAN 000164 COMMUNITY #1 F 36 Admission: 06/01/15 LVS: NOT DOCUMENTED PATIENT2, SARAH 000127 COMMUNITY #1 F 35
AC Admission: 06/01/15 LV
PATIENT3, JOHN 000151 COMMUNITY #1 M 36 Admission: 06/01/15 LVS: 06/03/15 Proc 88.72 Admission: 05/01/15 LVS: 05/01/15 Meas CEF 40 000125 COMMUNITY #1 M 47 PATIENT4, ROGER Admission: 06/01/15 LVS: NOT DOCUMENTED 000129 COMMUNITY #1 M 57 PATIENT5, DANIEL Admission: 06/01/15 LVS: 06/01/15 CPT 78468 AC

Figure 2-100: Sample Patient List: Heart Failure and Evaluation of LVS Function

# 2.9 STD-Related Measure Topics

# 2.9.1 HIV Screening

## **GPRA Measure Description**

During FY 2015, achieve the target rate of 86.6% for the proportion of pregnant patients who are screened for HIV.

#### **Denominators**

All pregnant Active Clinical female User Population patients with no documented miscarriage or abortion and with no recorded HIV diagnosis ever (GPRA Denominator).

*User Population patients* ages 13 through 64 with no recorded HIV diagnosis prior to the Report Period. (GPRA Developmental Denominator).

#### **Numerators**

Patients who were screened for HIV during the past 20 months.

**Note**: This numerator does *not* include refusals. (GPRA Numerator).

Patients with documented HIV screening refusal during the past 20 months.

Patients who were screened for HIV during the Report Period.

**Note**: This numerator does *not* include refusals. (GPRA Developmental Numerator)

Patients with documented HIV screening refusal during the Report Period.

No denominator. This measure is a total count only, not a percentage. Number of HIV screens provided to User Population patients during the report period, where the patient was not diagnosed with HIV any time prior to the screen.

**Note**: This numerator does not include refusals. (GPRA Developmental Numerator)

# **Logic Description**

Age of the patient is calculated at the beginning of the Report period.

Pregnancy definition: At least two visits during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. The time period is extended to include patients who were pregnant during the Report Period but whose initial diagnosis (and HIV test) were documented prior to Report Period.

*HIV Screening definition*: For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted.

**Notes:** The time frame for both screening and refusals for the pregnant patients denominator is anytime during the past 20 months and for User Population patients 13–64 is anytime during the Report Period.

Refusals are allowed during the past 20 months for pregnant patients (vs. only during the Report Period) in the event the patient is at the end of her pregnancy at the beginning of the Report Period and refused the HIV test earlier in her pregnancy during the previous year

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC	Taxonomy
Subject Defined	CF1 Codes	ICD and Other Codes	Codes	Taxononing
Pregnancy		<b>POV</b> : ICD-9: 640.*3, 641.*3, 642.*3,		
(at least 2 visits in		643.*3, 644.*3, 645.*3, 646.*3, 647.*3,		
past 20 months		648.*3, 649.*3, 651.*3, 652.*3, 653.*3,		
with 1 during the		654.*3, 655.*3, 656.*3, 657.*3, 658.*3,		
Report Period)		659.*3, 660.*3, 661.*3, 662.*3, 663.*3,		
		665.*3, 668.*3, 669.*3, 671.*3, 673.*3,		
		674.*3, 675.*3, 676.*3, 678.*3, 679.*3,		
		V22.0-V23.9, V28.81, V28.82, V28.89,		
		V72.42, V89.01-V89.09; ICD-10:		
		O09.00-O10.02, O10.111-O10.12,		
		010.211-010.22, 010.311-010.32,		
		010.411-010.42, 010.911-010.92,		
		011.1-015.1, 015.9-024.02, 024.111-		
		024.12, 024.311-024.32, 024.41*,		
		O24.811-O24.82, O24.911-O24.92,		
		O25.10-O25.2, O26.00-O26.62,		
		O26.711-O26.72, O26.811-O26.93, O29.011-O30.93, O31.*-O48.*, O60.0*,		
		O61.*-O66.*, O68, O69.*, O71.00-		
		O71.1, O71.89, O71.9, O74.0-O75.81,		
		O75.89, O75.9, O76-O77.*, O88.011-		
		088.02, O88.111-088.12, O88.211-		
		O88.22, O88.311-O88.32, O88.811-		
		O88.82, O90.3, O91.011-O91.019,		
		O91.111-O91.119, O91.211-O91.219,		
		O92.011-O92.019, O92.20, O92.29,		
		O98.011-O98.02, O98.111-O98.12,		
		O98.211-O98.22, O98.311-O98.32,		
		O98.411-O98.42, O98.511-O98.52,		
		O98.611-O98.62, O98.711-O98.72,		
		O98.811-O98.82, O98.911-O98.92,		
		O99.011-O99.02, O99.111-O99.12,		
		O99.210-O99.214, O99.280-O99.284,		
		O99.310-O99.314, O99.320-O99.324,		
		O99.330-O99.334, O99.340-O99.344,		
		O99.350-O99.354, O99.411-O99.42,		
		O99.511-O99.52, O99.611-O99.62,		
		O99.711-O99.72, O99.810, O99.814,		
		099.820, 099.824, 099.830, 099.834,		
		O99.840-O99.844, O99.89, O9A.111-		
		O9A.12, O9A.211-O9A.22, O9A.311-		
		O9A.32, O9A.411-O9A.42, O9A.511-		
		O9A.52, Z03.7*, Z32.01, Z33.1, Z34.*, Z36		
Minanuin	50040 50000			-
Miscarriage	59812, 59820,	<b>POV</b> : ICD-9: 630, 631, 632, 633*, 634*;		
(after second	59821, 59830	ICD-10: O03.9		
pregnancy POV in past 20 months)				
pasi zu monins)				

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Abortion (after second pregnancy POV in past 20 months)	59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260—S2267	POV: ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2  Procedure: ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z		
HIV Diagnosis (documented anytime prior to the end of the Report Period)		POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 042, 042.0–044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711-O98.73		
HIV Screening	86689, 86701- 86703, 87390, 87391, 87534- 87539		Yes	BGP HIV TEST TAX
Refusal of HIV lab test in past 20 months				BGP HIV TEST TAX

# **Key Logic Changes from CRS Version 14.1**

1. Added ICD-10 codes O02.0 through O03.0, O03.2, O03.30, O03.34 through O03.5, O03.7, O03.80, O03.84 through O04.5, O04.7, O04.80, O04.84 through O04.89 to abortion definition.

# **Patient List Description**

List of pregnant patients or User Population patients with documented HIV test or refusal, if any.

#### **Measure Source**

HP 2020 HIV-14.3

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	88.0%
IHS FY 2013 Performance	87.7%
IHS FY 2012 Performance	85.8%
IHS FY 2011 Performance	80.0%
IHS FY 2010 Performance	78.0%
IHS FY 2009 Performance	76.0%
IHS FY 2008 Performance	75.0%

Performance	Percent
IHS FY 2007 Performance	74.0%
IHS FY 2006 Performance	65.0%
IHS FY 2005 Performance	54.0%
HP 2020 Goal	74.1%

DU November 25, 2015 Page 256  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
HIV Screening									
					CHG from PREV YR %				
Pregnant AC Pts w/ HIV ever (GPRA)	no 39		38			32			
<pre># w/HIV screening -No Refusals (GPRA) # w/HIV screening</pre>	15	38.5	6	15.8	+22.7	0	0.0	+38.5	
refusal	1	2.6	0	0.0	+2.6	0	0.0	+2.6	
User Pop Pts 13-64 w/ no HIV (GPRA Dev.)	2,024		1,663			1,519			
# w/HIV screening -No Refusals (GPRA Dev.)	46	2.3	21	1.3	+1.0	0	0.0	+2.3	
# w/HIV screening refusal	4				+0.2				
# HIV screens for T w/ no prior HIV-No	_	ts							
(GPRA Dev.)	51		21		+30	0		+51	

Figure 2-101: Sample Report, HIV Screening

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

```
UP 03/31/15 Lab; Screen Count: 1
PATIENT2,CECELIA 000002 COMMUNITY #1 F 19
UP
PATIENT15,BRENDA G 000015 COMMUNITY #2 F 30
UP 03/14/15 CPT 87534; 02/14/15 CPT 86689; Screen Count: 2
PATIENT16,ALYSHA 000016 COMMUNITY #2 F 33
UP,AC PREG 08/25/15 Lab; Screen Count: 1
```

Figure 2-102: Sample Patient List, HIV Screening

# 2.9.2 HIV Quality of Care

#### **Denominator**

All *User Population patients* ages 13 and older with at least two direct care visits (i.e., not Contract/CHS) with HIV diagnosis during the Report Period, including one HIV diagnosis in last 6 months.

#### **Numerators**

Patients who received CD4 test only (without HIV viral load) during the Report Period

Patients who received HIV viral load only (without CD4) during the Report Period

Patients who received both CD4 and HIV viral load during the Report Period

Total patients receiving any test

Patients who received at least one prescription for an Antiretroviral medication.

#### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPI COdes		LOINC Codes	Taxonomy
HIV		POV: ICD-9: 042, 042.0-044.9 (old codes), 079.53, V08, 795.71; ICD- 10: B20, B97.35, R75, Z21, O98.711- O98.73		

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
CD4	86359, 86360 86361, G9214		Yes	BGP CD4 TAX
HIV Viral Load	87536, 87539, G9242, G9243		Yes	BGP HIV VIRAL LOAD TAX
Antiretroviral medication				BGP PQA ANTIRETROVIRAL MEDS - Medications must not have a comment of RETURNED TO STOCK.

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS code G9214 to CD4 count definition.
- 2. Added HCPCS codes G9242, G9243 to viral load definition.
- 3. Updated BGP PQA ANTIRETROVIRAL MEDS taxonomy.

# **Patient List Description**

List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

## **Measure Source**

HP 2010 developmental measure 13–13a Viral Load Testing

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS 2020 goal for viral load testing	Nearly 100%
IHS 2020 baseline for CD4 testing	Nearly 100%

HIV Quality of Care	DU November 25, 2015 Page 258  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %	HIV Quality of Care							
User Pop Pts >13 w/ HIV Dx 7 2 2	-	7	2	2				
<pre># w/CD4 only</pre>	# w/viral load							

# w/both TOTAL # w/	1	14.3	1	50.0	-35.7	2 100.0	-85.7
any tests	3	42.9	1	50.0	-7.1	2 100.0	-57.1
# w/ART Rx	1	14.3	0	0.0	+14.3	1 50.0	-35.7

Figure 2-103: Sample Report HIV Quality of Care

Figure 2-104: Sample Patient List, HIV Quality of Care

# 2.9.3 Hepatitis C Screening

#### **Denominator**

*User Population patients* born between 1945 and 1965 with no recorded Hep C diagnosis. Broken down by gender.

*User Population patients* born between 1945-1965 with documented Hep C diagnosis ever. Broken down by gender.

#### **Numerators**

Patients screened for Hepatitis C ever.

Patients who were given a Hepatitis C confirmation test.

- a. Patients with a positive result.
- b. Patients with a negative result.
- c. Patients with no result.

## **Logic Description**

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined	CPT Codes	ICD and Other Codes	LOINC Codes	Taxonomy
Hepatitis C diagnosis (documented any time prior to the end of the Report Period)		POV or Problem List entry where the status is not Inactive or Deleted: ICD-9: 070.41, 070.44, 070.51, 070.54, 070.70-070.71; ICD-10: B17.10, B17.11, B18.2, B19.20, B19.21		
Hepatitis C Screening	86803		Yes	BGP HEP C TEST TAX
Hepatitis C Confirmation Test (documented any time prior to the end of the Report Period)	86804, 87520, 87521, 87522, G9203, G9207, G9209		Yes	BGP HEP C CONF TEST TAX
If patient has more than one confirmatory test, CRS will use the first test that has a result recorded, if any. If there is no test with a result, CRS will use the first test documented.				

Positive confirmation test result defined as a number greater than zero.

Negative confirmation test result defined as result containing "<15 IU/mL" or "<1.18 LogIU/mL" or comment containing "Not Detected".

No result defined as any confirmation test that does not have a positive or negative result.

## **Key Logic Changes from CRS Version 14.1**

1. Added new measures and corresponding logic.

## **Patient List Description**

List of patients with documented Hepatitis C screening or confirmatory test ever, if any.

DU *** IHS 2015 Sel	ected	Measu		Commur		fied Rep		age 258		
DEMO INDIAN HOSPITAL Report Period: Jan 01, 2015 to Dec 31, 2015										
Previous	Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Baseli	ne Pe 	r10a: 	Jan 01,	t	to Dec 31,	 2010				
Hepatitis C Screening										
	PORT				CHG from	BASE	%			
PE.	RIOD		PERIOD		PREV YR %	PERIOD		BASE %		
User Pop Pts w/ no Hep C	790		628			551				
# w/Hep C										
Screening	48	6.1	33	5.3	+0.8	22	4.0	+2.1		
Male User Pop Pts w/no Hep C	371		292			253				
# w/Hep C Screening	24	6.5	17	5.8	+0.6	11	4.3	+2.1		
Female User Pop Pts w/ no Hep C	419		336			298				
# w/Hep C screening	24	5.7	16	4.8	+1.0	11	3.7	+2.0		
User Pop Pts w/ Hep C	17		18			20				
# w/confirmation test		70.6	9	50.0	+20.6	7	35.0	+35.6		
A. # w/ positive result w/ % of Total										
Screened B. # w/ negative result		33.3	3	33.3	+0.0	5	71.4	-38.1		
w/ % of Total Screened C. # w/ no result resul		25.0	2	22.2	+2.8	0	0.0	+25.0		
w/ % of Total Screened	5	41.7	4	44.4	-2.8	2	28.6	+13.1		

Figure 2-105: Sample Report Hepatitis C Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

```
Hepatitis C Screening: List of patients with documented Hepatitis C screening ever, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1, MARY 000001 COMMUNITY #1 F 50

UP Screen: 08/17/01 Lab Test
PATIENT2, TANYA 000002 COMMUNITY #1 F 52

UP, HEP Conf 09/09/09 Lab result=POS
PATIENT15, JOHN 000015 COMMUNITY #2 M 65

UP Screen: 02/03/14 CPT 86803
PATIENT16, HAROLD 000016 COMMUNITY #2 M 66

UP Screen: 08/20/11 Lab Test
```

Figure 2-106: Sample Patient List, Hepatitis C Screening

## 2.9.4 Chlamydia Screening

### **Denominators**

Female Active Clinical patients ages 16 through 25.

- a. Female Active Clinical 16 through 20.
- b. Female Active Clinical 21 through 25.

Female User Population patients ages 16 through 25.

- a. Female User Population 16 through 20.
- b. Female User Population 21 through 25.

### **Numerator**

Patients tested for Chlamydia during the Report Period.

## **Logic Description**

Age is calculated at beginning of the Report Period. The following codes are used to determine a test for Chlamydia.

Subject Defined	ICPT COdes		LOINC Codes	Taxonomy
Chlamydia Test	86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F, G9228	<b>POV</b> : ICD-9: V73.88, V73.98	Yes	BGP CHLAMYDIA TESTS TAX

### **Key Logic Changes from CRS Version 14.1**

1. Added HCPCS code G9228 to Chlamydia testing definition.

## **Patient List Description**

List of patients with documented Chlamydia screening, if any.

### **Measure Source**

HP 2020 STD-4, annual screening for genital Chlamydia—females enrolled in commercial MCOs (aged 25 years and under); STD-3, annual screening for genital Chlamydia—females enrolled in Medicaid MCOs (aged 25 years and under).

## **Measure Past Performance and Long-Term Targets**

Performance	Percent
HP 2020 goal for Females 16 through 20 with Medicaid (STD-3.1)	57.9%
HP 2020 goal for Females 21 through 24 with Medicaid (STD-3.2)	65.3%
HP 2020 goal for Females 16 through 20 with Commercial Health Insurance (STD-4.1)	44.1%
HP 2020 goal for Females 21 through 24 with Commercial Health Insurance (STD-4.2)	47.9%

DU November 25, 2015 Page 260  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014									
					to Dec 31,				
Chlamydia Testing									
	PORT				CHG from PREV YR %			CHG from BASE %	
Female Active Clinical 16-25	166		143			128			
# w/Chlamydia Screen	53	31.9	49	34.3	-2.3	43	33.6	-1.7	
A. Female Active Clinic 16-20	al 70		55			57			
# w/Chlamydia Screen	24	34.3	16	29.1	+5.2	23	40.4	-6.1	
B. Female Active Clinic 21-25	al 96		88			71			
# w/Chlamydia Screen	29	30.2	33	37.5	-7.3	20	28.2	+2.0	
Female User Population 16-25	287		255			239			
# w/Chlamydia Screen	69	24.0	58	22.7	+1.3	51	21.3	+2.7	

A. Female User Populat: 16-20	ion 139		118			119			
# w/Chlamydia Screen	32	23.0	19	16.1	+6.9	25	21.0	+2.0	
B. Female User Population 21-25 148 137 120									
# w/Chlamydia Screen	37	25.0	39	28.5	-3.5	26	21.7	+3.3	

Figure 2-107: Sample Report Chlamydia Testing

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Chlamydia Testing: List of patients with documented Chlamydia screening, if
any.
                      HRN COMMUNITY SEX AGE
PATIENT NAME
DENOMINATOR
                              NUMERATOR
PATIENT1, MELISSA ANNE 000001 COMMUNITY #1 F 16
UP,AC
PATIENT2, LISA MARIE 000002 COMMUNITY #1 F 16
                              04/04/15 Lab test
UP,AC 04/04/15 Lab test
PATIENT3,CRYSTAL LEE 000003 COMMUNITY #1 F 17
UP,AC 07/25/15 Lab test
PATIENT4,DANIELLE 000004 COMMUNITY #1 F 18
UP,AC
                        06/01/15 CPT 87490
UP,AC 06/01/15 CPT 87490 PATIENT5,KELLYE 000005 COMMUNITY #1 F 19
```

Figure 2-108: Sample Patient List, Chlamydia Testing

# 2.9.5 Sexually Transmitted Infection Screening

### **Denominators**

HIV/AIDS screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

#### **Numerators**

No denominator; count only. The total count of *Active Clinical patients* who were diagnosed with one or more key STIs during the period 60 days prior to the Report Period through the first 300 days of the Report Period. Broken down by gender.

No denominator; count only. The total count of separate *key STI incidents for Active Clinical patients* during the defined period.

*Number of needed HIV/AIDS screenings* performed from one month prior to the date of first STI diagnosis of each incident through 2 months after.

**Note**: This numerator does *not* include refusals.

### **Logic Description**

Key STIs are Chlamydia, Gonorrhea, HIV/AIDS, and Syphilis. Key STI diagnoses are defined with the following codes.

STI	ICD and Other Codes
Chlamydia	<b>POV</b> : ICD-9: 079.88, 079.98, 099.41, 099.50-099.59; ICD-10: A56.*, A74.81-A74.9
Gonorrhea	<b>POV</b> : ICD-9: 098.0-098.89; ICD-10: A54.*, O98.2*
HIV/AIDS	<b>POV</b> : ICD-9: 042, 042.0-044.9, 079.53, 795.71, V08; ICD-10: B20, B97.35, R75, Z21, O98.711-O98.73
Syphilis	<b>POV</b> : ICD-9: 090.0-093.9, 094.1-097.9; ICD-10: A51.*-A53.*

Logic for Identifying Patients Diagnosed with Key STI:

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period.

Logic for Identifying Separate Incidents of Key STIs:

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs 2 months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.

Example of Patient with Multiple Incidents of Single STI:

Visit	Total Incidents
08/01/14: Patient screened for Chlamydia	0
08/08/14: Patient diagnosed with Chlamydia	1
10/15/14: Patient diagnosed with Chlamydia	2
10/25/14: Follow-up for Chlamydia	2
11/15/14: Patient diagnosed with Chlamydia	2
03/01/15: Patient diagnosed with Chlamydia	3

Denominator Logic for Needed Screenings:

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed HIV screening tests denominator, the count will be derived from the number of separate non-HIV STI incidents. HIV screening tests are recommended for the following key STIs: Chlamydia, Gonorrhea, Syphilis.

"Needed" screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

- 1. Only one screening for HIV is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening is needed for HIV/AIDS.
- 2. A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

### Numerator Logic:

To be counted in the numerator, each needed screening in the denominator must have a corresponding laboratory test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through 2 months after the STI incident.

Key STI screenings are defined with the following codes.

<b>STI</b>	CPI COdes	LOINC Codes	Taxonomy
HIV/AIDS	86689, 86701– 86703, 87390– 87391, 87534– 87539	Yes	BGP HIV TEST TAX

## **Key Logic Changes from CRS Version 14.1**

1. Removed many measures.

### **Patient List Description**

List of patients diagnosed with one or more STIs during the defined time period with related screenings.

#### **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 266  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Sexually Transmitted Infe	ection (S	TI) Screen	ing (con't)					
REP(		PREV YR PERIOD	CHG from PREV YR					
Active Clinical Pts w/ Key STI Dx	41	13	+28	1.0	+31			
-		13	. 20	10	. 51			
Male Active Clinical Pts w/ Key STI Dx	10	7	+3	8	+2			
Female Active Clinical Pt w/ Key STI Dx	31	6	+25	2	+29			
Total # Key STI Incidents Active Clinical Pts		13	+31	10	+34			
# HIV/AIDS Screens Needed for Key STIs-AC Pts (GPRA Dev.)	8	25		29				
# Needed HIV/AIDS Screens Performed-No Refusals (GPRA Dev.)		9	36.0 +14.0	5	17.2 +32.8			
# HIV/AIDS Screens Needed for Key STIs- Male AC Pts	d 2	7		12				
# Needed HIV/AIDS Screens Performed-No Refusals		3	42.9 +7.1	0	0.0 +50.0			
# HIV/AIDS Screens Needed for Key STIs- Female AC Pts	d 6	18		17				
# Needed HIV/AIDS Screens Performed-No Refusals		6	33.3 +16.7	5	29.4 +20.6			

Figure 2-109: Sample Report Sexually Transmitted Infection (STI) Screening

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;

```
HR=High Risk Patient
Sexually Transmitted Infection (STI) Screening: List of patients diagnosed with
one or more STIs during the defined time period with related screenings.
PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR
PATIENT1, DIANE 000001 COMMUNITY #1 F 15
UP; AC Visit 1) 02/12/15 POV: HIV 042. 1) N/A
PATIENT2, LEIGHANN 000002 COMMUNITY #1 F 18
UP;AC Visit 1) 11/02/15 POV: GC 098.89 1) HIV-Y 12/02/15 CPT [87390]
PATIENT3, WHITNEY 000003 COMMUNITY #1 F 25
UP; AC Visit 1) 06/17/15 POV: CHL 078.89 1) HIV-N
PATIENT4, NANCY 000004 COMMUNITY #1 F 29
UP;AC Visit 1) 03/01/15 POV: CHL 079.88 1) HIV-Contraind Prior DX 04/11/07 POV: HIV
[079.53]
PATIENT5, JOHN 000005 COMMUNITY #1 M 40
UP;AC Visit 1) 06/15/15 POV: GC 098.89; 2) 07/15/15 POV: HIV 042. 1) HIV-N; 2) N/A
PATIENT6, NORMAN 000006 COMMUNITY #1 M 42
UP;AC Visit 1) 10/11/15 POV: CHL 079.98, 10/11/15 POV: GC 098.891) HIV-N
```

Figure 2-110: Sample Patient List, Sexually Transmitted Infection (STI) Screening

# 2.10 Other Clinical Measures Topics

## 2.10.1 Osteoporosis Management

#### **Denominators**

Female Active Clinical patients ages 67 and older who had a new fracture occurring 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period with no osteoporosis screening or treatment in year prior to the fracture.

Female User Population patients ages 67 and older who had a new fracture occurring 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period with no osteoporosis screening or treatment in year prior to the fracture.

### **Numerator**

Patients treated or tested for osteoporosis after the fracture.

### **Logic Description**

Age is calculated at the beginning of the Report Period. Fractures do not include fractures of finger, toe, face, or skull. CRS will search for the first (i.e., earliest) fracture during the period 6 months (182) days prior to the beginning of the Report Period and the first 6 months of the Report Period. If multiple fractures are present, only the first fracture will be used.

Index Episode Start Date definition: The Index Episode Start Date is the date the fracture was diagnosed. If the fracture was diagnosed at an outpatient visit (Service Category A, S, or O), the Index Episode Start Date is equal to the Visit Date. If diagnosed at an inpatient visit (Service Category H), the Index Episode Start Date is equal to the Discharge Date.

### **Denominator Exclusions**

- 1. Patients receiving osteoporosis screening or treatment in the year (365 days) prior to the Index Episode Start Date. Osteoporosis screening or treatment is defined as a Bone Mineral Density (BMD) test (see below for codes) or receiving any osteoporosis therapy medication (see below for codes).
- 2. Patients with a fracture diagnosed at an outpatient visit, which also had a fracture within 60 days prior to the Index Episode Start Date.
- 3. Patients with a fracture diagnosed at an inpatient visit, which also had a fracture within 60 days prior to the ADMISSION DATE.

Osteoporosis Treatment and Testing definition: (1) For fractures diagnosed at an outpatient visit: a nondiscontinued prescription within 6 months (182 days) of the Index Episode Start Date (i.e., visit date) or B) a BMD test within 6 months of the Index Episode Start Date. (2) For fractures diagnosed at an inpatient visit, a BMD test performed during the inpatient stay.

CRS uses the following codes to define fracture and BMD test.

Subject Defined	CPT Codes	ICD and Other Codes
Fracture Codes	21800 through21825, 22305 through 22314, 22316 through 22324, 22520, 22521, 22523, 22524, 23500 through 23515, 23570 through 23630, 23665 through 23680, 24500 through 24585, 24620, 24635, 24650 through 24685, 25500–25609, 25611 (old code), 25620 (old code), 25622-25652, 25680, 25685, 27193 through 27248, 27254, 27500 through 27514, 27520 through 27540, 27750 through 27828, S2360, S2362	POV: ICD-9: 733.1*, 805*-806*, 807.0*-807.4, 808*-815*, 818*-825*, 827*, 828*; ICD-10: M48.5*XA, M80.***A, M84.40xA-M84.443A (ending in A only), M84.451A-M84.476A (ending in A only), M84.48xA, S22.0*0A, S22.0*0B, S32.0*0A, S32.0*0B, S52.001A-S52.236C (ending in A, B, or C only), S52.251A-S52.279C (ending in A, B, or C only), S52.291A-S52.336C (ending in A, B, or C only), S52.351A-S52.366C (ending in A, B, or C only), S52.351A-S52.366C (ending in A, B, or C only), S62.001A-S62.186B (ending in A or B only), S72.001A-S72.019C (ending in A, B, or C only), S72.031A-S72.92xC (ending in A, B, or C only), S82.891A-S82.92XC (ending in A, B, or C only), S82.891A-S82.92XC (ending in A, B, or C only)  Procedure: ICD-9: 79.01-79.03, 79.05-79.07, 79.11-79.13, 79.15-79.17, 79.21-79.23, 79.25-79.27, 79.31-79.33, 79.35-79.37, 79.61-79.63, 79.65-79.67, 81.65-81.66; ICD-10: OPSC***, OPSD***, OPSF***, OPSG***, OPSH***, OPSJ***, OPSH***, OPSJ***, OPSH***, OPSJ***, OPSH***, OPSJ***, OPSG***, OQSG***, OQSG****, OQSG***, OQSG****, OQSG***, OQGG***, OQG
BMD Test Codes	77078, 76070 (old code), 77079, 76071 (old code), 77080, 76075 (old code), 77081, 76076 (old code), 77083, 76078 (old code), 76977, 78350, 78351, G0130	POV: ICD-9: V82.81; ICD-10: Z13.820 Procedure: ICD-9: 88.98

Treatment medication codes are defined with medication taxonomy BGP HEDIS OSTEOPOROSIS MEDS. (Medications are: Alendronate, Alendronate-Cholecalciferol (Fosomax Plus D), Calcium carbonate-risedronate, Ibandronate (Boniva), Risedronate, Zoledronic acid, Calcitonin, Denosumab, Raloxifene, Estrogen, Injectable Estrogens, and Teriparatide.) Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of female patients with new fracture who have had osteoporosis treatment or testing, if any.

### **Measure Source**

**HEDIS** 

### **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 277  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Osteoporosis Management								
					CHG from PREV YR %			
Female Active Clinical 67 and older w/fracture	Pts 8		0			0		
<pre># w/osteoporosis treatm   or testing</pre>		37.5	0	0.0	+37.5	0	0.0	+37.5
Female User Pop Pts 67 and older w/fracture	9		0			0		
<pre># w/osteoporosis treatm   or testing</pre>	ent 4	44.4	0	0.0	+44.4	0	0.0	+44.4

Figure 2-111: Sample Report Osteoporosis Management

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Osteoporosis Management: List of female patients with new fracture who have had osteoporosis treatment or testing, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1, ALWENA 000001 COMMUNITY #1 F 68
UP, AC FX: 01/01/15 CPT 22524
PATIENT2, SYBIL 000002 COMMUNITY #1 F 69
UP, AC FX: 02/10/15 CPT 22524 TX: 02/10/15 CPT G0130
```

```
PATIENT3, ELIZABETH 000003 COMMUNITY #1 F 78
UP, AC FX: 02/15/15 CPT S2362

PATIENT4, KATIE 000004 COMMUNITY #1 F 80
UP, AC FX: 02/05/15 PROC 81.66

PATIENT5, LINDSAY 000005 COMMUNITY #1 F 81
UP FX: 02/01/15 DX 733.13 TX: 02/15/15 CPT 77081

PATIENT6, ELIZABETH 000006 COMMUNITY #1 F 86
UP, AC FX: 01/15/15 DX 733.13 TX: 01/31/15 CPT 77081
```

Figure 2-112: Sample Patient List, Osteoporosis Management

## 2.10.2 Osteoporosis Screening in Women

### **Denominators**

Female Active Clinical patients ages 65 and older without a documented history of osteoporosis.

Female User Population patients ages 65 and older without a documented history of osteoporosis.

### **Numerators**

Patients who had osteoporosis screening documented after the age of 65.

**Note**: This numerator does *not* include refusals.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

Osteoporosis definition: No osteoporosis diagnosis ever (POV ICD-9: 733.\*; ICD-10: M80.\*\*\*A, M81\*, M84.4\*\*A, M84.6\*\*A).

CRS uses the following codes to define osteoporosis screening.

Subject Defined	V Radiology or CPT Codes	ICD and Other Codes
Osteoporosis Screening (any test documented after age 65)	Central DEXA: 77080, 76075 (old code) Peripheral DEXA: 77081, 76076 (old code) SEXA: G0130 Central CT: 77078, 76070 (old code) Peripheral CT: 77079, 76071 (old code) US Bone Density: 76977	Procedure: ICD-9: 88.98 (Quantitative CT) POV: ICD-9: V82.81 Special screening for other conditions, Osteoporosis; ICD-10: Z13.820

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of female patients ages 65 and older with osteoporosis screening after age 65, if any.

### **Measure Source**

None.

## Measure Past Performance and Long-Term Targets

None

DU November 25, 2015 Page 279  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Osteoporosis Screening in Women  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %								
Female Active Clir Pts =>65 # w/osteoporosis s	57		31			29		
after age 65 -No Refusals	13	22.8	1	3.2	+19.6	0	0.0	+22.8
Female User Pop Pts =>65	112		85			81		
# w/osteoporosis s after age 65 -No Refusals	screening 13	11.6	3	3.5	+8.1	1	1.2	+10.4

Figure 2-113: Sample Report, Osteoporosis Screening in Women

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient

Osteoporosis Screening in Women: List of female patients ages 65 and older with osteoporosis screening after age 65, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR
```

```
PATIENT1, SHERRY
                      000001 COMMUNITY #1 F 68
                            05/15/12 Proc 88.98
UP,AC
                      000002 COMMUNITY #1 F 68
PATIENT2, APRIL
UP,AC
                            04/01/13 CPT G0130
PATIENT3, JACKIE
                      000003 COMMUNITY #1 F 69
                            08/21/11 RAD CT, BONE MIN DENSITY, 1/+, APPEND
UP,AC
PATIENT4, PAULINE
                      000004 COMMUNITY #1 F 70
UP,AC
                      000005 COMMUNITY #1 F 72
PATIENT5, SHANNON
UP,AC
PATIENT6, TINA MARIE
                      000006 COMMUNITY #1 F 78
                            04/15/10 CPT 77081
UP,AC
```

Figure 2-114: Sample Patient List, Osteoporosis Screening in Women

## 2.10.3 Rheumatoid Arthritis Medication Monitoring

#### **Denominator**

Active Clinical patients ages 16 and older diagnosed with *rheumatoid arthritis* (RA) prior to the Report Period and with at least two RA-related visits any time during the Report Period who were prescribed maintenance therapy medication chronically during the Report Period.

#### **Numerator**

Patients who received appropriate monitoring of chronic medication during the Report Period.

## **Logic Description**

Age is calculated at the beginning of the Report Period.

RA defined as diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 714.\*; ICD-10: M05.\*through M06.\*, M08.0\*, M08.2 through M08.99, M12.0\* prior to the Report Period, and at least two RA POVs during the Report Period.

For all maintenance therapy medications *except* intramuscular gold, each medication must be prescribed within the past 465 days of the end of the Report Period (i.e., the Medication Period) and the sum of the days supply equal to or greater than (=>)348. This means the patient must have been on the medication at least 75% of the Medication Period. Two examples are shown below to illustrate this logic. *All* medications must not have a comment of RETURNED TO STOCK.

Example of Patient Not on Chronic Medication (not included in Denominator):

Report Period: January 1 through December 31, 2015

Medication Period: 465 days from end of Report Period (December 31, 2015): September 22, 2014 through December 31, 2015

Medication Prescribed:

Diclofenac: 1st Rx: Oct 15, 2014, Days Supply=90; 2nd Rx: Jan 01, 2015: Days Supply=90; 3rd Rx: Mar 15, 2015: Days Supply=90.

Total Days Supply=270. 270 is not greater than (>) 348. Patient is not considered on chronic medication and is not included in the denominator.

Example of Patient on Chronic Medication (included in Denominator):

Report Period: January 1 through December 31, 2015

Medication Period: 465 days from end of Report Period (December 31, 2015): September 22, 2014 through December 31, 2015

Medications Prescribed:

Sulfasalazine: 1st Rx: Sep 30, 2014, Days Supply=90; 2nd Rx: December 30, 2014, Days Supply=90; 3rd Rx: March 15, 2015 Days Supply=180.

Total Days Supply=360. 360 is greater than (>) 348. Patient is considered on chronic medication and is included in denominator.

The days' supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the Medication Period. However, for all medications, there must be at least one prescription filled during the Report period.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

For intramuscular gold, the patient must have 12 or more prescriptions during the Report Period.

Appropriate monitoring of rheumatoid arthritis medications is defined with lab tests and varies by medication, as shown in the table below. If patient is prescribed two or more types of medications, patient must meet criteria for all of the medications.

Maintenance Therapy Medications Definition

Medications shown in table below. Except for Gold, Intramuscular, all
medications requiring more than one of each type of test during the Report Period,
there must be a minimum of ten days between tests. For example, if a
Sulfasalazine test was performed on March 1, March 7, and March 21, 2015, the
March 7 test will not be counted since it was performed only 6 days after the
March 1 test.

Medication	Required Monitoring Tests
Gold, Intramuscular	CBC and urine Protein on same day as each injection during Report Period
Azathrioprine or Sulfasalazine	4 CBCs during the Report Period
Leflunomide or Methotrexate	6 each of CBC, Serum Creatinine, and Liver Function Tests during the Report Period
Cyclosporin	CBC, Liver Function Tests, and Potassium within past 180 days from Report Period end date 12 Serum Creatinine tests during the Report Period
Gold, Oral or Penicillamine	4 each of CBC and Urine Protein during the Report Period
Mycophenolate	CBC within past 180 days from Report Period end date

The medications in the above table are defined with medication taxonomies: BGP RA IM GOLD MEDS, BGP RA AZATHIOPRINE MEDS, BGP RA LEFLUNOMIDE MEDS, BGP RA METHOTREXATE MEDS, BGP RA CYCLOSPORINE MEDS, BGP RA ORAL GOLD MEDS, BGP RA MYCOPHENOLATE MEDS, BGP RA PENICILLAMINE MEDS, BGP RA SULFASALAZINE MEDS.

- 1. **NSAID Medications**: All of the following medications must have Creatinine, Liver Function Tests, and CBC during the Report Period: Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celocoxib. All of these medications *except* aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS. Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.
- Glucocorticoid Medications: Dexamethasone, Methylprednisolone, Prednisone, Hydrocortisone, Betamethasone, Prednisonolone, Triamcinolone. These medications defined with medication taxonomy BGP RA GLUCOCORTICOIDS MEDS. Glucocorticoids must have a glucose test, which must be performed during the Report Period.

Example of Patient Not Included in Numerator:

Medications Prescribed and Required Monitoring:

- Gold, Oral, last Rx June 15, 2015. Requires CBC and Urine Protein within past 90 days of Report Period end date.
- CBC performed on December 1, 2015, which is within past 90 days of Report Period end date of December 31, 2015. No Urine Protein performed during that period. Patient is not in numerator.

Example of Patient Included in Numerator:

Medications Prescribed and Required Monitoring:

- Diclofenac, last Rx Sep 1, 2015. Requires LFT and CBC during Report Period.
- Mycophenolate, last Rx March 10, 2015. Requires CBC within past 180 days from Report Period end date.
- LFT and CBC performed during Report Period. CBC performed November 1, 2015, which is within past 180 days of Report Period end date of December 31, 2015. Patient is in numerator.

Monitoring Test	CPT Codes	LOINC Codes	Taxonomy
CBC	85025, 85027	Yes	BGP CBC TESTS
Urine Protein		Yes	DM AUDIT URINE PROTEIN TAX
Serum Creatinine	82540, 82565-75	Yes	DM AUDIT CREATININE TAX
Liver Function Tests-ALT	84460	Yes	DM AUDIT ALT TAX
Liver Function Tests-AST	84450	Yes	DM AUDIT AST TAX
Liver Function	80076	Yes	BGP LIVER FUNCTION TESTS
Glucose	82947, 82948, 82950, 82951, 82952, 82962	Yes	DM AUDIT GLUCOSE TESTS TAX
Potassium	84132	Yes	BGP POTASSIUM TESTS

## **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of RA patients age 16 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with YES and patients who did not meet the measure are prefixed with NO The chronic medications and all laboratory tests the patient *did* have are displayed.

#### **Measure Source**

None

### **Measure Past Performance and Long-Term Targets**

None

```
DIJ
                            November 25, 2015
                                                                    Page 284
       *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Rheumatoid Arthritis Medication Monitoring
                            % PREV YR % CHG from BASE
PERIOD PREV YR % PERIO
                    REPORT
                                                                  % CHG from
                                               PREV YR % PERIOD
                                                                      BASE %
                    PERTOD
Active Clinical Pts =>16
w/RA DX and maintenance
                                       0
                                                              0
therapy RX
# w/RA chronic med
                       2 66.7
                                       0 0.0 +66.7 0 0.0 +66.7
monitoring
```

Figure 2-115: Sample Report, Rheumatoid Arthritis Medication Monitoring

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Rheumatoid Arthritis Medication Monitoring: List of RA patients 16 and older prescribed maintenance therapy medication with monitoring lab tests, if any. The numerator values for patients who meet the measure are prefixed with "YES:" and patients who did not meet the measure are prefixed with "NO:". The chronic medications and all lab tests the patient DID have are displayed. HRN COMMUNITY SEX AGE PATTENT NAME DENOMINATOR NUMERATOR PATIENT1, RUTH 000001 COMMUNITY #1 F 64 AC YES: NSAID: 10/21/15 PATIENT2, SHANNON 000002 COMMUNITY #1 F 72 YES: NSAID: 10/21/15 CREAT, 09/22/15 CBC, 05/21/15 LFT YES: Glucocorticoids: 11/02/15 Glucose PATIENT34, CATHERINE 000034 COMMUNITY #3 F 50 NO: Glucocorticoids: does not have Glucose

Figure 2-116: Sample Patient List, Rheumatoid Arthritis Medication Monitoring

## 2.10.4 Osteoarthritis Medication Monitoring

#### Denominator

Active Clinical patients ages 40 and older diagnosed with osteoarthritis (OA) prior to the Report Period and with at least two OA-related visits any time during the Report Period and prescribed maintenance therapy medication chronically during the Report Period.

#### **Numerator**

Patients who received appropriate monitoring of chronic medication during the Report Period.

### **Logic Description**

Age is calculated at the beginning of the Report Period.

OA defined as diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 715.\*; ICD-10: M15.\* through M19.\* prior to the Report period, and at least two OA POVs during the Report Period.

For all maintenance therapy medications, each medication must be prescribed within the past 465 days of the end of the Report Period (i.e., the Medication Period) and the sum of the days supply equal to or greater than (=>) 348. This means the patient must have been on the medication at least 75% of the Medication Period. Two examples are shown below to illustrate this logic. Medications must not have a comment of RETURNED TO STOCK.

*Example of Patient Not on Chronic Medication (not included in Denominator):* 

- Report Period: January 1 through December 31, 2015
- Medication Period: 465 days from end of Report Period (December 31, 2015):
   September 22, 2014 through December 31, 2015
- Medication Prescribed:
  - Diclofenac: 1st Rx: October 15, 2014, Days Supply=90; 2nd Rx: January
     1, 2015: Days Supply=90; 3rd Rx: March 15, 2015: Days Supply=90.
  - Total Days Supply=270. 270 is not greater than (>) 348. Patient is not considered on chronic medication and is not included in the denominator.

Example of Patient on Chronic Medication (included in Denominator):

- Report Period: January 1 through December 31, 2015
- Medication Period: 465 days from end of Report Period (December 31, 2015): September 22, 2014 through December 31, 2015
- Medication Prescribed:

- Etodolac: 1st Rx: September 30, 2014, Days Supply=90; 2nd Rx:
   December 30, 2014, Days Supply=90; 3rd Rx: March 15, 2015: Days Supply =180.
- Total Days Supply=360. 360 is greater than (>) 348. Patient is considered on chronic medication and is included in denominator.

The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the Medication Period. However, for all medications, there must be at least one prescription filled during the Report Period.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Appropriate monitoring of OA medications is defined with laboratory tests and varies by medication, as shown below.

Maintenance Therapy Medications Defined with the Following NSAID Medications: Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celocoxib. All of these medications, except aspirin, are defined with medication taxonomy BGP RA OA NSAID MEDS. Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

All NSAID medications must have Creatinine, Liver Function Tests and CBC during the Report Period.

Example of Patient Not Included in Numerator:

- Medication Prescribed and Required Monitoring:
  - Diclofenac, last Rx June 15, 2015. Requires Creatinine, LFT and CBC during Report Period. Only the LFT was performed during Report Period. Patient is not in numerator.

Example of Patient Included in Numerator:

- Medications Prescribed and Required Monitoring:
  - Diclofenac, last Rx September 1, 2015. Requires Creatinine, LFT and CBC during Report Period. Creatinine, LFT, and CBC performed during Report Period. Patient is in numerator.

CRS uses the following codes to define the monitoring tests.

Monitoring Test	ICPT COMPS	LOINC Codes	Taxonomy
Serum Creatinine	82540, 82565-82575	Yes	DM AUDIT CREATININE TAX
CBC	85025, 85027	Yes	BGP CBC TESTS
Liver Function Tests-ALT	84460	Yes	DM AUDIT ALT TAX
Liver Function Tests-AST	84450	Yes	DM AUDIT AST TAX
Liver Function	80076	Yes	BGP LIVER FUNCTION TESTS

### **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of OA patients 40 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with YES and patients who did not meet the measure are prefixed with NO. All laboratory tests the patient did have are displayed.

#### Measure Source

None

## **Measure Past Performance and Long-Term Targets**

None

```
DU
                            November 25, 2015
                                                                 Page 287
      *** IHS 2015 Selected Measures with Community Specified Report ***
                           DEMO INDIAN HOSPITAL
                Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Osteoarthritis Medication Monitoring
                  REPORT % PREV YR
                                          % CHG from BASE
                                                               % CHG from
                   PERIOD
                                            PREV YR % PERIOD
                               PERIOD
                                                                  BASE %
Active Clinical Pts =>40
w/OA DX and maintenance
therapy RX
                                      6
                                                            4
# w/OA chronic
med monitoring
                        2 66.7
                                      3 50.0
                                              +16.7
                                                            2 50.0
                                                                      +16.7
```

Figure 2-117: Sample Report, Osteoarthritis Medication Monitoring

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic

Figure 2-118: Sample Patient List, Osteoarthritis Medication Monitoring

### 2.10.5 Asthma

### **Denominators**

All *Active Clinical patients*. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

Patients who have had two asthma-related visits during the Report Period or with persistent asthma. Broken down by age groups (under 14, 15 to 34, 35 to 64, and 65 and older).

#### **Numerators**

Patients who have had two asthma-related visits during the Report Period or with persistent asthma.

Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the Report Period.

Patients from Numerator 1 who have visited the ER or Urgent Care for asthma during the Report Period.

Patients from Numerator 1 who have a Severity of 1.

Patients from Numerator 1 who have a Severity of 2.

Patients from Numerator 1 who have a Severity of 3.

Patients from Numerator 1 who have a Severity of 4.

Patients from Numerator 1 who have no documented Severity.

### **Logic Description**

Age is calculated at beginning of Report Period.

Asthma visits definition: Diagnosis (POV) ICD-9: 493.\*; ICD-10: J45.\*.

Persistent asthma definition: Any of the following:

- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*;
   ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented *any* time before the end of the Report Period.

Severity definition: Severity of 1, 2, 3 or 4 in an active entry in the PCC Problem List for ICD-9: 493.\*; ICD-10: J45.\* or in V Asthma.

*Hospitalizations definition*: Service Category H with primary POV ICD-9: 493.\*; ICD-10: J45.\*.

ER and Urgent Care definition: Clinic codes 30 or 80 with primary POV ICD-9: 493.\*; ICD-10: J45.\*.

## **Key Logic Changes from CRS Version 14.1**

1. Added ICD-10 codes J45.901-J45.998 to Asthma definition.

### **Patient List Description**

List of patients diagnosed with asthma and any asthma-related hospitalizations.

#### **Measure Source**

HP 2020 RD-2

### **Measure Past Performance and Long-Term Targets**

Measure	Target
HP1998 baseline for hospitalizations for asthma:	
Under 5	45.6 per 10,000
5-64	12.5 per 10,000
65 and older	17.7 per 10,000
HP 2020 goal for hospitalizations for asthma:	
Under 5	18.1 per 10,000
5-64	8.6 per 10,000
65 and older	20.3 per 10,000

```
DU November 25, 2015 Page 289

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

Previous Year Period: Jan 01, 2014 to Dec 31, 2014
```

В	aseline Pe	riod:	Jan 01,	2010	to Dec 31,	2010		
Asthma (con't)	REPORT	%	PREV YR	%	CHG from	BASE	%	CHG from
	PERIOD		PERIOD		PREV YR %	PERIOD		BASE %
Total Active Clini	cal							
Patients	1,646		1,224			1,101		
# w/asthma	58	3.5	42	3.4			2.3	+1.3
A. Under 15	28	48.3	22	52.4	-4.1	17	68.0	
в. 15-34	7	12.1	•	16.7		3	12.0	+0.1
C. 35-64	15	25.9	8	19.0	+6.8	3	12.0	+13.9
D. 65 and older	8	13.8	5	11.9	+1.9	2	8.0	+5.8
# w/asthma	58		42			25		
# w/asthma								
hospitalization	2	3.4	2	4.8	-1.3	2	8.0	-4.6
A. Under 15	1	50.0	0	0.0		1	50.0	+0.0
в. 15-34	0	0.0	1	50.0		0	0.0	+0.0
C. 35-64	0	0.0	0	0.0	+0.0	1	50.0	-50.0
D. 65 and older	1	50.0	1	50.0	+0.0	0	0.0	+50.0
# w/ ER/UC								
visit		10.3	6	14.3	-3.9	9	36.0	-25.7
A. Under 15	2	33.3	3	50.0	-16.7	7	77.8	-44.4
в. 15-34	0	0.0	2	33.3	-33.3	1	11.1	-11.1
C. 35-64		33.3		0.0		1		
D. 65 and older	2	33.3	1	16.7	+16.7	0	0.0	+33.3
# w/ Severity 1	3	5.2	0	0.0	+5.2	0	0.0	+5.2
# w/ Severity 2	7	12.1	3	7.1	+4.9	0	0.0	+12.1
	4		0	0.0		0	0.0	+6.9
	6	10.3	2	4.8	+5.6	0	0.0	+10.3
# w/ No Severity	38	65.5	37	88.1	-22.6	25	100.0	-34.5

Figure 2-119: Sample Report, Asthma

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Asthma: List of patients diagnosed with asthma and any asthma-related
hospitalizations/ER/Urgent Care visits.
                    HRN
PATIENT NAME
                            COMMUNITY SEX AGE
DENOMINATOR
                           NUMERATOR
PATIENT1,GENEVA 000001 COMMUNITY #1 F 47
                           Severity 4 on visit 02/02/13; ER/UC: 11/02/15;
Severity: 4
PATIENT2, JACKIE
                    000002 COMMUNITY #1 F 69
                           Severity 2 on PL; Severity: 2
PATIENT3, PAULINE 000003 COMMUNITY #1 F 70
                            2 Dx PCC: 03/01/15, 03/03/15; ER/UC: 10/01/15;
Severity: 1
PATIENT4, WILLIAM R 000004 COMMUNITY #1 M 7
```

```
AC 2 Dx PCC: 05/05/14, 06/06/14; Hospital: 05/05/14; ER/UC: 06/06/14 
PATIENT5, ZACHARY 000005 COMMUNITY #1 M 11
AC 2 Dx PCC: 03/20/14, 08/08/14
PATIENT42, JOSEPHINE 000042 COMMUNITY #2 F 4
AC 2 Dx PCC: 07/01/14, 09/19/14; Severity: 2
```

Figure 2-120: Sample Patient List, Asthma

### 2.10.6 Asthma Assessments

#### **Denominators**

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

### **Numerator**

Patients with asthma management plan during the Report Period.

Patients with severity documented at any time before the end of the Report Period.

Patients with control documented during the Report Period.

Patients who were assessed for number of symptom free days during the Report Period.

Patients with number of symptom free days score of 0 through 5.

Patients with number of symptom free days score of 6 through 12.

Patients with number of symptom free days score of 13 through 14.

Patients who were assessed for number of school/work days missed during the Report Period.

Patients with number of school/work days missed score of 0 through 2.

Patients with number of school/work days missed score of 3 through 7.

Patients with number of school/work days missed score of 8 through 14.

### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Emphysema definition: Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 492.\*, 506.4, 518.1, 518.2; ICD-10: J43.\*, J68.4, J68.8, J98.2, J98.3.

*COPD definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8.

### Persistent asthma definition:

- 1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with primary diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
- 2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
  - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

Asthma management plan definition: Patient Education code ASM-SMP.

Severity documented definition:

Meeting any of the following criteria below:

- 1. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at ANY time before the end of the Report Period or
- 2. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented ANY time before the end of the Report Period.

Control documented definition: POV ICD-9: 493.\*; ICD-10: J45.\* with Asthma Control recorded in the V Asthma file.

*Number of symptom free days definition:* The most recent V Measurement documented during the Report Period.

*Number of school/work days missed definition:* The most recent V Measurement documented during the Report Period.

## **Key Logic Changes from CRS Version 14.1**

1. Added ICD-10 codes J45.901-J45.998 to Asthma definition.

# **Patient List Description**

List of asthmatic patients with assessments, if any.

### **Measure Source**

None

## **Measure Past Performance and Long-term Targets**

None

DU November 25, 2015 Page 295  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Asthma Assessments									
	REPORT PERIOD				CHG from B. PREV YR % P.			CHG from BASE %	
Active Clinical									
Pts =>5 w/ persister									
asthma	29		11			5			
<pre># w/management plan # w/severity</pre>	1	3.4	0	0.0	+3.4	0	0.0	+3.4	
documented	17	58.6	5	45.5	+13.2	1	20.0	+38.6	
<pre># w/control documented</pre>	3	10.3	0	0.0	+10.3	0	0.0	+10.3	
# w/# symptom free	J	10.3	· ·	0.0	. 10.5	Ü	0.0	. 10.5	
days	3	10.3	0	0.0	+10.3	0	0.0	+10.3	
<pre># w/# symptom free days 0-5</pre>	1	3.4	0	0.0	+3.4	0	0.0	+3.4	
# w/# symptom free	1	3.4	U	0.0	73.4	U	0.0	+3.4	
days 6-12	1	3.4	0	0.0	+3.4	0	0.0	+3.4	
<pre># w/# symptom free days 13-14</pre>	1	3.4	0	0.0	+3.4	0	0.0	+3.4	
# w/# school/work	1	J. 1	O	0.0	, 3. 1	9	0.0	,3,4	
days missed	3	10.3	0	0.0	+10.3	0	0.0	+10.3	
# w/# school/work days missed 0-2	1	3.4	0	0.0	+3.4	0	0.0	+3.4	
# w/# school/work	_	3.4	U	0.0	⊤J.¶	U	0.0	+3.4	
days missed 3-7	1	3.4	0	0.0	+3.4	0	0.0	+3.4	
<pre># w/# school/work days missed 8-14</pre>	1	3.4	0	0.0	+3.4	0	0.0	+3.4	

Figure 2-121: Sample Report, Asthma Assessments

```
DU November 25, 2015 Page 95

*** IHS 2015 Selected Measures with Community Specified Report ***

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015
```

Previous Year Period: Jan 01, 2014 to Dec 31, 2014 Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Asthma Assessments (con't)									
Active Clinical Pts =>5 w/Persistent Asthma $5-14$ $15-34$ $35-64$ $65+$									
CURRENT REPORT PERIOD Active Clinical Pts =>5									
w/persistent asthma	11	6	6	6					
<pre># w/management plan % w/management plan</pre>	1	0	0	0					
<pre># w/severity documented % w/severity documented</pre>	7 63.6	3 50.0	6 100.0	1 16.7					
% w/control documented % w/control documented	0	1	1 16.7	1					
<pre># w/# symptom free days % w/# symptom free days</pre>		0.0	0.0	2 33.3					
<pre># w/# symptom free days 0-5 % w/# symptom free days 0-5</pre>		0	0	1 16.7					
<pre># w/# symptom free days 6-12 % w/# symptom free days 6-12</pre>	1 9.1	0.0	0.0	0.0					
# w/# symptom free days 13-14		0	0	1					
% w/# symptom free days $13-14$	0.0	0.0	0.0	16.7					
<pre># w/# school/work days missed</pre>	1	0	0	2					
% w/# school/work days									
missed	9.1	0.0	0.0	33.3					
<pre># w/# school/work days missed 0-2</pre>	1	0	0	0					
% w/# school/work days missed 0-2	9.1	0.0	0.0	0.0					
# w/# school/work days									
missed 3-7 % w/# school/work days	0	0	0	1					
missed 3-7	0.0	0.0	0.0	16.7					
# w/# school/work days				_					
missed 8-14 % w/# school/work days	0	0	0	1					
missed 8-14	0.0	0.0	0.0	16.7					

Figure 2-122: Sample Age Breakdown Report, Asthma Assessments

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

```
Asthma Assessments: List of asthmatic patients with assessments, if any.
PATIENT NAME HRN COMMUNITY
DENOMINATOR NUMERATOR
                                        SEX AGE
DENOMINATOR
                     NUMERATOR
PATIENT1, GENEVA 000001 COMMUNITY #1 F 47
UP, AC Severity 4 in V Asthma 02/02/14 Severity: 4; Symptom Free Days: 03/01/15 [12];
Days Missed: 03/01/15 [0]
PATIENT2, JACKIE 000002 COMMUNITY #1 F 69
UP,AC Severity >1 on PL for 493.00 Severity: 2
PATIENT3, PAULINE 000003 COMMUNITY #1 F 70
UP,AC Severity >1 on PL for 493.00 Mgmt Plan: 06/01/15; Severity: 3
PATIENT4, WILLIAM R 000004 COMMUNITY #1 M 7
UP,AC 4 meds
PATIENT5, ZACHARY 000005 COMMUNITY #1 M 11
AC Severity 4 in V Asthma 04/04/15 Severity: 4; Control: 05/06/15
PATIENT42, JOSEPHINE 000042 COMMUNITY #2 F 4
AC DX ON HOSP/OR ER ON 05/05/14 DX ON HOSP/OR ER ON 06/03/15 Control: 10/03/15;
Symptom Free Days: 07/01/15 [3]; Days Missed: 07/01/15 [3]
```

Figure 2-123: Sample Patient List, Asthma Assessments

## 2.10.7 Asthma Quality of Care

### **Denominators**

Active Clinical patients ages 5 through 56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 9, 10 through 17, and 18 through 56).

*User Population patients* ages 5 through 56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema and chronic COPD. Broken down by age groups (5 through 9, 10 through 17, and 18 through 56).

#### Numerator

Patients who had at least one dispensed prescription for preferred asthma therapy medication during the Report Period.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

*Emphysema definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 492.\*, 518.1, 518.2; ICD-10: J43.\*, J98.2, J98.3.

*COPD definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8.

### Persistent asthma definition:

- 1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)
  - b. At least one acute inpatient discharge with Primary Diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
  - c. At least four outpatient visits on different dates of service, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* and at least two asthma medication dispensing events (see definition below)
  - d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
- 2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
  - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

To be included in the numerator, patient must have a non-discontinued prescription for preferred asthma therapy (see list of medications below) during the Report Period.

Preferred asthma therapy medication codes for numerator defined with medication taxonomy: BGP HEDIS PRIMARY ASTHMA MEDS Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline). Medications must not have a comment of RETURNED TO STOCK.

## **Key Logic Changes from CRS Version 14.1**

1. Added ICD-10 codes J45.901-J45.998 to Asthma definition.

### **Patient List Description**

List of asthmatic patients with preferred asthma therapy medications, if any.

#### **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 292  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Asthma Quality of Ca	re (con'	t)						
	REPORT PERIOD				CHG from PREV YR %			CHG from BASE %
Active Clinical Pts w/persistent asthma	5-56		10			5		
<pre># w/ preferred asthm control med</pre>		33.3	5	50.0	-16.7	3	60.0	-26.7
A. Active Clinical ages 5-9	11		3			1		
<pre># w/ preferred asthm control med</pre>		27.3	1	33.3	-6.1	1	100.0	-72.7
B. Active Clinical ages 10-17	2		2			1		
<pre># w/ preferred asthm control med</pre>		100.0	2	100.0	+0.0	0	0.0	+100.0
C. Active Clinical ages 18-56	8		5			3		
# w/ preferred asthm		25.0	2	40.0	-15.0	2	66.7	-41.7
User Pop Pts 5-56 w/persistent asthma	21		11			6		
# w/ preferred asthm		33.3	5	45.5	-12.1	3	50.0	-16.7
A. User Pop ages 5-9	11		4			1		
# w/ preferred asthm	a 3	27.3	1	25.0	+2.3	1	100.0	-72.7
B. User Pop ages 10-17	2		2			1		

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

# w/ preferred asthma control med	2 100.0	2 100.0 +0.0	0 0.0 +100.0
C. User Pop ages 18-56	8	5	4
# w/ preferred asthma control med	2 25.0	2 40.0 -15.0	2 50.0 -25.0

Figure 2-124: Sample Report, Asthma Quality of Care

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Asthma Quality of Care: List of asthmatic patients with preferred asthma
therapy medications, if any.
DENOMINATOR HRN COMMUNITY SEX AGE
PATIENT NAME
PATIENT1, ZACHARY 000011 COMMUNITY
                                             F 5
UP, AC, Severity 4 in V Asthma 02/02/14
PATIENT12, TINA DANIELLE 000012 COMMUNITY F 6
UP,AC,Severity >1 on PL for 493.00,NUM: 06/01/15, MOMETASONE/FORMOTEROL 100/5MCG INH
PATIENT13, THERESA LYNN 000013 COMMUNITY M 47
UP,AC,Severity 2 in V Asthma 03/03/15,NUM: 06/01/15, FLUTICASONE PROPIONATE 110MCG
INHALER
PATIENT36, NATHAN BRADLEY 000014 COMMUNITY M 16
UP,AC,DX ON HOSP/OR ER ON 09/26/14,4 POVS AND 2 MEDSNUM: 09/19/15, FLUTICASONE
PROPIONATE 110MCG INHALER
PATIENT37, JANELLE MARIE 000015 COMMUNITY F 50
UP, AC, Severity 2 in V Asthma 09/04/13
PATIENT38, THOMAS ELLIS 000016 COMMUNITY M 6
UP,AC,4 meds
```

Figure 2-125: Sample Patient List, Asthma Quality of Care

# 2.10.8 Medication Therapy for Persons with Asthma

#### **Denominators**

Active Clinical patients ages 5-50 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD) who had two or more prescriptions for a LABA during the Report Period. Broken down by age groups (5 through 14, 15 through 34, 35 through 64, and greater than (>) 65).

#### **Numerators**

Suboptimal Control: Patients who were dispensed more than three canisters of a short-acting beta2 agonist inhaler during the same 90-day period during the Report Period.

Absence of Controller Therapy: Patients who were dispensed more than three canisters of short acting beta2 agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period.

Patients who were prescribed two or more controller therapy medications during the Report Period.

Patients who were prescribed two or more inhaled corticosteroid medications during the Report Period.

Patients who were not prescribed two or more inhaled corticosteroid medications during the Report Period.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Emphysema definition: Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 492.\*, 506.4, 518.1, 518.2; ICD-10: J43.\*, J68.4, J68.8, J98.2, J98.3.

*COPD definition:* Any visit at any time on or before the end of the Report Period with POV codes: ICD-9: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4; ICD-10: J44.\*, J68.4, J68.8.

Persistent asthma definition:

- 1. Meeting any of the following four criteria below within the year prior to the beginning of the Report Period *and* during the Report Period:
  - a. At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493\*; ICD-10: J45.\* (asthma)

- b. At least one acute inpatient discharge with Primary Diagnosis ICD-9: 493.\*; ICD-10: J45.\*. Acute inpatient discharge defined as Service Category of H
- c. At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.\*; ICD-10: J45.\* *and* at least two asthma medication dispensing events (see definition below)
- d. At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then *must* also have at least one visit with POV ICD-9: 493.\*; ICD-10: J45.\* in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.)
- 2. Meeting any of the following criteria below:
  - a. Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.\*; ICD-10: J45.\* with Severity of 2, 3 or 4 at any time before the end of the Report Period, or
  - b. Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Dispensing event definition: One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Belclomethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Aminophylline, Dyphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

To be included in the Suboptimal Control and Absence of Controller Therapy numerators, patient must have one or more non-discontinued prescriptions for short acting Beta2 Agonist inhalers totaling at least four canisters in one 90-day period. Short acting Beta2 Agonist inhaler medications defined with medication taxonomy BGP PQA SABA MEDS. (Medications are: Albuterol, Levalbuterol, Pirbuterol). Medications must not have a comment of RETURNED TO STOCK.

#### Controller Therapy definition:

At least one non-discontinued prescription of controller therapy medications during the same 90 day period.

Controller therapy medications defined with medication taxonomy BGP PQA CONTROLLER MEDS. (Medications are: Beclomethasone, Budesonide, Budesonide-Formoterol, Ciclesonide, Flunisolide, Fluticasone, Fluticasone-Salmeterol, Formoterol, Mometasone, Mometasone-Formoterol, Montelukast, Salmeterol, Theophylline, Zafirlukast, Zileuton). Medications must not have a comment of RETURNED TO STOCK.

Inhaled corticosteroid medications defined with medication taxonomy BGP PQA ASTHMA INHALED STEROIDS. (Medications are: Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Mometasone, Triamcinolone, Budesonide-formoterol, Mometasone-formoterol.) Medications must not have a comment of RETURNED TO STOCK.

Long-Acting Beta-2 Agonist (LABA) medications defined with medication taxonomy BGP ASTHMA LABA MEDS. (Medications are: Aformoterol, Formoterol, Salmeterol.) Medications must not have a comment of RETURNED TO STOCK.

# **Key Logic Changes from CRS Version 14.1**

- 1. Added ICD-10 codes J45.901-J45.998 to Asthma definition.
- 2. Updated BGP PQA SABA MEDS taxonomy.
- 3. Updated BGP PQA CONTROLLER MEDS taxonomy.
- 4. Updated BGP PQA ASTHMA INHALED STEROIDS taxonomy.

# **Patient List Description**

List of patients with asthma with suboptimal control and controller therapy, if any.

#### **Measure Source**

PQA (Pharmacy Quality Alliance)

## Measure Past Performance and Long-term Targets

DU November 25, 2015 Page 299  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014								
		: Jan 01,	-		-			
Medication Therapy for I	ersons w	ith Asthma						
	-	PREV YR PERIOD						
Active Clinical ages 5-50 w/ asthma	19	8			5			
# w/ Suboptimal Control # w/ Absence of Control:		3 0	0.0	+5.3	0	0.0	+5.3	
Therapy	1 100.	0 0	0.0	+100.0	0	0.0	+100.0	
Active Clinical Pts =>5 w/persistent asthma	29	11			5			
<pre># w/ 2 or more   controller Rx # w/ 2 or more inhaled</pre>	10 34.	5 5	45.5	-11.0	3	60.0	-25.5	
steroid Rx	3 10.	3 3	27.3	-16.9	0	0.0	+10.3	
Active Clinical =>5								

w/persistent asthma and LABA Rx	4		0			0		
# w/o 2 or more inhaled steroid Rx	3	75.0	0	0.0	+75.0	0	0.0	+75.0

Figure 2-126: Sample Report, Medication Therapy for Persons with Asthma

DU November 25, 2015 Page 95  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010										
Medication Therapy for Persons with Asthma (con't)										
Active Clinical Pts =>5 w/persistent asthma										
	5-14 15-34 35-64 65+									
CURRENT REPORT PERIOD Active Clinical Pts =>5										
w/persistent asthma	11	6	6	6						
<pre># w/ 2 or more controller Rx % w/ 2 or more controller Rx</pre>	6	2	1	1						
% w/ 2 or more controller Rx	54.5	33.3	16.7	16.7						
# w/ 2 or more inhaled										
<pre>steroid Rx % w/ 2 or more inhaled</pre>	3	0	0	0						
steroid Rx	27.3	0.0	0.0	0.0						
PREVIOUS REPORT PERIOD Active Clinical Pts =>5 w/persistent asthma	4	2	3	1						
<pre># w/ 2 or more controller Rx % w/ 2 or more controller Rx</pre>	2 50.0	1 50.0	1 33.3	0.0						
<pre># w/ 2 or more inhaled   steroid Rx % w/ 2 or more inhaled</pre>	1	1	1	0						
steroid Rx	25.0	50.0	33.3	0.0						
CHANGE FROM PREVIOUS YR % # w/ 2 or more controller Rx # w/ 2 or more inhaled	+4.5	-16.7	-16.7	+16.7						
steroid Rx	-22.7	-50.0	-33.3	+0.0						
BASELINE REPORT PERIOD Active Clinical Pts =>5 w/persistent asthma	2	2	1	0						
<pre># w/ 2 or more controller Rx % w/ 2 or more controller Rx</pre>	1 50.0	1 50.0	1	0.0						

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

<pre># w/ 2 or more inhaled   steroid Rx % w/ 2 or more inhaled</pre>	0	0	0	0	
steroid Rx	0.0	0.0	0.0	0.0	
CHANGE FROM BASELINE YR % # w/ 2 or more controller Rx # w/ 2 or more inhaled	+4.5	-16.7	-83.3	+16.7	
steroid Rx	-22.7	-50.0	-100.0	+0.0	

Figure 2-127: Sample Age Breakdown Report, Medication Therapy for Persons with Asthma

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Medication Therapy for Persons with Asthma: List of patients with asthma
with asthma medications, if any.
                  HRN COMMUNITY
PATIENT NAME
                                         SEX AGE
DENOMINATOR
                            NUMERATOR
PATIENT1, GWEN 000001 COMMUNITY #1 F 5
AC, Severity 4 in V Asthma 02/02/14
PATIENT2, ALICE 000002 COMMUNITY #1 F 6
AC, Severity >1 on PL for 493.00 SABA: 06/15/15 ALBUTEROL 90MCG/INHALATION MDI(4)
PATIENT3, GENEVA 000003 COMMUNITY #1 F 47
AC, Severity 2 in V Asthma 03/03/15 2+ CONT: 06/01/15 FLUTICASONE PROPIONATE 110MCG
INHALER, 10/15/15 FLUTICASONE PROPIONATE 110MCG INHALER; 2+ STEROID: 06/01/15
FLUTICASONE PROPIONATE 110MCG INHALER, 10/15/15 FLUTICASONE PROPIONATE 110MCG
INHALER
PATIENT22, MELANIE 000022 COMMUNITY #1 F 47
AC, Severity >1 on PL for 493.00
PATIENT27, RANDALL 000027 COMMUNITY #1 M 6
AC, Severity >1 on PL for 493.00 LABA2+ CONT: 03/03/15 MOMETASONE/FORMOTEROL 100/5MCG
INH, 05/01/15 MOMETASONE/FORMOTEROL 100/5MCG INH; 2+ STEROID: 03/03/15
MOMETASONE/FORMOTEROL 100/5MCG INH, 05/01/15 MOMETASONE/FORMOTEROL 100/5MCG INH
```

Figure 2-128: Sample Patient List, Medication Therapy for Persons with Asthma

# 2.10.9 Chronic Kidney Disease Assessment

#### **Denominators**

Active Clinical patients ages 18 and older with serum creatinine test during the Report Period.

*User Population patients* ages 18 and older with serum creatinine test during the Report Period.

#### **Numerators**

Patients with Estimated GFR.

a. Patients with GFR less than (<) 60.

b. Patients with normal GFR (i.e., greater than or equal to (>=) 60).

# **Logic Description**

Age is calculated at beginning of the Report Period.

For the GFR less than (<) 60 numerator, CRS will include GFR results containing a numeric value less than 60 or with a text value of "less than (<) 60". For the normal GFR (greater than or equal to (>=) 60) numerator, CRS will include GFR results containing a numeric value equal to or greater than 60 or with a text value of "60"

CRS uses the following codes and taxonomies to define the denominator and numerators.

Subject Defined		ICD and Other Codes	LOINC Codes	Taxonomy
Creatinine test	82540, 82565-75		Yes	DM AUDIT CREATININE TAX
Estimated GFR test			Yes	BGP GPRA ESTIMATED GFR TAX

## **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of patients with Creatinine test, with GFR and value, if any.

#### **Measure Source**

None

# Measure Past Performance and Long-Term Targets

```
DIJ
                            November 25, 2015
                                                                    Page 303
       *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Chronic Kidney Disease Assessment (con't)
                   REPORT
                               PREV YR
                                           % CHG from BASE
                                                                 % CHG from
                                                                     BASE %
                    PERIOD
                                PERIOD
                                               PREV YR % PERIOD
Active Clinical Pts
=> 18 with Serum
```

Creatinine test	271	258	221	
w/Est GFR A. # w/ GFR <60 B. # w/Normal GFR	189 69.7 52 19.2	33 12.8 30 11.6	+57.0 16 7.2 +7.6 15 6.8	+62.5 +12.4
(>=60)	137 50.6	2 0.8	+49.8 0 0.0	+50.6
User Pop Pts =>18 with Serum				
Creatinine	331	311	262	
# w/ Est GFR	221 66.8	33 10.6	+56.2 16 6.1	+60.7
A. # w/GFR <60 B. # w/Normal GFR	55 16.6	30 9.6	+7.0 15 5.7	+10.9
(>=60)	165 49.8	2 0.6	+49.2 0 0.0	+49.8

Figure 2-129: Sample Report, Chronic Kidney Disease Assessment

Figure 2-130: Sample Patient List, Chronic Kidney Disease Assessment

# 2.10.10 Proportion of Days Covered by Medication Therapy

#### **Denominators**

Active Clinical patients ages 18 and older who had two or more prescriptions for beta-blockers during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for RAS Antagonists and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for calcium channel blockers (CCB) during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for biguanides during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for sulfonylureas during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for thiazolidinediones during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for DiPeptidyl Peptidase (DPP)-IV Inhibitors during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for Diabetes All Class medications and no documented history of ESRD during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for statins during the Report Period

Active Clinical patients ages 18 and older who had two or more prescriptions for non-warfarin oral anticoagulants during the Report Period.

Active Clinical patients ages 18 and older who had two or more prescriptions for antiretroviral agents during the Report Period.

#### **Numerators**

Patients with proportion of days covered (PDC) greater than or equal to (>=)80% during the Report Period.

Patients with a gap in medication therapy greater than or equal to (>=)30 days.

Patients with proportion of days covered (PDC) greater than or equal to (>=)90% during the Report Period.

## **Logic Description**

Age is calculated at the beginning of the report period.

To be included in the denominator, patients must have at least two prescriptions for that particular type of medication on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK.

For the Non-warfarin anticoagulants measures, the two unique dates of service must be at least 180 days apart and the patient must have received greater than 60 days supply of the medication during the Report Period. Patients who received one or more prescriptions for warfarin, low molecular weight heparin (LMWH) or heparin (defined by medication taxonomy BGP PQA WARFARIN) will be excluded from the denominator.

The Index Prescription Start Date is the date when the medication was first dispensed within the Report Period. For all measures except Non-warfarin anticoagulants, this date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

The medications in the measures are defined with medication taxonomies: BGP PQA BETA BLOCKER MEDS, BGP PQA RASA MEDS, BGP PQA CCB MEDS, BGP PQA BIGUANIDE MEDS, BGP PQA SULFONYLUREA MEDS, BGP PQA THIAZOLIDINEDIONE MEDS, BGP PQA DPP IV MEDS, BGP PQA DIABETES ALL CLASS, BGP PQA STATIN MEDS, BGP PQA NON-WARFARIN ANTICOAG, BGP PQA WARFARIN, BGP PQA ANTIRETROVIRAL MEDS.

ESRD diagnosis/treatment definition: Any of the following ever: (A) CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, or S9339; (B) POV ICD-9: 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.\*; ICD-10: N18.6, Z48.22, Z49.\*, Z91.15, Z94.0, Z99.2; (C) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, or 55.6\*.

#### For each PDC numerator:

Proportion of days covered = # of days the patient was covered by at least one drug in the class / # of days in the patient's measurement period.

#### Measurement Period definition:

The patient's measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

**Note**: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4.

#### **Example of Proportion of Days Covered:**

- Report Period: January 1 through December 31, 2015
- 1st Rx is Index Rx Start Date: 3/1/15, Days Supply=90
- Rx covers patient through 5/29/15
- 2nd Rx: 5/26/15, Days Supply=90
- Rx covers patient through 8/27/15
- 3rd Rx: 9/11/15, Days Supply=180
- Gap = (9/11/15 8/27/15) = 15 days
- Rx covers patient through 3/8/16
- Patient's measurement period: 3/1/15 through 12/31/15 = 306 Days
- Days patient was covered: 3/1/15 through 8/27/15 + 9/11/15 through 12/31/15 = 292 Days
- PDC = 292 / 306 = 95%

#### For each Gap numerator:

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days supply between consecutive medication fills.

#### Example of Medication Gap greater than or equal to (>=) 30 Days:

- Report Period: January 1 through December 31, 2015
- 1st Rx: 4/1/15, Days Supply=30
- Rx covers patient through 4/30/15
- 2nd Rx: 7/1/15, Days Supply=90
- Gap #1 = (7/1/15 4/30/15) = 61 days
- Rx covers patient through 9/28/15
- 3rd Rx: 10/1/15, Days Supply=90

- Gap #2 = (10/1/15 9/28/15) = 2 days
- Rx covers patient through 12/29/15
- Gap #1 greater than or equal to (>=) 30 days, therefore patient will be included in the numerator for that medication.

# **Key Logic Changes from CRS Version 14.1**

- 1. Added HCPCS code G9231 to ESRD definition.
- 2. Updated the following taxonomies: BGP PQA BETA BLOCKER MEDS, BGP PQA RASA MEDS, BGP PQA CCB MEDS, BGP PQA BIGUANIDE MEDS, BGP PQA SULFONYLUREA MEDS, BGP PQA THIAZOLIDINEDIONE MEDS, BGP PQA DPP IV MEDS, BGP PQA DIABETES ALL CLASS, BGP PQA STATIN MEDS, BGP PQA NON-WARFARIN ANTICOAG, BGP PQA WARFARIN, BGP PQA ANTIRETROVIRAL MEDS.

## **Patient List Description**

List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

#### **Measure Source**

PQA (Pharmacy Quality Alliance)

# Measure Past Performance and Long-Term Targets

DU November 25, 2015 Page 314  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Proportion of Days Cov	ered b	y Medi	cation Th	erapy					
<del></del>	EPORT ERIOD	%	PREV YR PERIOD		CHG from BA PREV YR % PE			CHG from BASE %	
Active Clinical Pts w/beta-blockers	53		44			37			
		58.5 50.9			+3.9 -1.3			-1.0 +10.4	
Active Clinical Pts w/ RAS Antagonists	97		80			74			
# w/ PDC >=80%	60	61.9	55	68.8	-6.9	39	52.7	+9.2	

# w/ gap >=30 days	45	46.4	32	40.0	+6.4	42	56.8	-10.4	
Active Clinical Pts w/ CCBs	56		48			55			
# w/ PDC >=80% # w/ gap >=30 days		60.7 53.6		62.5 41.7	-1.8 +11.9		67.3 40.0		
Active Clinical Pts w/ biguanides	30		26			11			
# w/ PDC >=80% # w/ gap >=30 days		40.0 63.3		69.2 38.5	-29.2 +24.9		27.3 72.7	+12.7 -9.4	
Active Clinical Pts w/ sulfonylureas	7		6			7			
# w/ PDC >=80% # w/ gap >=30 days		42.9 71.4		16.7 83.3	+26.2 -11.9		57.1 42.9		
Active Clinical Pts w/ thiazolidinediones	20		15			4			
# w/ PDC >=80% # w/ gap >=30 days	13 8	65.0 40.0	10 7	66.7 46.7	-1.7 -6.7	2 1	50.0 25.0	+15.0 +15.0	
Active Clinical Pts w/ DPP-IV Inhibitors	2		0			0			
# w/PDC >=80% # w/ gap >=30 days		50.0	0	0.0	+50.0 +50.0	0	0.0	+50.0 +50.0	
Active Clinical Pts w/ Diabetes All Class	36		30			13			
# w/ PDC >=80% # w/ gap >=30 days	17 20	47.2 55.6		60.0 46.7	-12.8 +8.9		46.2 53.8	+1.1 +1.7	
Active Clinical Pts w/ statins	60		49			37			
# w/ PDC >=80% # w/ gap >=30 days	43 24	71.7 40.0		67.3 38.8	+4.3 +1.2		67.6 43.2	+4.1 -3.2	
Active Clinical Pts w/ antiretrovial agents		2	0			1			
# w/ PDC >=90%	1	50.0	0	0.0	+50.0	0	0.0	+50.0	

Figure 2-131: Sample Report, Proportion of Days Covered by Medication Therapy

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Proportion of Days Covered by Medication Therapy: List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

```
PATIENT NAME DENOMINATOR NUMERATOR

Patient75, PAULA KAY 000075 COMMUNITY #1 F 34
AC CCB: IXRD: 03/24/15 [282] Days=228 >80 GAP=52
Patient76, CRSCT 000076 COMMUNITY #1 F 36
AC CCB: IXRD: 06/01/15 [213] Days=180 >80 GAP=31
Patient77, CRSAC 000077 COMMUNITY #1 F 44
AC RASA: IXRD: 06/05/15 [209] Days=60 <80 GAP=118
Patient78, DEBORA ELLEN 000078 COMMUNITY #1 F 45
AC BB: IXRD: 07/23/15 [161] Days=126 <80; RASA: IXRD: 01/29/15 [336] Days=267 <80 GAP=31; BIG: IXRD: 01/29/15 [336] Days=272 >80
Patient79, STELLA LYNN 000079 COMMUNITY #1 F 46
AC BB: IXRD: 01/21/15 [344] Days=299 >80 GAP=38; CCB: IXRD: 01/21/15 [344] Days=299 >80 GAP=38; Patient80, TARA MARIE 000080 COMMUNITY #1 F 51
AC BB: IXRD: 08/25/15 [128] Days=56 <80 GAP=70; RASA: IXRD: 01/15/15 [350] Days=314 >80; CCB: IXRD: 01/15/15 [350] Days=218 <80 GAP=103
Patient81, CRSNK 000081 COMMUNITY #1 F 51
AC SULF: IXRD: 09/01/15 [121] Days=120 >80
```

Figure 2-132: Sample Patient List, Proportion of Days Covered by Medication Therapy

# 2.10.11 Primary Medication Non-adherence

#### **Denominator**

Number of e-prescriptions for newly initiated drug therapy for chronic medications for *Active Clinical patients* ages 18 and older.

#### **Numerator**

Number of medications returned to stock within 30 days.

# **Logic Description**

Age is calculated at beginning of the Report Period.

To be included in the denominator, the e-prescription must be for a chronic medication during the Report Period.

#### **Denominator Exclusions**

- 1. Any prescription where there is a prescription dispensing record in the preceding 180 days for the same drug.
- 2. Any duplicate medications, defined as any medication that has been e-prescribed twice in a 30-day period with no prescription fill in between the e-prescriptions.
- 3. Any prescription sent to an outside pharmacy, as it is not possible to know if the medication was returned to stock.

Chronic medications are defined with medication taxonomies: BGP PQA ASTHMA INHALED STEROIDS, BGP PQA COPD, BGP PQA DIABETES ALL CLASS, BGP PQA RASA MEDS, BGP PQA STATIN MEDS.

To be included in the numerator, the e-prescription medication must have a comment of RETURNED TO STOCK within 30 days of the prescription date (i.e., visit date).

# **Key Logic Changes from CRS Version 14.1**

 Updated the following taxonomies: BGP PQA ASTHMA INHALED STEROIDS, BGP PQA COPD, BGP PQA DIABETES ALL CLASS, BGP PQA RASA MEDS, BGP PQA STATIN MEDS.

## **Patient List Description**

List of patients 18 and older with an e-prescription for chronic medications, with returned to stock, if any.

#### **Measure Source**

PQA (Pharmacy Quality Alliance)

## Measure Past Performance and Long-Term Targets

November 25, 2015  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010							
Primary Medication Non-adherence (con't)  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PREV YR % PERIOD BASE %							
<pre># e-prescriptions for AC =&gt; 18</pre>	500		0		0		
# med returned to stock	200	40.0	0	0.0	+40.0 0 0	.0 +40.0	

Figure 2-133: Sample Report, Primary Medication Non-adherence

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

Primary Medication Non-adherence: List of patients 18 and older with an e-prescription for chronic medications, with returned to stock, if any.
```

```
PATTENT NAME
                            COMMUNITY
                                         SEX AGE
DENOMINATOR
                           NUMERATOR
PATIENT1, ANDREA MARY 000001 COMMUNITY #1 F 33
AC 1) 03/25/15 IPRATROPRIUM BR / ALBUTEROL SO4 INH1) 03/25/15 IPRATROPRIUM BR /
ALBUTEROL SO4 INH-RTS
PATIENT2, VIRGINIA A 000002 COMMUNITY #1 F 34
AC 1) 03/25/15 ROSIGLITAZONE 4MG TAB
PATIENT3, MICHAELA 000003 COMMUNITY #1 F 37
AC 1) 03/25/15 CAPTOPRIL 50MG TABS
PATIENT4, DIANE LOUISE 000006 COMMUNITY #1 F 41
AC 1) 04/09/15 IPRATROPRIUM BR / ALBUTEROL SO4 INH; 2) 04/09/15 CAPTOPRIL 50MG
TABS1) 04/09/15 IPRATROPRIUM BR / ALBUTEROL SO4 INH-RTS
PATIENT5, ALYSHA 000008 COMMUNITY #1 F 55
AC 1) 08/14/15 ROSIGLITAZONE 4MG TAB
PATIENT6, SHELLY 000009 COMMUNITY #1 F 62
AC 1) 06/25/15 CAPTOPRIL 50MG TABS
```

Figure 2-134: Sample Patient List, Primary Medication Non-adherence

#### 2.10.12 Medications Education

#### **Denominators**

Active Clinical patients with medications dispensed at their facility during the Report Period.

All *User Population patients* with medications dispensed at their facility during the Report Period.

#### **Numerator**

Patients who were provided patient education about their medications in any location.

## **Logic Description**

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility. The purpose of this definition is to ensure that sites are not being held responsible for educating patients about medications received elsewhere that may be recorded in RPMS. CRS assumes that the appropriate facility is the one the user has logged onto to run the report.

**Note:** If a site's system identifier, i.e., ASUFAC code, has changed during the period between the Baseline start date and the Current Year end date, due to compacting/contracting or other reasons, your report may display zeros (0s) or very low counts for some time periods.

CRS uses the following patient education codes to define the numerator:

Medication Education	Any Patient Education code containing "M-" or "-M" (medication)
	or
	DMC-IN (Diabetes Medicine-Insulin)
	FP-DPO (Family Planning–Depot Medroxyprogesterone Injections
	FP-OC (Family Planning–Oral Contraceptives)
	FP-TD (Family Planning–Transdermal (Patch))
	*-NEB (*Nebulizer)
	*-MDI (*Metered Dose Inhalers)

# **Key Logic Changes from CRS Version 14.1**

None

# **Patient List Description**

List of patients receiving medications with medication education, if any.

# **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

Measure	Target
IHS 2020 Goal	75.0%

DU November 25, 2015 Page 316  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
Medications Education	n (con't	.)						
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %			CHG from BASE %
Active Clinical Pts medications	receivin 757	.g	631			592		
# receiving medication educ	490	64.7	268	42.5	+22.3	81	13.7	+51.0
User Pop Pts receivi medications	ng 981		800			753		
<pre># receiving medication educ</pre>	599	61.1	306	38.3	+22.8	87	11.6	+49.5

Figure 2-135: Sample Report, Medications Education

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Medications Education: List of patients receiving medications with med education or refusal, if any PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR -----\_\_\_\_\_\_ PATIENT1, ANDREA MARY 000001 COMMUNITY #1 F 0 UP,AC UP,AC
PATIENT2,VIRGINIA A

UP

08/06/15 HTN-M
PATIENT3,MICHAELA

UP

03/10/15 M-I
PATIENT4,MISTY

UP,AC
PATIENT5,RITA ANN

UP,AC

05/16/15 M-DI
PATIENT5,RITA ANN

UP,AC

07/05/15 M-I
PATIENT6,DIANE LOUISE

08/21/15 M-I
PATIENT7,ALICIA

000007 COMMUNITY #1 F 15
UP,AC PATIENT8, ALYSHA 000008 COMMUNITY #1 F 16 UP,AC UP,AC
PATIENT9,SHELLY 000009 COMMUNITY #1 F 18 03/12/15 PP-M UP,AC

Figure 2-136: Sample Patient List, Medications Education

# 2.10.13 Medication Therapy Management Services

#### **Denominators**

Active Clinical patients equal to or greater than (=>)18 with medications dispensed at their facility during the Report Period.

#### **Numerator**

Patients who received medication therapy management (MTM) during the Report Period.

## **Logic Description**

Age is calculated at the beginning of the report period.

Patients receiving medications at their facility are identified by any entry in the VMed file for your facility.

*Medication Therapy Management (MTM) definition*: 1) CPT 99605 through 99607 or 2) Clinic codes: D1, D2, D5.

# **Key Logic Changes from CRS Version 14.1**

None.

## **Patient List Description**

List of patients greater than or equal to (>=) 18 receiving medications with medication therapy management, if any.

#### **Measure Source**

None

# Measure Past Performance and Long-Term Targets

```
November 25, 2015
DU
                                                                      Page 316
       *** IHS 2015 Selected Measures with Community Specified Report ***
                             DEMO INDIAN HOSPITAL
                  Report Period: Jan 01, 2015 to Dec 31, 2015
              Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Medications Therapy Management Services (con't)
                     REPORT % PREV YR % CHG from BASE PERIOD PREV YR % PERIOD
                                                 PREV YR % PERIOD
                                                                     % CHG from
                     PERIOD
                                   PERIOD
                                                                        BASE %
Active Clinical Pts
=>18 receiving
                        594
                                       472
                                                              424
medications
                              0.8
                                                     +0.8
                                                               0.0
# w/MTM
                          5
                                           0.0
                                                                            +0.8
```

Figure 2-137: Sample Report, Medications Therapy Management Services

```
UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic
PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease;
HR=High Risk Patient
Medications Education: List of patients receiving medications with med
education or refusal, if any (con't)
PATIENT NAME
                             COMMUNITY
                                          SEX AGE
DENOMINATOR
                           NUMERATOR
PATIENT5, RITA ANN 000005 COMMUNITY #1 F 18
                            06/01/15 CPT 99607
PATIENT6, DIANE LOUISE 000006 COMMUNITY #1 F
                            07/28/15 CPT 99606
                      000007 COMMUNITY #1 F 21
PATIENT7, ALICIA
PATIENT8, ALYSHA
                       000008 COMMUNITY #1
                            04/01/15 Cl D1
```

I	PATIENT9, SHELLY	000009 COMMUNITY #1	F	52
Z	AC	07/01/15 Cl D2		

Figure 2-138: Sample Patient List, Medications Therapy Management Services

# 2.10.14 Self Management (Confidence)

#### **Denominators**

Active Clinical patients assessed for confidence in managing their health problems during the Report Period.

#### **Numerator**

Patients who are very confident in managing their health problems during the Report Period.

# **Logic Description**

Confidence in managing health problems definition: Any health factor for category CONFIDENCE IN MANAGING HEALTH PROBLEMS.

Very confident definition: The most recent health factor in the CONFIDENCE IN MANAGING HEALTH PROBLEMS category of VERY SURE.

# **Key Logic Changes from CRS Version 14.1**

None

#### **Patient List Description**

List of patients who are confident in managing their health problems.

#### **Measure Source**

None

# Measure Past Performance and Long-Term Targets

Measure	Target
IHS 2020 Goal	75.0%

	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %	
Active Clinical Pts for confidence	assessed 8		1			0			
# very confident	4	50.0	0	0.0	+50.0	0	0.0	+50.0	

Figure 2-139: Sample Report, Medications Education

Figure 2-140: Sample Patient List, Medications Education

# 2.10.15 Public Health Nursing

#### **Patient-Related Measures**

#### **Denominator**

All *User Population patients*.

#### **Numerators**

For User Population only, the number of patients in the denominator served by Public Health Nurses (PHNs) in any setting, including Home.

For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in any setting.

For User Population only, the number of patients in the denominator served by PHNs in a HOME setting.

For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in a HOME Setting.

#### **Visit-Related Measures**

#### **Denominators**

Number of visits to User Population patients by PHNs in any setting, including Home

- Number of visits to patients ages 0 to 28 days (Neonate) in any setting.
- Number of visits to patients ages 29 days to 12 months (infants) in any setting.
- Number of visits to patients ages 1 through 64 years in any setting
- Number of visits to patients ages 65 and older (Elders) in any setting
- Number of PHN driver/interpreter (Provider Code 91) visits

Number of visits to User Population patients by PHNs in Home setting

- Number of Home visits to patients age 0 to 28 days (Neonate)
- Number of Home visits to patients age 29 days to 12 months (Infants)
- Number of Home visits to patients ages 1 through 64 years
- Number of Home visits to patients aged 65 and over (Elders).
- Number of PHN driver/interpreter (Provider Code 91) visits in a HOME setting.

#### **Numerator**

No numerator: count of visits only

# **Logic Description**

PHN visit is defined as any visit with primary or Secondary Provider Code 13 or 91. Home visit defined as: (1) Clinic 11 and a primary or Secondary Provider Code 13 or 91 or (2) Location Home (as defined in Site Parameters) and a primary or Secondary Provider Code 13 or 91.

## **Key Logic Changes from CRS Version 14.1**

None

## **Patient List Description**

List of patients with PHN visits documented.

Numerator codes in patient list: All PHN = Number of PHN visits in any setting; Home = Number of PHN visits in home setting; Driver All = Number of PHN driver/interpreter visits in any setting; Driver Home = Number of PHN driver/interpreter visits in home setting.

#### **Measure Source**

# **Measure Past Performance and Long-Term Targets**

Performance	All PHN visits	PHN Home Visits
IHS FY 2005 Performance	438,376	Not Reported
IHS FY 2004 Performance	423,379	192,121
IHS FY 2003 Performance	359,089	160,650
IHS FY 2002 Performance	343,874	156,263

DU November 25, 2015 Page 317  *** IHS 2015 Selected Measures with Community Specified Report ***											
DEMO INDIAN HOSPITAL Report Period: Jan 01, 2015 to Dec 31, 2015 Previous Year Period: Jan 01, 2014 to Dec 31, 2014 Baseline Period: Jan 01, 2010 to Dec 31, 2010											
Public Health Nursing (con't)											
	REPORT PERIOD	%	PREV YR PERIOD	%	CHG from PREV YR %	BASE PERIOD	%	CHG from BASE %			
All User Population patients	2,896		2,456			2,346					
<pre># served by PHNs in any Setting # served by PHN driv</pre>		0.4	13	0.5	-0.1	13	0.6	-0.1			
interpreter - in any Setting	0	0.0	0	0.0	+0.0	0	0.0	+0.0			
# served by PHNs in a Home Setting # served by PHN	1	0.0	1	0.0	+0.0	0	0.0	+0.0			
drivers/interpreter in Home Setting		0.0	0	0.0	+0.0	0	0.0	+0.0			
Total # PHN Visits - Any Setting	18		16		+2	19		-1			
A. Ages 0-28 days	0		0		+0	0		+0			
B. Ages 29 days - 12 months	1		3		-2	0		+1			
C. Ages 1-64 years	16		13		+3	19		-3			
D. Ages 65+	1		0		+1	0		+1			
E. Driver/Interprete visits - any setting	or 0		0		+0	0		+0			
Total # PHN Visits - Home Setting	3		1		+2	0		+3			

A. Ages 0-28 days	0	0	+0	0	+0
B. Ages 29 days- 12 months	0	1	-1	0	+0
C. Ages 1-64 years	3	0	+3	0	+3
D. Ages 65+	0	0	+0	0	+0
E. Driver/interpreter visits - Home Setting	0	0	+0	0	+0

Figure 2-141: Sample Report, Public Health Nursing

Figure 2-142: Sample Patient List, Public Health Nursing

# 2.10.16 Breastfeeding Rates

#### **GPRA Measure Description**

During FY 2015, achieve the target rate of 29.0% for the proportion of 2-month olds who are mostly or exclusively breastfeeding.

#### **Denominators**

Active Clinical patients who are 30 to 394 days old

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 2 months (45 to 89 days) (GPRA Denominator)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 6 months (165 to 209 days)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 9 months (255 to 299 days)

Active Clinical patients who are 30 to 394 days old who were screened for infant feeding choice at the age of 1 year (350 to 394 days)

#### **Numerators**

Patients who were screened for infant feeding choice at least once

Patients who were screened for infant feeding choice at the age of 2 months (45 to 89 days)

Patients who were screened for infant feeding choice at the age of 6 months (165 to 209 days)

Patients who were screened for infant feeding choice at the age of 9 months (255 to 299 days)

Patients who were screened for infant feeding choice at the age of 1 year (350 to 394 days)

Patients who, at the age of 2 months (45 to 89 days), were either exclusively or mostly breastfed (GPRA Numerator)

Patients who, at the age of 6 months (165 to 209 days), were either exclusively or mostly breastfed

Patients who, at the age of 9 months (255–299 days), were either exclusively or mostly breastfed

Patients who, at the age of 1 year (350 to 394 days), were either exclusively or mostly breastfed

#### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period. Therefore, this measure may include patients up to 25 months old if they were within the eligible age range on the first day of the report period, and will not include any patients that were born after the first day of the report period. Patients born after the first day of the report period will be included in the following report period.

Infant feeding choice definition: The documented feeding choice from the file V Infant Feeding Choice that is closest to the exact age that is being assessed will be used. For example, if a patient was assessed at 45 days old as half breastfed and half formula and assessed again at 65 days old as mostly breastfed, the mostly breastfed value will be used since it is closer to the exact age of 2 months (i.e., 60 days). Another example is a patient who was assessed at 67 days as mostly breastfed and again at 80 days as mostly formula. In this case, the 67 days value of mostly breastfed will be used. The other exact ages are 180 days for 6 months, 270 days for 9 months, and 365 days for 1 year.

In order to be included in the age-specific screening numerators, the patient must have been screened at the specific age range. For example, if a patient was screened at 6 months and was exclusively breastfeeding but was not screened at 2 months, then the patient will only be counted in the 6 months numerator.

# Key Logic Changes from CRS Version 14.1

None

## **Patient List Description**

List of patients 30 to 394 days old, with infant feeding choice value, if any.

Note: "DO" represents "Days Old."

#### Measure Source

HP 2020, MICH-21.4 Exclusive breastfeeding-through 3 months, MICH-21.5 Exclusive breastfeeding-through 6 months.

# **Measure Past Performance and Long-Term Targets**

Performance	Percent
IHS FY 2014 Performance	35.1%
IHS FY 2013 Performance	29.0%
IHS FY 2012 Performance	30.3%
IHS FY 2011 Performance	26.7%
IHS FY 2010 Performance	33%
IHS FY 2008 Performance	28%
HP 2020 goal for breastfeeding through 3 months of age	44.3%
HP 2020 goal for breastfeeding through 6 months of age	23.7%

DU November 25, 2015 Page 321

\*\*\* IHS 2015 Selected Measures with Community Specified Report \*\*\*

DEMO INDIAN HOSPITAL

Report Period: Jan 01, 2015 to Dec 31, 2015

					4 to Dec 31,			
Breastfeeding Rates								
	REPORT PERIOD				CHG from PREV YR %			
Active Clinical Pts 30-394 days	46		30			34		
<pre># w/infant feeding   choice screening # w/screening @</pre>	11	23.9	0	0.0	+23.9	1	2.9	+21.0
2 mos	4	8.7	0	0.0	+8.7	1	2.9	+5.8
<pre># w/screening @ 6 mos</pre>	3	6.5	0	0.0	+6.5	0	0.0	+6.5
<pre># w/screening @     9 mos</pre>	4	8.7	0	0.0	+8.7	0	0.0	+8.7
# w/screening @ 1 yr	3	6.5	0	0.0	+6.5	0	0.0	+6.5
AC Pts 30-394 days screened @ 2 mos (GPRA)	4		0			1		
# @ 2 mos exclusive/ mostly breastfed (GPRA)	4	100.0	0	0.0	+100.0	1	100.0	+0.0
AC Pts 30-394 days screened @ 6 mos	3		0			0		
# @ 6 mos exclusive/mostly breastfed	2	66.7	0	0.0	+66.7	0	0.0	+66.7
AC Pts 30-394 days screened at 9 mos	4		0			0		
# @ 9 mos exclusive/mostly breastfed	3	75.0	0	0.0	+75.0	0	0.0	+75.0
AC Pts 30-394 days screened @ 1 yr	3		0			0		
# @ 1 year exclusive/mostly breastfed	2	66.7	0	0.0	+66.7	0	0.0	+66.7

Figure 2-143: Sample Report, Breastfeeding Rates

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

```
Breastfeeding Rates: List of patients 30-394 days old, with infant feeding choice value, if any.

PATIENT NAME HRN COMMUNITY SEX AGE
DENOMINATOR NUMERATOR

PATIENT1, AMANDA DEBRA 000001 COMMUNITY #1 F 0

AC Scrn: 33 DO, 02/09/15 MOSTLY BREASTFEEDING
PATIENT2, LEROY JAMES 000002 COMMUNITY #1 M 1

AC Scrn: 2 MOS: 48 DO, 01/20/15 EXCLUSIVE BREASTFEEDING;
6 MOS: 178 DO, 05/30/15 EXCLUSIVE BREASTFEEDING; 9 MOS: 276 DO, 09/05/15 EXCLUSIVE BREASTFEEDING;
BREASTFEEDING; 1 YR: 382 DO, 12/20/15 MOSTLY BREASTFEEDING
PATIENT3, TERRY SCOTT 000003 COMMUNITY #1 M 0

AC Scrn: 6 MOS: 187 DO, 08/11/15 EXCLUSIVE BREASTFEEDING
PATIENT11, STEVEN CODY 000011 COMMUNITY #2 M 0

Scrn: 2 MOS: 60 DO, 11/03/15 MOSTLY BREASTFEEDING
```

Figure 2-144: Sample Patient List, Breastfeeding Rates

# 2.10.17 Use of High-Risk Medications in the Elderly

#### **Denominators**

Active Clinical patients ages 65 and older. Broken down by gender and age groups (65 through 74, 75 through 84, greater than (>) 85).

User Population patients ages 65 and older. Broken down by gender.

#### **Numerators**

Patients who received at least one high-risk medication for the elderly during the Report Period.

Patients who received at least two different high-risk medications for the elderly during the Report Period.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

**Note:** The logic below is a deviation from the logic written by PQA, as PQA requires at least two prescriptions fills for the same high-risk medication during the Report Period, while the logic below only requires one prescription fill.

For nitrofurantoin, a patient must have received a cumulative days supply for any nitrofurantoin product greater than 90 days during the Report Period.

For nonbenzodiazepine hypnotics, a patient must have received a cumulative days supply for any nonbenzodiazepine hypnotic products greater than 90 days during the Report Period.

*Medication definitions*: High-risk medications for the elderly defined with medication taxonomies:

- BGP HEDIS ANTICHOLINERGIC MEDS: First-generation antihistamines (Includes combination drugs) (Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine, Dexbrompheniramine, Dexchlorpheniramine, Diphenhydramine (oral), Doxylamine, Hydroxyzine, Promethazine, Triprolidine); Antiparkinson agents (Benztropine (oral), Trihexyphenidyl)
- BGP HEDIS ANTITHROMBOTIC MEDS: (Ticlopidine, Dipyridamole, oral short-acting)
- BGP HEDIS ANTI-INFECTIVE MEDS: (Nitrofurantoin)
- BGP HEDIS CARDIOVASCULAR MEDS: Alpha blockers, central (Guanfacine, Methyldopa, Reserpine); Cardiovascular, other (Disopyramide, Digoxin, Nifedipine, immediate release)
- BGP HEDIS CENTRAL NERVOUS MEDS: Tertiary TCAs (Includes combination drugs) (Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine); Antipsychotics, first-generation (conventional) (ThioridazineBarbiturates (Amobarbital, Butabarbital, Butalbital, Pentobarbital, Phenobarbital, Secobarbital); Central Nervous System, other (Chloral hydrate, Meprobamate); Nonbenzodiazepine hypnotics (Eszopiclone, Zolpidem, Zaleplon); Vasodilators (Ergoloid mesylates, Isoxsuprine)
- BGP HEDIS ENDOCRINE MEDS: Endocrine (Desiccated thyroid, Estrogens with or without progesterone (oral and topical patch products only), Megestrol); Sulfonylureas, long-duration (Chlorpropamide, Glyburide)
- BGP HEDIS GASTROINTESTINAL MEDS: (Trimethobenzamide)
- BGP HEDIS PAIN MEDS: Other (Meperidine, Pentazocine); Non-COX-selective NSAIDs (Indomethacin, Ketorolac)
- BGP HEDIS SKL MUSCLE RELAX MED (Includes combination drugs) (Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

Note: For each medication, the days supply must be greater than (>) 0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

# **Key Logic Changes from CRS Version 14.1**

1. Updated the following taxonomies: BGP HEDIS NONBENZODIAZ MEDS, BGP HEDIS ANTICHOLINERGIC MEDS, BGP HEDIS ANTITHROMBOTIC MEDS, BGP HEDIS ANTI-INFECTIVE MEDS, BGP HEDIS CARDIOVASCULAR MEDS, BGP HEDIS CENTRAL NERVOUS MEDS, BGP HEDIS ENDOCRINE MEDS, BGP HEDIS GASTROINTESTINAL MED, BGP HEDIS PAIN MEDS, BGP HEDIS SKL MUSCLE RELAX MED.

## **Patient List Description**

List of patients 65 and older with at least one high-risk medication.

#### **Measure Source**

**HEDIS** 

# **Measure Past Performance and Long-Term Targets**

DU November 25, 2015 Page 324  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010								
REI	Use of High-Risk Medications in the Elderly  REPORT % PREV YR % CHG from BASE % CHG from PERIOD PERIOD PREV YR % PERIOD BASE %							
Active Clinical Pts =>65	122	71	65					
<pre># w/exposure to at   least 1 high-risk med # w/exposure to   multiple high-risk   meds</pre>	48 39.3 17 13.9	15 21.1 5 7.0						

Male Active Clinical =>65	56		33			27		
<pre># w/exposure to at   least 1 high-risk med # w/exposure to</pre>	3	4 60.7		6 18.2	+42.5	1	1 40.7	+20.0
multiple high-risk meds	9	16.1	3	9.1	+7.0	3	11.1	+5.0
Female Active Clinical =>65	66		38			38		
<pre># w/exposure to at   least 1 high-risk   med # w/exposure to</pre>	14	21.2	9	23.7	-2.5	14	36.8	-15.6
multiple high-risk meds	8	12.1	2	5.3	+6.9	6	15.8	-3.7
User Pop Pts =>65	225		164			144		
<pre># w/exposure to at   least 1 high-risk   med # w/exposure to   multiple high-risk</pre>	49	21.8	16	9.8	+12.0	26	18.1	+3.7
meds	17	7.6	5	3.0	+4.5	9	6.3	+1.3
Male User Pop =>65	99		68			54		
<pre># w/exposure to at   least 1 high-risk   med # w/exposure to</pre>	35	35.4	6	8.8	+26.5	11	20.4	+15.0
multiple high-risk meds	9	9.1	3	4.4	+4.7	3	5.6	+3.5

Figure 2-145: Sample Report, Use of High-Risk Medications in the Elderly

*** IHS 2015 Selected Mea	MO INDIAN F Jan 01, 20 od: Jan 01	Community Spe HOSPITAL 015 to Dec 31 1, 2014 to Dec	, 2015 c 31, 2014	Page 326 : ***			
Use of High-Risk Medications in	the Elderly	(con't)					
ACTIVE CLINICAL PATIENTS 65+  Age Distribution  65-74 75-84 85+							
CURRENT REPORT PERIOD AC Patients 65+	70	36	10				

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures November 2014

W/				
<pre># w/exposure to at least     1 high-risk med</pre>	15	6	2	
<pre>% w/exposure to at least 1 high-risk med</pre>	21.4	16.7	20.0	
I IIIgii-IIsk med	21.4	10.7	20.0	
<pre># w/exposure to multiple high-risk meds</pre>	8	2	1	
% w/exposure to multiple	Ü	_	_	
high-risk meds	11.4	5.6	10.0	
PREVIOUS YEAR PERIOD				
AC Patients 65+	39	19	6	
# w/exposure to at least	_			
<pre>1 high risk med % w/exposure to at least</pre>	7	4	1	
1 high-risk med	17.9	21.1	16.7	
# w/exposure to multiple				
high-risk meds % w/exposure to multiple	1	0	0	
high-risk meds	2.6	0.0	0.0	
CHANGE FROM PREV YR %				
w/exposure to at least				
1 high risk med w/exposure to multiple	+3.5	-4.4	+3.3	
high-risk meds	+8.9	+5.6	+10.0	

Figure 2-146: Sample Report, Use of High-Risk Medications in the Elderly

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Use of High Risk Medications in the Elderly: List of patients 65 and older with at least one high-risk medication. PATIENT NAME HRN COMMUNITY
DENOMINATOR NUMERATOR SEX AGE PATIENT1, JONELLE 000001 COMMUNITY #1 F 69 UP,AC 2 drugs: 08/04/14 ESTERIFIED ESTROGENS 0.625MG TAB (ORAL ESTROGEN); 08/04/14 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) PATIENT2, PAULINE 000002 COMMUNITY #1 F 70 UP,AC 1 drug:11/02/14 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) PATIENT3, NADINE 000003 COMMUNITY #1 F 82 UP,AC 2 drugs: 09/25/14 DIAZEPAM 5MG TAB (BENZODIAZEPINE); 09/25/14 PROPOXYPHENE-N 100MG/APAP 650MG TAB (NARCOTIC) PATIENT4, JESSE NATHAN 000004 COMMUNITY #1 M 77 UP,AC 1 drug:08/27/14 CYCLOBENZAPRINE HCL 10MG TAB (SKL MUSCLE)

Figure 2-147: Sample Patient List, Use of High-Risk Medications in the Elderly

# 2.10.18 Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

#### **Denominators**

Active Clinical patients ages 65 and older.

User Population patients ages 65 and older.

#### **Numerators**

Patients who received at least two prescription fills for any benzodiazepine sedative hypnotic medications for more than 90 days.

## **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

The patient must have received a cumulative days supply for any benzodiazepine sedative hypnotic products greater than 90 days during the Report Period.

*Medication definitions*: Benzodiazepine sedative hypnotic medications defined with medication taxonomy BGP PQA BENZODIAZ MEDS (Estazolam, Flurazepam, Quazepam, Temazepam, Triazolam).

Note: For each medication, the days supply must be greater than (>) 0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2015, Discontinued Date=11/19/2015, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.

# **Key Logic Changes from CRS Version 14.1**

1. New topic.

#### **Patient List Description**

List of patients 65 and older with two or more prescriptions for benzodiazepine sedative hypnotic medications.

#### **Measure Source**

**PQA** 

# **Measure Past Performance and Long-Term Targets**

None

```
DU
                            November 25, 2015
                                                                   Page 324
      *** IHS 2015 Selected Measures with Community Specified Report ***
                            DEMO INDIAN HOSPITAL
                 Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
                Baseline Period: Jan 01, 2010 to Dec 31, 2010
Use of High-Risk Medications in the Elderly
                   REPORT
                                PREV YR
                                           % CHG from BASE
                                                                 % CHG from
                    PERIOD
                                PERIOD
                                              PREV YR % PERIOD
                                                                     BASE %
Active Clinical Pts
                       124
                                     118
                                                            109
=>65
# w/ 2+ benzodiazepine
sedative hypnotic
                       10 8.0
                                       0 0.0 +8.0
meds
                                                                 0.0
                                                                         +8.0
User Pop Pts
                       146
                                     139
                                                            129
=>65
# w/ 2+ benzodiazepine
sedative hypnotic
                        15 10.2
                                       0
                                         0.0
                                                  +10.2
                                                              0
                                                                 0.0
                                                                         +10.2
```

Figure 2-148: Sample Report, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Use of High Risk Medications in the Elderly: List of patients 65 and older with at least one high-risk medication. PATIENT NAME HRN COMMUNITY SEX AGE NUMERATOR DENOMINATOR 000001 COMMUNITY #1 F 69 PATIENT1, JONELLE UP,AC PATIENT2, PAULINE 000002 COMMUNITY #1 F 70 UP,AC 02/02/13 TEMAZEPAM 15MG CAP (60); 06/02/13 TEMAZEPAM PATIENT3, NADINE 000003 COMMUNITY #1 F 82 UP,AC PATIENT4, JESSE NATHAN 000004 COMMUNITY #1 M 77

Figure 2-149: Sample Patient List, Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly

#### 2.10.19 Functional Status Assessment in Elders

#### Denominator

Active Clinical patients ages 55 and older. Broken down by gender.

#### **Numerator**

Patients screened for functional status at any time during the Report Period.

# **Logic Description**

Age is calculated at the beginning of the Report Period.

Functional status screening definition: Any non-null values in V Elder Care for (1) at least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence and (2) at least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the Report Period.

# **Key Logic Changes from CRS Version 14.1**

None

# **Patient List Description**

List of patients equal to or greater than (=>) 55 with functional status codes, if any. The following are the abbreviations used in the Numerator column:

- TLT–Toileting
- BATH–Bathing
- DRES–Dressing
- XFER-Transfers
- FEED–Feeding
- CONT-Continence
- FIN-Finances
- COOK–Cooking
- SHOP–Shopping
- HSWK–Housework/Chores
- MEDS–Medications
- TRNS–Transportation

#### **Measure Source**

# **Measure Past Performance and Long-Term Targets**

None

DU November 25, 2015 Page 328  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Functional Status Asse	ssment	in El	ders						
					CHG from PREV YR %			CHG from BASE %	
Active Clinical Pts =>55	271		162			127			
# w/functional status screening	2	0.7	0	0.0	+0.7	0	0.0	+0.7	
Male Active Clinical =>55	135		77			60			
# w/functional status screening	1	0.7	0	0.0	+0.7	0	0.0	+0.7	
Female Active Clinical =>55	136		85			67			
# w/functional status screening	1	0.7	0	0.0	+0.7	0	0.0	+0.7	

Figure 2-150: Sample Report, Functional Status Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Functional Status Assessment in Elders: List of patients => 55 with functional status codes, if any. HRN COMMUNITY SEX AGE PATIENT NAME NUMERATOR DENOMINATOR PATIENT1, GLENDA JOYCE 000001 COMMUNITY #1 F 57 PATIENT2, NADINE 000002 COMMUNITY #1 F 61 PATIENT3, CHARLOTTE MAE 000003 COMMUNITY #1 F 64 YES: 02/24/15 BATH, CONT, COOK, DRES, FEED, FIN, HSWK, MEDS, SHOP, TLT, TRNS, XFER PATIENT4, KATHERINE ANN 000004 COMMUNITY #1 F 66 YES: 07/11/15 BATH, FIN PATIENT5, ANNA MARIE 000005 COMMUNITY #1 F 66

PATIENT6, DIANA AC	000006 COMMUNITY #1 F
PATIENT7, PEGGY ANN	000007 COMMUNITY #1 F
AC	NO: 05/20/15 FIN

Figure 2-151: Sample Patient List, Functional Status Assessment in Elders

#### 2.10.20 Fall Risk Assessment in Elders

#### **Denominators**

Active Clinical patients ages 65 and older. Broken down by gender.

User Population patients ages 65 and older. Broken down by gender.

#### **Numerators**

Patients who have been screened for fall risk or with a fall-related diagnosis in the past year.

**Note**: This numerator does *not* include refusals.

- a. Patients who have been screened for fall risk in the past year
- b. Patients with a documented history of falling in the past year
- c. Patients with a fall-related injury diagnosis in the past year
- d. Patients with abnormality of gait/balance or mobility diagnosis in the past year

Patients with a documented refusal of fall risk screening exam in the past year

#### **Logic Description**

Age of the patient is calculated at the beginning of the Report Period.

Fall risk screening/fall related diagnosis is defined as any of the codes in the table below.

Subject Defined	ICD and Other Codes	Exam Code	E Codes (Injury)
Fall Risk Exam	<b>CPT</b> : 1100F, 1101F, 3288F	Exam: 37 (Fall Risk)	
History of Falling	POV: ICD-9: V15.88 (Personal History of Fall); ICD-10: Z91.81		

Subject Defined	ICD and Other Codes	Exam Code	E Codes (Injury)
Fall-related Injury			POV (Cause Codes #1-3): ICD-9: E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.*; ICD-10: (All codes ending in A or D only) W01.*, W06.*-W08.*, W10.*, W18.*, W19.*
Abnormality of Gait/Balance or Mobility	POV: ICD-9: 781.2, 781.3, 719.7, 719.70 (old code), 719.75–719.77 (old codes), 438.84, 333.99, 443.9; ICD-10: G25.7*, G25.89, G25.9, G26, I69.*93, I73.9, R26.*, R27.*		
Refusal		Exam: 37 (Fall Risk)	

# **Key Logic Changes from CRS Version 14.1**

None.

# **Patient List Description**

List of patients 65 years or older with fall risk assessment, if any.

#### **Measure Source**

HP 2010 15–28 Reduce hip fractures among older adults.

# **Measure Past Performance and Long-Term Targets**

DU November 25, 2015 Page 331  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Fall Risk Assessment in	Elde	rs (con'	t)						
Active Clinical Pts 65+	116		64			65			
<pre># w/ fall risk screen/ Dx-No Refusals A. # w/ fall risk</pre>	14	12.1	8	12.5	-0.4	8	12.3	-0.2	
screen	5	4.3	0	0.0	+4.3	0	0.0	+4.3	
B. # w/ history of fall C. # w/ fall injury D. # w/ abnormal		0.9		0.0	+0.9 +0.2		0.0 4.6		

			_						
gait	6	5.2	· ·	10.9	-5.8	5		-2.5	
# w/ refusal	3	2.6	0	0.0	+2.6	0	0.0	+2.6	
Male Active Clinical									
Male Active Clinical	53		28			27			
05+	53		28			21			
# w/ fall risk screen/									
Dx-No Refusals	6	11.3	3	10.7	+0.6	2	7.4	+3.9	
A. # w/ fall risk	O	11.5	3	10.7	10.0	2	/ • 1	13.5	
screen	2	3.8	0	0.0	+3.8	0	0.0	+3.8	
B. # w/ history	2	3.0	Ü	0.0	13.0	Ü	0.0	13.0	
of fall	1	1.9	0	0.0	+1.9	0	0.0	+1.9	
C. # w/ fall injury	0	0.0	0	0.0	+0.0	1	3.7	-3.7	
D. # w/ abnormal	ŭ	•••	· ·	•••		_	J • /	J.,	
gait	3	5.7	3	10.7	-5.1	1	3.7	+2.0	
# w/ refusal	1	1.9	0	0.0	+1.9	0	0.0	+1.9	
Female Active Clinical									
65+	63		36			38			
# w/ fall risk screen/									
Dx-No Refusals	8	12.7	5	13.9	-1.2	6	15.8	-3.1	
A. # w/ fall risk									
screen	3	4.8	0	0.0	+4.8	0	0.0	+4.8	
B. # w/ history									
of fall	0	0.0	0	0.0	+0.0	0	0.0	+0.0	
C. # w/ fall injury	2	3.2	1	2.8	+0.4	2	5.3	-2.1	
D. # w/ abnormal									
gait	3	4.8	4	11.1	-6.3	4	10.5	-5.8	
# w/ refusal	2	3.2	0	0.0	+3.2	0	0.0	+3.2	
# w/ refusal	2	3.2	0	0.0	+3.2	0	0.0	+3.2	

Figure 2-152: Sample Report, Fall Risk Assessment in Elders

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Fall Risk Assessment in Elders: List of patients 65 years or older with fall risk assessment, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR PATIENT1, SHERRY 000001 COMMUNITY #1 F 68 UP,AC PATIENT2, LORETTA LYNN 000002 COMMUNITY #1 F 78 UP,AC Refused 03/03/ PATIENT17,NICOLE 000017 COMMUNITY #2 Refused 03/03/15 Ex 37 F 71 UP,AC Abnormal Gait: PATIENT18,VERONICA 000018 COMMUNITY #2 Abnormal Gait: 11/24/15 POV 443.9 F 72 Screen: 03/03/15 CPT 1100F UP Screen: 03/03/15 CPT 1 PATIENT19,STEPHANIE 000019 COMMUNITY #2 F 76 Fall Injury: 11/10/15 E-CODE E883.9 UP,AC

Figure 2-153: Sample Patient List, Fall Risk Assessment in Elders

#### 2.10.21 Palliative Care

#### **Denominators**

No denominator; count only.

#### **Numerators**

No denominator; count only. The total number of *Active Clinical patients* with at least one palliative care visit during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

No denominator; count only. The total number of palliative care visits for *Active Clinical patients* during the Report Period. Broken down by age groups (less than (<) 18, 18 through 54, greater than (>) 55).

## **Logic Description**

Age is calculated at the beginning of the Report Period.

Palliative care visit definition: POV ICD-9: V66.7; ICD-10: Z51.5.

## **Patient List Description**

List of patients with a palliative care visit.

# **Key Logic Changes from CRS Version 14.1**

None.

#### **Measure Source**

None

# Measure Past Performance and Long-Term Targets

```
DU
                                                                   Page 334
                            November 25, 2015
      *** IHS 2015 Selected Measures with Community Specified Report ***
                           DEMO INDIAN HOSPITAL
                Report Period: Jan 01, 2015 to Dec 31, 2015
             Previous Year Period: Jan 01, 2014 to Dec 31, 2014
               Baseline Period: Jan 01, 2010 to Dec 31, 2010
Palliative Care
                   REPORT
                               PREV YR
                                              CHG from BASE
                                                                    CHG from
                    PERIOD
                                PERIOD
                                             PREV YR PERIOD
                                                                    BASE
Total # of Patients
```

w/At Least 1 Palliative Care Visit	40	0	+40	0	+40
A. Total # of Patients <18 w/At Least 1 Pallia Care Visit	tive 1	0	+1	0	+1
B. Total # of Patients 1 w/At Least 1 Palliative Care Visit		0	+25	0	+25
C. Total # of Patients 5 w/At Least 1 Palliative Care Visit		0	+14	0	+14
Total # of Palliative Care Visits	62	0	+62	0	+62
A. Total # of Palliative Care Visits-Pts <18	2	0	+2	0	+2
B. Total # of Palliative Care Visits-Pts 18-54	38	0	+38	0	+38
C. Total # of Palliative Care Visits-Pts 55+	22	0	+22	0	+22
Active Clinical Pts 18+ w/ 2+ types of cancer	28	3		3	
# w/ 2+ Palliative Care Visits	14 50.0	0 0.0	+50.0	0 0.0	+50.0

Figure 2-154: Sample Report, Palliative Care

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Palliative Care: List of patients with a palliative care visit, if any. HRN DENOMINATOR PATIENT NAME COMMUNITY SEX AGE NUMERATOR PATIENT1, JOHN 000012 Community #1 M 57 AC 1 visit: 05/01/15
PATIENT2, ROBERT 000013 Community #1 M 59 1 visit: 05/01/15 2 visits: 01/25/15, 05/10/15 AC 2 Visits: U1/25/15, U1/ 0 visits: PATIENT4, TONYA 000015 Community #3 F 78 1 visit: 06/01/15 PATIENT5, RITA ANN 000016 Community #3 F 96 2 visits: 06/01/15; 06/07/15

CRS Clinical Performance Measure Logic Manual for FY 2015 Clinical Measures
November 2014

PATIENT6,Clifford	000017 Community #3 M 24	
AC	3 visits: 01/25/15, 05/10/15, 08/01/15	

Figure 2-155: Sample Patient List, Palliative Care

# 2.10.22 Annual Wellness Visit

#### **Denominators**

Active Clinical patients ages 65 and older. Broken down by gender.

#### **Numerators**

Patients with at least one Annual Wellness Exam in the past 15 months.

# **Logic Description**

Age is calculated at the beginning of the Report Period.

Annual Wellness Exam: CPT G0438, G0439, G0402.

# **Patient List Description**

List of patients with an annual wellness visit in the past 15 months.

# **Key Logic Changes from CRS Version 14.1**

None

#### **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

DU November 25, 2015 Page 337  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010										
Annual Wellness Vis	Annual Wellness Visit  REPORT PREV YR CHG from BASE CHG from PERIOD PREV YR PERIOD BASE									
Active Clinical Pts 65+ # w/ Annual Wellnes	116	64		65						

Exam	2	1.7	0	0.0	+1.7	0	0.0	+1.7
Male Active Clinical Pts 65+	53		28			27		
# w/ Annual Wellness Exam	0	0.0	0	0.0	+0.0	0	0.0	+0.0
Female Active Clinical Pts 65+	63		36			38		
# w/ Annual Wellness Exam	2	3.2	0	0.0	+3.2	0	0.0	+3.2

Figure 2-156: Sample Report, Annual Wellness Visit

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Annual Wellness Visit: List of patients with an annual wellness visit in the past 15 months, if any. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR NUMERATOR Patient1,DENISE 000001 Community #1 F 65 AC 12/31/14 G0402 Patient2, MELISSA GAYLE 000002 Community #1 F 66 Patient3, JESSICA DAWN 000003 Community #1 F 67 02/22/15 G0438 Patient4, RUTH ALICE 000004 Community #1 F 69 Patient5, BRYSON DEWAY 000005 Community #1 F 72 Patient6, BRITTNEY ANN 000006 Community #1 F 73 05/31/15 G0439 Patient7, MARK 000007 Community #1 M 67 Patient8, HOWIE 000008 Community #1 M 72 10/01/15 G0402

Figure 2-157: Sample Patient List, Annual Wellness Visit

# 2.10.23 Goal Setting

#### **Denominators**

*User Population patients.* 

Number of goal topics set during the Report Period.

Number of goal topics met during the Report Period.

#### **Numerators**

Number of patients who set at least one goal during the Report Period.

Number of goals set for ALCOHOL OR OTHER DRUGS.

Number of goals set for DIABETES CURRICULUM.

Number of goals set for MEDICATIONS.

Number of goals set for MONITORING.

Number of goals set for NUTRITION.

Number of goals set for OTHER.

Number of goals set for PHYSICAL ACTIVITY.

Number of goals set for STRESS AND COPING.

Number of goals set for TOBACCO.

Number of goals set for WELLNESS AND SAFETY.

Number of patients who met at least one goal during the Report Period.

Number of goals met for ALCOHOL OR OTHER DRUGS.

Number of goals met for DIABETES CURRICULUM.

Number of goals met for MEDICATIONS.

Number of goals met for MONITORING.

Number of goals met for NUTRITION.

Number of goals met for OTHER.

Number of goals met for PHYSICAL ACTIVITY.

Number of goals met for STRESS AND COPING.

Number of goals met for TOBACCO.

Number of goals met for WELLNESS AND SAFETY.

# **Logic Description**

Patient education codes must be the standard national patient education codes, which are included in the Patient and Family Education Protocols and Codes (PEPC) manual published each year. If codes are found that are not in the table, they will not be reported on (i.e., locally-developed codes).

## Numerator Logic:

For Goal Set, the Goal Setting value must be "Goal Set" and the Goal Start Date must be during the Report Period..

For Goal Met, the Goal Status value must be "Goal Met" and the Date/Time Last Modified must be during the Report Period. The patient is not required to have set a goal during the Report Period.

## **Patient List Description**

List of User Population patients with goal setting information during the Report Period.

# **Key Logic Changes from CRS Version 14.1**

Added new measures for each patient goal topic.

#### **Measure Source**

None

# **Measure Past Performance and Long-Term Targets**

DU November 25, 2015 Page 338  *** IHS 2015 Selected Measures with Community Specified Report ***  DEMO INDIAN HOSPITAL  Report Period: Jan 01, 2015 to Dec 31, 2015  Previous Year Period: Jan 01, 2014 to Dec 31, 2014  Baseline Period: Jan 01, 2010 to Dec 31, 2010									
Goal Setting									
	REPORT PERIOD	PREV PERI				BASE PERIOD	CHO BA	G from SE	
# User Pop w/ Pat Ed	1,024		858			644			
# w/ goal set # w/ goal met	8 6	0.8			+0.8		.0	+0.8 +0.6	

Figure 2-158: Sample Report, Goal Setting

UP=User Pop; AC=Active Clinical; AD=Active Diabetic; AAD=Active Adult Diabetic PREG=Pregnant Female; IMM=Active IMM Pkg Pt; CHD=Active Coronary Heart Disease; HR=High Risk Patient Goal Setting: List of User Population patients who received patient education during the Report Period with goal setting information. PATIENT NAME HRN COMMUNITY SEX AGE DENOMINATOR PATIENT NAME \_\_\_\_\_\_ Patient1, Paula 000001 Community #1 F 34 GS: 11/17/15 Patient2, PENNY 000002 Community #1 F 43 Patient3, RITA 000003 Community #1 F 64 GS: 04/15/15, GM: 06/15/15 Patient4, HARRY 000004 Community #1 M 50 GM: 10/30/15 Patient5, ROSS 000005 Community #1 M 55 UP
Patient6, FELIPE
UP
GS: 09/10/15
000007 Community #1 M 67 Patient8, CATHERINE 000008 Community #2 F 72 GM: 07/30/15

Figure 2-159: Sample Patient List, Goal Setting

# **Contact Information**

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

Phone: (888) 830-7280 (toll free)Web: <a href="http://www.ihs.gov/helpdesk/">http://www.ihs.gov/helpdesk/</a>

Email: support@ihs.gov